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Background: This study expands the understanding of lay attitudes towards, and
perceptions of cardiovascular risk by exploring beliefs in the context of a large trial
of screening and prevention in a 'healthy' population.
Aims: To investigate public attitudes towards screening for cardiovascular risk,
prevention of cardiovascular disease (in particular aspirin as a preventive
medication), and participation in a preventive research trial.
Methods: Participants were members of a healthy population (50-79 years) invited
to attend screening for asymptomatic atherosclerosis, some of whom were
subsequently invited to participate in a randomised control trial assessing the efficacy
of aspirin in preventing cardiovascular events. The study sample included those who
had not attended screening, those who were ineligible for the trial, those who had
declined to participate in the trial, as well as trial participants. Semi-structured
qualitative interviews and focus groups were conducted and transcribed verbatim.
Transcripts were analysed inductively and interpretatively for emergent themes.
Findings: Attitudes and beliefs varied both between and within groups of
participants from different stages and situations from the screening and trial process.
Prominent themes included:
Screening attendance: Participants discussed their own attitudes often as distinct
from those of 'known' or 'general' others. Salient explanations of barriers included
fatalism, optimistic bias, denial and disinterest. The common phrase "what's not
broken, you don't fix" seemed to imply a low risk perception for asymptomatic
conditions. Conversely participants who were positive about screening attendance,
due to the benefits of early diagnosis, implied individual responsibility, but often in
hindsight.
Screening experience: An 'at risk' result often mismatched expectations, and
provoked varying reactions: some participants maintained prior beliefs about
personal health and risk, seeking alternative explanations; others reinterpreted their
pre-screening beliefs. Key influences on participants' reactions included the nurse-
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participant dialogue, understanding, and perceptions of the novel screening
measurement (ankle-arm blood pressure ratio). An 'at risk' result led many to trial
participation, a few declined seeking guaranteed medication, and others took no
action.
Preventive medicine: Attitudes and behaviour appeared to contradict: prevention was
typically described as "better than cure", and aspirin emerged as a favoured drug
with assumptions of trust, safety, and low perceived risk. But a prevailing tendency
and preference for avoiding medication, and lack of awareness of aspirin as a
possible preventive drug for heart disease, inhibited the appeal of engaging in such
practice, particularly until the condition was symptomatic and/or medication was
deemed "necessary".
Trial Participation: Participants' accounts revealed a wide range of influences on
trial participation. When considering benefits and drawbacks of the trial, attitudes
expressed ranged from feelings about personal gain or loss, to altruistic attitudes. The
trial tablet was central to many participants' attitudes, which were rooted in beliefs
about aspirin specifically and medication in general. Misunderstandings were
common regarding the purpose, concept and procedure of the RCT, the selection
criteria and screening measure. Whilst there was some recognition of the need for the
trial and its required randomisation process, preference for the active drug was
overwhelming, and discontent focused on the commitment as well as the idea of
being a 'guinea pig'. A major role in the decision to participate seemed to be played
by perceptions of personal susceptibility to cardiovascular risk.
Conclusion:
The present study demonstrates the salience of the concept of cardiovascular risk in
members of a general public population, and how this underlay attitudes towards
screening and prevention, and participation in a preventive research trial. A multitude
of factors were shown to contribute to people's perception of risk, amidst the
complex context of personal and situational factors in which people make decisions
about their health. However, a definite 'marker' of risk seemed particularly
necessary; the asymptomatic nature of atherosclerosis, and lack of awareness of the
screening measure emerged as particularly important contributors to low perceived
VI
risk. The findings have implications for, and can inform, the promotion of preventive
health for asymptomatic conditions. Furthermore, the findings about attitudes
towards, and understanding of, trial participation have implications for those
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Chapter 1: Introduction
Background
Cardiovascular disease is the main cause of mortality, and one of the largest causes
of morbidity in Britain, accounting for four out of ten of all deaths; coronary heart
disease (CHD) alone accounts for half of these (most result from a heart attack) and a
quarter are due to stroke (British Heart Foundation, 2003). CHD is the most common
cause of premature death. Whilst death rates from CHD have reduced significantly
over the past few years, morbidity from CHD has risen by a quarter in older people
over the past 15 years (BHF, 2003). UK CHD death rates are amongst the highest in
the world and within Britain the highest rates are in Scotland and the North of
England. For manual workers, the death rate remains much higher than non-manual
workers and the rate is also falling much more slowly (BHF, 2003).
Concerning risk factors for heart disease, unhealthy lifestyle remains a problem in
Britain despite health promotion campaigns: 29% ofmen and 25% ofwomen smoke,
the habit is more common in manual workers (35% ofmen and 30% of women) and
in Scotland (BHF, 2003). The average diet is still considered too unhealthy, typically
involving an excessive intake of saturated fat and salt, and insufficient intake of fruit
and vegetables, particularly in those with lower incomes, and in Scotland, the North
of England and Northern Ireland (BHF, 2003). The recommended amount of weekly
physical activity (to lower CHD risk) is carried out by just 37% men and 25%
women in the UK; this and the unhealthy diet contribute to rapidly increasing rates of
overweight (45% of men, 34% of women) and obesity (20% of men, 19% of
women). Regarding physiological risk factors, approximately 40% of British adults
have high blood pressure (or are receiving treatment for high blood pressure), 67%
have blood cholesterol levels above the recommended level (BHF, 2003), around 3%
of British adults have diagnosed diabetes which is on the increase and a further 2%
are thought to have undiagnosed diabetes (Diabetes UK, 2003; BHF, 2003).
The prevalence of heart disease and associated risk factors is a huge problem in
Scotland in particular; Scotland's high rate of heart disease has been attributed to
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smoking, poor diet and poverty (NHS Scotland, 2003a). The Scottish Executive has
identified reducing coronary heart disease and stroke as a national priority and is
aiming to halve the number of deaths from these conditions in people under 75 by
2010 as outlined in the white paper 'Towards a healthier Scotland' (1999; NHS
Scotland, 2003). NHS Health Scotland (formerly Health Education Board for
Scotland or HEBS) has conducted numerous campaigns relating to reducing key
lifestyle risk factors such as smoking. Secondary prevention strategies in practice
include rehabilitation, training on lifestyle behaviour change and stress management
for survivors of cardiovascular and cerebrovascular events, for example use of the
Heart Manual (Lewin, Robertson, Cay et al., 1992). Community based projects such
as 'Have a Heart Paisley' are incorporating many smaller prevention projects, both
secondary and primary (NHS Scotland, 2003b).
Secondary prevention deals with individuals with established clinical disease, but
this group accounts for just 20% of cardiovascular events whilst the majority of such
events occur in those individuals who are considered 'healthy' (Rose, 1992). Thus,
primary prevention is vital for reducing the incidence of cardiovascular disease, and
presents a huge challenge for public health (Price, Fowkes, Murray et al., 1997).
Current primary prevention in the general public consists of identifying and
prescribing appropriate treatment for those with established cardiovascular risk
factors: high cholesterol, high blood pressure and smoking, usually through General
Practice (Sleight, 1991; Kannel, 1987). However criticisms of this approach include
first, that it has an ineffective cost-benefit ratio, and second, that it overlooks those
who despite having lower or average risk on these factors will still experience
cardiovascular disease (Price et al., 1997). Thus other potential indicators of risk in
the 'healthy' population have been researched; these include sub-clinical
atherosclerosis which has been found to be associated with increased risk of
cardiovascular events in this population (Leng, Fowkes, Lee, et al., 1997; Kuller,
Shemanski, Psaty, et al., 1995; Criqui, Langer, Fronkek, et al., 1992; Kornitzer,
Dramaix, Sobolski, et al., 1995; Ogren, Hedblad, Isacsson, et al., 1995).
Atherosclerosis is the narrowing of the arteries due to fatty plaques developing on the
inner artery walls which eventually obstruct blood flow and is the principal cause of
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coronary heart disease, stroke and circulatory disease in the legs (Oxford Medical
Dictionary, 1998; Fowkes, Housley, Maclntyre, et ah, 1988).
The most effective and simplest method of identifying asymptomatic atherosclerosis
is with the ankle brachial pressure index (ABPI). This is a measure of the ratio of the
systolic blood pressure in the ankle to that in the arm (Price et ah, 1997). This non¬
invasive measure has high patient acceptability, and is reliable and accurate (Leng at
ah, 1997; Ouriel, McDonnel, Metz, et ah, 1982; Yao, Hobbs & Irvine, 1969; Fowkes
et ah, 1988). It has been found to be a good predictor of both increased mortality and
future cardiovascular events (Kornitzer, et ah, 1995; Vogt, Cauley, Newman, et ah,
1993). In the Edinburgh Artery Study (a cohort study of the general population aged
55-74 years), amongst participants with a low ABPI (< 0.9) the incidence of
cardiovascular events was 30% compared to 17% amongst those with an ABPI
greater than 0.9. The ABPI was not only a good predictor of cardiovascular events
but improved the prediction beyond that of conventional risk factors; the authors
explain that the low index reflects the combined effect of various risk factors over
time and that once atherosclerosis has developed, it is a better predictor than any
single risk factor (Leng, et ah, 1997). The most interesting finding was that in
participants with no risk factors (non-smokers, normal cholesterol and blood
pressure) those with a low ABPI (<0.9) had a 23.1% chance of a cardiovascular
event compared to 7.9% in those with an ABPI greater than 0.9 (Leng, et ah, 1997).
The ABPI therefore could be a particularly useful measure for GPs to carry out in the
conduct of an assessment of other cardiovascular risk factors in their patients: it
would indicate patients who would require further monitoring and who could benefit
from preventive treatment (Leng, et ah, 1997). One treatment currently used widely
in secondary prevention is antiplatelets such as aspirin; these drugs have been found
to reduce the rate of cardiovascular events in those with angina, and reduce by a third
the rate of further cardiovascular events in those who have had a heart attack, stroke
or transient ischaemic attack (Antiplatelet Trialists' Collaboration, 1994). Research
has shown that a high dose of aspirin is not needed; low doses seem to be of the same
efficacy in reducing the rate of further cardiovascular events (Hirsch, Dalen, Fuster,
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et al., 1992). Furthermore, lower doses should cause less gastrointestinal problems
(Levy, 1974). Until recently, there has been a lack of research into the use of
antiplatelets in those with asymptomatic atherosclerosis, i.e. as a preventive drug.
The Aspirin for Asymptomatic Atherosclerosis (AAA) Trial
A large randomised control trial is currently assessing the efficacy of low dose
aspirin (lOOmg/daily) in members of the 'healthy' population identified with
asymptomatic atherosclerosis according to a low ABPI measure. 165,832 people (50
to 79-year-olds with no history of cardiovascular disease, identified through GP
records) in Lanarkshire, Glasgow and Edinburgh were sent a letter inviting them to
reply if they were interested in attending a screening with the ABPI at a research
clinic, 48,015 (29%) replied and 42,767 (26%) were sent an appointment for a
screening (which they could change if inconvenient). 28,980 (17.5%) people were
screened, 4715 (16.3%) of these had a low ABPI (<0.95) and of these 437 were not
eligible (due to previous heart disease, allergy to aspirin and other diseases and
conditions), 164 were excluded by their GP, and 764 declined to join the trial. 3350
people were entered into the double blind RCT where they have been randomised to
receive either aspirin or a placebo for the duration of the trial (Stewart, Douglas,
Price et al., in progress)1. See Figure 1 depicting the AAA trial process.
The first trial entrants began the trial in May 1998 and due to the lengthy screening
process across the three areas the final screenings were carried out in December
2001. The final participants therefore began the trial medication in January 2002. At
the start of the trial, participants were invited to remain in the trial for 5 years.
However, due to an event rate lower than anticipated, fitting with the incidence of
heart disease in Scotland dropping (NHS Scotland 2003a), the trial has now been
extended to minimum 8 year participation, or until a clear result is attained before
this point. At the time of writing (January 2004) approximately 2200 participants are
still taking their trial medication, other participants have stopped, the most common
reasons being starting on aspirin or medication contraindicating to aspirin (GP
prescribed or in some cases self prescribed), side effects attributed to the trial
1 For further information about the AAA trial, contact Prof F G R Fowkes
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medication, cardiovascular related event, 'other' medical reasons or 'changing their
mind'.
Figure 1: Different groups involved in the AAA trial
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Research aims
A screening and prevention process such as that being tested in the AAA trial raises
many issues in addition to the epidemiological and clinical issues that are the focus
of the trial. Should the trial have a successful outcome, a similar screening and
prevention programme may well be conducted in the general population. However,
successful implementation (for example in a primary care setting) requires
knowledge about the public's health relevant attitudes, beliefs and practices. For
example, would people want to attend such a screening? The screening uptake rate in
the AAA trial demonstrates that there are many individuals who do not take up such
an invitation; 82.5% of those sent the first invitation letter and 32% of those who
were sent an appointment did not attend. Second, how would people react to the
diagnosis of a low ABPI, or a healthy ABPI? Third, what would people think about
taking an aspirin as a preventive drug? In particular would a preventive drug like
aspirin have more appeal than making other lifestyle changes such as stopping
smoking? Furthermore, understanding all these issues in the context of trial
participation could be a useful elaboration of epidemiological focus. For example,
what would people think about participating in such a trial? How do they feel about
the randomisation of aspirin and placebo?
Awareness of these issues led the principal investigator of the AAA trial (Prof
Fowkes) and a medical sociologist (Dr Cunningham-Burley) to apply for funding
from the Chief Scientist Office, Scottish Executive, to enable this research to be
conducted through a PhD studentship. The overall aims were to explore the healthy
lay public's attitudes towards and beliefs about screening for cardiovascular risk,
aspirin as a preventive medication for heart disease and participation in a preventive
research trial. More specifically, the aims that I outlined at the start of the project
were:
♦ Explore attitudes towards attending screening for cardiovascular risk in both
individuals who attended and who declined
♦ Explore reactions to the screening and ABPI result, and perceptions of personal
cardiovascular risk
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♦ Investigate attitudes towards preventive medicine, in particular aspirin, in relation
to future cardiovascular events, and attitudes towards preventive medicine in
comparison to making other lifestyle changes
♦ Investigate attitudes towards participating in a double blind randomised control
trial of preventive medicine
Alongside these runs the aim to further develop research into lay beliefs about
cardiovascular risk within a novel context.
The study was conducted in an interdisciplinary environment; knowledge of
epidemiological, sociological, psychological and health services research were drawn
upon to develop the project. The project involved interviewing individuals within the
population invited to the AAA screening who were at different stages in the
screening and trial process; the timeline of the trial (and staggered screening process)
enabled a diverse range of participants to be included; from those recently attending
screening to those several years into the trial. The AAA trial and the population
invited to it, have provided an ideal opportunity and site to explore the wider context
of screening, health beliefs and practices, and trial participation. It is hoped that the
findings will help both shape the practice of clinical trials in the future and inform
the development ofprevention programmes such as screening.
Thesis outline
The current thesis reports on this work and is structured as follows. The literature
review in Chapter 2 covers relevant literature from various disciplines relevant to the
research aims. The chapter is divided into five sections: First, I cover literature on lay
beliefs about heart disease and cardiovascular risk including the existence of lay
epidemiology and use of explanatory models to account for the occurrence of heart
disease, and its relation to perceptions of personal cardiovascular risk. Second, I
outline research on attitudes to screening covering influences on screening uptake,
lay meanings of screening, and the psychological impact of screening. The third
section covers literature exploring lay beliefs about medication, from research on
(non)-compliance to that which places lay ideas about medication in the context of
risk. In the fourth section I cover literature relevant to public participation in
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research. The first half considers the many potential influences on the decision to
participate, the second half considers the concept of altruism. The fifth and final
section is a brief overview of literature on risk perception, a theme which underlies
research in this area and links the diverse aims of the research and analysis of data.
Chapter 3 outlines the methodological approach taken and process engaged in to
conduct the research. First, concerning the research design, I outline the purpose of
the research, the research questions, the choice of methodology and approach. Next I
describe the initial phase of the research including the pilot work and topic guide
development. The main fieldwork is then discussed incorporating sampling,
recruitment, ethics and reflexivity. This is followed by describing the analytical
approach and conduct.
Chapter 4: The first findings chapter focuses on participants' attitudes towards the
screening. Starting with barriers, I present and discuss four particularly salient
phrases in participants' accounts that seem to reflect or represent beliefs that appear
to contribute to screening non-attendance. These phrases seem to be used as cultural
shorthands of shared lay knowledge and beliefs. I explore how participants' accounts
of their own attitudes compare with the attitudes they impute to other people. This
moves the discussion onto individuals' rights versus responsibilities regarding
screening and preventive health. Participants' beliefs about benefits of screening are
then considered, linking back to discussion of prior expectations of screening, and
whether expectations are met at the actual screening. Leading onto the screening
experience, I present how people appear to make sense of the screening result, in
particular where expectation-reality mismatch has occurred, and the role of the
research nurse in participants' interpretations. Finally reactions to a low risk result
are examined.
When discussing screening and preventive health, a phrase which was prominent in
many individuals' accounts was "prevention is better than cure." Chapter 5 focuses
on beliefs about prevention and preventive medicine, exploring what people say they
think about prevention and what they say they do about prevention. First I present
8
how some participants' accounts emphasise the attitude that "prevention is better
than cure". Then I demonstrate and discuss why for other participants, "prevention is
better than cure, but..." Despite citing the phrase, these people's accounts provide
reasons against engaging in active prevention, in particular preventive medication
use. I next explore how aspirin appears to be considered as different to other
medication. Finally I present participants' attitudes towards the use of preventive
medication as opposed to lifestyle change.
Chapter 6 presents and examines participants' attitudes towards participating in the
AAA trial. The first section explores the emergence of a spectrum of altruistic
attitudes in participants' accounts about participation. The second section examines
views about the risks and benefits of participating. This includes attitudes towards
the RCT procedure, and incentives, barriers and reactions to experiences in the trial.
Third, misunderstandings of the trial are presented and discussed.
An underlying theme which emerges in chapters 4, 5 and 6 is perception of
cardiovascular risk. Chapter 7 presents further data relating to participants' views
about cardiovascular risk perception. The focus is on risk factors including family
history of heart disease, lifestyle, Scottish identity and clinical measures of
cardiovascular risk, and how participants applied these risk factors to themselves and
others.
In Chapter 8, I discuss the data presented in the previous chapters with a particular
focus on the emerged importance of risk perception and its relation to participants'
attitudes towards screening, prevention and trial participation. The first two sections
discuss the relation between risk perception and screening. First, screening
attendance and second, reactions to the screening experience. The third section
discusses how participants' views about aspirin as a preventive medication relate to
both perceived cardiovascular risk and perceived risk from medication. The fourth
section discusses the interrelationship between these two perceptions and attitudes
towards participating in the AAA trial. Finally, I will focus more generally on the
notion of risk and how the research findings have contributed to knowledge about
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risk in health research. To conclude, I will discuss implications of the findings for
screening and prevention programmes, clinical trials, and for further research.
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Chapter 2: Literature review
Introduction
The overall context of the research, and its specific aims, led to a literature search
spanning several disciplines, reflecting the interdisciplinary approach to the study. The
areas of literature I chose to focus on at the outset included: attitudes towards screening
and prevention (including preventive medication), trial participation, and cardiovascular
risk. This search spanned several disciplines, particularly health psychology, and
medical sociology, also medical ethics, epidemiology, and anthropology. The
development of the literature search and the progression of the fieldwork led to
searching further areas that I considered relevant. Overall the literature covered falls into
five sections as outlined below. These are large bodies of literature, thus, my aim in this
chapter is to outline a broad range of research and perspectives within each area.
• Part I: Beliefs about heart disease and cardiovascular risk. Due to the focus
of the AAA trial screening, I felt it important to search for literature on people's
attitudes towards cardiovascular risk and heart disease to provide a grounding in
the disease/condition area. This led predominantly to medical sociological
research on lay beliefs of heart disease, its aetiology, development and risk
factors.
• Part II: Attitudes towards screening. A large amount of research in the health
psychology literature has investigated attitudes towards screening focusing
mainly on cancers, largely concerning influences on uptake and the
psychological impact of screening. Debates in the medical literature regarding
the ethics of screening, and sociological research placing screening in the context
of risk and exploring lay meanings of screening provided further perspectives.
• Part III: Beliefs about medication. Searches revealed little literature focusing
on attitudes towards preventive medication specifically, however both health
psychology and sociology literatures have considered beliefs about medication
(general or other specific types). The psychological perspective has largely
focused on compliance to prescribed medication and demonstrated the
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development and application of models for predicting and explaining
medication-taking behaviour. Qualitative sociological research has explored lay
meanings of medication and related these to the concept of risk.
• Part IV: Attitudes towards research participation. Initially, searching for
relevant literature regarding attitudes towards trial participation led me to studies
of influences on uptake in the epidemiological and medical journals, and a few
recent qualitative studies from the social sciences. I also consulted social
psychology research for a perspective on possible social influences on the
decision to participate. However, the fieldwork itself led me to consult a further
body of literature not considered at the outset - that concerning altruism and pro-
social behaviour from sociology, anthropology and social psychology.
• Part V: Risk. The theme of risk runs through the four preceding areas, thus, I
decided to consult a number of key pieces of psychological and sociological
literature to provide a grounding in different perspectives on risk, to enable
consideration of heart disease, screening, prevention and participation in the
context of risk.
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Part I: Beliefs about heart disease and cardiovascular risk
In this initial section, I cover literature on beliefs about heart disease and cardiovascular
risk. I begin by outlining findings of a key piece of ethnographic research in medical
sociology which illustrated the process of lay epidemiology and use of the 'coronary
candidacy' model in lay accounts of coronary events, and how awareness of fallibilities
and fatalism related to lay people's ideas about risk factors. I move on to cover findings
of this and other literature on beliefs about risk factors including family history and
gender, the application of risk factors to oneself generally and retrospectively, and the
interplay with behaviour.
Lay epidemiology and coronary candidacy
There has been a long tradition of research on lay health beliefs in medical sociology
(for example, Pill & Stott, 1982, 1985; Calnan, 1987; Blaxter, 1990; Backett & Davison,
1992, 1995J. This in-depth work has led research to a deeper understanding of the lay
public's understandings and beliefs about illnesses, their aetiology and treatment. More
recently, heart disease has been the subject of a few prominent research studies, not least
because it is one of the major causes of mortality and has been the focus of a range of
public health and health promotion initiatives. Ethnographic research into lay beliefs
about heart disease in South Wales by Davison, Davey-Smith and Frankel (1991)
demonstrated the existence of an explanatory model widely used by people to account
for coronary heart disease: coronary candidacy. This cultural mechanism is described as
developing through the process of 'lay epidemiology' which the authors define as:
"a scheme in which the individuals interpret health risks through the routine
observation and discussion of cases of illness and death in personal networks and the
public arena, as well as from formal and informal evidence arising from other
sources, such as television and magazines..." (Frankel, Davison & Davey-Smith
1991, pp428).
Input from experience and observation of family, friends and self, health professionals,
the media and official bodies, is incorporated into the resulting explanatory theory of
coronary candidacy: the type of person likely to have heart problems based on physical,
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social and personal criteria (Davison et al., 1991). Physical factors include those who are
overweight, unfit, those with a red/flushed face complexion or grey pallor, social factors
comprise family history of heart disease, occupation (mental stress from work
responsibility and pressure, physical stress from manual labour, poor work
environmental conditions, sedentary work) and geographical residence. Finally personal
factors cover behaviour (bad lifestyle) and nature (excessive worriers and anger)
(Davison et al., 1991). Constructs such as the coronary candidate serve to explain the
occurrence of adverse events: "how and why did this happen to this person at this time?"
(question posed by Rose, 1985; Davison et al., 1991). In the case of coronary candidacy,
Davison and colleagues describe four uses: regarding other people it is used to both
predict and retrospectively explain heart disease morbidity and mortality, similarly
regarding personal contemplation, it is used to predict one's own risk of developing
heart disease and retrospectively explain it (Davison et al 1991).
Whilst there is often an overlap between factors in the theories developed through lay
epidemiology and professional epidemiological opinion (for example Davison and
colleagues found almost universal knowledge of the risk factors for heart disease
promoted by health education (Davison, Frankel & Davey-Smith, 1992)), the lay
epidemiologist notes several fallibilities in the medical professional model. Thus to the
lay epidemiologist coronary candidacy status is not regarded as straightforward, whilst it
increases one's risk it does not guarantee heart disease incidence. Experience and
awareness of anomalies are evident and need accounting for: two particular extreme
anomalies being the 'unwarranted survivor' typically described as a drinking, smoking,
unfit old man who lives to a ripe old age, and the anomalous death of a young, healthy
jogger who 'drops down dead' (Davison et al., 1991). Thus the randomness of heart
disease is recognised and incorporated into the model. This is linked with fatalistic
feelings within lay beliefs about heart disease but Davison et al. (1991) emphasise the
distinction between the fatalistic feelings they found and Pill and Stott's (1981) fatalist-
lifestylist dichotomy which implies ignorance. Rather, the authors regard a fatalistic
component of the lay epidemiologist's theory as "the realistic recognition that some
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barriers exist on the road which may not be surmountable through personal, individual
effort" (Davison et al 1992, pp679). There are various such influences on health beyond
the individual's control including personal factors (such as heredity), the social
environment and the physical environment, all of which have a complex relationship
with an individuals' lifestyle and health status (see Davison et al., 1991). However a
fourth external influence noted in people's beliefs is regarded as less modifiable: the
influence of fate, chance, luck in attempting to explain inability to find a causal link for
heart disease in their family (Davison et al., 1991; see also Preston, 1997).
The research by Davison et al. (1991) further highlights the prevention paradox
originally noted by Rose (1981). This paradox is inherent in population strategies of
preventive health promotion and may therefore limit their effectiveness in producing
behavioural modification for example regarding coronary prevention. Population
strategies aim to shift the whole distribution of risk factors, reducing the mean towards
lower risk; as compared to high risk strategies which aim to target and curtail those at
the top end of the risk distribution. Whilst benefiting the population as a whole, on an
individual level there is little gain, this is the prevention paradox (Rose, 1981; Davison
et al., 1991; Hunt & Emslie, 2001). Davison et al. (1991) suggest that lay awareness of
the prevention paradox, in the context of broad health promotion messages about
reducing risk factors for heart disease, contributes to mistrust of expert advice (Davison
et al., 1991; Hunt & Emslie, 2001). Scepticism arising from contradictory medical
advice has been shown to contribute to low motivation to behaviour change (Nic
Gabhainn, Kelleher, Naughton et al., 1999). Health promotion in these contexts may be
working against lay and popular culture, and is therefore unlikely to succeed (Backett &
Davison, 1992).
Lay beliefs about heart attacks
Further research (for example Hunt & Emslie, 2001, in Scotland) extended
understanding of issues around the coronary candidacy model. First the belief that a
heart attack would be 'a good way to go' was common (Emslie, Hunt & Watt, 2001),
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this builds upon observations in the research in South Wales that a heart attack was
regarded as a status symbol, and evidence of success achieved through hard work
(Davison et al., 1991). Also contributing to its preferable status is the widespread belief
of a heart attack as sudden, dramatic and fatal (Ruston, Clayton & Calnan, 1998). It is
perceived as desirable for its quickness in young deaths and naturalness in old age
deaths; this belief ignores the possibility of surviving with a disability, despite the large
percentage of heart attack survivors and the experience of this in family members
(Emslie et ah, 2001). Regarding vascular disease, heart attacks seem to be regarded as
favourable to strokes, which tend to be considered more disabling (Carroll, Naylor,
Marsden & Doman, 2003). In people's comparisons with cancer, heart disease is
reported as much less feared (Nic Gabhainn et al., 1999; MacFarlane & Kelleher, 2002).
Lay views on cardiovascular risk factors and aetiology
Family history
Davison, Frankel and Davey-Smith (1989) highlighted the major role played by heredity
in lay beliefs about heart disease aetiology. Emslie and colleagues' study focused
particularly on family history, and found a common belief that health-damaging factors
in one's past (family history, past health damaging behaviours) could not be undone by
modifying one's behaviour at a 'late' stage in one's life (Emslie, Hunt & Watt, 2000).
Ambivalence was apparent in discussions of these risk factors and in assessing personal
risk from these past 'legacies' (Hunt, Emslie & Watt, 2000). Heredity or genes were
mentioned spontaneously as a cause of heart disease by two thirds of participants in the
Scottish study. Again ambivalence and uncertainty prevailed in discussions of family
history of heart disease as a risk factor; there were difficulties in defining a premature
death and categorisation of a 'family history'. Recognition of a family history did not
always lead to perception of a personal risk depending on one's perceived resemblance
to different 'sides' of one's family (Hunt et al., 2000). Thus family history could be
perceived and interpreted in various ways, therefore not lending complete support to the
existence of fatalism in the population regarding heart disease.
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Gender
Emslie and colleagues note how the coronary candidacy ignores gender, other than
generally considering women at less risk than men; they argue that gender is a key
element of the construct (Emslie et ah, 2001). Accounts of those with heart problems,
and the anomalies, are of men. To initiate mention of female cases, discussions were
moved towards family members; descriptions of male relatives focused on sudden fatal
heart attacks whereas with female relatives less dramatic imagery was used and they
focused on limiting illness (Emslie et al., 2001). The authors elaborate on this finding in
the context of wider debates about gender and health in medical sociology, for example
mechanical metaphors of the male body contrasted against the organic and natural
female body in medical and cultural discourse (Emslie et ah, 2001).
Ruston and Clayton (2002) explored the low levels of perceived vulnerability to
coronary heart disease in women, including those who had experienced a CHD related
event. Participants were found to engage in three strategies ofminimising risk perceived:
first, attributing risky lifestyle to men. Second, subjectively manipulating the potential
threat arising from their personal risk factors; risk factors that contributed to a man's
candidacy were regarded as less relevant for a woman, indeed some were regarded as
beneficial, thus were discounted when women applied them to themselves. Third, over¬
emphasising the importance of social position in relation to risk; the traditional role of
the male breadwinner was associated with stress and physical strain whereas that of the
female housewife was regarded as morally healthy and cardio-protective. Furthermore, a
woman adopting a man's traditional breadwinning role was seen as placing herself at
increased risk (Ruston & Clayton, 2002). This and Emslie et al.'s findings have
implications for understanding the beliefs, awareness and practices amongst women and
men in the general population, and amongst the medical and research community.
Established and experienced cardiovascular risk
So far the research discussed has focused on the beliefs of the general public. Other
research has explored the beliefs of specific groups of people who have a high
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cardiovascular risk. Type 2 diabetes is a major risk factor for cardiovascular disease
(Stamler, Vaccaro, Neaton, et al., 1993; Simons & Simons, 1998; Diabetes UK, 2003).
A recent qualitative study of people with diabetes including half with and half without
cardiovascular disease found only a minority associated diabetes with increased
cardiovascular risk, particularly in those who had no cardiovascular disease themselves;
furthermore when assessing their individual risk the majority rated their risk as low
(Carroll et al., 2003). Participants generally weighed up quality against length of life
when considering lifestyle changes relating to long term health gain; whereas those with
cardiovascular disease regarded the long term gains highly, those without disease
referred to the short term benefits of their 'bad' lifestyle behaviours more favourably
(Carroll et al., 2003).
People who have experienced heart disease, heart attacks and/or cardiovascular related
problems have been the focus of much research; these individuals provide the
opportunity for researchers to explore retrospective beliefs about cardiovascular risk
before, and current beliefs after an event. As described above, a widespread belief is the
image of a heart attack as a sudden, dramatic, fatal event involving chest pain (Davison
et al., 1991; Emslie et al., 2001). Many heart attack survivors reportedly shared these
expectations prior to the event (Ruston et al., 1998). Such expectations could have
negative consequences for survival and prognosis: in terms of symptoms, research has
found that when symptoms experienced were generally considered 'typical' for a heart
attack (chest pain, radiating pain, collapse), individuals were less likely to delay in
seeking medical help than those who experienced 'atypical' symptoms (including
shortness of breath, nausea, faintness, sweats). A mismatch of individuals' own
expectations and experience was also associated with delay (Home, James, Petrie, et al.,
2000). A recent study found that, despite awareness of one's own risk and experiences
of heart attacks in one's family, this did not guarantee acting 'appropriately' upon the
experience of one's own symptoms. Again misinterpretation and disregard of symptoms
was common (Brink, Karlson & Hallberg, 2002). Regarding prior beliefs about personal
risk, heart attack victims who sought medical help within four hours of their attack were
18
more likely to have higher prior perceptions of personal risk of a heart attack then those
who delayed seeking care (Ruston et ah, 1998). Similarly, disregard and endurance of
symptoms has been explained as due to illusions of invulnerability despite objective risk
indicators (Brink et al., 2002).
Wiles (1998) explored how patients made sense of their heart attack after the experience
interviewing them soon after the event and several months later. Initial shock and
disbelief were expressed both at having the heart attack and surviving it, again
demonstrating lack of prior perceived personal risk, and prior expectations about a
sudden fatal event. Interestingly, lack of perceived risk continued for some: around a
third made a full recovery but no longer considered themselves as having heart disease;
those who did not make a full recovery reinterpreted their event as more serious and
sought attempts to explain its aetiology (Wiles, 1998). An additional finding related to
the information given about likely recovery time: the author pointed out that such
information is derived from epidemiology and thus based on population data and
averages. This is used by health professionals without realising patients' tendency to
interpret it as personally relevant, thus decreasing trust in health professionals and
possibly giving up lifestyle change when the expected (average) recovery is not reached
(Wiles, 1998).
Several studies highlight the association of patients' illness perceptions to their
attendance at cardiac rehabilitation and their recovery; in particular belief in control of
the illness and belief in aetiology from lifestyle was associated with higher attendance at
rehabilitation (Petrie, Weinman, Sharpe et al., 1996; Cooper, Lloyd, Weinman, et al.,
1999).
In summary, the research covered in this section has demonstrated the complexity
involved in people's understandings and beliefs about heart disease and their perceptions
of cardiovascular risk (in everyday life, during an event and after surviving an event).
Through the process of lay epidemiology, information and messages from health
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professionals, health promotion and media sources are observed and noted, as is
personal experience and that of others conveyed in conversations or publicised through
the media. The resulting model of coronary candidacy is used in predicting and
accounting for cardiovascular risk and events. Lay awareness of fallibilities in the
relationship between risk factors and events contributes to fatalistic attitudes, and
explains people's feelings about behaviour related to lifestyle risk factors. Research has
shown distinctions in the way risk factors are applied to oneself in comparison to others,
demonstrating methods of minimising personal perceived risk. The interplay between
personal perceptions of risk and expectations and ideas about cardiac events and
symptoms has consequences regarding behaviour and action upon experiencing an
event. All this has implications regarding motivation to engage in a preventive lifestyle.
The focus of the work reported in this thesis will expand this area to focus on the
relationship between lay beliefs about perceived cardiovascular risk and attitudes
towards screening and prevention regarding heart disease.
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Part II: Attitudes towards screening
In this section, I cover some of the literature on attitudes towards screening within three
main parts. First, I discuss research literature investigating influences on screening
uptake. This is mainly quantitative research and comprises analyses of
sociodemographics and social cognition models including criticism of this approach. I
then draw upon qualitative research that challenges the perspective of the public health
experts contrasting it with that of the meanings lay people hold about screening. Third, I
consider the literature on the psychological impact of screening and screening results.
Current screening programmes
Before discussing the literature it is useful to consider a definition of screening:
"a public health service in which members of a defined population, who do not
necessarily perceive they are at risk of, or are already affected by a disease or its
complications, are asked a question or offered a test, to identify those individuals
who are more likely to be helped than harmed by further tests or treatment to
reduce the risk of a disease or its complications" (National Screening Committee,
2003)
In addition, by identifying and alerting those who are at risk for a certain condition,
screening can help bring about reduction in unhealthy behaviour contributing to an
individual's risk status (Pitts, 1996). Screening's overall aim is reducing disease
incidence, morbidity and mortality; it is either primary prevention involving screening
for risk factors (such as cardiovascular risk) or secondary prevention involving screening
for presence of disease (for example cancers). Tertiary screening and prevention also
exists, for example sensorineural deafness (Jepson, Clegg, Forbes, et al., 2000), but will
not be covered here. In the UK there are currently national screening programmes for
breast cancer and cervical cancer; all GP registered women aged between 25 and 64
years (cervical) and 50 and 64 years (breast) are currently offered regular screening. For
other cancers, such as colorectal, pilot screening programmes have been carried out and
recommendations for national screening programmes have been made (NHS, 2003).
There is also antenatal and neonatal screening. The Department of Health has recently
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allocated funding to the NHS National Screening Committee for the Diabetes, Heart
Disease and Stroke Prevention Project to engage in screening and intervention
programmes for these conditions (NHS, 2003).
Attitudes towards screening attendance
Despite the apparent benefits of screening, many people do not take up screening
opportunities when invited; often these are those in the most 'at risk' groups (Nielson &
Jones, 1998). Therefore factors that potentially influence screening uptake have been the
focus of a large amount of research. The majority of these studies has focused on
cervical and breast cancer screening as these screening programmes have been underway
for several decades thus providing populations to be studied.
Sociodemographical factors
Initially research investigated the importance of sociodemographics in determining
uptake. As Britain becomes increasingly diverse in ethnicity, culture and religion, these
have been investigated as potential determinants of screening uptake. A systematic
review reported that the majority of studies of breast and cervical cancer uptake found
no significant association with ethnic origin, although a few studies found higher uptake
in black women (Jepson et ah, 2000). However, qualitative research has identified
cultural beliefs that inhibit screening uptake; Underwood, Shaikha and Bakr (1991)
identified Islamic beliefs that inhibited women from engaging in breast and cervical
cancer screening. First, the belief that lives were controlled by Allah (God) thus it is
God's will if someone is sick, so while willing to seek care when ill, preventive check¬
ups are uncommon. Interestingly another study (Holschneider, Felix, Satmary, et al.,
1999) found the same belief in Latino women in the US. A second Islamic belief
prevents women from exposing their body to men other than family; women described
avoiding physical examinations by male doctors, they lacked confidence in health
professionals' respect of their cultural values regarding this issues and thus avoided
attending at all (Underwood et al., 1991).
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Screening uptake has been found to be lower in those from more deprived
socioeconomic backgrounds (for example Harper, 1993; Neilson & Jones, 1998;
Bostick, Sprafka, Virnig, et ah, 1994; Friedman, Webb, Richards, et al., 1999; Gatrell,
Garnett, Rigby, et al., 1998; Pelfrene, Bleyen & De Backer, 1998; Lagerlund, Maxwell,
Bastani, et al., 2002). A systematic review found that a majority of US studies reported
those with health insurance (an indicator of higher socioeconomic status) were more
likely to attend mammograms than those without (Jepson et al., 2000). Research has
focussed on identifying and targeting barriers and perceptions that are more pronounced
in lower socioeconomic groups (for example Orbell, 1996; Wardle, Williamson,
McCaffery, et al., 2003). Level of education has been investigated as a potential
determinant of screening uptake, however a systematic review found no association in
the majority of studies (Jepson et al., 2000).
Knowledge and understanding
Research has focused on misunderstanding as a potential barrier to screening uptake.
Neilson and Jones (1998) following up women who had declined a GP invitation to
cervical screening, found that the invitation letter had failed to explain the purpose of the
test; a quarter of the decliners wanted to know more about the purpose and the meaning
of the results. Further misunderstandings involved misperceptions of causes of cancers
(for example, McKie, 1993; Mouchawar, Byers, Cutter, et al., 1999). A major issue of
misunderstanding is the view that whilst asymptomatic screening is unnecessary
(McCaffery, Borril, Williamson, et al., 2001), and that symptoms would be required to
initiate screening attendance (McKie 1993); such misunderstandings are problematic for
chronic conditions as once symptomatic, prognosis is often fatal (Pitts, 1996; McCaffery
et al., 2001). A second important aspect that is crucial for screening programmes is
provision of sufficient explanation of the possibility of false results, i.e. both false
positive and false negative results. This will be discussed further within the
psychological impact section.
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Whilst it is important that invitations should be clear and informative, some past health
promotion campaigns have assumed that understanding and knowledge of risk would be
sufficient in provoking behaviour, such as screening uptake, but such decisions are much
more complex involving many factors as discussed in the following sections.
Invitations to attend
The GP can have a significant influence on an individual's screening uptake (Rakowksi,
Dube, Marcus, et ah, 1992); opportunistic invitations during GP consultations for other
reasons can produce a high percentage of screening uptake (Norman, 1993). Influences
on a GP to make an opportunistic invite include their own beliefs and family history
(Woo, Cook, Weisberg, et al., 1985; Marteau & Johnston, 1990), and national policies
such as GP targets for cervical cancer screening (McKie, 1993) and GP contracts. Such
policies are not always adhered to by GPs (Frolkis, Zyzanski, Schwarz, et al., 1998;
Norman, 1993) or can lead to insensitivity and controversy (McKie, 1993). Norman
(1993) found no difference in percentage uptake for general heath checks between
opportunistic invites (using tagged patient records) and postal invitations; however, the
latter generated greater coverage. Invitation letters containing an appointment time
generally produced greater screening uptake than open invites, but the latter invoked
more satisfaction with type of approach (Norman & Conner 1992; Williams & Vessey
1989; Wilson & Leeming 1987).
McCaffery et al (2001) point out a hurdle for 'new' screening programmes; all female
non participants in a colorectal screening programme reported having attended cervical
and breast cancer screenings, one of the explanations being that these had become
routine (which fits with the latest UK attendance figures of approximately 81% and 75%
respectively) whereas bowel cancer screening being novel probably entails stronger
intention (McCaffery et al., 2001).
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Health beliefs and social cognition models
Whilst pinpointing sociodemographic factors associated with screening uptake may be
useful, as particular barriers associated with certain groups can be targeted,
psychologists have focused on cognitive factors and models that explain how cognitions
are related to health behaviours: social cognition models (SCMs). These are variables
that can potentially be changed and can mediate the effects of other factors (Conner &
Norman, 1995). The two SCMs that have been most widely applied to preventive health
behaviour are the health belief model (HBM) and the theory of planned behaviour
(TPB). The HBM (Rosenstock, 1966; 1974; Becker, Haefner & Maiman, 1977), an
expectancy-value model specific to health related behaviours, comprises of components
relating to four key beliefs: perceived susceptibility to a health event, perceived severity
of the condition and its consequences, and perceived benefits and costs of the related
health behaviour. A review of the HBM (Harrison, Mullen & Green, 1992) reported
these four variables as typically significant predictors, however effect sizes were small.
The TPB (Ajzen 1985; 1988; 1991) and its predecessor the theory of reasoned action
(Fishbein and Ajzen, 1975; Ajzen & Fishbein, 1980) which also developed from
expectancy-value theory, holds that the main determinant of volitional behaviour is the
intention to engage in that behaviour (Conner & Sparks, 1995). Behavioural intention is
determined by one's attitude towards the behaviour, subjective norms (the belief about
whether significant others think one should engage in the behaviour), and perceived
behavioural control (the perceived ease or difficulty of performing the behaviour.
Reviews and meta-analyses of research applying social cognition models to predict
screening intentions and behaviour have found generally poor predictions, and focused
on intentions or past behaviour, rather than measuring actual screening uptake (Godin &
Kok, 1996; Harrison et ah, 1992). This has been tackled (Bish, Sutton & Golombok,
2000) with a prospective study of cervical screening uptake investigating the predictive
use of the HBM and TPB with an added measure of anticipated affect. However, neither
model was found to account for a significant proportion of variance in the behaviour i.e.
a significant predictor of screening uptake. The TPB was a good predictor of screening
25
intentions, in particular the attitude component showing that women's attitudes are a
good predictor of their intention (Bish et al., 2000). The most useful component of the
HBM was perceived susceptibility. Explaining the findings the authors note that
questionnaires assess only a 'proxy measure' of an intention and are often hypothetical,
whereas decisions regarding screening in reality are less likely to follow a habitual
response, involving different thoughts and influences each time (Bish et al., 2000).
Further criticism of social cognition models include the failure to acknowledge
emotional influences and responses which are likely to be heightened when waiting for
results that could include diagnosis of a disease such as cancer (McCaffery et al., 2001).
Sutton (1998) noted that while SCMs are designed to predict behaviour, much of the
variance in behaviour remains unexplained. This unexplained variance led Ogden (2003)
to question the conclusions of studies applying SCMs which give support to the models
despite low levels of explained variance, rather than using the data to challenge the
models. She notes how authors' explanations included poor operationalisation of the
models, problems with the population used or the behaviour of focus, or advocating
extension of the models (Ogden, 2003). She further criticises the focus on analytic rather
than synthetic truths in the models' operationalisation, and suggests that rather than
accessing cognitions, SCM questionnaires could be creating or changing cognitions
(Ogden, 2003).
Other criticism of applying SCMs to attitudes towards this and other areas includes
overestimation of the significance of cognition and calculation involved; the assumption
that individuals are rational and autonomous ignores the lived and embodied experience
of screening, which extends beyond cognitive processing to the wider social context in
which decisions take place (Howson, 1998). Furthermore, if rational processing does
take place, only a decision to attend is considered a 'rational' choice. Howson (1998)
contests the expectation that the public should choose to attend screening, and that non-
attendance or not deciding are often regarded as "failure in one's social duty to maintain
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health and well being" so shifting the responsibility onto the individual (Howson, 1998;
Greco, 1993; Singleton, 1995).
Lay meanings of screening
Surveillance and the risky self
Howson (1998) places screening in the context of surveillance by medical culture to
monitor and eliminate risk of disease but argues that this contributes towards a
generalisation of risk, development of risk consciousness and the 'risky self (Howson,
1998; Ogden, 1995). Lupton (1993) notes that while people have a right to know their
risk, should they not also have a right not to know their risk?
Uncertainty and reliability
Duncan, Hart and Scoular (2001a) describe the disparity between expert and lay
definitions of certainty of screening tests: medical opinion is based on probabilistic
reasoning applicable to the population whereas the layperson is concerned with
prediction and control of individual health. People generally attend screening to
ascertain their disease-free status (Posner & Vessey, 2001). Women in Howson's (1998)
study reported attending cervical screening for 'peace of mind', not because they
perceived themselves to be at risk. Duncan et al. (2001a) state how this expert-lay
mismatch is not due to public misunderstanding, rather a result of the way screening is
presented. For example, cervical screening is considered a triumphant medical progress:
safe, simple and successful, with no mention of side effects and accuracy of the test
(Howson, 1998). But her participants talked with great anxiety about the reliability of
the screening test (for example from media reports and others' experiences of missed or
misinterpreted results resulting in disease and death); even a 'normal' result would leave
them in doubt. Uncertainty may thus not be alleviated by screening and may even be
exacerbated reinforcing their sense of risk, not just from the disease but from the test
itself (Howson, 1998).
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Discussing chlamydia, Duncan et al. (2001a) warn how scepticism of screening's ability
to control future health may impact upon uptake, and may lead to anxiety in women
arising from this uncertainty. They advocate presenting screening to the public in a way
that acknowledges the uncertainties (Duncan et al., 2001a). Furthermore, dissatisfaction
is not confined to the public, as many health professionals display concern over the
ethics of recruitment strategies (Duncan et al., 2001a). Recent articles and letters in the
British Medical Journal have outlined the negative side of screening programmes, and
debated honesty in informing the public of the limitations of screening (for example
Austoker, 1999; Kmietowicz, 2000).
Psychological impact of screening
It is important to consider the psychological impact of screening, not only as a potential
influence on future screening attendance (Wardle, Pernet & Stephens, 1995), but also
because screening programmes aim to benefit health. Thus, any costs including
psychological harm must be considered. People usually consider themselves healthy
before being offered screening; health tends not to be thought about until our own health
or that of someone close to us deteriorates (Shickle & Chadwick, 1994). Shickle and
Chadwick (1994) suggest that to be offered screening casts doubt over our 'healthiness'
and can provoke anxiety until a negative (healthy) test result is received. The authors
describe this state as the 'worried well'. Receipt of a screening invitation itself has been
associated with anxiety (Nathoo, 1988). Applying optimistic bias to attitudes towards
screening (when people perceive their risk of getting ill as lower than those around them
- discussed in Part V) would predict people to expect a negative (healthy) test result.
Indeed as mentioned, Howson's (1998) participants reported attending cervical
screening for reassurance rather than anticipating any risk. If these expectations are not
matched and a positive result is actually received, it is likely that anxiety both general
and specific to the condition will be generated. Raised anxiety has been found in women
receiving positive cervical cancer screening results compared to negative (Wardle et al.,
1995). Research has shown varying amounts of adverse psychological effects of
screening.
28
Positive results bring about the transition from being a 'well' person, through potentially
ill, to 'ill' (Duncan et al., 2001a). Duncan et al. (2001a) criticise research for
concentrating on cognitive processes and ignoring the 'lived experience' of those
attending screening and obtaining results. Focusing on the meanings people attach to the
situation, they draw upon Bury's (1982) concept of 'risk to meanings' whereby the
uncertainty from living with a chronic illness challenges our ability to maintain
culturally ordered meanings (Duncan et al., 2001a). They argue that managing meanings
and risk to meanings are central to women's accounts of chlamydia diagnoses; once
diagnosed, participants reinterpreted their meanings to maintain their 'nice' image thus
minimising threat to their identity (Duncan et al., 2001a).
Receipt of a positive result could increase anxiety through feelings of being 'labelled'
with a condition. Certain conditions are associated with stereotypical images of the type
of person susceptible, sometimes involving stigma for example from sexually
transmitted diseases or conditions associated with risk from sexual activity such as
cervical cancer (Posner & Vessey, 1988; Wardle et al., 1995). Such stigma will add to
the impact of being diagnosed with the condition, for example shock, distress and
anxiety in women diagnosed with chlamydia (Duncan, Hart, Scoular, et al., 2001b).
Regarding other conditions detection and labelling of hypertension has been associated
with reduced well being, more psychological distress and other psychosocial effects (for
example Irvine, Garner, Olmsted, et al., 1989). High cholesterol detection was not found
to have such adverse psychosocial effects, except slightly increased worry about
cholesterol (Irvine & Logan, 1994). The authors propose several explanations for this
distinction. First, focusing on the role of perceived control, high cholesterol control and
treatment could be viewed as more under individual control and optimistic bias could be
operating. Second, high cholesterol has been perceived as less symptomatic, thus an
individual's expectations regarding symptoms may be more salient than anticipated
consequences at this point (Irvine & Logan, 1994).
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In addition to 'positive' results, uncertainty can also arise from 'abnormal' or
'inconclusive' results that request recall for a further test; this process and its uncertainty
could increase psychological morbidity (Lerman, Trock, Rimer, et ah, 1991). Comparing
women with negative results and two severity levels of abnormal results from a
mammogram, Lerman et al. (1991) found those with both levels of abnormal result
reported more worry about breast cancer than those with normal results. Overall the
negative psychological impact increased with level of suspicion of mammogram, and
this impact persisted after the women had had further tests ruling out cancer, suggesting
increased perception of personal risk (Lerman et al., 1991).
This highlights the issue of false positive results. Whilst attendance at breast screening
was not found to increase anxiety, Sutton and colleagues (Sutton, Saidi, Bickler, et al.,
1995) found that women who received positive results (later found to be false positives)
reported significantly more anxiety at the stage of receiving the results letter than those
with negative results. The authors also note how the false positives reported higher
anxiety at earlier stages in the process (being screened and awaiting results) and reported
more discomfort than the negatives. As anxiety was reported retrospectively, this
indicates that the experience of receiving a positive result coloured their memory of
earlier stages in the screening (Sutton et al., 1995). With no interference from
retrospective reporting, another study (Sandin, Chorot, Valiente, et al., 2002) comparing
women attending for a regular breast cancer screening with those recalled for further
screening, found women in the recalled group had higher levels of specific worry, fear
and thoughts about breast cancer. However, the negative impact was not found to persist
following notification of a negative result contrasting Lerman et al. (1991). Several
authors have advocated minimising uncertainty by reducing the time delay of awaiting
results and recall screening (Lerman et al., 1991; Wardle et al., 1995).
It is important to consider lay understandings of results. Regarding cancers, 'abnormal'
results which require further testing do not equate to diagnosis of cancer (as discussed
above many turn out to be false positives); misunderstanding of 'pre-cancer' and
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'premalignancy' has been discussed in the literature as a cause of distress (Wardle et al.,
1995; Wardle et al., 2003) highlighting the need for adequate explanations to
participants of these results (Duncan et al., 2001b). Regarding screening for
cardiovascular risk factors, the issue is slightly different in that most such risk factors are
along a scale with different cut off points above which indicate varying levels of
increased risk.
Positive results are not always accepted. Irvine and Logan (1994) found that over half
the men in their study who were told they had high cholesterol did not accept it. Denial
could have different consequences; it could be linked with positive affect and well-
being. However, in this study deniers had more negative attitudes towards health
behaviour change, so made less changes and improved their cholesterol less than those
who accepted the label (Irvine & Logan, 1994).
Negative (healthy) screening results can also have psychological impact. This can be
positive, for example providing reassurance of prior beliefs about personal health and
lack of risk, as demonstrated by Howson (1998) regarding negative cervical screening
results. Perceived risk and worry has been found to reduce post screening, for example
in a colorectal cancer screening programme (Wardle et al., 2003), in which transient
emotional benefits were also apparent. A positive effect demonstrated in a
cardiovascular risk screening programme was a significant change in behaviour by men
identified as high risk particularly regarding diet. Although promising, the authors
acknowledged that as changes were assessed only in the short term, they may not have
been maintained in the long term (Tymstra & Bieleman, 1987).
However, negative results can also have a more worrying impact through false
reassurance of healthiness. Tymstra and Bieleman (1987) described this as the
'certificate of health' effect; almost half of the participants who received 'healthy'
results (cardiovascular risk factors) agreed that the result was proof of no need to change
their lifestyle, despite the fact that these men engaged in the same amount of 'unhealthy'
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behaviour as the other respondents and engaged in less care about their diet. In another
cardiovascular screening and intervention programme, the intervention group's
perceptions of current health shifted in a positive direction after one year matching
objective measures of reduced cholesterol and weight, however their perceived ability to
reduce risk of future heart attacks decreased (Marteau, Kinmouth, Thompson, et al.,
1996). The authors suggest this may be from complacency with the level of objective
risk that participants had achieved, despite this reduction being modest, indicating that
the intervention had generated false reassurance.
As mentioned previously it is crucial to ensure participants' correct understanding of
screening results, in particular that 'normal' or 'negative' results are not understood as
very low risk as opposed to no risk whatsoever (Marteau, Senior & Sasieni, 2001).
Marteau et al. (2001) found that when manipulating presentation of cervical screening
results in a hypothetical situation, adding one accompanying sentence, "low risk of
having or developing cervical cancer in the next five years", resulted in a marked
increase in understanding of residual risk thus avoiding false reassurance. The
perception that screening has given a 'clean bill of health' has also been shown in those
who did not receive a 'healthy' result; in an annual screening assessment for elderly
people Mcintosh and Power (1993) found such misperceptions in large numbers of those
whose objective screening result placed them in the medium or high health risk groups.
To summarise, this part of the literature review has presented an overview of some of
the key research into attitudes towards screening. Literature focusing on influences on
uptake was outlined incorporating sociodemographic factors, knowledge, triggers, and
application of social cognition models. Whilst of some use predicting uptake, criticism
of these approaches included the amount of variance left unexplained. Literature
exploring lay meanings of screening was outlined, highlighting feelings of uncertainty
and risk associated with the experience of receiving an invite, attending the screening
and interpreting the results. Finally, literature concerning the psychological impact of
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screening was covered illustrating the effects of positive, uncertain and negative
screening results.
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Part III: Beliefs about medication
In this section I present an overview of literature which has investigated people's beliefs
about medication. I begin by highlighting an issue which provoked the majority of this
research, namely non-compliance to prescribed medication. I outline how psychological
research has applied and developed models to investigate beliefs related to compliance. I
then discuss implications of the terms 'compliance' and 'adherence', and criticism of the
dominance of this issue in research about attitudes to medication. Next, from the medical
sociology literature, some qualitative research is outlined which explores people's ideas
about medication and aspects of the doctor-patient interaction in the prescribing
situation. Finally I consider literature which places patients' ideas about medication
within the wider social context incorporating the notion of risk.
Medication and compliance
The focus of the majority of research investigating patients' attitudes towards
medication has been compliance, or rather «o«-compliance, to prescribed medication.
Non-compliance/adherence to medication has been estimated as up to 50% (Sackett &
Snow, 1979; Meichenbaum & Turk, 1987) added to which is the large amount of
prescriptions not redeemed which in one study was 14.5% (Beardon, McGilchrist,
McKendrick, et al., 1993). Non-adherence is more than simply not taking the
medication; it involves altering the dose, frequency and/or duration of the prescribed
regimen (Conrad, 1985). The potential adverse consequences of non-adherence are both
at the individual level, with obvious adverse effects to an individual's health and illness,
and at the population level, for example treatment resistant variants of viruses and
infections (for example HIV) developing rapidly from under or irregular dosage
(Kalichman, Ramachandran & Catz, 1999), along with monetary costs to society from
prescription wastage and hospital readmissions (Kent & Yellowlees, 1994).
Research, particularly in psychology, has investigated non-adherence with the aim of
tackling this huge challenge to health care (Home, Weinman & Hankins, 1999; Home,
1993); potential contributing factors investigated have been sociodemographics, illness
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type and medication type. Certain conditions and their required medication were
identified as less likely to be associated with adherence, for example asymptomatic
illnesses when treatment is preventive and lengthy/indefinite (Rand, 1993). Various
models have been applied to the area including social cognition models such as the TPB
(described in Part II) (Fishbein & Ajzen, 1980; Ajzen, 1985, 1991) and HBM
(Rosenstock, 1974; Becker et al., 1977). Particular components of these models have
been associated with adherence rates (see Home et al., 1999). Stage models such as the
precaution adoption process model have shown some use in this area (Weinstein, 1988).
The self regulation model (SRM) (Leventhal, Diefenbach & Leventhal, 1992), a hybrid
of the social cognition models and stage models (Brewer, Chapman, Brownlee, et al.,
2002), proposes that individuals' illness cognitions comprise of five attributes which the
SRM questionnaire items measure: First, the 'identity or symptoms' assess individuals'
labelling and somatic experience. Second, 'consequences' assesses their expectations of
the illness and the risks it may pose for other/further complications/events. Third,
'timeline' assesses the likely duration and course of the illness. The fourth assesses
perceptions of 'cause', and the final attribute assessed is 'controllability and cure'
(Leventhal, et al., 1992; Brewer et al., 2002). The SRM can conceptualise non-
adherence as a coping mechanism for dealing with the illness threat (Leventhal, Meyer
& Nerenz, 1980; Leventhal, Benyamini, Brownlee, et al., 1997), this decision being
guided by beliefs about the five illness attributes above (Home et al., 1999). The SRM
has shown some use in predicting adherence in hypertensive patients (Meyer, Leventhal
& Gutmann, 1985), and asthmatics (Jessop & Rutter, 2003), and in explaining adherence
in patients with high cholesterol (Brewer et al., 2002). For example, the latter found that
those with a model of hypercholesterolaemia similar to an 'expert model' (in particular
in terms of the consequences, symptoms and timeline) demonstrated more adherence
and control of their cholesterol (Brewer et al., 2002). However that those with an expert¬
like model of their illness show better adherence implies that an expert, i.e. biomedical
model, of an illness is superior and that patients should be encouraged to hold the same
model. This belittles and does not acknowledge the patient's own beliefs, meanings and
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explanations about the illness and more importantly the medication. Furthermore in
these studies a large proportion of variance in adherence was still left unexplained.
A further criticism of the SRM is the focus on the patient's beliefs about illness, whilst
their beliefs about medication are perhaps more relevant (Home et al., 1999). Home et
al., (1999) found that whilst studies that have investigated patients' representations of
medicines indicated that certain representations seem to be common across different
illnesses, different questionnaires had been used making a systematic comparison of
findings a difficult task. This provoked the development of a model with the aim of
comparing beliefs about medication in general with beliefs about specific medicines,
investigating the distribution of these beliefs, and how the two sets of beliefs relate to
one another and to adherence behaviour: The Beliefs about Medicines Questionnaire
(BMQ) (Home et al., 1999). The development drew upon interviews with patients and
qualitative research (for example: Britten, 1994; Fallsberg, 1991; Lorish, Richards &
Brown, 1990; Morgan & Watkins, 1988; Conrad, 1985). The resulting BMQ comprises
of two scales: The 'BMQ-specific' assesses an individual's views on their prescribed
medicines; participants rate (on a 5-point scale) their agreement with statements about
dependency, adverse effects, and efficacy of their medication. The 'BMQ-general'
similarly requires participants to rate their agreement with statements about medications
in general such as doctors' overuse and trust in medication, addictiveness, harm and
safety (Home et al., 1999).
Home and Weinman (1999) used the BMQ to investigate adherence in four illness
groups (asthma, renal, cardiac and oncology patients). Medication beliefs were found to
be the strongest predictor of adherence (stronger than demographics and illness type).
Whilst the majority of patients believed their medication was necessary for maintaining
their health, a third had strong concerns about the potential adverse side effects,
furthermore stronger concerns were associated with lower reported adherence (Home &
Weinman, 1999). The authors found that the necessity-concerns differential was more
strongly related to adherence than either construct alone. They propose that this implies
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a cost-benefit analysis of concerns versus necessity, and that this is a possible
mechanism by which beliefs about medication influence adherence behaviour. This
mechanism could be an explicit, deliberate strategy to minimise harm from medication,
or implicit, relating to perceived (un)importance of the medication resulting in forgetting
to medicate (Home & Weinman, 1999). Interesting distinctions between illness groups
were also found; the asthmatic and cardiac patients reported less adherence. The authors
suggest that whilst this could be simply linked with these patients' high concerns-
necessity differential, it could also be related to symptomatology and perceived
association between medication use and presence/absence of symptoms (Home &
Weinman, 1999). A further explanation could relate to perceived severity of the different
illnesses; as previously described heart disease tends to be much less feared than cancer.
Whilst the BMQ can provide an insight into lay beliefs of medication and is useful for
gaining an overview into the medication beliefs of different patient/illness groups on a
large scale and predicting adherence, a sizeable amount of variance in adherence
behaviour is left unexplained in many of the studies which have applied it. Sociological
qualitative research on patients' views about medication has shifted the focus away from
adherence, and whilst findings support constructs identified by BMQ research, this
research has extended our understanding of this area by considering the wider context in
which the individual makes decisions about medication. This will be discussed shortly,
however, at this point it seems appropriate to discuss criticisms expressed about several
aspects of compliance research.
Criticism of a focus on 'compliance'
Use of the term 'compliance' in this context has received much criticism as it implies
obedience to doctors' orders and paints a negative picture of patients who are not fully
committed to their prescribed routine as 'deviant' (Shumaker, Schron & Ochrene, 1990;
Mullen, 1997; Conrad, 1985). Simultaneous to the move away from the paternalistic
model of the doctor-patient relationship, this movement (advocated by the Royal
Pharmaceutical company's working party on medicine, 1997) rejects the term
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'compliance' and even 'adherence' in favour of 'concordance' or 'therapeutic alliance'
which imply more of a partnership in the relationship (Marinker, 1997; Mullen, 1997).
However, a change in terminology is useless without an accompanying change in
culture, in particular in the prescribing relationship (Marinker, 1997). To the
consultation, the doctor brings medical knowledge, and the patient brings their beliefs
about health, illness and medicine, both should be equally influential on the outcome
(Marinker, 1997). The barriers to achieving concordance are ample, the requirements of
such a cultural change involve re-training, public awareness, and of course longer
consultations (and thus increased funding and resources) (Marinker, 1997; Mullen,
1997). Research is already investigating and developing methods/models for creating
concordant decision making in prescribing relationships, such as Dowell and Hudson
(1997).
Conrad (1985) criticised research for locating the problem of non-compliance in the
doctor-patient interaction or the patient's knowledge and/or beliefs, instead advocating a
patient-centred approach where the "meanings for everyday life are more salient..[]..for
understanding why people alter their prescribed routines" (Conrad, 1985, pp.29). Conrad
(1985) argued that patients were active agents in their treatment rather than the passive
recipients expected by the medically centred perspective. The epileptic patients in
Conrad's study spoke about developing their own medication practice, often engaging in
a similar method of 'trial and error' which they regarded the doctor as doing, and testing
the medication. They regarded their behaviour as self-regulation rather than non¬
compliance for various reasons, summarised by Conrad as an attempt to assert control
over a condition which appears out of control (Conrad, 1985).
Patients' ideas about medication
Britten (1994) criticises the research literature for paying too much attention to
adherence and insufficient attention to patients' ideas about medication. In a qualitative
study of patients' ideas about medicines, Britten explored and explained non-adherence
within a wider context: First, patients' views of the properties of medicines were
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discussed including some positive beliefs, for example the acceptability of longstanding
medication, and many negative views of medicines such as their harm and
unnaturalness. She also identified more elaborate beliefs such as the doctor using
medication to treat the symptom not the cause. Second, patients' orientations to
medicine were identified; both positive and negative features were found including
preference to avoid medication until necessary and as a last resort, plus fears of shame
and labelling as 'ill'. Third, patients expressed views on appropriate use versus actual
use of medication. Patients who were more adherent tended to have positive
orientations, however, situational and contextual influences were important, sometimes
involving judgements about value and balancing of risks and benefits, or influenced by
the doctor-patient relationship. From her findings, Britten (1994) argued that doctors
should not assume that medicines are always the most acceptable treatment and that
assessing a patient's orientation to medication can help address concerns and deal with
adherence issues.
Britten's (1994) study was among the pieces of research which Home and colleagues
(1999) mention as informing the development of the BMQ. A more recent qualitative
study of hypertensive patients (Benson & Britten, 2002) revealed themes fitting with the
BMQ components: patients discussed both specific and general reservations about their
medication, and a large proportion mentioned balancing these reservations against their
positive perceptions about the medication. However, the study added further insights and
explanations behind their beliefs: patients discussed the role of their past, both previous
adverse experiences from medicines and the lasting family value of being brought up to
avoid drugs. The past experience with their doctor comprising trust had a positive effect
on some: other positive factors included achieving a positive outcome, making them feel
better and gaining 'peace of mind' from their medication. Despite general dislike of
medication, some was accepted due to absence of a practical alternative, or sometimes
regarded as minimal compared to more damaging drugs such as steroids (Benson &
Britten, 2002).
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A recent qualitative study addressed the issue of views specific to preventive medication
for asymptomatic risk (Lewis, Robinson & Wilkinson, 2003); a hypothetical drug was
presented to both patients and health professionals to explore the minimum benefit
people believed would justify daily drug treatment for preventing heart attacks. Similar
to the cost-benefit analysis discussed previously, many expressed their need for
information about side effects which they would weigh up against the benefits, and most
lay people expressed desire for shared decision making in the prescribing decision.
Perhaps not surprisingly, in discussing the concept of minimum absolute benefit
required to be met by the hypothetical drug over 10 years, doctors would accept a
smaller benefit (10% or less), nurses slightly higher and lay people's acceptable benefit
ranged from 10 to 99% (Lewis et al., 2003). This indicates the idealistic expectations of
medications that lay people seem to hold.
The prescribing relationship
Although one criticism of non-compliance research was locating the problem in the
doctor-patient interaction and communication, the role of the doctor and their discourse
in the consultation appears to be influential on the patient's subsequent medication
taking behaviour: Britten (1994) demonstrated how some patients took "whatever their
doctor prescribed" without questioning, perhaps due to their faith in the doctor. Benson
and Britten (2002)'s study emphasises the importance of the doctor's discourse on a
patient's weighing up of reservations and benefits of medication. Insufficient
communication in the doctor-patient interaction continues to be a problem; Britten and
colleagues (Britten, Stephenson, Barry, et al., 2000) studied consultations, interviewed
both parties and discovered many misunderstandings in prescribing decisions arising
from communication failure such as lack of exchange of relevant information (in both
directions), conflicting information from other sources, insufficient explanation and
factors about the relationship itself. A movement towards shared decision making would
be needed to tackle these problems; the authors discuss whose responsibility it should be
to improve communication. They argue that while both sides can change, the power
imbalance inherent in consultations leans towards placing the responsibility on the
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doctor to encourage patients to express their views and beliefs (Britten et al., 2000).
Dowell and Hudson (1997) developed a therapeutic decision model through qualitative
work with patients as a strategy for GPs to explore patients' beliefs within the
consultation. This had promising results; over half the patients seemed to improve their
management of their condition (Dowell, Jones, & Snadden, 2002). Despite various
limitations, the findings demonstrate the benefits of investing in time exploring patients'
beliefs.
Medication and risk
The qualitative research outlined so far has explored people's beliefs about medication
and extended our understanding of explanations behind beliefs about medication. In the
same way that beliefs about illness are formed through lay epidemiology, input from
personal experience of medication use, that of family and friends, advice from doctors
and pharmacists, media coverage, promotions from pharmaceutical companies, and
national policy/recommendations is incorporated into beliefs about medication.
The sociological literature places lay beliefs about medication within the area of risk.
Bissell and colleagues (Bissell, Ward & Noyce, 2001, pp. 6) point out how the focus of
risk research in sociology has been on 'high-level' risks and has "by-passed those more
mundane dimensions of health and health-related behaviours which perhaps more
concretely characterise lay people's engagement with science and scientific medicine".
These authors highlight interpretation of risk information as a key area in risk
perception; applying Beck's theory, considering the speed at which information about
risk promulgates and how reflexive the area is, the difficulty is in the establishment of
factual information which people can evaluate, and this results in multiple competing
sources of 'expert' information (Bissell et al., 2001; Beck, 1992).
In addition, sociological research has concentrated on the difference between the beliefs
of patients and health professionals about prescribed medication. Research has shown
how patients continually reassess their medication's efficacy (Donovan & Blake, 1992).
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The difference between lay and professional beliefs reflects a growing critique by an
increasingly assertive public, inquisitive of scientific medicine and its guidance
(Vaughan & Seifart 1992; Williams, Popay & Bissell, 1995). Bissell and colleagues
(2001) use Giddens' (1991) writings on public mistrust of expertise in late modernity to
explain the active nature of trust which must be won and constantly be renegotiated with
the lay public. 'Lay reskilling' (rejection or alteration of various technologies) has
emerged from both the mistrust and the acknowledged limitations of science (Bissell et
al., 2001).
Bissell et al. (2001) explored lay beliefs about non-prescription medicines using
qualitative methods, and had the unforeseen opportunity to do this before and after a
'scare' surrounding a non-prescriptive medication. Before the scare there was much
emphasis on benefits of medication in people's accounts and many did not consider
risks, assuming that a medicine's position in the pharmacy as a non-prescriptive
indicated its safety. These beliefs seem incompatible with risk society theories
suggesting that the taking of non-prescription medicine receives little reflexive thought.
After the scare, however, there was great awareness of the uncertainty of medical
knowledge, and concerns over future risks. The authors proposed, therefore, that
regarding lay beliefs of «o/z-prescriptive medicines, mistrust of expertise, reflexivity and
lay reskilling are not as pervasive as suggested in the theories of Giddens and Beck, but
are more occasional and emerge in response to specific health scares. A further finding
was that participants continued to buy and use the implicated medicine after the scare;
they acknowledged the risk and simultaneously displayed faith in medicine. Participants'
continued use was not about lack of understanding about the risks, rather it showed their
dependence on the medicine for therapeutic use (Bissell et al., 2001).
The dynamic nature of risk perception and related beliefs emphasise the importance of
qualitative, ideally longitudinal, methods in this area as these methods are able to
explore dynamic changes in ideas about risk over time (Bissell et al. 2001).
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In summary, this section has outlined literature investigating people's attitudes towards
medication. Whilst literature focusing on compliance has received criticism, it has
identified factors and beliefs that contribute towards patients' views about use of
prescribed medication, and has recommended investing more time exploring these
beliefs with patients in general practice consultations. Exploration through qualitative
research has expanded knowledge of patients' insights and explanations behind their
medication-related beliefs, and has demonstrated the relationship with people's
(dynamic) perceptions of risk. Less is known, however, about people's ideas and beliefs
about preventive medication, particularly related to asymptomatic conditions, although
literature has indicated that ideas about its necessity are likely to differ from medication
for ongoing and symptomatic conditions. Similarly, aspirin itself has received little
attention.
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Part IV: Research participation
The literature referred to in this section spans several disciplines: medicine and
epidemiology, medical ethics, social psychology, sociobiology and sociology. I begin by
outlining research into influences on (primarily medical) research participation including
demographics and perceived benefits and barriers. Focusing on the randomised control
trial (RCT) procedure I next present research into lay understanding of participation.
Research investigating the influence of the media and the medical community is
covered, including mention of the role change for clinicians involved in trials. The social
context and social influences on participation decisions are then considered. The second
half of this section was provoked by my fieldwork in which the expression of altruism
was salient and led me to explore a different area of literature. Drawing from key texts in
sociobiology, social psychology and sociology, I explore how 'altruistic' behaviour has
been examined and discussed in the context of behaviour relevant to research
participation.
Research participation 1
Influences on participation uptake
The literature covering public attitudes towards research participation has generally
focused on the public's interest (or not) in participating in clinical research and the
potential influences on an individual's decision to participate; it has been largely
quantitative such as questionnaire based studies of trial participants (Madsen, Holm,
Davidsen, et al., 2000), or hypothetical questions involving the general public (Purdy,
Finkelstein, Fletcher, et al., 2000) and those not typically invited to participate in trials
(Fouad, Partridge, Green, et al., 2000). In hypothetical situations, studies have reported
positive opinion towards participation, however the ability of hypothetical scenarios to
represent 'real' participation decisions can be questioned (Featherstone & Donovan,
2002). Much of the early research into attitudes towards participation can also be
questioned ethically, as the aim was often to increase accrual rates in trials (Ross, Grant,
Counsell, et al., 1999).
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Early research in this area highlights sociodemographic factors as an important influence
on clinical trial participation, particularly regarding barriers; certain barriers are more
pronounced for the more disadvantaged such as transport, and financial and time
constraints. In America, the situation is further complicated by the medical cost system;
the disadvantaged worry that their medical insurance may not cover research
participation, conversely this same group may participate as a means of obtaining free
health care and attention (Merz, 2000). Regarding ethnic minorities, mistrust ofmedical
research remains salient in the African-American community from unethical medical
practice such as the Tuskegee Syphilis Experiment (Fouad et ah, 2000; Skrabanek,
1990). Other barriers against participation reported include inconvenience, too much
time commitment required, and worries about side effects of treatment (Schwarz & Fox,
1995; Bevan, Chee, McGhee, et ah, 1993).
Regarding benefits, both overt and more subtle personal benefits are likely to be
influential (Madsen et ah, 2000). The question of offering incentives has received much
ethical debate as pharmaceutical company run research usually offers financial
incentives whereas NHS/Charity/University run trials are less likely to offer overt
incentives, particularly financial. In a survey of HMO members (US) over 40% reported
they would be more likely to participate in medical research if there was a financial
incentive, however, a working group (including members of the lay public) set up to
discuss participation issues reported that incentives should not be the driving force and
that they may be inappropriate (Fouad et ah, 2000). Regarding less overt benefits, time
and attention given to patients involved in RCTs can create a feeling of being medically
monitored and cared for which would not be received otherwise, even in the placebo
group (Madsen et ah, 2000). The mere presence of a health professional may suffice to
provide a form of placebo effect in itself (Elander & Hermeren, 1995); single physician
designs which provide doctor continuity can further increase satisfaction (Madsen et ah,
2000). For some, the 50% possibility of access to a new medication has been reported as
sufficient reason to participate, others regard participating as doing something active for
oneself and one's condition (Madsen et ah, 2000).
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Past experience of trials is likely to be important. Positive experiences are likely to
increase favourable opinion of future participation; such reported benefits include
increased knowledge about one's health problem, longer clinician contact, having one's
opinion valued, the feeling of being a 'hand picked' patient and the opportunity to meet
others with the same condition (Madsen et al., 2000; Purdy et al., 2000; Wynne, 1989).
Adverse trial experiences that could dissuade from future participation include lack of
feedback of results, uncomfortable or invasive procedures such as endoscopies or blood
samples, radiation, length of time involved in the trial, and finally non-disclosure
agreements about bad experiences in the trial (pharmaceutical company trials) (Madsen
et al., 2000; Fouad et al., 2000; Merz, 2000). Further, procedural aspects of the RCT can
cause discontent; in particular the randomisation of treatment arms (Madden, 1994).
Informed consent from participants is a legal requirement for all medical research
participation. Participant information must be clear and thorough covering the purpose
of the research, the procedures, drugs, duration, follow up involved, also the possible
outcomes and side effects. In addition, any randomisation and placebo involved should
be outlined and the purpose explained (Snowdon, Garcia & Elbourne, 1997). Medical
Research Ethics Committees must approve participant information. Information leaflets
and consent forms have been criticised for being cluttered with legal and medical jargon
(Wogalter, Howe, Sifuentes, et al., 1999). In the past, the majority of consent forms had
readability scores only slightly lower than medical journals (Morrow, 1980); revising
such forms to improve understanding of the subject matter and the actual message
increased perception of choice and better overall understanding in recipients (Bjorn,
Rossel & Holm, 1999). Other improvements include making forms more informal,
information more accessible, less time pressure, and oral presentation of the contents or
a follow up phone call to ensure understanding (Wogalter et al., 1999; Davis, Holcombe,
Berkel, et al., 1998; Edwards, Braunholtz, Lilford, et al., 1998). Particular effort should
be made to make information clear when research includes groups who may have more
difficulty understanding, for example older (75+) participants showed a worse grasp of
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the RCT procedure than younger participants in a comparison of two trials (Bjorn et ah,
1999). Information should not be limited to the recruitment and consent phase of a trial;
feedback and explanation of results is equally important (Purdy et ah, 2000).
Understanding the RCT procedure
In studies which examined perceptions of the RCT process, only a few respondents
explained their non-participation as due to the placebo and trial procedure (Schwarz &
Fox, 1995; Mohanna & Tunna, 1999); however people's understanding of RCTs is
likely to influence their attitude. Participants' understanding of the procedure and
purpose must be ensured. RCTs have widespread acceptance as the most efficient way to
enhance knowledge about medical treatment when a state of clinical (or collective)
equipoise exists i.e. when there is clinical uncertainty amongst doctors about the best
treatment in a given medical situation (Snowdon et al., 1997; Robinson, Kerr, Stevens,
et al., 2003). Participants are randomised to a treatment arm for both ethical and
scientific purposes (Robinson et al., 2003). Due to the state of equipoise, it is ethical to
only allocate treatment at random. Furthermore scientifically, selection bias is avoided
through random allocation thus maximising impartial results and increasing bona fide
knowledge (Schulz, Chalmers, Hayes, et al., 1995; Robinson et al., 2003). Double
blinding (neither participants, clinicians nor researchers know any participant's
treatment identity) further minimises selection bias.
The concept of blinding can be difficult to grasp, as people want to know what is being
done to them (Madsen et al., 2000; Purdy et al., 2000) and anxiety arising from such
uncertainty could alter a patient's prognosis (Baum, 1990). Patients whose health does
not improve may drop out of the trial in order to get better medication, altering the
reliability of the research (Elander & Hermeren, 1995) or may experience such
improvement or side effects that they correctly guess their medication, effectively
unblinding the study as far as the participant is concerned (De Deyn & D'Hooge, 1996).
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Participants' awareness and understanding of the randomisation concept and its purpose
has been the focus of a few recent studies. Much confusion regarding randomisation and
its aims was found in a study of parents of babies who had been entered into a neonatal
trial of treatments for respiratory failure (Snowdon et al., 1997), also in men invited to
participate in a benign prostate trial, who verbally acknowledged the confusion they felt
(Featherstone & Donovan, 2002). Misunderstandings arose from the word 'trial'
(relating to its use in other situations like trial period) and the method of treatment
allocation. Although analogies such as 'tossing a coin' or 'lottery' were common in the
babies' parents' accounts indicating comprehension, more detailed inquiry revealed very
different beliefs of how treatment was allocated, in particular therapeutic determination
depending on individual needs (Snowdon et al., 1997). Similarly, Appelbaum and
colleagues (Appelbaum, Roth & Lidz, 1982) found a third of psychiatric participant-
patients shared this misunderstanding, as did over half of Featherstone and Donovan's
(2002) participants, which Appelbaum et al. (1982) termed 'therapeutic misconception'.
Use of a computer in the allocation process was acknowledged but there was confusion
over the computer's role and on what basis it made decisions, rather than awareness of
its use as a randomisation tool. Men in the prostate trial, despite showing fairly good
understanding and recall of the trial design (in particular randomisation), struggled to
make sense of the concept and accept it (Featherstone & Donovan, 2002). Participants in
both this and the parents' study engaged in several approaches of trying to make sense of
the randomisation, such as becoming distrustful of the trial, or conversely becoming
trusting of the doctors or turning to fate or destiny. In both, randomisation was
sometimes attributed to ideas about rationing of treatment due to lack of available
clinical resources, or as an ethical resolution to remove responsibility from someone
making a decision (Snowdon et al., 1997). Parents rationalised the concept, for example
in hindsight reporting that randomisation had led to them avoiding risks from the
experimental treatment or by minimising chance (by discussing the influence of higher
powers or God) (Snowdon et al., 1997). The majority expressed a strong preference for
the experimental treatment and expressed few concerns about its potential risks
(awareness of its use overseas further added to this). This led to the belief that
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randomisation was unfair and to expressions of moral overtones about being owed the
experimental treatment (Snowdon et al., 1997).
As demonstrated, despite sometimes actively trying to make sense of the purpose of
randomisation, participants' explanations do not show accurate understanding of clinical
equipoise (Robinson et al., 2003; Featherstone & Donovan 1998, 2002). MRECs now
have guidelines for producing trial participant information containing a descriptive
statement explaining clinical equipoise and random allocation (Robinson et al., 2003).
However Appelbaum et al (1982; Appelbaum, Roth, Lidz et al., 1986) argue that
explanations of equipoise may make little difference due to the prevailing lay
assumption that a doctor will always act in the patient's best interest. Considering these
findings, Robinson et al. (2003) explored public understanding and assumptions relating
to random allocation and clinical equipoise in RCTs through a series of studies using
hypothetical scenarios and highlighted three main sources of misunderstanding: First,
many participants could not accept that an individual doctor, or doctors collectively,
could be totally unsure about which of two treatments is best. Second, the idea of a
doctor suggesting treatment allocation at random was considered unacceptable, and
third, participants did not regard random allocation as producing more knowledge than
allocation by choice or matching (Robinson et al., 2003). The findings indicate that
descriptive information about equipoise and random allocation can be difficult to make
sense of (Robinson et al., 2003), supporting earlier findings. However, the need for
accurate comprehension of equipoise, randomisation and change from standard doctor-
patient roles is crucial for informed consent (Appelbaum et al., 1982; Featherstone &
Donovan, 2002; BMJ Editorial, 1995), and could reduce anxiety caused by confusion
(Snowdon et al., 1997).
Social influence and social context
Participation is influenced by 'others' at different levels. The media is in a powerful
position. While it is without question that coverage of severe unethical conduct in
research should make headline news, and the media is quick to highlight this (for
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example concern over payments to doctors or institutions for enrolling patients), it is
rare to see equally high profile coverage of good ethical practice (Madsen et ah, 2000;
Fouad et al., 2000; Merz, 2000). Another less personal influence by a third party is the
role ofMedical Research Ethic Committees whose approval must be sought for running
any medical trial. Linked with this is the importance of perceived safety of a trial,
endorsement by an authority including MRECs and LRECs (local) or even the church
has been found to increase participants' perceptions of safety (Madsen et al., 2000;
Purdy et al., 2000; Fouad et al., 2000). Distrust of medicine or hospitals are reported
reasons for non-participation (Schwarz & Fox, 1995; Bevan et al., 1993).
On a more personal level, health care professionals are often the gatekeepers for access
to potential research populations. Approval by a known or trusted GP can contribute to
perceived safety (Fouad, et al., 2000; Daugherty, Ratain, Grochowski, et al., 1995).
Referrals depend on appreciation of the need for the particular trial, time to counsel
patients, information, and adequate assessment of a potential participant's preferences
regarding participation (Fouad et al., 2000; Featherstone & Donovan, 2002). In addition,
there is conflict between the role of clinician and of scientist, and between the goals of
therapy and of research (Elander & Hermeren, 1995; De Deyn & D'Hooge, 1996;
Groudine & Lumb, 1997). A doctor's Hippocratic obligation to apply all existing
knowledge to providing patients with the best possible treatment may be contested by
scientific obligation to acquire new knowledge to benefit future patients (De Deyn &
D'Elooge, 1997; Hellman & Flellman, 1991). By referring a patient to an RCT, a doctor
cannot guarantee the patient will receive the best treatment (Groudine & Lumb, 1997).
The role change from providing individualised care to the role of researcher can lead to
poor compliance or non participation from the doctor (Snowdon et al., 2003). However,
RCTs are the only method of reducing the number of ineffective drugs (De Deyn &
D'Hooge, 1996).
The context of consenting to participate must be considered. The illness or condition that
the trial is concerned with will alter the situational context in which the decision to
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participate is made; trials for life threatening conditions are likely to add anxiety and
urgency to the participation decision. For example in the trial studied by Snowdon et al
(2003), parents of babies with high risk of death were forced to make a quick decision
when under great anxiety and without the time to consider all the information, which
included novel concepts such as randomisation.
Considering the social context, the hospital setting itself is likely to be influential. Grisso
(1996) applied Goffman's (1961) concept of the 'total institution' to institutional
members (for example hospital residents, students, prisoners) and officials (doctors,
professors, prison officers) when considering research participation in such settings. The
officials maintain superiority and members become socialised, losing their personal
identity, altering expectations and decisions about life and social interaction (Grisso,
1996). Grisso (1996) questioned the likelihood of an institutionally socialised member
dropping member identity and thinking autonomously when asked by an official to
participate in something even if presented as something entirely voluntary.
The social psychology literature can help explain reasons for consenting to participate
by considering the huge body of research into social influence, 'norms', and conformity.
Whilst too large an area to discuss in detail here, a few key research findings can be
considered. Asch (1951, 1952, 1956) demonstrated the ease with which people
conformed on unambiguous tasks to the incorrect answers of a majority (stooges who
were pretending to be fellow participants) whereas on the identical task in isolation,
conformity was almost entirely removed. Criticism of the lack of perceived
consequences in Asch's studies was one factor leading to Milgram's infamous obedience
experiments in which the presence of an authority figure induced 65% participants to
administer what they believed to be electric shocks (increasing in severity) to their
supposed fellow participant (a stooge) upon every incorrect answer in a staged learning
experiment, despite cries of pain and eventual silence. This demonstrated the high rate of
obedience to an authority (Milgram, 1963, 1974; Hogg & Vaughan, 1995). Further
social influences found to increase compliance that could be applied to participation
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include reciprocity and guilt. The 'reciprocity principle' proposes that if we do others a
favour they will feel obliged to reciprocate (Isen and Levin 1972). Guilt arousal has also
been shown to increase compliance (for example Carlsmith & Gross 1969).
Combining the social context and social influences summarised in the previous few
paragraphs, if a member (socialised into member status) witnesses fellow members
consent to the request of a researcher (fitting the role of an official), and considering the
ease with which people have been shown to conform and obey, compliance to
researchers' requests is likely to be high (Grisso, 1996). Requests for participation are
not uncommon in 'institutions' such as medical settings. In such settings there exists
what Grisso terms a "normative power residual: a shared expectancy about generalised
power arrangements and modes of influence in interactions between officials and
members of the institution" (Grisso, 1996). Despite moves towards a more consumer-
oriented health care service, patients may still tend to assume a fairly passive role within
the institutional context, where decision-making may not be truly individual.
Research Participation 2
Altruism
In the first half of this section I have outlined research into influences on participation,
moving towards considering the situational and social context within which individuals
make such decisions. The second half focuses on a different social influence: altruism.
Altruism was mentioned in the quantitative studies (Madsen et al., 2000; Purdy et ah,
2000; Fouad et ah, 2000) but in no great detail. The salience of expressions of altruism
in my participants provoked me to consult further literature (not considered at the outset
of the current research) on altruism in social psychology and sociology.
Altruism is defined in the Oxford dictionary as: "selfless concern for the wellbeing of
others" and as applied to zoology, "behaviour of an animal that benefits another at its
own expense." Rapport and Maggs (2002) stress the difficulty in finding a clear single
definition for altruism, as definitions range from completely unconditional giving to
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more mutually beneficial acts. Reciprocal altruism is considered the form of altruism
most appropriate to human behaviour (Trivers, 1971; Rapport & Maggs, 2002).
Dawkins' influential book "The selfish gene" proposes that we will only engage in
behaviours which benefit our genes. Thus altruistic behaviour will only occur if we
recognise something of ourselves (familiarity or similarity) in the recipient of the pro-
social behaviour, thus benefiting genes of ours also present in the recipient (Rapport &
Maggs, 2002). Badcock (1986) refers to this as 'kin altruism'. Pro-social behaviour for
an altruistic motive with no benefit to the actor or to their genes, and to the actor's
expense, is termed 'induced altruism' by Badcock (1986). This does not occur in the
animal kingdom as it goes against natural selection (Rapport & Maggs, 2002). Such self
sacrifice seems idiosyncratic to humankind.
Bierhoff (2002) argues that altruism can be defined depending on the ultimate goal of
the behaviour; true altruism is when the ultimate goal is reduction of suffering in another
individual, alongside which any benefits to oneself are merely unintended consequences.
There is ongoing debate, however, over the existence of true selflessness. Sociobiology
and social psychology share the belief that people are basically egoistic (Bierhoff, 2002).
Some even argue that selfless acts are actually disguised forms of self seeking behaviour
(Hobbes, 1968 cited in Page, 1996), thus questioning whether the ultimate goal of pro-
social behaviour is ever truly altruistic. However, Haddow (2002) argues that such
discussions lack distinction between selfishness and self-interest:
"worthy of note, is that individuals can often pursue their own self-interest,
without necessarily being selfish. Individuals who are selfish, by contrast, will
necessarily be pursuing their own self-interest, often to the detriment of others."
(Haddow, 2002, ch. 4, pp. 6).
Social psychologists have attempted to break down apparently altruistic behaviour into
different motivating pathways. Bierhoff (2002) describes pathways which Batson (1991)
proposed lead to pro-social behaviour, demonstrating how benefits are derived from
seemingly altruistic behaviour. First, egoistic motivation involves self-reward, for
example self-congratulation for one's responsible behaviour. Second, motivation to
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attain negative state relief; engaging in the behaviour elevates one's mood or reduces
personal distress from the situation. Third, motivation to avoid negative consequences
such as personal feelings of guilt or social rejection, i.e. the behaviour increases either
one's own positive self-evaluation or that of others. Finally, perspective taking and
empathy can motivate the behaviour, which could be argued as the closest to 'real'
altruism. These different motivating factors are not exclusive, they could exert an
influence both individually or through combination with each other (Bierhoff, 2002).
Individuals can also have mixed motives, altruistic and non-altruistic (Fladdow, 2002).
Explanations for pro-social behaviour in social psychology led to the development of the
empathy-altruism hypothesis which, along with alternative hypotheses, has been tested
by instructing participants to consider hypothetical situations and manipulating factors
hypothesised to influence pro-social behaviour. The empathy-altruism hypothesis states
that perspective taking (through attachment to the other (kinship, friendship, or
romantic); similarity to the other, familiarity with the situation, or feeling sorry for the
other) leads to empathic concern which in turn motivates altruistic behaviour (Bierhoff,
2002; Rapport & Maggs, 2002). Various challenges to the hypothesis have further
developed it, for example the proposal that perspective taking alone is insufficient and
rather that empathic emotion is the crucial factor which remains stronger than others
such as personal distress (Bierhoff, 2002). Cialdini and colleagues (Cialdini, Brown,
Lewis, et al., 1997) challenged the existence of empathy instead arguing for 'felt
oneness' (a non altruistic motivating factor) whereby a high level of identification with
the recipient is suggested to blur the distinction between self and other, and thus also
between selfishness and selflessness, leading to felt oneness and consequently pro-social
behaviour. Thus the empathy which leads to altruism actually results from self-other
merging (Cialdini et al., 1997), demonstrating accordance with the selfish gene theory
(Bierhoff, 2002). Bierhoff (2002) combines Batson's empathy-altruism hypothesis,
Cialdini et al.'s 'felt oneness' and Hoffman (2000)'s developmental theory of empathic
distress and empathy, concluding that:
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"whether focusing on self or victim, the actor's emotional responses are part of a
biologically pre-wired behavioural system which unfolds from an
undifferentiatied egocentrism into a dichotomy of personal distress and empathic
concern" (Bierhoff, 2002, pp.213)
Once developed, the ultimate goal of the behaviour will reveal whether the motivation is
altruistic or egoistic (Bierhoff, 2002).
The above theories from social psychology are useful in considering the pathways to
'altruistic' behaviour and whether that behaviour is 'truly' altruistic. Other work has
applied the concept of altruism and explored it within the context of 'real' situations.
Titmuss's influential book, 'The gift relationship', in 1970, explored altruism within the
context of blood donation and the wider health and welfare systems. His main
contention was that the UK blood donation system ran entirely on altruism through the
donation of blood by unpaid volunteers and was a safer and more efficient system, in
addition to being more moral, than the privatised market system in the US. He also
argued that a move from a voluntary system would change the nature of society. His
work was an important argument against economists at the time, who were advocating a
change to a market system. It is also thought that his work provoked a change to a
voluntary system in the US (Oakley & Ashton, 1997).
Titmuss described donors by dividing them into (8) types according to the motivation
attributed to them; as these descriptions were of the US system the typologies related to
how money affected people's motivations. For example, those for whom cash is the
main motivation, those with more reciprocal motivations such as 'paying back' for blood
received in the past, or those who saw it as a 'pre-deposit' to insure future needs of self
or family members (Titmuss, 1970). He described all donors in the British system under
'voluntary community donor':
"This type is the closest approximation in social reality to the abstract concept of
a 'free human gift'. The primary characteristics of such donations are: the
absence of tangible immediate rewards in monetary or non-monetary forms; the
absence of penalties, financial or otherwise; and the knowledge among donors
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that their donations are for unnamed strangers without distinction of age, sex,
medical condition, income, class, religion or ethnic group." (Titmuss, 1970)
As part of a survey ofUK donors, Titmuss included an open question of why donors had
first decided to donate and categorised the responses. The largest group of responses
(26.4%) he classified as altruistic, comprising those who reported a general desire to
help and those who were more specific about particular groups in society. The second
and third largest reported reasons were responding to an appeal either general (18%) or a
personal appeal from someone known to the individual (13.2%). Reciprocity for blood
received personally or by known others (either already received or contemplating future
need) made up 9.8% of responses. Titmuss (1970) himself acknowledged
methodological problems of the survey and stated that caution should be taken regarding
the findings and whether they can be interpreted as showing individuals' true
motivations. However, he argued that the three most common motives provide support
and context to his proposition of blood donation fitting a gift relationship (Titmuss,
1970; Oakley & Ashton, 1997).
Titmuss used Mauss' (1954) writings on gift exchange theory to inform these ideas.
Mauss' gift exchange theory derived from studying indigenous cultures as an example of
pre-capitalist society. The political economy paradigm in social science proposed that
gift-giving in pre-capitalist societies was the pervading economic transaction, whereas
capitalism replaced this moral exchange system with one of market-exchange, whereby
transactions became monetary based and temporary between unknown individuals and
incurred no lasting debt (Polanyi, 1957). Mauss (1954) wrote how the exchange system
that existed in pre-capitalist societies ran according to gift-giving: the gift was crucial for
creating and enhancing solidarity in society, the transactions were more than simply
economic exchanges and rather than being voluntary they were part of a tripartite system
of obligations: to give, to receive and to reciprocate. Unlike in market exchange where
parties leave the transaction with no debt, the gift exchange system formed and
conserved social bonds (Mauss, 1954).
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Titmuss (1970) applied the analogy regarding the UK blood donation system as a gift
exchange system, but departed from Mauss in that there are no obligations to give or
receive with the gift of blood, rather voluntariness and altruism are considered the
driving forces of the system, with no reciprocal expectations. Some critics focus on this
absence of obligation and reciprocity which are central components of gift exchange
theory (for example, Leach, 1971; Frow, 1996, cited in Tutton, 2002). Can gift-giving
ever be unreciprocated and engaged in solely for an 'other'? (Haddow, 2002). Frow
(1996, cited in Tutton, 2002) argued that 'gifts are precisely not objects at all, but
transactions and social relations'. Gifts without expectation of reciprocity, i.e. through
altruism, invalidate gift exchange theory and require an alternative explanation, and
proving that no reciprocation is expected is itself difficult (Haddow, 2002).
Tutton (2002) discusses the work of Titmuss and Mauss relating it to blood donation in a
different context (genetic research). He argues that while it is the same substance,
donated through the same scientific procedure, the donated blood's use and purpose
incurs different motivations. He argues that gift exchange applied to blood donation in
this context is more complex and the outcome less transparent to the donor; the gift
changes from the blood as a substance for therapeutic purposes to the genetic
information which can be extracted from it (Tutton, 2002). Gift exchange theory fits
well as Tutton found more expectations of reciprocity; participants were keen to learn
more about their own genetic ancestry as well as contributing to furthering knowledge of
the society's genetic ancestry as a whole.
Haddow (2002) questioned whether gift exchange theory could be applied to another
donation system: organ donation. Similar to blood donation, the UK organ donation
system runs according to voluntariness and anonymity with no reciprocal expectations
(Haddow, 2002). Haddow (2002) argues that the assumption by many that families
donate through altruism does not account for the variety of forms and reasons different
individuals in society have for giving. As discussed earlier, social psychologists have
attempted to explain motivations behind pro-social behaviour, this is generally carried
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out through engaging participants in hypothetical scenarios or through behavioural
observation. However, individuals' accounts of their reasons for their behaviour should
not be rejected. Haddow (2002) criticises those who deem these untrustworthy, instead
emphasising the importance of listening to individuals' own interpretations of the
underlying reasons for their actions.
The second half of this section has drawn from key texts in different disciplines which
have explored and attempted to explain the concept of altruism and how it has been
studied in the context of behaviours relevant to research participation. Titmuss saw the
need to ask donors themselves their reasons for donating, and Haddow presents a strong
argument for listening to the accounts of donors themselves. It is questionable whether
we can establish individuals' true motivations (or even whether such motivations exist)
or the ultimate goals of their behaviour from their accounts, and therefore whether we
can find evidence for 'true' altruism. However, individuals' presentations of their own
interpretations of their behaviour will provide useful insights, in the case of this study, in
relation to research participation. As discussed in the first half of this section, there have
been relatively few qualitative studies with research participants, or with participants
who have declined to participate. There is a clear need for listening to and interpreting
the accounts of such individuals.
Part IV of the literature review has outlined many potential influences on research
participation ranging from aspects and understandings of the trial procedure, to social
and contextual influences and altruism. One could however question the ethics of
research that attempts to understand lay reasons for and against participation. Whilst
such research is useful and important, particularly as some advocate lay involvement in
implementation of trials (Hanley, Truesdale, King, et al., 2001), the question remains of
whether the findings could be used to exploit the public, and manipulate them into
participating. By discussing their reasons for and against participating in research,
people believe that their opinion is being sought and valued, and even as researchers we
hope that the study will help trials to be more sensitive to participants' needs. However,
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once published, the findings could potentially be used by any researcher, with the
explicit aim of increasing participation rates. It is hoped that this is not the case, rather
that the findings will be useful in developing more ethical practice relating to informed
consent and provision of information.
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Part V: Risk
In all four preceding sections of the literature review there has been reference to risk
perception, for example in discussing perceptions of cardiovascular risk, influences on
screening uptake and attitudes towards medication. The literature on risk is immense and
multidisciplinary (Gabe, 1995). In this final section I outline some of the literature,
mainly from psychology and sociology, which I consider most relevant to risk in the
context of preventive health. I begin by focussing on control, considering the distinction
made in the literature between externally and internally imposed risks, and how these
and associated issues (such as risk management, responsibility and blame) relate to risk
perception. Next, the discussion focuses on research into the process of risk perception
including optimistic bias and the weighing up of costs and benefits. Finally, I refer back
to the research that explores lay meanings of cardiovascular risk covered in Part I.
Control
The notion of risk has become the subject of much attention, theorising and research due
to the increased awareness of risk in modern society, in particular arising from
knowledge about risks from technology and from lifestyle (Lupton, 1993). These two
sources of risk are often discussed and distinguished in terms of the extent of control the
individual has relative to the source; the former being controlled externally (for example
environmental hazards beyond the individual's control) and the latter internally (for
example 'risky' behaviour such as smoking). Both sources of risk have implications for
the individual's health and illness, however perception of the respective risk is proposed
to differ relating to perceived control (Pidgeon, 2001). In the public health arena,
Frankel et al. (1991) demonstrated this distinction using the example of two differing
risk scares from egg consumption: salmonella and cholesterol; the former, associated
with fairly instant serious illness from one egg (beyond the individual's control), was
perceived as more risky than the latter for which consumption over a number of years
increases one's risk of a chronic disease (individual's choice and control regarding the
quantity consumed). Controllability is related to the voluntariness associated with the
risk source; we willingly take risks such as engaging in dangerous sports, even though
60
such activities may be a thousand times more risky than involuntary risks which we find
less acceptable (Starr, 1969; Denscombe, 1993).
Externally imposed risks
Linked with control is the issue of risk management for which we rely upon the
government and experts. Before managing a risk, the level of risk is assessed with the
aim ofmeasuring it (quantitatively). This enables comparison with the risk of harm from
different sources in order to allow rational decision-making regarding management of
the source (Gabe, 1995). Inherent in this approach is the assumption that all risks can be
measured, and there is an optimism about risk management (Gabe, 1995.). Slovic (2000)
argues that our perception and acceptance of externally imposed risks is associated with
our perception of the efficacy of their management, for example we perceive dangerous
animals in zoos to be managed more effectively than technological risks. In addition,
within technological risks, chemicals and radioactivity are potential risk sources in both
industrial and medical situations, but people tend to accept prescribed medicines and X-
rays attributing them with much benefit and low risk, whereas pesticides and nuclear
power were less accepted and considered much lower benefit and higher risk (Slovic,
1992; Gabe 1995). Slovic (2000) explains this distinction by emphasising the
importance of the risk management agency; people tend to have more trust in medical
risk managers (GPs) than in technological risk managers (government). Gabe (1993)
describes how the deterioration of trust in expert authorities has provoked much
sociological writing. The dominance of authority regarding interpretation of risks has
now been replaced and is undermined by an increasingly critical public (Giddens, 1991);
Gabe (1993) relates this change to Beck's (1992) concept of a risk society and notes
that:
"Social and economic processes have created global, nuclear, chemical, genetic
and ecological hazards for which there is no satisfactory aftercare. These
structural features reinforce the need for trust in expert authority at the very time
that increasing reflexivity and a growing recognition in the indeterminate status
of knowledge about risk work to undermine it." (Gabe, 1993, pp.11)
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The general public depend on the government and experts not only for risk management
but also for information about risks, as the public itself does not have the expertise to do
the job (Lupton, 1993). External environmental and technological hazards, and the
associated lack of personal control, often elicit anger in the lay public and mistrust
towards authorities (Lupton, 1993; Gabe, 1995). The government's response to this
'crisis in confidence' has led to the birth of risk communication, which aims to find
ways of bringing the public and the experts into alignment (Kasperson, Jhavari &
Kasperson, 2001; Gabe, 1995).
But, whilst we rely on experts, campaigners and the media for risk information, Lupton
(1993) points out that such mediators have their own agenda and may distort facts in
order to influence opinion. Psychological research produced the 'social amplification'
process model of the information flow in risk communication; it highlighted the news
media's controlling role in dramatising and framing the source of risk by selecting
'facts', altering the language used, and by interpreting the social meaning of the risk
(Kasperson et al., 2001). Less trust in the risk managers is proposed to increase social
amplification (Kasperson et al., 2001); whilst trust is easily destroyed, its creation and
rebuilding is a long difficult process (Slovic, 2000). Slovic (2000) thus argues that risk
communication has not yet succeeded in its aims.
Internal/self control
Regarding risks under our own control, there has been increasing emphasis over the past
few decades on the role our lifestyle plays in increasing our risk of various diseases.
Risk factors are identified and their relative risks calculated by epidemiology. This
informs the government who may then instigate or encourage health promotion
campaigns to warn the public of the risks with the aim of motivating them to change
their behaviour (Lupton, 1993; Gabe, 1995). In the context of heart disease, campaigns
have advised us to reduce behaviours that increase cardiovascular risk: smoking, a diet
high in fat and salt and a sedentary lifestyle. The assumption that knowledge and
awareness about the risks associated with such activities will lead to behaviour change
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has received much criticism (for example Lupton, 1993; Gabe, 1995). Criticisms include
failure to take into account the impact of people's social circumstances, also the
assumption of rationality in people's behaviour (Lupton, 1993). However, some
programmes promote behavioural change through specific inetrventions, rather that just
providing knowledge about risk. In addition, Lupton (1993) questions whether public
communication of risk is always desirable and in the public's best interest and whether
the ethical implications of such communication are considered thoroughly. Whilst
accepting the valuable aims of government health promotion campaigns, i.e. promoting
and improving the population's health, Lupton (1993) also challenges the risk discourse
in such campaigns for being paternalistic and removing the individual's autonomy; she
criticises the emphasis on danger rather than safety. She asks whether individuals should
have the right not to be continually bombarded with reminders of risk and vulnerability
(Lupton, 1993).
Lupton (1993) explains how individual responsibility is invoked at two levels: for the
individual's personal health; and for 'the good of society', as those whose behavioural
choices increase their risk of illness or disease cost rather than contribute towards
society. In addition to acting on information about risks relating to lifestyle, individuals
are encouraged to assess their level of risk for major diseases through health risk
appraisals such as screenings. A problem of such appraisals is the application of
epidemiological data (of population averages) to estimates of individual risk (Lupton,
1993); as mentioned in Part I when discussing beliefs about heart disease, people can
regard these estimates as definite and incongruence with reality may lead to uncertainty
and anxiety (Wiles, 1998; Davison et al, 1991).
Associated with control and trust is the issue of blame. Slovic (2000) notes how experts
blame the public for 'risky' lifestyle choices, while the public blames the authorities for
technological and environmental risks. A risk's categorisation as internal or external will
influence moral judgements about blame and responsibility (Lupton, 1993), fitting with
the earlier noted association between voluntariness and acceptability. Blame then leads
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to a further distinction within externally imposed risks; man-made risks (for example
from technological sources) are less accepted than natural risks such as volcanoes and
floods as for the latter, there is no-one to blame (Denscombe, 1993), as supported by
insurance policies which categorise such events as 'acts ofGod'.
Lay risk perception
Pidgeon (2001, pp. 231) advocates that:
"to understand understandings of risk, we need to go beyond simple one-way
efforts to improve public understanding of science. Scientists need to understand
the public as much as the public needs to understand science".
As mentioned earlier, risk assessment by experts is through rational and quantitative
methods; much psychological research into lay perception of risk assumes rational
cognitive processing in the individual too (Lupton, 1993). Denscombe (1993) describes
research investigating how people perceive risk i.e. what methods they use to interpret
risk information. For example, 'heuristics' are discussed as facilitators of the process:
this model proposes that rather than considering new risk information in depth each time
it is received, novel information is interpreted by comparison with knowledge about
more familiar risks (Kahneman & Tversky, 1982; Denscombe, 1993). Factors proposed
as particularly important in this process are as follows (Denscombe, 1993): the 'dread
factor' or severity of harm anticipated from the incident or behaviour; the vividness of
the risk, i.e. the ease with which it can be imagined, influenced by experience and
knowledge of the risk; the frequency of risk, whereby increased exposure to the risk
source reduces the expectation of resulting harm; the tendency to ignore risks with
particularly low probability, and a sense of invulnerability (Denscombe, 1993).
The final key aspect outlined above is more commonly referred to as optimistic bias or
unrealistic optimism and has been the focus of much attention. When evaluating,
consciously or unconsciously, our level of perceived risk of experiencing a negative
event, there is a tendency to believe that our chances are less than average (and higher
than average when perceiving our risk of experiencing a positive event). Whilst on an
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individual level this could plausibly be an accurate perception, if a group of people
collectively perceive this, systematic error is occurring and this is what is known as
unrealistic optimism (Weinstein, 1980; 1982). Applied to health, participants rated their
personal perceived risk of experiencing 75% of problems listed (including heart attacks,
cancer, addictions etc.) as lower than how they rated the risk in their peers (Weinstein,
1982; 1987).
Fitting with the influence of control as discussed earlier, factors reported as contributing
to optimistic bias were related to perceived self control over the event (personal actions
and psychological attributes), whereas external factors (hereditary and environmental)
were not associated with such unrealistic optimism (Weinstein, 1984). Characteristics
reported as affecting the level of bias included: the belief that if the problem has not yet
appeared, there will be exemption from future risk; that individual action could prevent
the problem; that the hazard is perceived as infrequent and that lack of experience with
the hazard (Weinstein, 1987). It is interesting to note the overlap between the influences
on optimistic bias and the key aspects of heuristics outlined previously, and that whilst
presented as distinct factors in the heuristics, optimistic bias research regards them as
interlinked.
Optimistic bias is associated with perceived self control over a negative event, therefore
increases self efficacy, i.e. the perceived ability to change behaviour. Such bias should
logically strengthen intentions to act, however, most positive illusions about risk instead
tend to weaken these intentions (Taylor & Gollwitzer, 1995) and precautionary
behaviour is inhibited by the reluctance to acknowledge personal vulnerability
(Weinstein & Lyon, 1999). Optimistic bias thus tends to be regarded as maladaptive
regarding health consequences (Weinstein, 1989), but it can also lead to beneficial
effects; optimism has been associated with less depression (Alloy & Ahrens, 1987) and
positive well being (McKenna, 1993). Potential health benefits from optimistic bias
however, will depend on the nature of the source of risk; whereas optimism may help
heart disease patients maintain health enhancing behaviours and improve their quality of
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life, optimism which leads to rejection of the risks of drug abuse could be fatal
(Weinstein, 1989; McKenna, 1993). Regarding some illnesses, people may actually
overestimate their risks; when estimating their absolute risk of breast and prostate
cancer, people overestimated personal risk, however, they still regarded their personal
risk as lower than that of other people so comparatively were still showing optimistic
bias (Clarke, Lovegrove, Williams, et al., 2000).
Research has indicated the functioning of a personalised cost-benefit analysis system
through which people's attitudes towards risk are formulated (Kahneman & Tversky,
1982; Denscombe, 1993). This is linked to tolerance of risks; risks are accepted if the
benefit is considered worthwhile. Such analysis is proposed to extend beyond the
individual level, to consideration of whether both the costs are shared equally by those
who benefit (Slovic, Fischoff& Lichenstein, 1980; Denscombe, 1993). Risky behaviour
has been explained in terms of the anticipated rewards gained from the behaviour
(Heimer, 1988). However, the benefit has also been argued as arising from the act of
risk taking itself which serves to fulfil inner psychological needs, thus suggesting
experience of benefits regardless of the anticipated consequences of the behaviour
(Denscombe, 1993).
The theories of risk perception outlined including optimistic bias and weighing up of
costs and benefits are useful in demonstrating important influences. However, the
assumption of rational cognitive processing in individuals, and the (generally
quantitative) methods used to assess lay risk perception, have been criticised for not
accounting for the social and cultural context in which people live and act (Lupton,
1993). Social psychology has demonstrated the extent to which the situational context
can influence the risks we are willing to take (Denscombe, 1993); group situations tend
to increase our acceptance through a normalising of risks and reduction of fear as
demonstrated in the conformity and obedience studies (Asch 1951, 1952, 1956;
Milgram, 1963, 1974; as mentioned earlier in the 'participation' section of the literature
review).
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Interpretative social research has examined lay perceptions of risk and risk behaviour
within the context of the social circumstances surrounding their lives and explored the
relationship between the perceptions of risk of the layperson and the expert (Gabe,
1993). An example is the work of Davison et al. (1991) outlined in Part I which
described the development of lay perceptions of cardiovascular risk through lay
epidemiology, a process where input from various sources and experiences led to an
explanatory theory for predicting and accounting for cardiovascular events, and
demonstrated the existence of fatalism.
Part V ends the literature review by focusing on a notion referred to in the four
preceding sections. It covered research on the relationship between control and risk
including externally imposed risk and its management, internally controlled risk and
individuals responsibility. Explanations of lay risk perception outlined were use of
heuristics, optimistic bias, weighing up of costs and benefits, and finally, reference was
made to the social and contextual circumstances within which lay perceptions of risk
develop.
Summary: Chapter 2
In this chapter I have outlined literature that I considered relevant to the aims and
context of the research. In Part I, I described existing literature on people's
understandings and beliefs about heart disease and cardiovascular risk including the
process through which these beliefs are proposed to form and be applied to predict and
account for cardiovascular events in oneself and others. In Part II, I outlined research
from different disciplines into attitudes towards screening; this overview covered
literature on influences on uptake, the impact of screening and associated meanings. As
a background to investigating people's attitudes towards preventive medication, part III
outlined research into attitudes towards medication (general and other types). In Part IV
I described literature from several disciplines that I considered relevant to investigating
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attitudes towards trial participation incorporating literature focusing on this specifically,
as well as literature regarding the potential social context and influences affecting a
decision to participate, and literature on altruism. Due to a theme of risk referred to in
the four preceding sections, Part V outlined perspectives on risk from psychological and




In this chapter I will present an overview of the methodological approach and
process I took and engaged in to conduct the research for this thesis. I begin by
discussing the design and plan of the research including the purpose of the research,
the research questions, the choice ofmethodological approach and research methods.
I then describe the initial phase of the research encompassing the pilot work and
development of the topic guide. Moving on to discussion of the main fieldwork, I
describe the sampling and recruitment, research ethics and discuss particulars of the
data generation process including reflexivity and strengths and weaknesses. Finally, I
outline my approach to the data analysis.
Purpose of the research
In the literature review chapter I highlighted areas where I felt gaps existed and
where a different methodological approach to the research areas could explore
attitudes towards and beliefs about the screening and prevention of heart disease, and
about research participation. In summary, first the psychological research literature
into attitudes towards screening attendance has been largely quantitative applying
social cognition models to investigate people's intentions to attend. This has been
useful for predicting uptake, but a couple of qualitative studies have demonstrated a
more complex picture behind people's decisions to attend screening, and some
qualitative sociological literature has explored in more depth lay meaning and beliefs
about screening and the particular diseases. The focus has largely been on diseases
such as cancer, but other research has illustrated the many factors contributing to lay
meanings of heart disease including the process of lay epidemiology indicating that
attitudes towards screening for heart disease would be equally complex. Second,
research into beliefs about medication has included psychological studies leading to
the development and application of theories and models to investigate attitudes,
usually focusing on compliance to prescribed medications. Sociological research has
also investigated compliance and has explored beliefs and meanings about risk of
medication. However, preventive medication specifically has received little attention
from either discipline. Thirdly, research into attitudes towards participating in RCTs
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has again been largely quantitative and usually with the aim of increasing uptake. A
couple of recent qualitative studies of trial participants' attitudes and beliefs have
revealed confusion and misconceptions regarding RCT procedure; the trials in focus
involved overt differences between the treatment arms rather than use ofmedication
and placebo, thus the placebo and preventive nature of the AAA trial provides a
novel focus for research.
From my review of the literature therefore I have not only outlined gaps in the
literature which provoked the development of the aims of the present research, but I
have also highlighted the initial basis for adopting a qualitative approach. Such an
approach is most appropriate to investigating these research areas, as will be
discussed in further detail in the following section.
Mason (1996) recommends acknowledging other purposes behind research, and in
addition to the purpose outlined above it is important to consider additional interests.
Considering the perspective from epidemiology, two areas of the findings will be of
direct interest. The first is developing knowledge of why people would (not) attend
screening for heart disease and whether they would take aspirin as a preventive
medication for heart disease, with the ultimate aim of gauging public opinion
because successful implementation of such a screening and prevention programme
will depend on the attitudes of the general public. This is linked with the purpose and
interest of a third party: the funding body, as the implementation of successful
screening and prevention programme would have the overall aim of reducing heart
disease in Scotland. A second line of interest to the epidemiologist focuses on
increasing knowledge of why people do or do not participate in RCTs and
considering how such information could inform and improve the running of research
trials. This raises important ethical issues which will be discussed in the ethics
section below.
Choosing a research methodology:
In the initial stages of planning a piece of research, Mason (1996) advocates asking
oneself questions about the research to identify and outline the ontological and
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epistemological position and the broad research area. From the answers, along with
defining the intellectual puzzle, the research questions can be more clearly defined:
Ontology. The nature of the phenomena that I wanted to investigate were people's
attitudes, beliefs, understandings, interpretations, accounts, experiences. I believe
these to be held individually, and also to exist in the interactions between individuals.
Epistemology: What represents knowledge and evidence of these phenomena? How
can one access their knowledge and evidence? From my perspective, obtaining and
analysing people's accounts would be the most appropriate way; accounts could be
generated through qualitative interviews, either individually or in a group. Although
Mason (1996) warns that interviews will provide recounts of experiences, and access
to how people present and account their attitudes and beliefs; from this perspective, it
is not possible to get inside a person's mind. In accessing such accounts, attitudes
and beliefs are treated as interpretations and versions. In my analysis I aim to
demonstrate this wider interpretative and cultural context.
The research questions can now be clearly defined as follows:
♦ What are people's attitudes towards attending screening for the risks for heart
disease? What are their explanations behind their decision to attend or not?
What are people's attitudes towards the ABPI measure? What were people's
reactions to the screening result? What are people's perceptions of their
personal risk of heart disease?
♦ What are people's attitudes towards using preventive medication for heart
disease? What are people's views about aspirin specifically?
♦ What are people's attitudes towards participating in a RCT? What are
people's explanations behind their decision to participate or not?
Coherence of research methodology to research questions
Defining my approach to the research and the research questions led to the decision
to conduct qualitative interviews to generate data, allowing me to explore people's
accounts and explanations of their attitudes and experiences relevant to the topic area
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and research questions. There are different types of qualitative interview and so it
was essential to consider the appropriateness and potential contribution of these on
several levels. First, considering the degree of structure to the interview, it was
decided that a semi-structured approach with open ended questions would ensure the
interview covered the research questions whilst encouraging a more informal
'conversational' style, allowing participants to answer in the way they wanted and
encouraging depth (Burgess, 1984; Mason, 1996). A second level of consideration
was concerning individual and/or group interviews. It was decided that both methods
could address the research questions in the desired way, as both methods allow
participants to address the subject matter in their own terms through the use of open
ended questions on a topic guide (Crabtree, Yanoshik, Miller, et ah, 1993). However,
the methods could also complement one another by generating different data; useful
contributions of the two approaches will now be briefly highlighted. I will not
compare the two approaches in terms of advantages and disadvantages per se, rather
I will outline a number ofways in which each method can contribute to achieving the
overall research aims through different types of data.
Regarding the data generated, individual interviews can reach more depth, whereas
focus groups can reach greater breadth; in an interview the researcher can engage in
deeper probing thus can clarify meanings more easily (Crabtree et ah, 1993), whereas
broader data can be generated in a focus group due to the range of attitude and
experience of the participants. The unit of analysis differs: interviews can focus on
the individual, their understanding and thus how individuals differ regarding the
subject matter, whereas focus groups are useful for exploring shared cultural
understandings of a group of people (Crabtree et ah, 1993) and provide an
opportunity to observe how a group consensus is achieved, how disagreements are
handled and follow the stages in a reasoning process (Barbour, 1995). Focus groups
can also be used to compare individuals' attitudes directly 'in situ' as opposed to
later theorising (Kitzinger, 1995; Morgan, 1997). Kitzinger (1995) points out that
focus groups can capitalise on the communication of the group to generate data and
when such group dynamics work well this can lead the research in unexpected
directions. In addition, focus group participants are not forced to express an instant
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opinion, they have time to think whilst fellow participants talk and can remain silent
when they choose (Barbour, 1995). A group setting may be intimidating for some
individuals, particularly those who may lack the confidence to voice disagreement
(Michell, 1999).
Altogether the choice of integrating two methods reflects the desire to explore the
research questions in both great depth and breadth, to investigate understandings and
beliefs of individuals in addition to exploring shared understandings, and to
maximise the diversity of people participating.
Pilot work
Pilot focus groups were conducted for several reasons, first for initial exploration of
the research questions and development of the topic guide, and second to develop my
own moderating and interviewing skills. It was also important to work out ideas
about appropriate group composition, size and organisational issues of the focus
groups in particular. I will therefore discuss how the pilot work helped contribute to
the development of the research within the context of these two key phases in the
following sections ('development of the topic guide' and 'sampling and
recruitment'). First I will present an overview of the pilot work: the recruitment,
conduct and reflection. I conducted three pilot focus group discussions.
Pilot focus groups A & B: The first two focus groups were conducted with members
of a retired persons' organisation outside the catchment area for the trial. None of the
members had any prior knowledge of the trial. I attended a meeting of the group with
an academic who had been invited to speak at their meeting about heart health
promotion. I distributed information leaflets and gave a brief presentation of the
purpose ofmy research, and invited those interested in participating in a pilot focus
group to indicate their interest by providing their phone number. I subsequently
arranged two focus groups (group A consisted of one male and five females, group B
of one male and three females) which I conducted with an assistant moderator who
took notes and detailed the sequence of talk (see later for explanation of sequence of
talk). Each discussion lasted approximately 30 minutes.
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A few points should be noted about the participants in the first pilot groups. First,
participants' unfamiliarity with the AAA trial and the ABPI measure meant that
detailed explanation of the screening and trial was necessary, and the focus of the
discussion was a hypothetical scenario rather than a situation that participants had
experienced themselves. Post focus group discussions with my assistant moderator
brought my attention to the way in which I presented the screening and trial to
participants. She pointed out that when describing the efficacy of the ABPI and
introducing the idea of aspirin as a preventive medication, I should take care to
present unbiased information, thus not swaying people's opinions. This provoked me
to reflect on the potential impact of being seen as a member of the trial team on
participants' discourse. Second, most participants were middle class and fairly well
educated; I felt therefore that the discussion may have missed issues which were
more salient to those from different backgrounds. Despite these two important points,
the first two pilot studies generated useful themes that contributed to the
development of the topic guide.
Pilot focus group C: For the third pilot focus group I contacted a charity who
organised 'self-help' groups for people with heart conditions, including those who
have experienced heart attacks, strokes and angina. Unlike the first pilot groups, I
conducted this focus group during one of their regular meetings, thus had no control
over the group composition and size, nor the location which proved to be a problem
as the group consisted of eleven people along a long dining table in a fairly noisy
canteen. In addition, I had no assistant moderator to take notes. All these difficulties
were noted and actively avoided when organising the main fieldwork. However, the
group composition was useful as the topic of heart disease was highly salient to all
members. Furthermore, as members lived within the catchment area for the trial,
there was some awareness of the trial and a few had acquaintances who were trial
participants. The majority of participants were from more disadvantaged
backgrounds than the first pilot groups, thus I felt this expanded the range of people
and opinion, further contributing to the development of the topic guide.
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It should also be noted that in all the pilot focus groups, participants were known to
each other as they met on a regular basis. Advantages of such naturally occurring
groups include participants being more confident in challenging each other's beliefs
and practices based on previous experience (Kitzinger, 1995), but existing dynamics
and hierarchies could also prevent disclosure by some members (Kitzinger, 1995)
and participants may not explain issues which they assume to be already known by
the rest of the group (Krueger, 1994; Morgan, 1997). In pilot group A, status within
the organisation seemed to have had an impact: a couple of participants were clearly
dominant which seemed to inhibit one participant from expressing her views.
Conversely in pilot group C familiarity seemed to help as participants often
prompted each other to mention particular experiences, and their history as a cardiac
rehabilitation group seemed to have creating a comfortable environment for
discussing personal health issues.
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Development of the topic guide
As previously mentioned, the initial topic guide was developed from the research
questions, which were formed as a result of studying literature relevant to the area
and the gaps that I identified as particular aspects to investigate. The initial topic
guide was used as a basis for the pilot focus groups (see appendix A5.2.1). As
discussed above, one of the key aspects that I changed as a result of the pilot studies
was to ensure my presentation of the trial and the ABPI measure was factual but
unbiased. However, with the exception of group 5 in the main fieldwork,
participants' awareness of the trial meant that an explanation of the trial was not
necessary; rather than discussing a hypothetical situation participants were able to
discuss their own experience of the screening and trial. Questions on the topic guide
for the main fieldwork were adapted to address this; the same basic topic guide was
used for individual interviews and focus groups (appendix A5.2.2-A5.2.6), but it was
adapted according to the participants' stage in the trial process. For example, pilot
group participants were asked, "Why do you think people would/wouldn't attend the
screening? Group 5 were asked, "What were your reasons for not attending the
screening?" Other participants were asked, "What were your reasons for attending
the screening?"
The basic topic guide was split into three broad topic areas: screening, aspirin as a
preventive medicine, and trial participation. There were several (7-10) questions for
each topic area, however often one question provoked discussion which covered
several of these questions. Additional questions and probes were made in response to
each participant's discourse. In some interviews, the order of topics discussed
followed the order on my topic guide (screening first, aspirin second, trial third).
This was more common in my first interviews where I was less confident and skilled
in the semi-structured approach, and also with interviewees who were less talkative
and went into less depth. However, as the study progressed, I rarely asked questions
in the order as shown on the topic guide, rather the list of questions served to provide
me with example questions to ask and as a back up when stuck for how to further
explore a participant's response. In many interviews, particularly as I became more
experienced, the nature of the overlap between the three topics or the extent to which
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the participant saw them as being enmeshed/linked tended to lead to a less ordered
and more merged discussion. In individual interviews, I felt the flexibility of the
topic guide approach encouraged more control for the participant and avoided
disrupting the flow (Burgess, 1984). Similarly, in focus groups, I was keen to let
participants' discussion with each other be as natural as possible, thus I tried to
explore issues that were raised through probing and encouraging participants to
probe each other, without dominating the direction of the discussion whilst trying to
keep the discussion in one of the three main areas to allow full exploration before
moving onto a different area. As I developed more skill throughout the fieldwork and
reached total familiarity with the topic areas and questions I wanted to cover, I rarely
looked at the topic guide other than towards the end of the interview to check that I
had covered all question areas with the participant. Therefore, the topic guide
became more of an 'aide memoire' (Burgess, 1984).
The first area focused on screening; with all participants I began the interview/focus
group with the question, "Thinking back to when you first received the invite to
attend the screening, what were your initial thoughts?" The nature in which the
discussion proceeded and unfolded depended on a participant's response to the initial
question. There was a wide range of responses to this initial question, for example
mentions of keenness to check one's own health led to discussion centring on the
screening and perceptions of risk, whereas mentions of altruistic feelings led to a
focus on the trial. Often participants mentioned several aspects simultaneously, or in
focus groups different participants mentioned different issues in response to one
question, in this case I tried to note (actually or mentally) the issue I wished to pick
up on later whilst pursuing one avenue first.
The topic guide further developed over the course of the fieldwork in response to
attitudes that were expressed and themes that emerged in earlier interviews. For
example, I often presented participants with previous participants' views
(anonymously) to explore agreement or disagreement. For example if a participant
expressed willingness to participate I often said, "some people have said to me that
they wouldn't enter the trial if they could not guarantee getting the aspirin, what do
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you think about that?" Using views attributed to others has several potential effects:
it can provoke expression of attitudes towards other people's views, which can in
turn reveal more about participants' own views, also it may indicate to the participant
the acceptability of expressing certain attitudes that they may have been too hesitant
to express themselves. A further development resulting from the fieldwork was in the
way I asked certain questions and presented particular issues. For example, one
participant challenged me by commenting that I seemed to be implying responsibility
to attend the screening. This challenge drew my awareness to adding a question
addressing this issue: "do you think people should attend screening?"
When I felt that the interview/focus group had covered all the research questions, I
glanced through the topic guide to check for any questions which had not been
covered and in this case raised these questions. I reminded participants of the
purpose of the research and the issues I had wanted to cover, and asked if they felt
that there was anything relevant that we had omitted (Krueger, 1994; Morgan, 1997),
often this provoked further response and discussion (see ending template, appendix
A5.3).
In addition to the topic guides, for the focus groups I prepared copies of newspaper
headlines about aspirin as stimulus material, five focusing on positive properties such
as use for heart disease and five focusing on negative properties such as potential
risks (see appendix A5.4); such stimuli can be useful in generating discussion
(Kitzinger, 1994). In focus groups comprising trial participants (la, lb and 2), I did
not use the material as participants' discussion flowed particularly well and also
covered the issues that the stimuli may have provoked. These participants had
experience of the trial tablet, thus the possibility of aspirin, and most could express
their opinion about aspirin referring to their experience. In the remaining focus
groups the stimuli may not have led to a more lengthy discussion on these issues than
a question, whereas in focus group 4a, which comprised of only 3 participants, I felt
it helped to extend the discussion somewhat.
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Sampling and recruitment
The research questions I wanted to address guided my decision about whom I wanted
to interview. Unlike quantitative research, qualitative research does not aim to access
a representative sample; rather purposive sampling allows targeting of people of
particular interest and relevance to the research, and exploring the diversity of the
intended population (Mason, 1996; Barbour, 2001). Through the sampling I engaged
in, I aimed to reflect different relationships to the screening and trial, to explore a
range and diversity of views. Studying the AAA trial process led me to identify
different stages throughout the whole screening and trial process at which I wanted to
recruit participants. I was in the fortunate position that when I started my recruitment
the trial had been screening and recruiting for two years; over half the intended
number of participants were enrolled into the trial and screening and recruiting was
still underway. Therefore, I could potentially reach participants ranging from those
who had been in the trial for two years to those who had just been screened,
hopefully exploring different perspectives. The five stages I identified are shown in
Figure 3.1.
Group 1: Trial participants (including a range from those who had recently
started the trial to those who had been participating for over two years)
Group 2: Trial participants who had stopped the trial medication (due to side
effects, cardiovascular events or other reasons) but who were still receiving
annual follow up by the trial team
Group 3: Individuals who had attended the screening, were eligible to enter
the trial but had declined to participate
Group 4: Individuals who had attended the screening but were ineligible to
enter the trial (normal ABPI)
Group 5: Individuals who had been invited to the screening but had not
attended
A key to the groups will be displayed as a footer on all pages of the data
chapters
Figure 3.1: Groups of participants in the present research relating
to different stages in the AAA screening and trial process
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Reaching participants in each of the five groups identified would allow exploration
of the research questions. Attitudes could be compared and contrasted within and
between groups. Regarding screening, the decision to attend could be explored
through group 1 to 4 participants' explanations for attending and group 5
participants' explanations for not attending. In groups 1 to 4, reaction to the
screening result could be explored, including reaction to a low ABPI (groups 1 to 3)
and a healthy ABPI (group 4). Regarding attitudes towards trial participation and
aspirin as a preventive medication, group 1 and 2 participants' experiences of the
trial can be explored including their attitudes towards aspirin, the placebo, and the
RCT process, as can the attitudes of group 3 including their explanations for
declining to participate.
Considering the time scale of the research, my views on the number of interviews I
could feasibly carry out and the amount of data I could feasibly analyse, my initial
aim was to interview approximately ten participants and conduct two focus groups
within each of these five groups. The number of participants I interviewed according
to group are shown in Figure 3.2. I used slightly different approaches for the
recruitment of the five different groups (for details of the recruitment process see
appendix A2).
Individual Interviews Focus groups (number
ofparticipants in each)
Group 1 9 2 groups (9; 7)
Group 2 11 1 group (6)
Group 3 11 -
Group 4 9 2 groups (3; 6)
Group 5 6 -
Figure 3.2: Number of participants according to group
Regarding the focus groups, I chose to conduct separate focus groups in each of the
separate groups outlined above i.e. not mixing people from different stages of the
trial. I wanted homogeneity regarding trial stage as I felt this would facilitate the
discussion (Morgan & Krueger, 1993) because mixing those from different 'stages'
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could have had negative consequences; for example mixing those with different
levels of risk seemed inappropriate, likewise mixing trial participants and non-
participants.
Additional criteria were considered when recruiting participants to maximise the
diversity of participants in terms of area of residence, social class, gender and age.
The trial was being carried out across three health boards, therefore I was keen to
include a roughly equal number of participants from each health board area.
Regarding social class I used participants' postcodes to work out their DEPCAT2
(Carstairs & Morris, 1991) score, and when recruiting for individual interviews, I
attempted to include participants from the entire range of DEPCAT score. Within
focus groups, I originally planned to achieve homogeneity regarding social class as I
felt this would facilitate interaction and minimise any hierarchical, and potentially
inhibiting, dynamic, but this proved to be a difficult logistical task, thus participants
came from a mix of backgrounds. Regarding gender I recruited roughly half male
and half female participants and the age of participants ranged from 52 to 78. (See
Figures 3.3-3.4 for participants' demographic details). Pseudonyms have been used
throughout the thesis to protect participants' anonymity.




Gender Age Carstairs DEPCAT score2
1 = most affluent
7 = most deprived
Wendy 1 F 55 4
Keith 1 M 59 3
Monica 1 F 66 4
Richard1 M 54 5
Imogen 1 F 61 1
Gordon 1 M 67 7
Hamishl M 70 7
Fergus 1 M 72 5
Moiral F 53 4
Hilary2 F 77 2
Fred2 M 62 3
2 Carstairs DEPCAT variables, derived from combining variables from small area census data,
represent levels of relative affluence and deprivation in small geographic localities (postcode sectors)
in Scotland ranging from l=most affluent to 7=most deprived (McLoone, 2000).
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Alison2 F 55 3
Warren2 M 72 5
Marie2 F 77 5
Peter2 M 55 3
Joe2 M 56 3
Harold2 M 63 7
Martha2 F 65 6
Jennifer2 F 61 4
Amy2 F 76 3
Isaac3 M 58 2
Eleanor3 F 62 2
Mandy3 F 59 2
Morag3 F 64 1
Graham3 M 58 5
Miriam3 F 73 1
Paul3 M 63 4
Geoffi M 68 1
IsobeB F 60 4
Patricia3 F 61 2
Rebecca3 F 73 6
Dennis4 M 75 2
Daniel4 M 54 1
Craig4 M 54 2
Maureen4 F 53 1
Owen4 M 52 6
Nancy4 F 69 1
Molly4 F 75 2
Joyce4 F 54 6
Ted4 M 77 1
Audrey5 F 72 3
Michelle5 F 63 3
Timothy5 M 61? 4
Jack5 M 66 4
Susan5 F 53 2
Mildred5 F 65 2





Gender Age Carstairs DEPCAT
Score
1 = most affluent


















Aileen F 67 2
Alf M 74 2
Rod M 53 2
Andrew M 59 5
Bob M 70 5
lb
Yvonne F 72 1
Anita F 74 7
Lorraine F 52 4
Nigel M 64 6
Maive F 67 4
Wayne M 69 3
Henry M 67 3
2
Emma F 70 5
Ursula F 61 1
Beatrice F 75 4
Cath F 63 -
Ella F 70 -
Deirdre F 68 -
4a
Wilf M 65 6
Janice F 70 1
Colette F 52 3
4b
Lucy F 57 2
Nora F 55 2
Jed M 57 2
Elsie F 60 -
Harriet F 61 -
Melanie F 64 -
Offering potential participants the choice between an individual interview and a
focus group discussion hopefully contributed to minimising some barriers against
participating. Individuals who were less mobile could opt for an interview in their
own home, and a couple of individuals expressed preference for an individual
interview due to shyness. Reasons given for a preference for a focus group included
feeling that they would not have enough to say in an individual interview, and
intrigue about meeting other trial participants. Convenience was not only an
additional influence on the method of interview opted for, but also a particularly
pertinent issue when attempting to arrange focus groups to suit the maximum number
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of available and interested potential participants. All but one interviewee attended
individual interviews (possibly as I minimised non-attendance by offering to conduct
interviews in the individual's home or workplace if preferred). However, several
people failed to attend their scheduled focus group, one focus group in particular
which unfortunately happened to be on a day with extremely bad weather. In
anticipation of some non-attendance I tended to over-recruit slightly when arranging
focus groups (Morgan, 1995; Krueger, 1994). Another influencing factor on
participation, common to most research, was self-selection; in addition to those who
failed to turn up at focus groups, there were many people who declined to participate
during the recruitment phase by declining the invitation from the research nurse
(groups 1-4) or not responding to the letter (group 5).
Thus, my sample cannot be assumed to be representative of the population from
which I recruited nor, of course, of the general population, but this is rarely an aim in
qualitative research (Mays & Pope, 1995; Barbour, 2001). Rather, I aimed to
interview a diverse range of people and thus hopefully explore a diverse range of
opinion, which I believe I achieved. My regret at lacking the exploration and thus
opinion of those who did not want to attend the screening was in some way
compensated by some participants' discussions of their friends and family who
do/did not attend screenings.
The decision to stop recruiting was made for several reasons: I had reached close to
the number of interviews and focus groups I had aimed for. Second, I felt that I had
reached theoretical saturation (Strauss & Corbin, 1990) as no new themes appeared
to be emerging in the interviews. Thirdly, during the week of my last scheduled
interviews, unforeseen changes in the trial organisation meant that trial staff and
research nurses were preoccupied with a pressing matter and I felt that adding to
their workload was inappropriate, in particular considering the large amount of help
they had already given to my recruitment.
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Ethics
Two approaches were taken when considering the ethical issues involved in the
research: one formal and one informal.
Gaining formal ethical approval
Application for ethical approval for the research was requested in the form of
application for amendment to the main RCT. A letter of application detailing the
proposed aims, methods and recruitment procedures was sent to the Local Research
Ethics Committee in each of the three health board areas where the trial was being
conducted. Two of the LRECs requested further information, therefore a more
detailed overview of the research, along with details of the likely topic content of the
interviews and example questions, and the recruitment letters and participant
information sheet were sent in reply. Ethical approval was granted by the three health
boards for access to groups 1-4. However, there was further problems with access to
group 5 (those who had not attended the screening). One LREC granted approval.
For the second LREC, this group were removed from the application as this health
board had recently brought in changes to access as a result of the Data Protection
Act. In the third health board area, the LREC approved my access to this group, but
the health board then brought in changes to the recruitment process for the main trial
team regarding the storage of data, which in turn prevented my access to the data I
would require in order to invite screening non-attendees to my research.
Informal ethical considerations
Ethical issues were considered when planning the recruitment of participants. The
information sheet (given to screening attendees and trial participants and sent to non-
attendees and trial decliners) explained the purpose of the study, emphasised lack of
obligation to participate, and lack of effect of their decision upon their treatment in
the main trial and/or any other health care. The research process was explained, the
choice of interview type (individual or group), location, and time was offered, and
confidentiality and anonymity were assured. In addition, where a research nurse was
involved in the recruitment, she answered any queries individuals had regarding the
study. Individuals had further opportunity to discuss the study and decline when I
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telephoned them. I began each interview by outlining the purpose of my research,
overview of the topics that I wanted to discuss, and how the findings would be used
(Burgess, 1984). I explained the process to the participant including recording,
transcribing, and anonymising transcripts; participants were asked if they were happy
to be recorded; all participants agreed. I asked participants to read a consent form
(see appendix), which they were then invited to sign if they agreed. Participants were
informed that they could stop the interview at any time.
Regarding focus groups, I administered consent forms as participants arrived. When
introducing the discussion I checked consent to record with all participants. I
explained confidentiality from my perspective and asked participants to respect each
other's confidentiality. The issue of confidentiality is more compromised in the
group setting of a focus group, as there is no guarantee that fellow participants will
maintain confidentiality (Morgan & Krueger, 1993; Kitzinger, 1995). However,
Michell (1999) points out that in the case of bringing people together for the sole
purpose of a research focus group, the assumption is that participants will not meet
again and thus providing anonymity post event. This could not be guaranteed,
particularly when participants lived in the same area, hence the importance of asking
participants to respect each other's confidentiality.
I undertook a MSc course module in ethical and political issues in social research,
which led me to consider ethical issues and implications of my research. As
highlighted earlier when considering other purposes and interests in my research,
there is a potential ethical problem as to how the research findings could be used, for
example to increase uptake of research participation. This is a particular problem as
this is one of my criticisms of existing research into attitudes towards RCTs. It is
hoped that rather than using the findings to manipulate individuals in order to
improve uptake, those conducting trials will consider the beliefs, attitudes and
meanings lay people hold about trial participation, in particular concerning aspects
where confusion and misunderstandings may arise, in order to ensure informed
consent and acceptability to the public.
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Main fieldwork overview
Individual interviews ranged from 25 to 90 minutes, the majority lasted 35 to 45
minutes. Focus group discussions ranged from 45 to 75 minutes. Focus group
participants were given a name label to aid the memories of myself, my assistant
moderator, and their fellow participants. I also introduced ground rules of the focus
group (see appendix A5.1.1), such as avoiding talking simultaneously; the template
for these and the introduction was developed referring to Krueger (1994) and
Morgan (1997). To facilitate transcription the assistant moderator noted the sequence
of talk of the discussion: each time a participant spoke, she noted the participant's
name and either the initial few words spoken or key words in their comment. In
addition, she noted other expressions such as non verbal utterances (for example
"hmm"), and some body language, such as head nodding.
I recruited and interviewed participants group by group, from the five stages of the
trial process I identified (for further details regarding recruitment refer to appendix
A2). I conducted the fieldwork in several stages of batches of interviews interspersed
with transcribing and preliminary analysis as follows. In the first batch, my fieldwork
included participants of groups 5, 4 and some from group 3. I began transcribing the
interviews as soon after conducting them as possible, and followed this first stage of
fieldwork by completing all transcribing, making notes simultaneously, and
subsequently carrying out some preliminary analysis of the data. I then conducted my
second batch of fieldwork including the remainder of group 3, group 1, and group2.1
transcribed the second batch of interviews, made further notes and developed my
analysis, although still at a preliminary phase. Further analysis followed this; the
analytical approach and process will be described shortly
Reflexivity
Consideration of the impact of the researcher on the data generated is encouraged in
qualitative research. Such reflexivity contributes to presenting the transparency of the
research process and the potential impact on the data of the researcher (Mays &
Pope, 1995; Richards & Emslie, 2000). Other literature, however, has warned about
being over reflexive if it detracts focus from the research participants (Finlay, 2002).
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Richards and Emslie (2000) explored and discussed the impact of the researcher's
presentation to their interviewees, comparing interviewees' reactions to a medical
doctor doing research with a university researcher, and amongst their findings
concluded that "who participants think you are affects what you get told". In addition
to considering how participants saw me possibly having an impact on the generation
of data, I regarded how I presented myself to participants as crucial for establishing a
good rapport in the interviews, aimed at encouraging openness in participants'
accounts and putting them at ease in expressing their views. By engaging in small
talk prior to the interview, I attempted to begin building a rapport. There is debate in
the literature over the increased benefits of a shared identity between researcher,
whilst it can increase rapport and thus improve the amount and content of what is
disclosed (Jones, 1991), sharing some identity does not necessarily guarantee the
researcher 'insider' status (Burgess 1984; Jones 1991). Obviously, similarities
between myself and the participants were often fairly minimal: my participants were
aged between 52 and 78, mainly Scottish, about half were male and few were
familiar with academic social research, whereas I was a female, English PhD student
in my mid twenties. Although who I was undoubtedly will have affected the research
relationship and data generated, and certain attributes prompted questioning by
participants (in particular about my origins), I did not feel that who I was, prevented
participants' discussion or disclosure. Indeed the lack of shared identity or
understanding may have been enabling.
For some of the interviews conducted in Lanarkshire I used a hire car to travel to
participants' homes which were spread over a large area with less public transport
and in some cases these were in fairly disadvantaged areas. I felt it important to
emphasise that the car was indeed on hire as I felt that arriving in a brand new car
would give participants a false impression about my status, and where possible I used
public transport. My presentation as a PhD student was written on my letter and
information sheets, however I did not explicitly emphasise this when meeting
participants and discussed it only if participants asked. In some cases I felt that this
persona possibly increased participation. Several participants mentioned keenness to
help a PhD student, some mentioned how their own children were at university or
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that they themselves had engaged in postgraduate study, and some were keen to
enquire more about my research and career.
Some participants mistook me for a doctor, in which case I corrected them,
particularly as interviews often included discussion about doctors, in particular
participants' GPs. I explicitly mentioned in my introduction to all interviews that I
was not a member of the trial staff, with the aim of encouraging them to voice any
negative views about the trial. In some cases however, particularly the focus groups,
it appeared that I was being regarded as a representative of the trial (one participant
used the phrase "the face of the trial") to which they could voice grievances. This
was difficult, as although I tried to emphasise my independence, I did answer
participants' queries about the trial process wherever I could, which probably
contributed to an identity as a trial representative to some extent.
Data management and analysis
Choosing an approach to the analysis
There are many approaches to analysing qualitative data across and within the
different disciplines of social research; when planning the research I studied different
ones, which thus informed my approach to the analysis without following a particular
prescriptive approach exactly. It was important to ensure that my approach to the
analysis followed on from, and fitted in with, my approach to the generation of data.
My reasoning for the use of qualitative methodology came from the ontological
position and epistemological position as discussed earlier; I wanted to explore
people's attitudes, beliefs, understandings and interpretations of the topic matter, and
felt that through qualitative interviews and focus groups, data about these could be
generated (Mason, 1996). I was keen that the findings generated by, and the theory
produced from, the research should of course be grounded in the data, therefore I
adopted an inductive and interpretive approach to the analysis, which Mason (1996)
describes as a 'theory comes last' view:
"The researcher will develop theoretical propositions or explanations out of
the data, in a process which is commonly seen as moving from the particular
to the general" (Mason, 1996, pp.142).
This approach has roots in Glaser and Strauss's (1967) grounded theorising:
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"A grounded theory is one that is inductively derived from the study of the
phenomenon it represents. That is, it is discovered, developed, and
provisionally verified through systematic data collection and analysis of data
pertaining to that phenomenon. Therefore, data collection, analysis, and
theory stand in reciprocal relationship with each other. One does not begin
with a theory, then prove it. Rather one begins with an area of study and what
is relevant to that area is allowed to emerge" (Strauss & Corbin, 1990, pp.23)
As previously described in the overview ofmy research process, preliminary analysis
followed the first batch of fieldwork and informed the second batch, in some cases
allowing emergent themes from the first batch to be further explored in the second
(Chamberlain, 1999).
The interviews were semi-structured around a topic guide which, as described
previously, was formed initially from the research questions. It is important to
acknowledge the influence of the relevant literature that informed the generation of
the research questions. Similarly, the potential influence of my knowledge of the
literature on my analysis of the data must be acknowledged (Strauss & Corbin,
1990). Whilst not specifically looking for previously documented models, theories or
concepts, evidence of these was bound to occur. For example, whilst I did not
specifically look for evidence of a concept such as 'optimistic bias' when exploring
the data, the concept emerged as an important theme concerning participants'
explanations for (not) attending screening. However, I did not use existing theories
or models in a deductive way, nor did I use the data to test theories or models. In a
multidisciplinary context, my data could investigate existing conceptualisations,
including specific models or theories, and identify strengths and weaknesses.
All interviews were recorded (with participants' permission) using digital recording
equipment; I then fully transcribed the interviews. I completed all transcription work
myself as I believed it to be an important part of the preliminary analysis. While
transcribing the interviews I made notes of interesting points and themes. The
interview transcripts were printed out and read several times interpretively (Mason,
1996); I made detailed notes upon the printed transcripts of emerging themes.
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After transcribing the first batch of interviews I engaged in preliminary analysis
using my notes on the transcripts regarding the emergence of themes, named the
themes, and began to build a picture of similarities and differences in the way
participants discussed each theme, and how these themes related to each other. From
this, I produced a written overview of how I saw the themes at this point. This
summary helped inform the second batch of interviews.
The same approach of recording, transcribing, printing, reading, and making detailed
notes was conducted on the second batch of interviews. Participants in the second
batch included those from stages of the trial in which I had not yet interviewed
people, thus new themes emerged. I conducted further preliminary analysis on the
second batch, which further developed themes from the initial analysis and led to
emergence and naming of new themes. A more detailed and more complex picture
could be built and a more detailed overview of themes was produced.
At this point I organised the themes into several broad groups. The themes and my
organisation of them led to development of the coding framework whereby groups of
themes became 'trees' with 'parent', 'child' and 'sibling' codes (see appendix A6 for
coding framework). Transcripts were entered onto QSR NUD*IST vivo (NVivo)
software and coded using the framework. The NVivo package facilitated storage and
retrieval of coded text. Taking one theme at a time I ran a search on NVivo to
retrieve every section of transcript coded with the theme. I compared and contrasted
different participants' discourse, noted similarities and deviant cases, and referred
back to the original transcripts where necessary. I studied the differences and
similarities between the different discourses coded by the code, formed ideas about
how these related to each other and developed interpretations. I then created a
structure for the presentation of the themes and their relation to one another, thus
building the structure of each thesis chapter
Regarding the focus group discussions, I adopted a similar approach: I transcribed
the discussions with the added aid of the sequence of talk produced by my assistant
moderator to help identify which participant was speaking and provided extra notes
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such as some comments on body language. I engaged in the same analytical process
detailed above for analysis of the interviews regarding noting the emergence of
themes. In addition, I studied the transcripts for interaction and dialogue between
participants to explore how shared understandings and interpretations of the topics
developed; how participants presented different stories/cases and the group used
these to form conclusions. For example, when discussing the relative importance of
different cardiovascular risk factors, participants in one focus group took turns to
present different cases of individuals' lifestyle and health, eventually coming to an
apparent group consensus. Furthermore I studied how challenges and disagreements
were handled and what they revealed. For example, in one focus group one
participant challenged another regarding their respective attitudes towards
medication and the trial tablet. In the data presented in the following chapters, I do
use some quotes from individual focus group participants but wherever possible and
appropriate, I use extracts of dialogue from several participants.
Reliability ofmethod, validity of data and generalisability of analyses
The process of making detailed notes during transcription and on the printed
transcripts, which led to the emergence and depicting of themes and eventually to the
coding framework, then using the framework to code the transcripts on NVivo
ensured rigour in the analysis. This was further ensured by going back and forth
between the transcripts and the retrieval reports when writing the chapters.
Validity of the data generation methods was enhanced by using both individual
interviews and focus groups to explore the intellectual puzzles in a rounded and
multi-faceted approach (Mason, 1996). Explanation of the research process including
acknowledgement of the impact of both the background literature and my own
potential impact as an interviewer, along with the extracts of dialogue presented in
the following chapters demonstrate the interpretation process in a transparent
manner.
Regarding generalisability of the findings, as previously mentioned, qualitative
research rarely aims to achieve a representative sample thus empirical generalisation
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to the wider population is not applicable (Mason, 1996). However the range and
diversity of participants and their opinions indicates that the research findings will be
useful and informative for those planning and implementing preventive health
initiatives particularly involving screening and preventive medication use, and
concerning cardiovascular risk and adults in this age range.
Chapter summary
This chapter has described the methodological approach and process involved in the
research for this thesis. From the initial research aims to the final analysis, I have
outlined the decisions I made and the work I conducted throughout all stages of the
research process, in a reflexive and transparent manner.
In the following four chapters I will present data and my interpretations. The
chapters relate to the groups of themes that emerged in the analysis: Chapter 4:
'Perspectives on screening for cardiovascular risk' presents analysis of data coded by
the 'screening' tree. Chapter 5: 'Attitudes towards prevention and preventive
medication' covers data coded by the 'medication' tree. Chapter 6: 'Attitudes
towards participation in the randomised control trial' analyses data coded by both the
'Altruism-self benefit' and the 'Participation influences' tree. Chapter 7: 'Perception
of cardiovascular risk' uses data coded by the 'Risk perception' tree.
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Chapter 4:
Perspectives on screening for cardiovascular risk
Introduction
As outlined in the literature review, the literature on screening has been largely
quantitative investigating sociodemographic factors and also applying social
cognition models with the aim of explaining and predicting uptake. More recently,
qualitative research has explored lay perspectives and also the psychological impact
of screening and screening results. Due to current screening programmes mostly
involving cancers, the majority of research has investigated attitudes towards and
impact of cancer screening; there is less literature investigating attitudes and beliefs
about screening for cardiovascular risk.
The present qualitative research enabled exploration of participants' accounts of
beliefs about cardiovascular risk, screening attendance, and experience, and
explanations behind these beliefs. Although it may be possible to identify costs,
benefits and rational decision making in some people's discussions about screening,
the present chapter situates the decision to attend screening within the context of
personal, cultural, and social circumstances.
This chapter begins by exploring respondent accounts about non-attendance at
screening, i.e. barriers to screening attendance. I have tried to progress beyond
outlining these barriers, to examine participants' explanations behind them. These
explanations included accounts of beliefs about health, illness, preventive health and
the health service, and more specifically heart disease and screening. As the
fieldwork progressed, it became apparent that a few key phrases were ubiquitous in
the accounts of participants across the different groups, phrases that seemed to
capture these beliefs about barriers. The first part of this chapter explores four key
phrases. I then reflect on how participants used these phrases and beliefs to discuss
their own or others' attitudes and behaviour. Exploration of the expressed attitudes
towards other people's beliefs moves the discussion onto consideration of the rights
versus responsibilities of the individual regarding screening. The following section
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examines participants' beliefs about the benefits of screening, again further exploring
the explanations behind these beliefs, and examining whether beliefs are particular to
the different groups that comprised the sample of respondents in this study. The final
section focuses on the screening experience, in particular exploring reactions and
interpretations of participants' pre-screening expectations and their actual screening
result, and the factors that seemed to underlie these interpretations.
Barriers & beliefs
"It won't happen to me"
"there's also the aspect about this, "it's not gonna happen to me, it's not
gonna happen to me", and we all think that way" David focus group la
(71yrs)
"...well I hadnae thought about it much you know, I hadn't put much
attention to it. Heart attacks and cancers and things like that happen to other
people" Timothy5 (61yrs)
When discussing reasons for non-attendance at screening, the quotes above were
common in participants' accounts, echoing the work by Weinstein and others on
optimistic bias, including use of the exact phrase, "it won't happen to me"
(Weinstein, 1984) as discussed in the literature review (Weinstein, 1980; 1982; 1984;
1987). To recall, optimistic bias refers to when evaluating, consciously or
unconsciously, our level of perceived risk of experiencing a negative illness event
such as a heart attack or cancer, we tend to believe our chances are lower, thus more
favourable, than the average person (Weinstein, 1980; 1982; 1987). As demonstrated
in the above quotes, such optimistic bias was implied by many participants in the
present research either when describing their own feelings, past and present, or the
attitudes of other people.
As discussed earlier, in some illness circumstances optimistic bias could in fact
improve health, for example positive well being helping heart disease sufferers to
maintain health enhancing behaviours (Weinstein, 1989; McKenna, 1993). However
with regard to preventive health behaviour and in this case screening, if optimistic
bias inhibits screening attendance, this will largely be maladaptive, as any
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asymptomatic risk factor will remain undetected. However, as the subsequent chapter
(on prevention) will argue, it is not only the screening, but also the choice of
behaviourfollowing screening which influences health outcome.
The work ofWeinstein and others has documented and quantified optimistic bias and
investigated its expression relating to different circumstances. In the present research
I explored the background behind this belief in individuals' accounts; in particular,
the extent to which it seemed to be a shared belief (perhaps influenced by culture)
with little reasoning behind it, or a belief based on personal reasons; and these
feelings were then investigated.
Many participants considered optimistic bias regarding heart disease as a normal and
acceptable attitude to have, and many admitted thinking in this way themselves. In
the first quote at the start of the chapter, D's use of the pronoun 'we' demonstrates
his assumption of the attitude's shared nature. Participants who assured that they did
not hold this attitude now often described holding it in the past, for example
Mildred5 (65yrs) described her attitude before she experienced a heart attack:
Mildred5: yeah, I was fortunate really 'cause I got a warning
HE: yeah
Mildred5: and they take me into hospital right away but I had cousins and
they just died, 'click' you know
HE: so it didn't make you think that you might have one?
Mildred5: no I'd think "it won't happen to me" eh? I mean don't you really?
Participants sometimes spoke about incidents (usually heart attacks) which triggered
their sudden rejection of optimistic bias, rather forcing them to face the fact that "it
can happen to you".
Imogen 1 (6lyre): erm well I think that if there's heart condition in your
family I think you're more aware of it, and you change your lifestyle,
whereas you hear somebody, if we were well and my husband was well and
he'd had no surgery and somebody passed [away] who had had, I would say
that's a shame for them but I wouldn't, I wouldn't think well I'll have to do
something about it so that that doesn't happen to me, you see, it's got to come
to you, it's got to come to your door before your realise, it isn't next door, it's
here. You could be there, "oh it just happens to everybody else" but it
doesn't, it happens to you.
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Speaking with hindsight, Imogen 1 explained how now she realised that heart attacks
can and do happen to people like herself, but emphasised that this realisation had
occurred only after her husband's heart attack had happened. So, it seems that until a
heart attack occurs either personally or to a close 'other', people are more likely to
continue being unrealistically optimistic.
In the quotes so far, participants demonstrated the normality and acceptability of
optimistic bias. However, not all participants agreed; some criticised this as typical
of apathy about health, which they considered widespread:
Aileen (focus group la, 67yrs): I think the attitude would be "don't care", I
think that's what I think people would be "it won't happen to me, I'm not
bothered", yeah apathy...I think it's like breast screening, the girl there told
me that most people don't turn up, they don't even bother to go, so they've
got the opportunity and they don't take it and I think that it would be the
same for the heart, that's what I think
The above participant struggled to understand why people did not take up the
opportunity. Others were less harsh but expressed concern over the implications of
such an attitude; Craig4 felt that more individual responsibility was something that
should be encouraged to initiate more realistic risk perception:
Craig4 (54yrs): ... I mean I think um as with any medical condition you've
got an uphill battle persuading the general public that it has to be taken
seriously and that there was a bit on this morning, all this publicity over
diabetes as it happens, you know
HE: yeah
Craig4: um, and I mean I think there's a lot of "it'll never happen to me"
syndrome as with all these serious medical conditions, so um you have to
somehow take the public on board, and um make them aware of the fact and
try to coerce them into taking some kind of positive...or at least keeping a
lookout on their own condition and so on, and maybe having regular health
checks and so on, just to make sure that everything's going along as it should.
You know I think not many people do that
Participants' emphasis on individual responsibility is discussed later in the chapter.
The application of social cognition models assumes rational thought processing in
decision-making. However, there is a tendency, in the literature, to treat only a
decision to attend screening as rational, whilst a decision not to attend or not
deciding tends to be considered irrational (Howson, 1998). Optimistic bias, due to its
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unrealistic nature, could be regarded as irrational. But in a small number of cases in
the present research, such as GeofO quoted below, some rational thought processing,
involving analysis of his likely risk, did indeed seem to have been carried out, or at
least this is how he accounted for his attitude. This analysis, prior to later discovering
actual increased risk, had resulted in optimism:
GeofO (68yrs): no, no I never thought about my health. As I say I couldn't
understand why people were ill and various things, unfortunately I lost two or
three of my agents through heart attacks and things like that. But it never
actually dawned on me that it could happen to me or something. They were
peers of mine as well so I'd known 'em many years and suddenly they
weren't there. We had always been used to looking ahead and saying, "oh
well so-and-so's gone but he was another twenty years or thirty years older,
when it started getting closer and closer, and then you start looking behind
you and discover people are going, then you say "oh hell"
HE: did that make you think about your own risk of having a heart attack?
Geoffi: not particularly but, I'd say, "it won't happen to me"
HE: why did you think that?
GeofO: 'cause I can analyse, I'm an engineer
HE: yeah
GeofO: and I'm paid, or I was trained to analyse and write down all the pros
and cons in what they call a SWOT analysis. I was doing that before it was
even called the SWOT analysis but that's beside the point. And er I did this
analysis, analysed everything I was thinking about and felt I had no need to-1
was active...
So in GeofO's case, it could be argued that, the attitude: "it won't happen to me"
implies more realistic, than unrealistic, optimism as he explained his analysis of his
own risk according to cardiovascular risk factors. However, whilst he gave examples
of risk factors for which he rated himself less at risk than others (exercise and stress)
he failed to include other contributing factors, such as diet, which elsewhere in the
interview he admitted had been rich and not terribly healthy in the past. So, maybe
his optimism was indeed more biased than he argued, yet perhaps he wanted to
appear as rational and leading a healthy lifestyle.
A further contributory factor to optimistic bias seemed to be age; generally other than
anecdotes about anomalies, people talked about heart attacks happening to older
people than themselves, so it seems that as long as a person feels young enough they
are less likely to consider themselves a candidate for a heart attack:
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Ted4 (77yrs):...I think the younger you are, I'm at the stage where I think
50's young, er yeah you think "I'm OK so I don't think I need to go into
this". Especially if you happen to be of the feeling that you're invincible
(laughs) and nothing like this is gonna happen to you. I think that would be
about it.
Some people were not as sympathetic to younger age being an excuse and felt that a
healthy lifestyle should start younger than 50, although this was often said with
hindsight. Expressing such attitudes with hindsight was common, for example
Michelle5 asserted her keenness to attend screening to discover any risk, insisted that
she would have attended invited screenings at a younger age and criticised others for
not wanting to know, for example:
Michelle5 (63yrs):.. .1 can't understand why people wouldn't want to know
And later:
Michelle5: I think there are still a lot of people who...I think they're wrong,
'cause I would rather know personally
However, whilst initially explaining others' non attendance as resulting from
optimistic bias, she continued by revealing that she too had shared this attitude prior
to having her heart attack:
HE:...you said you probably would have gone because you're the type of
person who wants to know but generally people do you think-
Michelle5: "it's not gonna happen to me"
HE: yeah do you think that's a problem as well 'cause people don't think-
Michelle5: yeah...I mean before I had my first heart attack, I did feel tired,
but I was just putting it down to-1 was busy in my work and er I was getting
older you know...but when I looked back on it I did feel tired I couldn't be
bothered doing things, I'm still a bit like that (laughter)...but er maybe that
was a sort of sign and I didn't realise.
Michelle5 had not attended the ABPI screening as she had suffered from a heart
attack and thus was ineligible; her husband had attended.
To summarise, optimistic bias was a common and understandable explanation for
screening non-attendance, particularly at the younger end of the age range amongst
the participants in this study, and was often discussed with hindsight, with a
subsequent change in attitude typically after an event or diagnosis.
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"If it's gonna happen, it's gonna happen"
Unrealistic optimism relates to one's beliefs about future health and low personal
susceptibility. In a way, this belief could be considered fatalistic: a person believes
that a heart attack is unlikely to happen to them so they are less likely to do anything
about checking the accuracy of their perceived invulnerability. A more explicit kind
of fatalistic belief discussed in people's accounts as inhibiting screening attendance
is epitomised by the phrase "if it's gonna happen, it's gonna happen", for example:
Aileen (focus group la, 67yrs): well I've got two friends, they're widows,
and they got invited to go up and they immediately said, "oh we don't want to
know if there's something wrong with us forget it, forget it"...()... they don't
go for breast screening, anything, they don't go, "if it's gonnae happen, it's
gonnae happen" that was their attitude
As this quote demonstrates, fatalism is a problem for screening attendance: if people
are fatalistic regarding illness, they are unlikely to see the benefit in finding out if
they are at risk. Alternatively, perceived inevitability coupled with a sense of
unpreventability may not entice preventive health behaviour and lifestyle change.
Fatalism was usually discussed when contemplating why other people did not attend
screening. Indeed, it was particularly common when discussing 'known others' as
demonstrated in the above quote. Similarly:
Patricia3 (61yrs): no I think, some people have this outlook, "well if it's
gonna happen, it's gonna happen" but I think- I know in Glasgow they are
particularly bad for that, they just don't want to know. My sister had never
gone for a screening
HE: really?
Patricia3: and I've gone on and on and on at her and she said, "no I'm not
going" she's just- her attitude is, "if it's there, it's there and that's it". But
she's really-1 can't understand, 'cause otherwise she's quite intelligent
Patricia3 found it hard to understand her sister's fatalism, which she deemed
inconsistent with her intelligence and awareness. This seems to echo assumptions of
some early health promotion campaigns where raised awareness was expected to
initiate action.
On the whole there were very few instances of individuals admitting fatalistic beliefs
themselves; one of the few examples involved focus group la participants. David
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compared and reflected on his own beliefs with those expressed by a fellow
participant
David (71yrs): I've got a sister and she's 83, and she's like a wee gazelle...a
retired school headmistress, er my father died when he was about 76, my
mother about the same age, just of natural causes, just died. I'm the same age
as Bob and I reckon all the time I've got now is a bonus, cause I've had my
three score and ten, and I'm philosophical about it, I- if I'm gonna die, I'm
gonna die. While I will not live recklessly, so I will die of something natural,
that's my attitude towards it I suppose
Later...
David: and it ends up you go back to, "when you've gotta go, you've gotta
go", there's a certain inevitability as Bob said, after we're born, we are gonna
die eventually (focus group 1 a)
In the next example, Alison2 justified her fatalistic attitude through acknowledging
awareness of the randomness of heart attacks, and the fallibility of publicised risk
factors in predicting all cardiovascular events, echoing the work of Davison et al.
(1991) and Hunt and Emslie (2001) on awareness of the prevention paradox in lay
epidemiology:
Alison2 (55yrs): well everybody's at risk, nobody knows- I don't think
anybody knows really do they that they-
Sister: it's not foremost in front of your mind is it?
Alison2: no it's not, that's what I say, just plod on and that's it I mean
nobody can truly say, "it can't happen to me" I don't think, because it could
do. I never even think about, "could I have heart attack, could I have this,
could I have other?" I just feel what has to be, will be...
Similarly, many participants gave examples of randomness and anomalies that could
have contributed to fatalistic beliefs, for example this extract from focus group 1 a:
Jen (64yrs): and yet look at the number of people who smoked and they're
90, and they're fine
David (71yrs): that's right
Andrew (59yrs): and you get them young athletes, and football players, that
drop dead with a heart attack when they're 19 or 20
David: that's right, my 83 year old sister, she smokes
?: really
David: over 20 a day
Jen: my grandfather smoked till he was 90,
Andrew: that's what they say innit, winning the lottery
Jen: and he liked his nip ofwhisky every night
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A particular case referred to in this focus group and in a few individual interviews,
involved a local 22-year-old footballer who had died of a heart attack very recently.
This served as a vivid example of a seemingly anomalous and random event,
something also identified in the lay epidemiology of Davison et al.'s (1991)
participants.
Interestingly, one participant's realisation of randomness had a different effect: it
heightened his awareness of potential risk and lessened any reassurance from test
results:
HE: oh right, did that- was that quite reassuring to have those tests?
Peter2 (55yrs): I suppose in a way but you know you just don't know what's
round the corner you know, you just don't know. I mean it could be a stroke,
it could be a heart attack, anything. I remember one of the wee cleaners in the
fire station, and she was a wee thin woman and that and she'd been in there
for years and one day she was just (clicks) like that, heart attack, massive
heart attack and that was her dead, but obviously you don't know what her
diet was and don't know her history or anything like that but that was...
So, for Peter2, fatalism persisted despite 'healthy' results. Such awareness of the
random and anomalous nature of cardiovascular events may have contributed to
fatalism regarding cardiovascular risk perception, however these expressions of
personally fatalistic attitudes were not discussed in relation to screening, rather in
relation to general cardiovascular risk perception and had not inhibited screening
attendance in these cases. So, it is possible that fatalism related to cardiovascular risk
would not necessarily influence screening attendance. Generally, fatalism was more
commonly used when talking about other people's non-attendance at screening, as
illustrated by the first quotes in this section, and was usually viewed as an ignorant
attitude that was hard to understand.
"Don't want to know"
Those who did not share unrealistically optimistic and/or fatalistic attitudes
sometimes rendered these attitudes as denial, often using the analogy of the ostrich
burying its head in the sand:
Eleanor3 (62yrs): but in the same token, if you do go and there is problem, it
will be dealt with before you lose your life. It really pays, the earlier you
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attend to it. It's like this as well, I think you know burying your head in the
sand, if you face up to it and I think that's- some people don't.
HE: yeah
Eleanor3: and I think that's why they don't take part 'cause they don't really
want to know, they just keep their fingers crossed that they're alright.
"Don't want to know" was a common explanation given for non-attendance at
screening, again predominantly when discussing others' attitudes. When explored
further, several explanations behind this attitude emerged. A first explanation
expressed by several participants ofwhy 'others' did not want to know was the idea
that non-attendees were simply not interested in their own health and body.
Peter2 (55yrs): really I think there's enough advertising and- but I think
really...it's getting through to people, and the biggest majority of people just
not interested, they're not interested, they don't care.
A couple of participants emphasised the difference between themselves and others
with regard to this explanation:
HE:.. .do you know any reasons why people don't go
Gordon 1 (67yrs): well again, they're nae interested in their health or
something, there must be something that- whereas I was really keen when I
find out cause I know I'm getting tested
A second explanation of not wanting to know was due to the possibility that
screening would reveal bad news:
Yvonne (focus group lb, 72yrs): well I've got a brother-in-law who's the
same age as I am and has the same doctor, and I got the letter and I said, "I've
got this thing to go to" and I had a date and he said "Oh I got one of those",
but he said, "not me", that was it, I said, "why?", "no reason", he said, "I'm
not going"
HE: why do you think?
Yvonne: he didn't want to know, he didn't want to find out if there was
anything wrong with him, I'm sure that was it. But you know, "it'll be good
you know", but no that was the end of the conversation he said, "no I'm not
going" and he didn't attend, and I couldn't understand that
In this quote, the participant found it hard to understand why her brother would not
want to know if there was something wrong with him as she herself could only see
the benefits of finding a risk if there was one. Other participants were less forgiving:
Nancy4 (69yrs): I think [screening's] a great idea, I think it's probably
unfortunate the uptake that you'll have...er judging by um the breast
screening uptake, you know which is not as high as it should be, so you
know...()...
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HE: do you think that's the main reason people don't attend?
Nancy4: they just can't be bothered for one thing, er and people say silly
things like "I'd rather not know" and things like that you know, um I would
think these are the main reasons.
Similarly, fear was often given as both a possible and actual reason for not wanting
to know and thus non-attendance. For example:
Jack5 (66yrs): well I think the fear element comes into it where they don't
want to- if they've got something that they don't want to know about it. It's
crazy I know, but a lot of people are like that...that er if they feel alright
reasonably alright they won't do it and they're quite happy about that, they
don't want to know anything...it's crazy I know but that's behind a lot of
people's thinking.
Whilst Jack5 deemed such fear to be crazy, others simply deemed it "wrong". These
participants struggled to understand how people could let their fear prevent them
from wanting to discover if they were at risk. Other participants expressed their own
fear of heart disease, and some of these who did not share this fear personally could
sympathise with those who did:
Ted4 (77yrs): I think people probably have a fear of having these kind of tests
because- because it might throw up something they would rather put off, I
think that certainly. There's aspects of that come into it I think as well, maybe
even when I was that time when I was- I could have this big survey where I
was gonna be investigated, although I said I had a medical not long before, I
think there were aspects of "I don't want to know in case maybe they're
gonna find I've got cancer or something like that you know" and that is a
fear, I think it's a natural fear
A couple of participants had experienced fear themselves but had forced themselves
to attend because to them, the benefit of discovering the risk outweighed the fear:
HE:.. .why do you think people don't come to this type of thing?
Mandy3 (59yrs): afraid? Or they don't have a family history, and they don't
really think they're affected at all and maybe if they do have but they're a
wee bit afraid ofwhat they might learn
HE: yeah.. .but you didn't think that?
Mandy3: I was apprehensive yeah I thought maybe they're gonna find out
that I've got something wrong with my heart or something you know, I was
apprehensive but I felt I wanted to do it
So, although she described being afraid when attending screenings, Mandy3 realised
that she would rather know if there was something wrong so there could be
something done about it. A few participants, including Mandy3, disclosed fears that
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they or their relatives had, not specific to screening, but which contributed to non-
attendance including fear of contact with the medical profession, hospitals and
needles.
Participants who compared heart disease with other illnesses admitted to having a
much stronger fear of cancer. For a few, this meant that they attended the present
screening but were too afraid to attend cancer screenings (Jennifer2 below), whereas
others attended cancer screenings but insufficient fear of heart disease seemed to
inhibit attendance at the present screening (Isaac3 below):
HE:.. .there's a large percentage of people () who don't come
Jennifer2 (61yrs): who don't go, I don't understand that, maybe because they
feel healthy and say, "I'm healthy and that's that" whereas they should have
gone and, I mean I would go even if it was somebody who came along for
cancer tae because if it was anything along the lines I would go y'know, see
because I think aye we're needing breakthroughs from heart disease and
cancer and that
HE: do you go for other screenings, have you been for the sort of cancer
screenings?
Jennifer2: no, no, never, no
HE: have you not been?
Jennifer2: ashamed to say, no I'll no' go. And I should go because my
daughter she's 39, and she actually went, she had a lump and they found out
she's got it's calcium, right doon here has broke away from bones and that
can go cancerous over night so she's going like every two month to get
mammogram every two month, so noo I think they're gonna do a big biopsy
and I don't know why because they say they're gonna take biopsies, they're
getting wee bits o' scar that they're wanting this big bit, so I don't know what
first but she gets called back every time she goes they phone, "will you come
back over?" so this is hanging over her and they're right, I should go and I
think that's what's making me frightened to go
HE: what because she's got something
Jennifer2: uh huh, that's frightened me
HE: yeah
Jennifer2: and I mean, just how you are that is. I think that my Mum having it
tae an' that, that was a wee bit.. .frightened o' that
HE: how do you see that as different like to going for a screening for heart
disease?
Jennifer2: I don't know, I've got more a dread, more a fear of cancer than of
heart attacks, aye aye, I have
So Jennifer2 began by expressing feelings of individual responsibility to attend all
screenings and declared her own keenness to attend all offered screenings,
emphasising her desire to help contribute to medical knowledge, mentioning both
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heart disease and cancer. However, she later admitted not attending cancer
screenings, and, as her reasoning unfolded, she divulged fear arising from cancer
scares and the experience of cancer in two first degree relatives. Whilst not
specifically mentioning the importance of heredity in her fear at this point in the
interview, the vividness of the experience seemed to be sufficiently daunting.
Conversely, Isaac3 explained how a similar distinction between heart disease and
cancer had manifested in the opposite behaviour in his wife:
HE: I was just wondering how you can get- how you could get someone like
your wife, or if people don't want to go, they don't want to go
Isaac3 (58yrs): they don't want to go, you could have er this and that and then
yet the well woman clinics, she (his wife) goes to that
HE: oh right, so how does she see that as different?
Isaac3: I don't know, it's probably something to do with maybe they read
more about it and everything, you know breast cancer, smear tests and all that
I think maybe that keeps them sort of saying "yeah it's good I'll go for that"
whereas the heart side I don't think people really look at it in the same way, I
don't know why but "it'll never happen to me".
The distinction between fear of heart disease and cancer echoes previous literature
(for example Nic Gabhainn et al., 1999; MacFarlane & Kelleher, 2002). Also
including the preference for dropping dead of a heart attack over lingering on with
cancer, which is problematic as heart disease often entails 'lingering on' of a
different kind with severe disability (Emslie et al. 2001).
A further explanation behind not wanting to know came from a contradictory belief
to unrealistic optimism: a couple of participants suggested that non-attendance could
stem from fear arising from people's awareness that they are likely to be at increased
risk of heart disease due to their lifestyle or family history:
Owen4 (52yrs): I would obviously have been a bit anxious and a bit
depressed I suppose but obviously I'd still be grateful that it had been picked
up and I certainly hope that wouldn't be a discouragement for people from
going but I do understand that for some people it might be- that some people
if they have a suspicion that they maybe are not as healthy as they are maybe
don't want to go to the screening programme and have that confirmed.
So, more along the lines of: "it will happen to me", not knowing one's risk (which
the screening test would reveal) may be a method of avoiding anxiety: as the well
known saying goes, "ignorance is bliss". Similarly, that screening could lead to bad
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news which would in turn might require unwanted lifestyle behavioural change, was
suggested as another reason behind not wanting to know. For example in focus group
2:
Cath (63yrs): no I think it was what you (Emma) were saying about fear
going on because of that time you went and you had- well was speaking to
another friend who's about my age and she said she just enjoys life, and she
just enjoys her wine and whatever and her food and she's put on a bit of
weight and all the rest of it, but she said, "I just don't want to know if I've got
high blood pressure, I don't want to know", it's like they're blocking out and
they just want to live the way they want to live, they don't particularly bother
about changing their- they would have to change a lot but they want to enjoy,
and they say, "if I drop dead tomorrow, fine" she says, um you know that's
their attitude
Ursula (61yrs): it is an attitude
Cath: whereas other people
Ursula: and there's lots of people like that
Cath: a lot ofpeople like that yeah
Ursula: they live for the moment
Cath: yes, I had a friend who was diabetic and he didn't stop drinking and he
didn't stop his lifestyle and I think he thought, "well, it's too late now, I'm"
he was in his 50s and he just carried on just drinking and
Ursula: that's young 50
Cath: smoking and exactly, but it was like, "oh well, I'm enjoying life and I
don't want to stop" and he didn't and he died at 66, but that goes to show you
that it was in the attitude, the problem
A few participants admitted that they were reluctant to change their lifestyle, for
example in the following extract from focus group la, one participant maintains this
attitude even when challenged by another focus group member:
Andrew (59yrs): that's exactly what I was like, ... I've not gone changing my
life, I still smoke, I've not stopped, I still smoke, I've not stopped drinking, I
always eat the same things and I eat what's nae good for you, cause these
health foods and that I don't like 'em. Putting it quite bluntly, I dinnae eat to
look after my heart, I eat what I like
David (71yrs): he's gonna die happy
(laughter)
Julie (56yrs): but do you not think that it gives you the opportunity to change,
the opportunity to change if you want to change?
Andrew: it probably does
Julie: it makes you aware, which surely it's a good thing
Andrew: I'm aware of the fact, but there's nothing wrong with heart, there's
nothing wrong with it...
In the above extract, whilst advocating individual responsibility regarding lifestyle
change, Julie questioned Andrew's refusal to make such changes, but Andrew's
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desire to lead an enjoyable life seems resistant to challenge. (Equally resistant to
change is his risk perception, as despite a low ABPI he saw no problem with his
heart; this will be discussed further in later chapters). Other participants were more
judgmental when discussing the reluctance of others to change their lifestyle, and
sometimes spoke stereotypically about people's lack of education, believing such
low awareness to be the root of non-attendance:
Lorraine (focus group lb, 52yrs, DEPCAT 4): and again that depends on you
being in the group of society that knows that what you do...()...I think a lot
ofpeople are frightened of going to doctors and you get that across the board,
but then there's also a group who feel perhaps because of their lack of
education and whatever that they won't understand what health professionals
say to them. Nobody here's gonna be like that but there are people- I've been
in hospital quite a lot over the years and it's always struck me that each time I
go in I think yeah well I know the system and I know how to play it. But
there are other people there that don't know, they don't understand the words,
they don't understand the terminology, they're living in a sort of.. .institution
that they're not used to and it makes them frightened and so the minute they
get out they don't want to go back, they don't want to follow up, they don't
want to go and see a nurse, they don't want to go and see anybody, just wish
it away, and it's fear and it's lack of education in any case
Another participant, less judgmental, expressed her concern about the impact of
socio-economic circumstances, acknowledging the difficulties of lifestyle change for
people from more socially disadvantaged backgrounds:
Moiral (53yrs, DEPCAT 4): well I think that's partly to do with the fact that
one doesn't necessarily want to know, if you see what I mean, I think it's-
and I recognise that syndrome that's the head in the sand thing, particularly if
you've got it in the family. Also I think, it's this my nervousness about
having the high blood pressure, if you know that your behaviour could
potentially be contributing to ill health, so if you smoke heavily or you're
drinking too much or you're overweight, or all three, or whatever, you think
"ooh God, do I really want to face up" because that might make me feel "god
I've got to change" or confirm what I know in my heart of hearts, I'm really
very unhealthy...()...and you see somewhere like Glasgow where there are
huge pockets of deprivation, huge, huge pockets, and you think, well I don't
blame anyone for saying "sod off, I don't want to know". It's people like me
that can afford their nice organic food and the olive oil, that get all terribly
good and conscientious
Moiral did not advocate individual blame and responsibility, rather she realised the
wider impact of social and cultural circumstances with particular referral to the
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context in Glasgow. Similarly, several participants felt that a rejection of a healthy
lifestyle was embedded in Glaswegian culture:
HE: so you think people don't want to know, why do you think that is?
Daniel4 (54yrs, DEPCAT 1): yes Glasgow, anyway and Em from Glasgow,
they are set in their ways
HE: uh huh
Daniel4: Instead of going home and cooking a good meal at night, they'll go
and buy a fish supper, and that doesn't help heart disease...OK I like fish
supper, it's nice, but now that I'm retired and I've sort of learned...that
there's more than fish suppers
IsobeB (60yrs, DEPCAT 4): .. .they may think that to come along they may
be curtailed, and the first thing, especially with heart I think everybody
thinks, "Oh, can't drink", so I would think in a Glaswegian population like
their drink! So they would rather not know, and give up their drink until it
was totally at death's door, I would think that is- or give up the smoking,
you'll get that, "they'll want me to give up smoke and drink and I'm not
going 'o"! They would see it as being maybe lectured
These participants recognised the difficulty of encouraging lifestyle change within
the context ofGlaswegian culture.
Although generally critical of the "don't want to know" attitude, and/or being keen to
discover their own risk, participants were familiar with this seemingly common
attitude and drew upon experiences and conversations with known others to propose
explanations behind it and its potentially inhibitory effect on screening attendance.
"What's not broken, you don't fix"
Timothy5 (61yrs): no that was this thing with cancer it happens to other
people.. .it's the same as a heart attack
HE: do you think that most people think like that, that's why they wouldn't
get checked up for-
Timothy5: aye- 'what's not broken you don't fix' you know, that's just the
way it is... it's not like er...it's not like what you call it plant maintenance
thing
In this quote, Timothy5 sums up a further common and seemingly logical belief: why
bother fixing something that is not broken? In relation to preventive health, as long
as we feel well why would we attend a doctor? Timothy5 also points out that this is
unlike the way we look after other 'mechanical' systems that are regularly checked
for faults. Although seemingly logical, this attitude may affect the likelihood of
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detection and treatment of asymptomatic illnesses and conditions. Serious illnesses
such as many cancers tend to be asymptomatic for a long duration, once symptoms
appear the illness may be quite advanced. Regarding risk factors for heart disease,
individuals can live for years without knowing that they have high cholesterol, high
blood pressure or furring of the arteries.
For some people this was a logical attitude; they regarded checking an apparently
well functioning system as pointless or unnecessary, as the following example
illustrates:
Keithl (59yrs):...I must have had poor circulation anyway even from then. I
don't know ifmy blood pressure was- 'cause no-one ever checked your blood
pressure then. I mean it's like everything, if there's something wrong you'd
have done something about it, if there wasn't, you just left it.
Cath (focus group 2, 63yrs): I tend to just go when I need to, I don't normally
go for check ups for unnecessary reasons
In particular, participants often said that as long as they felt fit or healthy, they would
not go for any check up; usually a key incident was required to provoke regular
checks:
HE: ...if you'd received a letter then inviting you, what do you think you
would have done, do you think you would have gone or not?
Susan5 (53yrs): I wouldn't have gone
HE: why not?
Susan5: I would say, "I'm healthy"...that's just the only answer, I wouldn't
have gone.. .but now I've got all this I would do
HE: do you think a lot of people think that because.. .because you felt healthy
and was it because you felt...?
Susan5: yeah I felt alright...I can't answer for other people I don't know,
there's a lot of people that love going to the doctor (laughs)...the doctor said
"You will come back", I said "aye I'll see you in two years"
HE: you yourselfwouldn't have gone
Susan5:1 wouldn't have gone then, no
HE: so what age do you think you maybe would have gone? If none ofwhat-
if you hadn't found out all this blood pressure business that you have
Susan5:1 wouldn't have gone
HE: you wouldn't go
Susan5: no
HE: just as long as?
Susan5: long as felt alright...that's stupid isn't it? I mean you should go and
get a check up there, if I hadn't gone for my skin I wouldn't have found
1 :trial participant 2:stopped trial tablet 3:trial decliner 4:healthy ABPI 5:screen non-attendee 110
out...but that is the truth, to be honest with you, I just want to say the truth
that's only way you're gonnae get answers
However for a few, even a low ABPI result in the present screening, or surviving a
heart attack did not encourage regular check ups:
HE: would you go for a check up now [after low ABPI] yourself at the doctor
in say a year's time again a sort of heart check up to follow it up or?
Morag3 (64yrs): I don't think I would go unless I felt I had problems
HE: do you go the doctor regularly now [post heart attack] for like check ups
and things?
Harold2 (63yrs): not really no, just if I feel something
HE: do you go for any check ups on your blood pressure?
Harold2: no, not really no. If I found, if I feel as if I would go and if I-, I
mean that's why you get repeat prescriptions and you don't need to go 'o the
doctor you know, you just hand it in
This attitude relates to participants' general attitude towards consulting their GP.
Some implied there was a tough mentality, particularly in older people, which led
people to wait until a condition had progressed to severity before getting help
Gordonl (67yrs):...so I believe in going to the, aye, I'm quite safe going to
that 'cause I know they're testing my blood, so I think they should be-
everybody should, especially when they get older, go for a regular check up
anyway. 'Cause my mother died and there was a lot of older ones in their
days because they didnae go to their doctor.
It seemed that for some people, consulting the doctor signified 'giving in' to illness
whereas avoiding the doctor demonstrated one's healthiness. This echoes findings of
Blaxter and Paterson (1982): their older participants explained tendency not to
consult due to preference for 'mind over matter' models of cure and not wasting
doctors' time, relating to both emphasising their strong character and fatalistic views
of illness. Similarly for Cornwell's (1984) participants, admitting ill health had
negative moral connotations and demonstrated one's moral failings. Linked with this
tough mentality, participants in the current research often distanced themselves from
those who they considered consulted the doctor too much who were regarded
negatively and were often referred to as "hypochondriacs", again echoing Cornwell's
(1984) findings.
Dennis4 (75yrs): well I was fairly fit, I mean I walk pretty often, I play golf, I
wasn't like unwell or anything like that
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HE: uh huh...() do you think a lot of people are like you and you know
ignore the first one (invite)?
Dennis4:1 think so, because unless you're a hypochondriac
HE: yes
Dennis4:.. .you let things ride I mean I just let things ride.
Monical (66yrs) stated how this was particularly true of older people, that they
consulted for unimportant instances. This contrasts with Gordonl's view above,
regarding 'older' people:
Monical: I wouldn't like to waste the doctor's time and I think that there are
a lot of elderly people () and they're never away from the doctor, and as you
say and I happened to say to one of them as well, "I'm getting really deaf', I
had a mastoid years ago, getting really deaf in that ear you know, but I'm not
doing anything about it. If it gets infected or discharges I go and get my
drops. [This older woman said,] "you know I've been like that as well, I was
away to the hospital, you know I went to the doctor's demanding that I see a
consultant". I said, "for heaven's sake" you know, to me that's time wasting,
because if you're 84, everybody gets dull hearing at 84, you know...
Others were less concerned with being perceived as hypochondriacs, and like
Monical above, they were more concerned about not wasting their doctor's time,
often due to an awareness that doctors are overworked.
Some participants expressed their awareness of why the "not broken, won't fix it"
attitude was a particular problem for heart disease, as they felt that the earlier that
problems are identified, the better:
Patricia3 (61yrs): People are lazy too, they think, "well if I'm alright at the
moment, why do I need to go?" they don't sort of see that anything that's
ongoing that hasn't had symptoms at the moment can be picked up and save
lots ofbig problems later on
The asymptomatic nature of heart disease was considered dangerous and concerning
by some:
Keithl (59yrs):...The thing is that it's a disease you can get, you don't know
you have it, there's nothing- it's not like you're- when you get the flu and
you've got a sniffly cold and there's something wrong with you, but you have
high blood pressure and you can be perfectly OK, it's not till it's got to the
point where it's really done all the damage that you usually know the effects
of it. So without really checking people earlier on, there's no way really you
can stop them getting the effects of it.
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The participants in focus group 2 concluded that it was a "silent killer". A few
participants pointed out that if symptoms were waited for, it could be too late as the
symptom could be a heart attack itself
Craig4 (54yrs): You wouldn't, I don't think, think to go along to your doctor
and say "I'll have my blood pressure checked" so er and that's exactly what
happened to my friend I mean he had no reason to believe that- people don't
know about high blood pressure- he had no reason to believe that and then
suddenly bang!
With this in mind, some participants recounted fortunate discoveries of an
asymptomatic risk, usually high blood pressure, diagnosed by chance, perhaps while
consulting the doctor for a separate reason, when registering at a new doctor's or
through an opportunistic check in the workplace. For example:
Ted4 (77yrs): and from the tests, which were given- taken at the time, they
found out I was diabetic, but the point is if I'd been still with the old doctor I
would never have known, you see this is the thing so it's a wee bit worrying
that to think that people you know can go through life like that and that it's
only just via chance, such as a doctor retiring that you find out by going to
another doctor who does tests.
HE: would you feel it'd be better to have sort of regular check ups?
Ted4: well this is a example, you know, a regular screening would take the
place of somebody having to find out things by like having to go to another
doctor.
Prior to these 'chance' diagnoses these participants had considered themselves in
good health and their tendency not to consult until symptomatic would not have led
to such a lucky discovery. Such instances thus led to concern and the realisation that
the asymptomatic nature of heart related risk factors does not fit with normal
consulting behaviour at present.
Considering the background to typical (non-) consulting behaviour, and lack of
preventive health consultations, participants attributed this widespread attitude to
British (and in particular Scottish) culture. A few participants compared this culture
with other countries where regular check-ups are commonplace; a couple of
participants mentioned the apparently efficient systems in the North Americas and
others described experiences in other European countries:
Owen4 (52yrs): But we don't have a culture in the UK, in Scotland, about
regular medical check ups, I mean that's part of the difficulty. Er I mean I
know it's easy to- it's almost fashionable to say but I do contrast even the
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kind of visit to the GP I would normally have, and I have no problem with the
service I get from the GP is absolutely excellent when I require it but er, but
the kind of approach in a standard appointment with my GP compared to the
unfortunately very odd time I've had to use health service abroad. Er because
I've been- er I had a number of doctor appointments when I was in France
and the service was, I mean, was superb in terms of time, in terms of going
through all the routine medical stuff while you were there, and I know from a
previous occasion some years back my wife had to go to the doctor in France
when on holiday and I mean again the service was excellent in that way- you
know everything but everything is checked in terms of blood pressure and so
on.
HE: when you turn up for something else?
Owen4: when you turn up, I mean nothing remotely connected with that kind
of issue but it's almost like a standard thing that they do now. That is not
unconnected with the differentiation of the health service and the way that it's
funded and so on and what-have-you but you'll know more about that than I
do I would imagine, but it certainly does contrast with you know the feeling
sometimes that you're kind of rushed with appointments at the doctors here
but I have to say I think that again we need to work to establish the culture
where all parties in the health service- in the health business here- the doctor
on the one hand and the patients on the other you know are quite happy for
people to come and get preventive health checks.
This explanation removes the responsibility from the individual, and the required
change is regarding to be at a higher level, i.e. the health service. A few participants
felt that such a change should entail incorporation ofmore preventive health:
Henry (focus group lb, 67yrs): talking about these things, I think this is one
of the big failures of the National Health Service, in that they don't do an
awful lot ofpreventative checks.. .if you intend to get an MOT, if you want to
call it that, every year or six months, they could catch an awful lot of illnesses
long before you know people have nearly died because it doesn't show until
the last minute.
This idea of regular "MOT" checks was suggested by many participants, for example
Keithl explicitly used the analogy of the car MOT to illustrate his feelings of
illogicality regarding the lack ofpreventive health:
Keithl (59yrs):...I was in my mid fifties when I'd seen the doctor and I
thought "well [my father] started to have problems then, when he was in his
late fifties". So I just thought, "well I'll ask him about it". A lot of times, a lot
of doctors don't really check you out as such. I feel it's a bit strange that you-
I bought a car, and after it's 3 years old, it's got to be checked every year
after that. Now, they go on about how much this costs the National Health,
the cost of treating people, but is prevention not better than cure? Would it be
not better if people were given, when you can after a certain age or
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something- was it 65 or 70 or something like that, you can have your doctor
give you a yearly MOT if you want 'o call it.
It is interesting to note that Keith 1 made this suggestion as it demonstrates how
participants' attitudes regarding preventive health change over time; earlier he was
quoted describing his "not broken, don't fix it" attitude which he said he held prior to
discovering his high blood pressure and low ABPI.
In some participants' GP practices, regular health checks were offered through '75+'
clinics and 'well woman/man' clinics. However, this varied with different practices
and continuation of such clinics depended on uptake. Such discussions in focus
groups led to a discovery amongst participants of inconsistencies between different
practices. This led some to feel almost cheated regarding provision at their particular
practice:
Rod (focus group la, 53yrs): my GP started er probably 6 or 7 year ago
erm...it was a 'well man' clinic, I think you went once a year and they took
blood and you gave urine samples, took the blood pressure etc etc etc, but it
was like this we were sent a letter, and it was- you were given you know
"from the week beginning the 6th to the 13th" and got it sorted it out between
things and such and such and it was purely voluntary, but general apathy so
they ended it,
HE: did you go?
Rod: of course I did
Jen (65yrs): you'd never get that in our surgery ever
Aileen (67yrs): you're lucky if you see a doctor
I asked participants what age they thought cardiovascular related screening should
start. Fifty was considered particularly appropriate by many participants as it was
deemed a physical milestone after which health problems increased. For others, it
was regarded as a psychological milestone, a turning point at which they began to
think more about their health and lifestyle, a marker of an older age at which more
careful and sensible lifestyle was required:
Morag3 (64yrs): ...I think 50 is probably quite a good age because for most
people it's when you get the beginnings of um little things perhaps going
wrong and you begin to realise that you're not as young as you once were
Joe2 (56yrs):...I would have thought that...well any sensible person getting
to the age of 50 is beginning to think, and beginning to waken up to stop
doing stupid things like too much drink or too much this or too many
excesses of any kind, er and I think that your health is just part of that as well
1 :trial participant 2:stopped trial tablet 3:trial decliner 4:healthy ABPI 5:screen non-attendee 115
A large number of participants felt that the starting point should be earlier for
example 40, due to the realisation that heart attacks can occur before 50, however
this was predominantly expressed in hindsight. Some of these through further
consideration, admitted the unlikelihood of attending at 40 themselves. Furthermore
50 was considered too young for some due to the dominance of work and family
commitments at this age. Also at 50, the "not broken, won't fix it" attitude was
considered more pronounced as most 50-year-olds will still feel fit and healthy.
HE:...do you think you would have attended at 50, thinking back to when
you were 50 if you'd got the same letter then?
Fred2 (62yrs): no I don't think so, no, erm thinking back, at 50 year old I
don't think I would have bothered, I wouldn't have taken it up, no
HE: why's that?
Fred2: er, because at that time I had no concerns or such like for it, I just
wouldn't have bothered with it you know and Fd probably never have read an
article if I'd seen something I would have just by-passed it, but because of the
last time, because I was over 60 and such like, I said to myself, "well maybe I
should get myself checked out" you know
HE: did you see 60 as some kind ofmilestone?
Fred2: well yes I did you know 60 you know, and with not attending the
doctor or going for any check ups, er I said well, "this is a way of having it
checked" you know
So for Fred2 (62yrs), 60 was a more appropriate age. Another participant discussed
the idea of a cut off age at the older end too:
Richardl (54yrs):... unless you're one of these unfortunate people that are
gonnae get a heart attack when they're 35, but they're a very small minority
aren't they? Not a lot of people you know. I would have thought 50 to- 40 to
60 would be a good screening age, I mean I maybe sound ageist but I can't
see the point of people worrying about things like heart disease when they're
over 70. You know why bother?! (laughs)
As previously mentioned, access was given as a difficulty regarding screening
attendance particularly referring to the fifties:
Henry (focus group lb, 67yrs): well man clinics, if you're working, are no
use, cause they're all held in working hours
HE: right yeah,
Henry: so you can't take time off work to go to 'em, so if you can't attend
these things
HE: so they could have evening clinics?
Henry: or even Saturday mornings, but they don't
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However, other participants regarded such reasons as an excuse for not wanting to
attend:
Isaac3 (58yrs): yeah well my wife got one, she said "no I'm not going", and I
said "it'd be worth it, you know you'd find out" but no she didn't
HE: why was that?
Isaac3: oh she saw it as, "no I'd have to get time offmy work and it wouldn't
be suitable" and I said "well, we'd make sure it was a morning", she only
works part time in the afternoons, so we'd make sure it was a morning, "no,
no, she said, too much hassle" (laughing)
HE: do you think that's her real reasons or
Isaac3: I'm not too sure to be honest (laughing) not too sure, I think partly
that was the reason, no it was gonna be awkward to fit it in, but er yes, she
might have just been like a lot of people "I don't want to find anything"
At a different level of consideration, participants usually recognised implications for
the NHS of regular MOT style checks for everyone:
HE: so you used to get checked at work
Amy2's husband (77yrs?): aye, aye cause you were either in BUPA or NPP,
something like that and they checked you out once a year.. .but I didnae know
that you could do what she [friend] did, go once a year and get this sort of
over all
HE: I think you'd have to pay
Amy2 (76yrs): aye it was a hundred pounds or something or two hundred
pounds so
HE: do you think things like that should be available through the GP?
Amy2: I suppose it would be- what would the National Health say about
that?! (laughs)
A further implication related to cost in terms of doctor time required for carrying out
MOT checks. Participants' awareness of the already overburdened GP workload led
many to comment that GPs have insufficient time to treat ill people, let alone the
healthy, and the difficult task of encouraging people to come would increase work:
Ted4 (77yrs): no I still think that people as I say should get more help from
the doctor but then doctors are claiming that they're overworked and very
little time for this kind of extra...it's very hard to get them on doing this,
which is treating healthy people isn't it? You're talking about those who are
already healthy so they'll continue to be healthy but then they don't go to the
doctor in the first place so where does that leave you?
Some participants questioned whether doctors themselves would regard health
check-ups appropriate use of their time:
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Isaac3 (58yrs): I think the private funded ones I think are maybe better
because people accept this, it's not like the doctor sort of saying "come
along", you go I think of your own volition to these, it's a case of well you
can go or you can turn it down. You get a full personal report of your own.
Um if you go to the doctor, I think nowadays you probably could ask for a
report but I've never ever went to the doctor and asked for a full medical,
er...I don't know if they even see that as what they should be doing to be
honest.
Furthermore, a few felt that their request for a check up might be rejected and that
they would feel as if they were making a fuss about nothing; this was backed up by
experience, for example GeofD recounted asking his GP:
GeofD (68yrs): no I once put my own practice to the test
HE: oh really?
GeofD: yeah I was about 55 at the time, I knew what I was in my work and I
said, "I really think at this age, it's time you gave me a full medical
assessment" and the fellow says, "what do you want that for, you look
healthy"
HE: really?
GeofD: yeah and that was that, I didn't push it, but I felt that between 50 and
55 people should be going on these things to see if they can catch now what
might be a problem when they're 65, 70.
In focus group la participants had a discussion about the potential impact of regular
MOTs on doctors' schedules and one participant reflected on the influence of
obligation:
David (71yrs):...You'd be just going through life having medical check ups
just in case you're gonna get something dreadful you know, you might even
get leprosy .. .or brittle bones, I mean when do you check?
Rod (53yrs): you check once a year, if you can
David: MOT, yeah an MOT every year or two years or, but then the whole
system would clog up and everybody would just be going for MOTs all the
time
Bob (70yrs): you only get an MOT (car) because it's compulsory, if it wasn't
compulsory...
This was an interesting realisation about the probable uptake of non-compulsory
regular 'MOT' health checks.
The reported tendency to consult once symptomatic is problematic for the
asymptomatic nature of heart related risk such atherosclerosis. Many participants
believed changes in the health care system, including more preventive health care
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such as MOT style checks starting at an appropriate age, could possibly tackle this
but recognised many additional barriers. Generally, with the realisation that a line
has to be drawn at some point, either 50 or retirement were considered appropriate
starting points for offering such screening, and earlier check ups were suggested for
those with a family history of heart disease. As discussed earlier, for many
participants their positive attitude towards screening and 'MOTs' was expressed with
hindsight and many admitted this. Their accounts of the belief that "what's not
broken, you don't fix" and their views about current consulting culture are useful for
those considering the planning and delivery preventive health checks of this kind.
In summary, the first part of this chapter has focused on explanations for non-
attendance at screening, i.e. barriers, which I have presented, illustrated and explored
centring on four key phrases which sum up these 'barrier beliefs': "it won't happen
to me," "if it's gonna happen, it's gonna happen," "I don't want to know" and
"what's not broken, you don't fix". The ubiquity of these key phrases in participants'
accounts across groups suggest that the phrases operate as cultural shorthands for
shared lay knowledge, and have significant lay meaning. The following section
reflects on the associated meanings, focusing on whose attitude or behaviour the
phrases were being used to describe.
Whose attitude?: Individual rights versus responsibilities
The key phrases discussed so far, and the beliefs and attitudes underlying them, were
used in participants' accounts to explain behaviour of themselves currently,
themselves in the past, other people in general and known others. Whose behaviour
and/or belief was being described seemed to be related to the participant's attitude
towards that belief in terms of its acceptability. In participants' accounts of their own
attitudes and behaviour both past and present, explanations justifying the attitude
allowed further exploration of the background to the attitude; distinctions between
past and present beliefs illustrated how people's attitudes change with time and
according to situation, life circumstances and health events. Accounts of the attitudes
of 'known others' were particularly interesting as they entailed explanations revealed
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in conversations with these relatives or friends rather than speculations about others
in general, and participants' accounts often included their own comparison between
the attitudes of themselves and the 'known other'. In some instances, particular
groups of others were discussed; a few participants generalised about the less
educated or more socially disadvantaged. Others, while attributing particular
attitudes to certain social groups, discussed this in recognition of the impact of
people's surrounding social and cultural context, with particular reference to
deprivation in Glasgow.
To recap, the majority of participants who introduced the "what's not broken, you
don't fix" attitude could empathise with it and embedded it in wider discussions
about British culture, particularly the health service. An optimistic bias was evident
when describing attitudes of both self and others; concerning their self such
optimism was present in beliefs reported as existing prior to a cardiovascular event or
risk diagnosis. Thus, the majority of participants could empathise with the belief
even if no longer thinking that way themselves; those who did not, criticised those
holding this attitude for a lack of personal responsibility. Whilst a few participants
had fatalistic attitudes ("if it's gonna happen, it's gonna happen") regarding health
and cardiovascular events, fatalism as a reason for screening non-attendance was
predominantly used to describe the reasoning of other people and in particular known
others such as relatives who reportedly had revealed this attitude in conversation
with the participant. Similarly non-attendance due to denial ("don't want to know")
and fear were common suggestions of other people's behaviour; participants who
disclosed fear themselves had still attended screening. Overall discussions of fatalism
and denial as explanations for non-attendance were fairly negative, and an
implication of individual responsibility ran through many accounts.
Implied individual responsibility, both to lead a healthy lifestyle and to attend
screening highlighted an interesting argument: that of the rights of the individual
versus their responsibilities. As mentioned earlier, some health promotion campaigns
in the past focused on the individual's responsibility for their own health with less
emphasis on the complexity of the sociocultural context in which individuals live and
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make decisions about their health. Some of the examples discussed earlier, for
example regarding criticism of optimistic bias, implied that people had a duty and
responsibility to attend screening (for example Craig4); when asked explicitly, a few
participants did express such a view. The following participant went further by
suggesting that such screenings should be mandatory:
Gordonl (67yrs, DEPCAT 7):...must be hard because people's no' interested
and that's where I come back again- I'm interested but there's a lot no'
interested, you find that, they're not bothered aboot their health, ken what I
mean, they just dinnae bother. And it would be hard but there should be a test
where you had to go, whether you like it or not, maybe once a year or you
know, everybody, and that would take a lot ofmoney, a lot o' expense.
A couple of participants felt that people should realise how lucky they are to have the
opportunity and therefore should demonstrate responsibility in appreciation:
Eleanor3 (62yrs, DEPCAT 2):...I always have gone for smears and
mammograms and I think we're lucky in this country that we do get the
opportunity, in some countries they don't, I think we're lucky that the
facilities are there
Not all participants shared such views; in fact one participant challenged me for
implying responsibility:
HE:... I mean do you think that this sort of screening check I mean
realistically do you think you can get to people if they don't want to go
Ted4 (77yrs, DEPCAT 1): well you must know, or something you'll
appreciate, when people are ill they start to think "we should have the
checks" and all this but when people are not, you know they don't think this
is necessary....()...Especially if you happen to be of the feeling that you're
invincible (laughs) and nothing like this is gonna happen to you. I think that
would be about it. I get a feeling that I know you don't really mean this but
you seem to befeeling that people should do this
HE: oh no not at all, I mean I'm just putting questions to you
Ted4: but then because it's obviously, it's commendable that people you
know think about this, but it's not also- you know it's understandable why
they don't
(my emphasis)
A closer look at Ted4's account revealed instances where he himself implies an
emphasis on individual responsibility, however the above quote demonstrates his
understanding and appreciation of reasons for non-attendance. Ted4's interview
however did lead me to reconsider my own stance on this issue, and examine
whether my questions or discourse which were intended to be neutral were in fact
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implying only benefits of screening attendance. For the remaining interviews, I
introduced a question to allow me to address this issue explicitly rather than
ruminating over implications in people's accounts: "do you think people should
attend such screenings?" However participants possibly still regarded me as
representing the trial and thus holding the view that people should attend.
The notion of responsibility can be further examined with regard to whom the
responsibility is directed. Howson (1998) discussed the idea of one's social
responsibility to maintain one's health; on other words a responsibility to society to
keep oneself healthy and thus reduce the burden on the NHS. A couple of
participants did express this kind of stance. For example Imogenl expressed strong
criticism regarding unhealthy lifestyle:
Imogenl (61yrs, DEPCAT 1):. I mean some people are as I say they have
their own life, they've got to live their life as they want, you know but I feel
that erm...maybe I should say this but if they continue and they still expect
the medical treatment, like my husband I mean he was- I mean somebody
said to him when he was in the hospital waiting for this surgery, "had he won
the pools or something?" because this surgery was thousands and thousands
of pounds, you know and he worried a little bit about that, because somebody
had wanted to be done, and they weren't getting it done and they felt like he
was taking their- he was going in first
HE: really?
Imogenl: yes, um this was and he was a counsellor of some sort
HE: oh right
Imogenl: at the time, I mean we- we know it's a lot of money to have this
surgery, but I mean that I feel that, it somebody has this and then they come
out, and then they have this surgery, you know the doctors put them right and
then they come out and they go straight back to the lifestyle they had before, I
mean to me it's wrong, but you see you can't tell people how to live, they
have to choose, but I don't think they should expect for people, you know
doctors and everything, to help them if they are not gonna do their part
HE: uh huh
Imogenl: I feel really strongly about it, you know it annoys me when I hear
of people having- they're having the surgery and then they just go back to the
way they lived before and they abuse it
The fact that Imogenl's husband's life was saved by his heart operation had led to
feelings of responsibility to lead a healthy lifestyle afterwards. She criticised people
who returned to an unhealthy lifestyle after such operations for their lack of
appreciation for life-saving care, and raised the issue that there is always someone
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else on a waiting list for the same operation who could be more deserving. She
recognised the right to personal choice regarding lifestyle but personally felt that
responsibility and gratitude were more important.
A different type of responsibility expressed by a couple of participants was one's
responsibility to one's family:
Janice (focus group 4a, 70yrs, DEPCAT 1): I was thinking ofmy son, there's
more a history of his father's side as well as my side
For this participant, joining the trial was regarded as synonymous with attending the
screening, her reasoning being her son's future health. Whilst implying altruistic
reasoning (discussed further in the participation chapter), this also seems to be linked
with feelings of responsibility towards a specific other, i.e. her son. This relates to
findings of Hallowell (1999) regarding feelings of responsibility in women with
hereditary breast and ovarian cancer towards other family members. However, the
issues were different for Hallowell's participants in that the risk identified was
genetic.
In contrast to the individual responsibility perspective, a few participants pointed out
that screening is not compulsory, so individuals have a right not to attend. As Lupton
(1993) argued, people should have as much right not to know their risk as they do to
know it. Some participants recognised this right not to attend:
Graham3 (58yrs, DEPCAT 5): we're all different, that's the problem, and a
lot of people um, they don't want to know certain things. Which is fine, that's
their prerogative
But Graham3's acknowledgement of this right was not without criticism::
HE:.. .do you think that everybody should go and get the check?
Graham3: well they should do but again what with the modern world we're
living in, they'd probably think it's a breach of their civil rights or something
like that, you'd fight to get anything nowadays, you know it's crazy. Course
they should, I mean everybody, I mean it's a short life
The debate between individual rights and responsibilities echoes debates in the media
in recent years regarding unhealthy lifestyles, for example whether smokers should
be allowed heart and lung transplants, and alcoholics allowed liver transplants. The
NHS and government funding become central to these debates; there are those that
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pertain that money is better spent on individuals with healthy lifestyles or who are
willing to change their lifestyles. But once again this ignores consideration of the
sociocultural influences on lifestyle and associated difficulties, particularly the costs
incurred in changing their lifestyle.
Benefits & beliefs
The previous section focused on the explanations, i.e. barriers, behind people's non-
attendance at the ABPI screening; it is interesting also to explore explanations of
why people did attend. When considering their reactions to receiving the invitation to
the screening many participants said that they had felt positive about attending and
had regarded it as a good opportunity to check for any problems.
HE: when you first received the invite, what were your initial reactions to
getting the letter to attend the screening?
Morag3 (64yrs): I think screening is a good exercise and therefore I was quite
happy to participate
Hilary2 (77yrs): well I thought it was a good idea to get everything (laughs)
you know, know what's wrong and what-have-you, if there is anything wrong
Often people who were positive about the ABPI screening were positive about
screenings in general and gave examples of other screenings they had attended;
usually women mentioned attending breast and cervical screening. Describing it as a
good opportunity was expressed at various age ranges; those in their 50s, particularly
men, were generally not offered regular health checks unless workplace health
checks were available, for example:
Richardl (54yrs):.. .when you went there initially was that they do a check up
for you anyway which is something- well I don't suppose many folk of my
age would bother to get check ups to be honest. So that was quite useful, I
mean I've had them at work anyway cause of they did that at work
Likewise men in this age range often said that they had not seen their own doctor for
a while:
Fred2 (62yrs):...I really just went to see if I was reasonably fit, if I had
anything to worry about, my heart condition or anything like that you know?
Aye so that's why I went along
(later)...well to me at that time you know when I was over 60, and as I say,
you know just repeating myself, I'd had no previous check ups or I hadn't
been ill for a long long time, not even ill, unwell, so I just decided that I
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would take up that you know, and that's all you know, and it's not what I
thought was gonna be in it
In some cases the screening was reported as having happened at a particularly
relevant and convenient time in their lives as they were experiencing some concerns
about their heart.
HE:...when you first received the invite to the screening, what were your
initial reactions?
Mandy3 (59yrs): it came just at the right time because I was having problems,
I was a bit worried about my heart and
HE: problems with your heart?
Mandy3: well yeah things just didn't seem quite right and I thought "ooh
that's come at a very apt moment",
Consequently, another advantage mentioned by many was the earlier a problem was
identified the better as some action could be taken:
HE: so what made you come along then?
Craig4 (54yrs): well I had got this letter and I mean I don't mind being
screened I mean I suppose it's better to know that there's something wrong
than go on in the happy delusion that there isn't you know because if there
was for instance high blood pressure or something at that then treatment
could be given for that sort of thing so before it got too dangerous.
However, of those participants quoted above from groups 1, 2 and 3 who were
positive about attending the screening, none viewed themselves as being at great risk
despite all having a low ABPI. This could explain such positive attitudes towards the
screening, i.e. because they felt that nothing of great concern was found. Their
positive views focussed on attending the screening but they did not perceive the
ABPI result significant.
Craig4's quote above was representative of group 4; generally most of this group
voiced very positive views about attending the screening and alleged that they would
have wanted to find out if they were at risk. When considering the alternative
scenario of receiving an 'at risk' ABPI result, some said they would have accepted
the result without too much concern, others admitted that an 'at risk' result would
have induced fear and/or provoked lifestyle change:
HE:...how do you think you would have felt?
Joyce4 (54yrs): I would have felt quite frightened actually
HE: yeah
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Joyce4: I think I would have...'cause I wasn't really expecting anything
adverse so I think I would have got quite a fright
Regardless of their feelings towards the result, group 4 participants were all keen to
attend. But as far as the screening and ABPI, this group were all labelled 'healthy'.
The positive attitudes expressed in the interview could have been swayed by this
'healthy' result. Indeed Craig4 admitted that this could be the case:
HE:...how do you think you would have felt?
Craig4 (54yrs): um.. .well I would I suppose-1 don't- that's hard to say really
um.. .1 think I would have been fairly philosophical about it, I mean I think I
tend to be a bit that way um and um.. .maybe I would have wanted to know
that. I think if you're going to go into a screening programme like this, you
have to be prepared to be told whatever it is that's going to show up at, you
wouldn't expect to have something concealed from you or whatever or.. .yeah
I think- I don't think I would have been terribly- but maybe that's coloured
by the fact that I suspected I wasn't going to be given any bad news anyway
so I don't really know.
Group4's screening result met their expectations, i.e. that they were 'healthy'. So for
Group 4, attending the screening seemed to serve as reassurance that they were
healthy, i.e. reassurance that their pre-screening beliefs about their health were met.
This echoes Howson's (1998) finding that women attended cervical screening for
reassurance of their 'healthiness' rather than anticipation of being at risk.
As mentioned in the literature review, reported unintended consequences of
screening have included false reassurance or a 'certificate of health' effect (for
example Tymstra and Bieleman, 1987), whereby a 'healthy' result was used as a
green light to continue to engage in an unhealthy lifestyle. This was rare in the
present research but there were a couple of cases, for example Joyce4's reaction to
her 'healthy' ABPI result:
Joyce4 (54yrs): the main advantage was being told I certainly wasn't at risk
However, elsewhere in her interview Joyce4 admitted that she smoked and could pay
more attention to eating a healthy diet and exercise, all known heart risk factors
which she said she would have changed if she had received an 'at risk' result. So
whilst demonstrating awareness of the riskiness of her lifestyle, as far as she could
tell, there was no risk at this point as the clinical measure revealed no risk, leading
her to maintain perceptions of healthiness and no change in behaviour. This
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introduces an issue which will be further discussed in the risk perception chapter -
that many people seemed to consider a clinical measure of risk a more significant
marker of risk than well known risk factors such as lifestyle behaviours.
Interestingly, 'healthy' results did not always lead to reassurance; as quoted earlier
when discussing fatalism, Peter2 (55yrs) recounting his feelings after regular medical
checks at work, showed how his awareness of the randomness of illnesses such as
heart disease inhibited any reassurance from receiving a healthy result.
Other than the Group4 examples above, the quotes earlier of positive attitudes to
screening focussed on attending the screening. Thus, it was interesting to explore
whether attitudes towards the screening had changed after receiving the screening




Positive reactions were not confined to the 'not at risk' group, in fact a few of those
identified with a low ABPI said that they were glad to discover this:
HE: and how did you feel when you found out that this sort ofmeasure-?
Gordonl (67yrs): well I was quite happy Helen because if they find oot,
that's another one, just like my high blood pressure, and then the other thing
Helen, they test your blood.
As a cholesterol measure was also carried out at the screening, a few participants
were glad to discover their high cholesterol, which led to treatment:
Alice (focus group la, 65yrs): I've not got anything wrong with me except
they discovered my cholesterol was high and that obviously benefited me,
you know, cause I wouldn't have known that.. .gone along in ignorance
Although this participant expressed no concern about her low ABPI result. Another
participant in the same focus group, glad of being informed of her low ABPI, had
regarded it as a trigger to make changes to their lifestyle:
Julie (focus group la, 56yrs): yes I was pleased, my husband actually got one
as well, and he thought it was an excellent idea that we should go and attend.
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And he attended and er he was in for about 5 minutes and told he had a heart
of an ox! And I was in about an hour (laughter), so I think it's an excellent
idea, it makes you aware, I didn't have any problems that I thought before,
and now we're starting to think of diet, exercise etc
Expectation-reality mismatch
However despite a handful of positive reactions to the 'at risk' result, not all
participants shared this attitude, particularly those who had expected not to be at risk.
Many were shocked at their result:
HE: and did you think you'd be in the sort of at risk group or?
GeofB (68yrs): no, I thought my wife would have been more at risk than me
HE: oh right, did she go as well then?
GeofB: yeah we both went aye. But when I heard she was clear, I hit the
roof! (laughs)
This raises an ethical issue concerning the potential impact of an 'at risk' screening
result on a participant previously believing themselves to be healthy, in particular
whether any anxiety results and whether measures are taken to deal with this. In
focus group la participants reflected on reacting to the result and the subsequent
identity change:
Bob (70yrs): I think one of the things that hits you is when you go to
screening first and you discover that you are slightly different to millions of
other normal people going about, you do start and say, "oh I didn't know
there was something wrong", and you have this attitude that you are- you
have now something wrong with you
HE: do you feel like that?
Bob: well you feel like there's something happened and yet you didn't, you
were never conscious about it, and it just made you think about heart and the
future
Andrew (59yrs): it's not that you're different to the other bodies, it's just that
you ken [know] and they dinnae
(laughter)
Andrew's comment, although made in jest, maybe helped the focus group normalise
the diagnosis of a low ABPI, and deal with the fact that they had no prior knowledge
of it, and even minimise the amount of risk perceived.
Searching for an explanation
For many, there was a mismatch between their expectation of the screening result
and their actual result, as demonstrated by GeofB above. This appeared to lead
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participants to search for an explanation of the result and risk, which in some cases
meant reflecting on their prior beliefs about their health and level of risk. In some
cases participants seemed to maintain pre-screening beliefs, and turned to alternative
explanations for the unexpected screening result, for example:
HE:. What were your expectations about um what would be found, the results
of this screening?
Morag3 (64yrs): ...I think I expected that I would be clearly in the category
which they did not want
HE: right
Morag3: because I consider myself to be a fairly healthy person for my age
HE: yeah
Morag3: and I was a little disappointed when I was borderline. My reading
was actually 9.5, and so I was given the option of either taking part or
declining to take part
HE: and how did you react when she said you were borderline? Cause you
said you weren't expecting to-
Morag3: no, I said I was disappointed that I was borderline, I had expected to
be classed as too healthy to be required, but um...she did say that it could be
a slightly false reading because I had walked from Princes Street to the Royal
which is uphill
HE: yeah
Morag3: and when you're going for anything like that, you are slightly
apprehensive, and she said the reading was so marginally under that on
another day it might have been marginally over
Morag3 drew upon two alternative explanations for her low ABPI, first the activity
of walking uphill to the screening, and second anxiety regarding clinical measures
demonstrating awareness of the concept of 'white-coat hypertension'. However, as
the ABPI is a ratio of the ankle blood pressure to the brachial blood pressure, the
result is unaffected by anxiety or activity unlike standard blood pressure measure.
Therefore, these explanations are inaccurate and problematic, indicating that she
lacked awareness of the meaning of the ABPI (this will be discussed shortly).
In a few other cases, participants initially sought explanations similar to Morag3
indicating low acceptance of the result, however as the interview progressed, the
participant appeared to think wider and considered further contributing factors and
explanations. For example Keithl initially spoke about the possible influence of
anxiety on the result, but later concluded that his poor circulation fitted in with the
findings:
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Keithl (59yrs): yeah, but another thing I feel is that 'white coat hypertension'
as they call it, is one of the things and invariably, it's like anything, if you go
and it was slightly up the previous time, the next time you go, you can
actually push it up a little bit higher without thinking you know. And I feel
it's pity they can't just check your blood pressure unknowingly to you, you
know like just er when you come in the door and wave a scanner past you
"yes you're OK" you know, something like that.
(later)...since I've been young, my feet have always been cold, I mean I go
cold quite quickly, so I've always had poor circulation in my feet, so I don't
know if that's maybe that could be because my blood pressure is slightly
higher
A further group of participants who accepted the screening result despite an
expectation-reality mismatch reinterpreted rather than maintained their pre-screening
beliefs and sought explanations for this mismatch drawing on their awareness of risk
factors, for example increasing age:
HE: yeah, yeah. And how did you actually feel when she said you were
eligible, that you had um this indicator?
Miriam3 (73yrs): no, er, I wasn't concerned because it appeared to be very
slight and er.. .so er something's bound to show up when you get to get to my
age, you can't just slide through
Also heredity:
Mandy3 (59yrs): I felt a bit panicky inside to be quite honest...something
inevitable, cause I think I've always felt that this is going to be an inevitable
happening in my life you know cause my mum died when she was 59 and I'm
59, all my life I kept thinking 59, 59, I'm nearly out of it but I think you know
I've still got a couple of months to go. But you know I've always had that
feeling because it's in my family and strangely enough about two or three
years ago I was talking to my younger sister and she said about 59, she
obviously thinks the same way you know
Building explanations entailing risk factors beyond the individual's control such as
age and heredity may have helped participants accept the result and minimise the
amount of risk perceived or personal responsibility for it. Further risk factors drawn
upon to explain the result involved factors under the individual's control, such as the
contribution of an unhealthy lifestyle:
Isobel3 (60yrs):...and it wasn't in my script in my head to be told that- I
knew my blood pressure was low, but when I asked why, it was to do this
foot, that the interviewer had found had been to do with circulation. And it
was to do with me being an ex-smoker, which had made furring of the
arteries. And I did find that quite frightening...()... I just felt shocked that
really- because my father had two strokes and my mother had had a stroke,
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so it was- hearing that there was low circulatory problems and I didn't want
to be their age with their problems and it sort ofprojected me forward which I
hadn't thought about
Perceptions of the ABPI
As indicated, in several cases it became clear that the participant believed there was
no problem with their ABPI despite it actually being low. For example:
Fred2 (62yrs): ...I also think I was- I'm positive that both feet readings were
the same, but being at the age I was, and I smoke
HE: oh right
Fred2: er.. .and the lady at the time said, "well you know we'll put you on the
trial" sort of thing. I think the smoking had something to do with it you know.
Similarly, in two focus groups misunderstanding became apparent regarding the
ABPI measure and its meaning. Some participants could not recall being told, some
being adamant about this. In focus group lb, my questioning about the measure led
to the following discussion:
Lorraine (52yrs): I'm not sure I was particularly aware of this, at all, I mean I
do remember being told at the time that the pressure was slightly lower there,
but I never attached any significance to it at all
HE: uh huh
Nigel (64yrs): has everybody who came on this been told that, it seems to be
the case that I thought blood pressure as being low.
HE: what it is is that the ankle pressure's lower than the arm, there's a certain
level at which they invited you to come into the trial
Nigel: so everybody in this [focus group] will have this
Yvonne (72yrs): they didn't tell me that
Lorraine: no I wasn't aware of that at all
Yvonne: I just [remember being] told that the ankle blood pressure was
slightly low
Similarly in focus group la, there were a few participants who had not been under
the impression that the low ABPI was an indicator of any type of risk for example:
Alice (focus group la, 65yrs): I was told to cut out butter, sugar, you know
those cheese and all the things you normally eat. But I have done, it's not
really drastic, and apparently it's going down, so that's good. But nobody
ever said I was at risk, and nobody ever said anything about anything, so...
These were difficult situations for me as moderator because within the focus groups
participants remembered different aspects and held different beliefs about the
measure and the screening dialogue; in both focus group la and lb these conflicting
accounts collectively led to concern and feelings that they had not been told the truth.
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Similarly, in a few individual interviews participants were adamant they were not
told about the ABPI:
Joe2 (56yrs):...I was interested in what they might find, I was interested
when they took the blood pressure, cause normally it was just round here, but
it was round the ankles and er they didn't tell you what they find
HE: pardon?
Joe2: they don't tell you what they find, well I certainly don't remember them
telling me anything about what they found, but at the time I was getting it
done I was down the doctors anyway and I knew it was, by his check I knew
it was fairly standard so.. .but aye I was just interested to see and to take part
HE: yeah cause the ankle one which may have been explained at the time, but
it was like, if this one's lower than that one, it means that there's slight
furring of the arteries and the beginnings of slowing of circulation which is
predictor of very future heart problems and you can't really remember them
saying anything about that?
Joe2: I don't remember coming away from that being alarmed
HE: right
Joe2: and I would have been tuned in to- Ed have been tuned in to that
Such instances were difficult as I wanted to avoid causing anxiety; I probed to
explore their understanding but did not correct them. They knew that I was not
clinically trained. However, I was able to feed back my concerns to the trial team
while maintaining anonymity. A common misunderstanding that emerged in many
participants' accounts was the confusion of the ABPI measure with standard blood
pressure, for example Isaac3:
HE:...so how did you actually feel when she actually said that [low ABPI
result]?
Isaac3 (58yrs): ah it didn't really worry me because the doctor had already
said that
HE: yeah
Isaac3: you know he said "we've gotta get your blood pressure down, cause,"
he says, "you're OK but in later years that could lead to big problems, we've
gotta get it down now". () So it didn't make a lot of difference, having said
that if I hadn't been to the doctor yeah I might have been a bit more alarmed.
One participant did not connect the ABPI with cardiovascular risk:
Andrew (focus group la, 59yrs): I'm aware of the fact, but there's nothing
wrong with heart
Some participants did not perceive the ABPI as a serious risk. For a few this was
probably because as above, they either misunderstood the meaning or did not recall
being told. There are several additional explanations for not rating the ABPI a
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significant risk: the ABPI is still a novel and not widely known clinical measure.
Whilst participants were familiar with standard measures of blood pressure and
cholesterol, only one participant in the study had heard of the ABPI prior to the
screening. For those not accustomed to medical terminology the ABPI may be a
difficult concept to grasp. For a few participants the little importance attributed to the
ABPI was furthered by their interpretations of their own GP's behaviour:
HE: so it didn't like alarm you- it didn't make you-?
Wendyl (55yrs): no it was good to know, it was good to know but my
doctor's never put me on any tablets or anything so he must think I'm alright.
So whilst not actually discussing the ABPI with her GP, the fact that her GP has
never carried out the test led her to not rate it as important. Another participant
(Graham3) wondered why the ABPI had not been found when he had a heart check¬
up at the hospital. The following participant probably mixed up his GP's reaction to
the test result and the cholesterol result (also taken at the screening):
Nigel (focus group lb, 64yrs): the first time, my doctor got a letter with all
the results and so did I, and it said in mine, I had to go and see my doctor, I
can't remember what was...anyway, I duly went out to the doctor and said,
"what does this mean?" and he said, "it depends on the laboratory that's done
the test," he said, "and I wouldn't worry about it", whatever it was, I mean it
was something like, a hundredth of a point above the aver- you know
something
So discussion with their GP regarding the cholesterol result had become associated
with the ABPI measure, leading them to not rate the ABPI as significant. Another
participant reported his GP dismissing the measure:
HE: did you tell your own GP about the result and that you were in this trial?
Warren2 (72yrs): yes, I think I did, um.. .1 think he just poo-pooed it, he said,
"that's nothing", you know I mean he knows me well, he knew my medical
records and you know, and "that's nothing untoward", that was his response
These quotes demonstrate the potential influence of dialogue with health
professionals on risk perception. For other participants, perception of the research
nurse's attitude seemed to influence reaction to the result:
Peter2 (55yrs): slightly lower that was she said aye slightly lower in the ankle
than it was elsewhere, er and I certainly have noticed er a few years ago I
found my feet were always warm now they're getting a wee bit colder. I
mean they're no' cold freezing, you know.
HE: how did you feel when she told you that at the time?
1 :trial participant 2:stopped trial tablet 3:trial decliner 4:healthy ABPI 5:screen non-attendee 133
Peter2: it didn't really bother me because she say well you're-1 don't think it
was giving her any cause for concern sort o' thing
Indeed the influence of the nurse-participant dialogue emerged as particularly salient
in participants' discussion and interpretation of the screening experience. Where a
mismatch occurred between expected and actual screening result, it appears that one
method of minimising the level of risk perceived was by utilising particular words
and phrases as used by the research nurse. For example, there are two cases of this in
the following quote:
Isaac3 (58yrs): urn...no I was quite- when she explained why they were
doing the ankle, I thought "ah well" and she did the first reading and it was
quite high, and then she did sort of the other eg and the other arm and
everything but she said "I'll do the other one again" so she redid it, and it had
fallen so she said "sometimes you get a false reading the first time you do it",
and she was very pleased with what the results were, they weren't too bad at
all, I can't remember what they were now but they were borderline for going
on the trial anyway
First, Isaac3 had picked up from the nurse's reaction that she was pleased with the
result, indicating that he interpreted no great risk. Second, he remembered the nurse's
comment that the result could have been due to a 'false reading', again minimising
the amount of risk perceived. Phrases, such as "marginal" and "just one ankle" were
common when describing the ABPI result, for example focus group la participants
discussed their result:
Bob (70yrs): when the nurse at the screening was doing the blood test- the
blood pressure test, three were OK and one was off
Jen (65yrs): I was the same
David (71yrs): it was just like one ankle?
Bob: one ankle
Jen: that's the way I was
However even "just one ankle" still means atherosclerosis in one leg. A similar term
used by a considerable number ofparticipants was "borderline"; the majority of these
were from group 3 (eligible but declined). For a few of these participants,
"borderline" status was further emphasised in their accounts by describing how the
research nurse had highlighted the choice involved due to this status:
Morag3 (64yrs): and I was a little disappointed when I was borderline. My
reading was actually 9.5, and so I was given the option of either taking part or
declining to take part.
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Perhaps participants held onto their alleged borderline status as a method of
minimising the risk perceived. As the influence of the nurse-participant dialogue
emerged as particularly salient, I discussed certain findings with the research nurses
themselves, in particular participants' common use of the term "borderline".
"Borderline" was decided upon by the research team as a term to use to avoid
causing anxiety, because it was advisable to avoid using the word "risk" whilst
explaining the meaning of the ABPI result. It is an interesting point for health
professionals to consider when choosing words to use when explaining medical
procedures, condition and results to the public. People will often pick up and
remember key words when making sense of the dialogue. A potential follow up piece
of research could focus more on the nurse-participant dialogue in such situations. In
illustrating and discussing the misunderstandings of the ABPI result, it is important
to emphasise that I am not imputing blame on either the research nurse or the
participant. Rather I am emphasising that in situations involving clinical measures
that may be complex and novel to the participant, it is likely that the participant will
draw upon their dialogue with the nurse when reflecting on the meaning of their
result, and use this in making their own interpretations. It is important that those
conducting screening programmes consider this issue and the wider issue of
information and understanding.
Often it could indeed have been the case that a participant's perception of borderline
status regarding their ABPI was in fact correct. However this introduces further
discussion relating to clinical measures involving a choice of 'cut-off point. Many
clinical measures such as the ABPI or cholesterol fall along a continuum of low risk
to high risk; cut off points are determined by epidemiological research and are
necessary for clinicians when making decisions about their patients' health care. The
general public however may regard such 'cut off points as black and white, i.e. at
risk or not at risk, rather than an informed indication of level risk. This will be
discussed further in the risk perception chapter.
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Summary: perspectives on screening
This first data chapter has explored participants' accounts of the ABPI screening.
Firstly focusing on screening attendance, discussions of explanations for non-
attendance led to the emergence of four salient phrases signifying four key beliefs
regarded as inhibiting attendance. The ubiquity of these phrases indicated their
operation as cultural shorthands of shared lay knowledge; lay meanings of, and
attitudes towards, the phrases were discussed particularly in relation to their
perceived acceptability. Participants' accounts demonstrated how perceptions of the
ABPI screening were influenced by feelings towards health, illness and preventive
health in general, and more specifically heart disease and screening. Furthermore, the
analysis has demonstrated the complexity of the context within which decisions
about attending such a screening are made in terms of personal, social and cultural
circumstances. Whilst reasons for attendance were explained when discussing and
comparing non-attendance, these were then explored further explicitly. The final part
of the chapter explored the screening experience. Reactions to the screening result
were examined, in particular relating to whether the result matched participants'
expectations or not. Interpretations of the screening result were explored along with
factors that emerged as particularly important in these interpretations including
perceptions of the ABPI and the nurse-participant dialogue.
Screening programmes require that individuals identified as at risk are "more likely
to be helped than harmed by further tests or treatment to reduce the risk of a disease
or its complications" (National Screening Committee, 2003). Thus, in addition to
exploring individuals' beliefs about screening, their accounts of beliefs about the
associated prevention programme will reveal more. The following chapter thus
explores participants' beliefs about the prevention of heart disease with particular
focus on preventive medicine and aspirin.
1 :trial participant 2:stopped trial tablet 3:trial decliner 4:healthy ABPI 5:screen non-attendee 136
Chapter 5:
Attitudes towards prevention and preventive medication:
Introduction
The present chapter explores participants' attitudes towards the prevention of heart
disease, with particular attention to preventive medication and aspirin. In addition to
exploring participants' accounts of their attitudes, it explores accounts of their behaviour
related to preventive health. The two often appear to be contradictory, thus explanations
behind the idea of engaging or not in active prevention and preventive medication use
are further examined and discussed. Salient issues covered include views about
medication including side effects and managing without, dependency, necessity, the role
of the GP, aspirin specific attributes and the idea of preventive medication as an
alternative to lifestyle change.
Prevention is better than cure
When discussing attitudes towards screening and preventive health, a phrase that
appeared in participants' accounts across all groups was "prevention is better than cure";
often these exact words were used, as some of the later quotes will demonstrate, or the
same meaning was implied. For example, when discussing preventive health and regular
check-ups, the following participant discussed benefits of catching something early:
Rebecca3 (73yrs): it's best to have some kind of knowledge of if there's anything
wrong with you, then you can catch it
Likewise when specifically discussing screening, the following participant summed up
her opinion:
Cath (focus group 4a, 63yrs): glad to hear it now rather than wait another 10
years or something
In addition to the benefits of prevention to the individuals, the same phrase was applied
to potential benefits at a societal level:
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Keith 1 (59yrs): now they go on about how much this costs the National Health,
but is prevention not better than cure?
Furthermore, the phrase was common when considering preventive medication:
Amy2 (76yrs): I think everybody should take a preventive thing, better prevent it
than try and cure it...
Some participants like Amy2 above felt a preventive approach should be generic; others
applied the notion to those with a specific risk:
Daniel4 (54yrs): well prevention's better than cure...um if you find out you've
got the lower count in your ankles and you're told to take it and you don't take it
then more fool you for not doing it
Often, as in the two quotes above, such expressions implied an emphasis on prevention
being the right thing that one 'should' do; a few participants went further explicitly
voicing this as a duty, for example:
Fergus 1 (72yrs):...er I'd keep 'em up, yeah, I mean if it prevented it, if it
prolongs your life, then obviously you haven't got a choice have you?
So, echoing the discussion in the previous chapter, the notion of responsibility was
implicit in many participants' expressed views about prevention.
For some participants who expressed such positive views about prevention, the
remainder of their accounts reinforced this preventive attitude with examples of their
own attempts to engage in preventive behaviour. For example, Moiral stated a firm
belief in prevention and in the rest of her interview talked about her own healthy
lifestyle and recognition of the need for prevention programmes such as free healthy
school meals to improve the health of those who were not as well off as herself. In
addition, as mentioned in the screening chapter, Group4 members often advocated a
preventive approach in many ways, but were in a different position to other participants
due to their ineligibility and 'healthy' screening result. Thus, the 'prevention is better
than cure' type views expressed by this group could possibly be accounted for by their
own low risk, as acknowledged by Craig4:
Craig4 (54yrs): well...not I mean I always think prevention's better than cure,
um, but...yeah I mean obviously my views on this would be tempered by what
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my circumstances were at any given time, um and er...that's what life is about,
you're continually making choices and you're reviewing who you are and so on,
and so yes I would have to review that in future if there was some imminent
danger, yeah.
In addition, as discussed in the screening chapter, many participants expressed positive
attitudes towards prevention in hindsight. For example, applying the idea of preventive
medication to another condition, Imogen 1 talked about how she wished she could have
taken medication to prevent the conditions that she now had:
Imogenl (61yrs):...I mean I wish I had been able to take something to stop me
having this thyroid problem, for having the blood pressure problem, it would be
great if you could sort of say, "if you take this, it'll stop you:...
However when looking more closely at other individuals who voiced the 'prevention is
better than cure' adage, and reading the rest of their accounts, it became clear that this
view was not confined to group 4 members, or to 'active preventive' participants like
Moiral, or to those talking in hindsight. Rather, this view was expressed by participants
across all groups including those with a low ABPI, many of whom were not engaging in
the ideal preventive lifestyle. Furthermore, when discussing actual behaviour a different
picture to 'prevention is better than cure' emerged.
Prevention is better than cure, but
More often than not, descriptions of actual behaviour contradicted the attitude stated by
the participant that 'prevention is better than cure'. Quotes from Graham3 (eligible but
declined to participate, aged 58yrs) demonstrate this contradiction; the following quotes
are all from the same interview with him:
"oh aye, aye because I mean prevention's better than cure isn't it, as they say"
(when discussing screening)
"and I thought, well if it's not serious. Which might sound stupid, I'm not going
to bother" (when discussing the ABPI and the trial)
"I've weathered the storm this long you know which again is silly" (when
discussing the effect ofsmoking on his health)
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"it's a bit late in the day, I won't bother with it" (when discussing giving up
smoking)
In the above quotes, Graham3 indicated several explanations behind not engaging in
active prevention despite clearly stating that 'prevention is better than cure'; his
reasoning included low perceived risk and severity from the ABPI result and feeling that
he was too old to start anything preventive, particularly as his smoking had not yet had
any noticeable effects on his health as far as he was concerned. However referring to his
decisions as "stupid" and "silly" suggest that he felt he ought to be engaging in active
prevention.
Similarly to Graham3, despite voicing the belief that 'prevention is better than cure',
many participants' accounts revealed seemingly contradictory behaviour but also
provided explanations behind this apparent contradiction, particularly regarding (not)
engaging in preventive medication use. The remainder of this chapter outlines and
discusses participants' explanations behind, and views about, engaging (or not) in
preventive medication: The next four sections focus on different aspects of medication
including side effects, avoidance, dependency and necessity. The following section
considers the reported effect of the doctor-patient relationship on attitudes towards
medication.
Views about medication: Chemicals and side effects
Many participants expressed dislike about medication due to the idea of chemicals or
unnatural substances entering their body, for example:
HE: have you got any reason for (disliking medication)?
Monical (66yrs): no, no, I just er- like my father always used to say to me, if I
had something wrong with me, I'd rather cut it out than put things in my system,
you know, so I don't know.
Avoiding medicines was a preference Monical had picked up from her father; Craig4
gave a detailed account of what lay behind similar feelings:
Craig4 (54yrs): I tend not to like taking medications of any description, I prefer
to keep chemicals out ofmy body if at all possible
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HE: why is that?
Craig4: um I just think that they create imbalances and often taking medication
can lead to complications, something else down the line, um I prefer as far as
possible to let my body fight its own battles and.... Having said that, I have
diabetes and have to take insulin, so you know the exception proves the rule
really you know but- but that's something I tolerate, but I don't like- I mean I-
my mother and her generation um I think ran to the doctor when they sniffed you
know and um I think...she had terrible problems with allergies at one time, and
she was on medications for this, that and the next thing you know and.. .1 used to
say to her "what are all these things doing to you? Is this not what's causing
this?" "Oh, no no no" and she was screened and she had this long long list of
things that she was alleged to be allergic to and I mean it was virtually being
allergic to the world and you know, now all that came to a sudden end when she
had the stroke and all medication were stopped, and gradually built up again and
whatever she has now, this irritation has not recurred. I mean I think all the way
down the line, it was the cocktail of drugs that she was on you know, and she
would go along to the doctor and say "I've got this and I've got this" and he
would give her another pill you know and I used to say " do they never say to
you, "what else do you take?" or is there any risk that this could react badly with
that or whatever" so my response to this is um don't have anything unless you
absolutely have to you know, keep it all in your system
Linked to dislike of the idea of chemicals entering the body was concern about side
effects both anticipated and experienced. As Craig4 explained, he had watched his
mother experience an increasing amount of adverse side effects from medication, which
in turn required further medication to counteract the side effects; the experience had led
him to avoid all medication other than that which he considered vital to survival. Peter2
described a similar scenario:
Peter2 (55yrs): As I say my wife she takes- she hasn't always kept the best of
health and medication, if you're taking a lot, it knocks the hell out your stomach
sort o' thing you know, the more medication you take, depending, it depends on
your constitution. Some people tend to have problems with their stomach other
people don't, er she the medication that she's been taking, certain medication she
just can't cope with, it knocks hell out of her stomach, and she's got to take
Zantac and things like that for it, is that right... she's got to take that for her
stomach and as I say well, the more medication you take, is it gonna come up
with something else. Given the choice, I'd rather not take medication full stop.
Peter2 felt that the occurrence and severity of side effects depended on the individual,
but like Craig4 the experience of watching someone close suffer had led him to strive to
avoid the risk of such suffering himself by avoiding medicines wherever possible.
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Participants in focus group 2, however, seemed to think that side effects were not
dependent on the individual, but could happen to anyone. Most of this focus group had,
in fact, experienced side effects to at least one medication and several had experienced
side effects attributed to the trial tablet, which may have contributed to their beliefs:
Ursula (61yrs): um and everything's bad for you, to a certain degree
Ella (70yrs): oh yeah that's right
Ursula: any medicine
Cath (63yrs): any medicine
Ursula: are bad for you, you know. If you can go through life without having to
take anything, you're very lucky, right. Anyone, anyone can go through life
without some kind of- they've all got side effects
Ella: yeah
Generally, the idea of unnatural chemicals entering the body and the potential side
effects was given as an explanation behind many participants' dislike and avoidance of
medication, and more specifically the rejection by many of preventive medication.
Side effects of aspirin
Regarding side effects of aspirin specifically, almost all participants were aware of at
least one potential side effect. Many participants spoke of their awareness of severe
effects such as stomach ulcers and bleeds, for example:
Morag3 (64yrs): well I'm a little worried about aspirin because it has side
effects, you can have internal bleeding, um if you have the beginnings of ulcer
developing inside you then it can cause problems, and so I would be wary of
taking it for no reason if I didn't require to take it () people might think that
it's quite safe to take, if they've been taking it all their lives for headaches
HE: yeah
Morag3: but if you read the small print in the packet, the instructions, you
become more wary about taking any kind of medication um indefinitely.
Some suspected their susceptibility to such side effects, thus actively avoided aspirin:
Isaac3 (58yrs): ...it was a doctor many many many years ago, when I was about
20 I think
HE: oh right?
Isaac3: and he said then, I think I had tummy problems and he said avoid aspirin
if you can
HE: yeah
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Isaac3: affects the lining your stomach and all this so I don't know medically if
that's true or not but er ever since then I've tried to avoid aspirin
Several participants weighed up the potential adverse side effects against the potential
benefits, leading to different conclusions; Craig4 felt the cons were greater:
Craig4 (54yrs): no but I mean I know it can I suppose it depends on the dose and
your own metabolism, I know it can be a bit severe on the stomach, so um
yeah...so it's the same story, while you're maybe curing one thing, what are you
doing to the other
In contrast, more participants felt that the benefits outweighed the costs, for example:
Imogen 1 (61yrs): ...that sort of can cause ulcers...you know of the stomach, and
there's a little niggle, when I was getting this indigestion, I've got to admit I did-
I thought about that, you know...but there again I think there's a risk with all
tablets. You know I feel there is, there's a side effect with everything, you know.
HE: so it doesn't worry you?
Imogenl: just this little niggle, but as I say it seems as if that's going away so it's
perhaps just been you know. But it wouldn't stop me- if at the end of the trial,
they said, "now look we feel that an aspirin would benefit you", it wouldn't stop
me. [I wouldn't] say, "well I'm not going to take the aspirin because of that".
HE: you'd try it
Imogenl: yeah because I feel, well if I had an ulcer, they could sort of do
something about that, but if I had a heart attack, there would be no point, I
probably wouldn't be here, you know, you've got to weigh the pros and cons.
Imogenl's explanation represented the conclusion of several participants: that for the
life-saving benefits of aspirin, the risk of experiencing adverse side effects was worth
taking and tolerating, and could be appropriately managed. Richard 1 came to the same
conclusion, further adding that susceptibility to side effects would occur in a minority
only:
Richardl (54yrs): but the good effects tend to be about things which are actually
dealing with- ameliorating things which are life threatening
HE: yeah
Richardl: whereas the bad effects either tend to be about things which are not
life threatening like they're bad for your stomach, or they're about things that um
happen to so few people that it's hardly worth considering,...()...Um so no I
mean bad effect don't get me excited because mostly they're either minor, or
you'll know about them anyway you know most cases you know, it's not like the
first time a two-year-old eats a peanut, it's people or adults mostly that are gonna
be exposed to it. The really nasty effect of anything like that would happen to a
child. By the time you're an adult, with common things like aspirin, there must
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have been a across your system more than once, you'll have a fair idea, I mean
there are people that are allergic to aspirin in various sorts of ways as far as I
understand, but you know people certainly get upset stomachs from them, and
these people don't take an aspirin
Others emphasised the distinction they had made between themselves and more
'susceptible' others who for example "had had stomach trouble for years". There seemed
to be some indication of an optimistic bias emerging in these participants' accounts,
however as discussed earlier, rather than such optimism being considered unrealistic,
comparison of the risk factors associated with these 'susceptible' others and themselves
may have led to a well thought out conclusion. Or, lack of occurrence of any adverse
effects whilst taking aspirin seemed to contribute to low perceived susceptibility to
adverse side effects, or made the issue less salient:
Hamishl (70yrs): well I'd heard there's still problems...aspirin affecting your
stomach, you know, your bleeding or something like that. That is because of a
friend of a family, who'd ulcers, and he was always taking aspirin somehow or
other to alleviate his problems but I think they were increasing his problem,
'cause I think his stomach was getting burnt you know, I don't know about the
blood, heard that he was coughing blood out and that but that was aspirin he was
taking. Which I suppose should have been the last thing he was taking...()...
HE: the fact that you had an ulcer, and that you know that aspirin affects ulcers
and stuff, does that not affect that your
Hamishl: no, I'm sure right away I would have found some sort of a side effect,
you know like the bleeding of the stomach, and you know wait a minute, this
could be the aspirin that's bringing this on, in which case I would have gone
back.
Discussion about side effects in focus group lb was the first time some participants had
considered the possibility of side effects and led some to realise minor effects that they
had previously not noticed, which seemed to cause some amusement:
HE: has anyone- do you know about side effects of aspirin
Lorraine (52yrs): bruising more easily
Maive (67yrs): your stomach, damage to your stomach
Anita (74yrs): bruising more easily.. .I'm just listening to L saying bruising more
easily...well I've got a big bruise there
(Laughter)
Nigel (64yrs): that's one of things that I've started to notice small bruises, and
never gave it a thought
(Laughter)
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Anita: it's not painful
(laughter)
HE: so has anyone got any concerns about side effects?
Wayne (69yrs): I never gave it a second thought till today
(laughter)
A few participants felt the dosage was high enough to cause problems, despite the
lOOmg dosage being considered low in medical terms, for example:
Molly4 (75yrs): and half an aspirin a day is quite a lot of medication to put into
your body isn't it?
In contrast, others felt the low dosage was a reason to not be concerned about side
effects:
Geoff3 (68yrs): I mean it's a small quantity of aspirin, it's not gonna cut the
lining ofmy stomach up I don't think so, or anything like that.
In focus group la, discussion about the low dosage involved in the active trial tablet
seemed to help participants build a reassuring group consensus of low risk:
David (71yrs): but the pills we take, they're just wee pills, they're not like the
aspirin you get in the chemist are they, so there's less chance of getting a bleed
or whatever from taking one of those, even a series of them, a number of them,
less chance of
Julie (56yrs): it's a low dosage that we are actually
David: well they're very very small aren't they?
Alf (74yrs): it's a third isn't it?
David: it's a third is it? Aye, it's a third so there's a fair amount of- two thirds
less chance of being affected I would think, I don't know
As these were trial participants, conferring with others and building a group consensus
of low risk may have helped reassure each individual of low risk from their trial tablet
given the 50% possibility that it was aspirin. Focus group 4b participants were in a
different position due to their healthy result and lack of aspirin use, so may have
considered the risks of aspirin differently. But a similarly safe picture of aspirin
emerged; again the low dosage seemed to contribute, as did aspirin's place as a
longstanding medication which needed no advertising compared to the mistrust of new
and advertised drugs:
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HE: how about Lucy's point about aspirin being sort of a common you know
commonplace medication, do you think that makes a difference to how you think
about it?
Elsie (60yrs): I would say possibly it is because there's always been aspirin and
you do probably have proper faith in it:
Lucy (57yrs): 'cause you know what it is,
Elsie: rather than if you take something different
Melanie (64yrs): yet it's contra indicated in certain things like duodenal ulcer
and things so you would need to watch that but it's a low dosage so is shouldn't
be
Lucy: it's been there forever, it was always "just take an aspirin", you don't see it
causing any harm particularly that's it, and because it's not sort of promoted as
well like all these Hedex and all these things, they don't have a big campaign on
TV for aspirin, you never see that, because aspirin's OK, and yet as you say it
could have a side effect on some- maybe another condition that you had.
In addition to the low dosage, participants gave other solutions for minimising potential
side effects including sugar-coated tablets, soluble aspirin and avoiding the drug on an
empty stomach.
Following discussion about side effects in both focus groups 4a and 4b, very similar
conclusions were reached, for example as summed up by a participant in 4a:
Wilf (65yrs): An aspirin a day's not gonna kill you
There was agreement and certainty regarding this conclusion in both of these focus
groups. Such assumptions about aspirin's safety ran through many participants'
accounts, for example:
Eleanor3 (62yrs): well given that it's a tried and tested drug that you would have
been taking, I mean obviously it's a small dose you'd be taking wasn't it? So
really they...certainly wouldn't do you any harm, one way or the other, well if
anything it would possibly do good, given what they'd discovered. So but as I
say if it had been something, if they'd said to have come and it was a drug they
were just testing, that would've been different but given it was aspirin, I
wouldn't have had a problem with it one way other...
The emergence of assumptions about aspirin's safety will be further discussed in the
participation chapter, as this assumption seemed to play a role in the (low) risk generally
perceived in relation to the trial tablet.
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Generally, despite much awareness of the possibility of side effects from aspirin, more
participants felt that the benefits outweighed the costs. The possibility of side effects
was minimised due to lack of their occurrence, creative solutions for preventing them, or
optimistic bias; assumptions about aspirin's safety prevailed.
Views about medication: Never taken medication
A further reason for avoiding medication came from the feeling that having never been
in the habit of taking medication, many participants did not want to start at this point in
their life. For example:
Fred2 (62yrs): just purely er...probably 'cause I was quite naive in quite a
number of things, as I said earlier I'd never taken, I'm not in the habit of taking
any kind of tablets you know I couldn't tell you the difference between them, a
disprin and an aspirin you know, so I said "Och if I've went through you know
60 years ofmy life without taking anything like that, I'm just gonna leave it, not
take it" and I decided that you know
Fred2 implied that his lack of medication use over the years was na'ive, whereas most
other participants who spoke about never using medication emphasised this as
something they seemed to be proud of:
Eleanor3 (62yrs):...I have been very lucky through my life, I've been a very
healthy person and I've never ever- in fact I don't know when I took an aspirin
last (laughs), I really don't, anything I mean I just don't ever take pain killers,
don't have any need to take pain killers or anything like that, aspirin or panadol
or any of these things
Eleanor3 seemed to be using her lack of medication use over the years to reinforce her
identity as a healthy person; Monical emphasised similar 'healthiness' by distinguishing
herself from others who do use medication:
Monical (66yrs): I don't like to take pills if I can help it you know, even
headache pills, you know. If I got- if I had it all day and I was forced to take, I'd
take a paracetemol, that's the only medication I would ever use, ordinarily...()...
I'm not a pill popper, like some people with their six bottles
This distinction and the choice of words indicate the negative connotations participants
like Monical associated with people who take medication. It seems that the use of
medication, like consulting the doctor as mentioned in the screening chapter, signifies an
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illness identity; participants like Monica 1 and Eleanor3 seemed to be distancing their
own identity from this and through this possibly emphasising a tough mentality. This
echoes attitudes of the women in Blaxter and Paterson's (1982) cross generational study
(as mentioned in the previous chapter), where illness was considered a state of moral
malaise, in particular in one's reaction to symptoms. The women presented themselves
as not giving in to illness or letting it disturb their functioning, and those who did were
regarded negatively. Regarding attitudes towards medication, older women in particular
preferred to rely on 'mind over matter' models of cure rather than using medicines,
which emphasised their strength of character (Blaxter and Paterson, 1982). Similar
beliefs seem to apply to medicine use in the present study; Eleanor3 continued to
describe how during a period when she was required to take medication, she waited until
the pain was unbearable before resorting to taking the prescribed medication:
Eleanor3:...I had my gall bladder out and of course I was given pain
killers...well I took...it did say take every four hours or something like
that.. .which I didn't do, I mean if I had been absolute- if it had been unbearable I
would have taken them, but I don't believe in taking things, just keep swallowing
pills unless...it's absolutely necessary. You know I just think I just don't think
it's necessary. If I can deal with it, I mean if I'd been rolling about on the floor or
something I'd have taken them but I thought- well sometimes when it was really
bad, I'd take a couple but I mean I'd never at any point did I take two every four
hours, I mean I'd just take maybe a couple and then maybe at bedtime another
couple so I could get some sleep or something. I just don't believe in putting a lot
of stuff into your body unless it's...
For some participants who emphasised this attitude, further probing revealed actual
medication use, for example:
Rebecca3 (73yrs): see because I like to know what I'm taking, and as I say I
don't take any other tablets, unless the doctor prescribes, even in the winter
months, if you've got a cold, you don't take nothing for it
HE: do you take any medication now at all?
Rebecca3: no, I only take my erm...water tablet, my blood pressure tablet, and
my two inhalers.
Rebecca3 initially replied that she took no medication but then described how she 'only'
took four lots. Like other participants she had managed most of her life without
medication and seemed to struggle with the fact that she now had four ongoing items to
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take so she appeared to try to minimise the significance of these medications when
answering the question. Similarly Monica 1 (quoted above) took thyroxin and the trial
tablet despite her emphasis on not being a pill popper; her acceptance of these medicines
was linked with beliefs about necessity (this will be discussed in more detail shortly).
A couple of participants felt that, as they had managed all their life without medication,
they were too old to begin a course of preventive medicine at this 'late stage', as shown
in quotes from Graham3 (58yrs) and Fred2 (62yrs) earlier in the section. Warren2
(71yrs) shared this attitude and reflected how with hindsight, after an event or once a
condition has become evident and symptomatic, it is easy to see the benefit of taking
preventive medication:
HE: so how do you feel yourself about preventive medication?
Warren2: um well (laughs) I suppose given that I'm 71 now um, I suppose I
think it's late in the day for preventive medicine in you know with a person like
myselfwith more often than not it's, you know, it's after the event has happened
that you start taking these things, you know my youngest son's wife, her father,
now he takes that (glucosamine) and he takes cod liver oil, but he sees that as
preventive you know that he won't suffer from arthritis or whatever when he's
older, you know and I think to myself, "yeah, if I'd thought about this when I
was 30 or 40" you know I played cricket four or five times a week you know, "I
might have done the same thing", arthritis and- you know my attitude to that is
I'm paying for all the years of sport that I spent, and you do suffer wear and tear
and you know lots of athletes suffer from the same thing. Yeah I suppose you
don't think about that when you're young, it's only when you're older.
Warren2 considered himself too old at 71 to begin preventive medication, implying a
fatalistic attitude in that he felt that whatever he does from this age onwards is unlikely
to have an influence on his health. In contrast, elsewhere in his interview he refers to 71
as too young to be taking medication:
Warren2: I prefer to avoid medication to be honest, you know
HE: is there any reason for that?
Warren2: um...I don't know I suppose that's a general...reaction, you know I
don't want to be taking tablets if I can avoid it, um and I suppose like perhaps
when I'm older I'll have to but rather not at the moment...()...I don't want to be
dependent upon medication
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His account thus implied that regarding medication avoidance, age was less of an issue
than fear of dependency.
Views about medication: Dependency
Fear of dependency on medication was divulged by a few participants; as with Warren2,
this tended to be divulged following several other reasons for medication avoidance. For
example, Mandy3 (59yrs) firstly explained her dislike of medication as due to side
effects and spoke about only medicating in severe pain, similar to those quoted
previously. She referred to herself in a negative light for this behaviour (elsewhere in the
interview described herself as a 'bad diabetic'). However, she eventually revealed her
dislike of the feeling of being dependent and controlled by medication:
Mandy3: I've been terrible all my life and I don't like taking any medication
HE: why is that?
Mandy3: I don't know what it is, I won't take a headache tablet or anything until
I'm forced to do it at the last minute, I mean I've got arthritis, I've got pains in
my hips and everything and I only take it when it's you know...(indicates severe
pain) and I know you're supposed to take it regularly to keep it down but I don't.
But I'm also um.. .what do you call it.. .opiate intolerant
HE: oh right
Mandy3: so I have problems in hospital with um...anaesthetics and things like
that, so maybe I don't know it's something to do with that
HE: so you don't like taking unless it's necessary
Mandy3: yeah mm...but I am now because...I'm accepting that things are going
wrong now and I really have to take my blood pressure tablets and if it was an
aspirin to prevent, then I would do that as well, and I have to take my insulin
because if I could do without that I wouldn't have that either, you know I think-
for many years again I've had problems having to take this insulin but er, just
reconciled with the fact I don't like taking things like that and having to do it...
HE: do you still feel like you don't like taking them?
Mandy3: I don't like taking things like that...the insulin is four times a day (). I
cope with it, the physical aspect has never been any problem, it's the mental
aspect of it you know it controls you sort of thing and I don't want to take it
HE: is that what you mean about it controlling- you haven't got control over
Mandy3: I've always thought that about the insulin yeah but I'm trying to get it
under control just now, struggle, but er I don't know what it is, it's just a part of
my make-up that I'm so reluctant to take things.
Despite seeming ashamed of her negative feelings towards medication she talked about
how she was trying to turn around the feeling of control with herself being the
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controller. This seemed to be a way of accepting and coping with having to take
medication.
Similarly to how participants described witnessing loved ones' adverse side effects
leading them to avoid medication themselves, the experience of watching her husband
become dependent on medication over the year had led Jennifer2 (61yrs) to actively
avoid any course ofmedication that she considered could be addictive:
Jennifer2: I don't like taking medication. I must be honest, I don't like taking
medication.
HE: is there any reason behind that at all?
Jennifer2: I really don't know but I don't- I maybe it's because I've watched my
husband- he started offwi' asthma, chronic asthma, he's never smoked, it runs in
his family and I've watched him over the years how he's went and now...he's
just really done, he's a done man, and he's taken like heart his heart's not
working right and everything through the stress of the asthma all his days an'
that. And when I was told to use inhalers I wouldn't, I've never ever used them,
because...my husband used to say they're like dummy to a baby, once you get
them you get used to them and you cannae do without them, and therefore I'll
no' take them
HE: so is it the addictive thing you're
Jennifer2: aye, that's what, aye, I just when the time really came if I had to, fine
but no, and there I've got away with years and years without using them, I've
never used them and that's the reason, just cause once you start, you cannae stop,
that's how I feel
HE: so how do you feel if like when you go back to the doctor in a month and if
he puts you on some tablets for your blood pressure or something,
Jennifer2: no, I would take them because I've got a fright aye, that's different
when you've had a fright, you would aye I would definitely take them because I
don't like the way I'm feeling
An interesting point about Jennifer's responses above is the contrast of dependency
with the notion of necessity; despite her fear of dependency leading to active avoidance
ofmedication, she said that if a point came when she 'had to' take medication then she
would take it. Indeed she was willing to participate in the trial, thus accepting the trial
tablet.
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Views about medication: Necessity
Martha2 (65yrs): see nobody likes taking pills but if you've got to, you've got to
The notion of necessity seemed to override reasons for disliking medication in many
participants and led them to accept the idea of taking it. For example in focus group2,
earlier quoted as concluding that all medication causes side effects, participants also
expressed that adverse side effects had to be tolerated if a medication was considered
necessary:
Ursula (61yrs): I think so, I just think any medicine taken long enough is bad for
you, it all has some side effects, all has some, but it all depends if you're living
longer and you know, if you have to take it, you take it, and deal with the side
effects, you just have to, my husband's on different things, he has to take them,
even with side effects.
What contributed to a medication acquiring status as a necessity? I explored
participants' accounts for their meanings of necessity. When describing medication as
necessary common phrases were used such as "keeping my blood thin" and keeping the
condition "under control". Life saving attributes were also used, for example "keeping
me going", "surviving on pills" and:
Harold2 (63yrs): I don't mind, not if it's helping me you know if it's keeping me
alive
Some participants gave more sophisticated explanations of their meanings of necessity,
for example due to their awareness of the condition and prognosis if left untreated:
Keithl (59yrs): well it's a- it's the only remedy if you want to call it, rather than
as you say arteries and veins, it's the only way really I'm gonna try and keep on
top of the problem. I mean if you let the problem go too hard or too high, I mean
my father, they reckoned, he had hardening arteries all over the body and he
died, and this is the root cause of high blood pressure would be. But er, it's the
only way I can see at this moment in time, how to do it.
Martha2's view about necessity was related to her acceptance of increasing age:
Martha2 (65yrs): At one point it was 7! Um I was a bit- not concerned but I felt,
oh you know this is what old age is all about probably, but er, I got used to
taking them and I just take them every morning and that's it, and if you've got to
take them to keep you going, then you do it
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HE: is that the way you see it?
Martha2: that's they way, yes, uh huh, I mean if I didn't need- I'd be happy to do
without them, but obviously I need them so
The importance of the notion of necessity in overriding participants' other dislikes about
medication included wanting to avoid side effects and dependency, has been illustrated.
Exploration of participants' meanings of necessity highlighted the interrelated issue of
perceived severity of illness or condition, which will now be discussed.
When does a 'risk' become a condition?
The question of the point at which a medication is perceived as necessary seemed to be
embedded within the wider issue of when an increased risk becomes perceived as a
condition or even an illness. Regarding the current situation, this is again linked to
people's perceptions of the ABPI. Participants generally seemed to consider high blood
pressure and high cholesterol as conditions requiring medication for control, whereas the
ABPI did not appear to be thought of in the same way. The screening chapter
demonstrated how many participants did not consider the ABPI as a significant risk;
consequently for many participants it was not considered a sufficient risk to require
medication. Warren2 sums up this attitude:
Warren2 (71yrs): I think if it had been medication that I needed to take, I would
have taken it.
The lack of risk perceived to be associated with a low ABPI is illustrated by Peter2, who
whilst advocating the benefit of being able to identify people with atherosclerosis,
showed no awareness of his own low ABPI indicating this, thus saw no point in
medicating:
Peter2 (55yrs):...you know as well as I do everybody's make up is entirely
different, some people are more prone to arteries furring than other people, er
and I would say if you can detect the people who are more prone to furring
arteries, if that was the case for me and I knew I was going to fur up quite easily,
I would take the aspirin to help stop that
HE: but did you not think this measure you had was enough to sort of indicate
that?
Peter2: er aye no, I wouldn't have said so, unless I could really feel-
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These quotes re-emphasise the lack of a perception of risk currently associated with the
ABPI as discussed in the previous chapter, and highlight a problem for interventions that
may involve preventive medication for atherosclerosis and similar asymtomatic
conditions.
The following dialogue extract from focus group lb shows an insightful discussion
about distinct types ofmedication relating to the distinction between illness types:
Wayne (69yrs): well I don't take medication, because if you're taking
medication, there's something wrong with you, you're ill, so I don't...I'm on
these decongestant tablets...
Maive (67yrs): medicine may give you a better quality of life
Yvonne (72yrs): that's right, but I wouldn't take like- medicine that I know
people that are "go and buy this from the chemist, it's good for you", you know
all kinds of things you get from you know- over the counter in the chemist, but I
wouldn't do that, ifI needed medicine and I got it from the doctor, good enough
I'll take it and I'll follow the instructions and take it you know correctly. But not
to take medication for the sake of it. I'm OK, I've got good health so I don't need
prescription medicine, I haven't had prescription medicine for three years
anyway 'cause my diary's been clear. But I've had prescription medicine in the
past and fair enough I mean I'm happy to take it because it does make you better.
Lorraine (52yrs): I've got a thyroid deficiency so I'm on a dose of thyroxin
Yvonne: ah but that's helping you
Lorraine: but it's yeah, but having said that I didn't even know I had a deficiency
so um whether it counts as an illness or not, as this gentlemen over here (W) was
saying, but er you know
HE: do you see that as kind of different?
Lorraine: yeah uh huh, I don't honestly think about it very much, but I mean I
know what this lady means about not taking medicine for the sake of it but it's
just I wouldn't give a thought to taking any medicine, whether I needed it
Yvonne: you 're getting thatfor a reason
Lorraine: uh huh yes
Yvonne: that's different but I seem to know many people that have cod liver oil,
buy as much stuff out the chemist for this and that
(italics: my emphasis)
This dialogue about medication and necessity brings together several issues covered in
this chapter, demonstrating various problems regarding the perception of preventive
medication. First, as discussed previously, participants made associations between
medication and an 'ill identity', which seemed to have negative connotations and was
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something participants wanted to avoid. Second, distinctions were made between
different kinds of medication: prescription medication for an acute and presumably
symptomatic episode of illness was regarded as necessary, as was medication for an
ongoing and less symptomatic condition (thyroid deficiency) which was referred to as
'helping' and 'for a reason'. However, medicines recommended as being 'good for you'
or 'for the sake of it', which seemed to be how they viewed preventive medicines, were
not considered necessary. The comment, "you're getting that for a reason" is interesting;
it seems that only established illnesses were being considered as 'reason' for medication
use, and but conditions where preventive medication could help were not included in
this reasoning. Participants seemed to be working together to build a model of different
levels of medication and illness and their related necessity; the resulting model treated
medications that participants themselves were taking as necessary, so once again
possibly helping participants to maintain perceptions of healthiness and avoid an 'illness
identity'. Lorraine's insightful question regarding a thyroid deficiency's status as an
illness, particularly as prior to discovering it she had no awareness of having a
'condition', further adds to the complicated perceptions of 'silent' conditions.
Views about medication: The doctor-patient relationship
Continuing the discussion of necessity, some participants' acceptance of medication and
views about its necessity seemed to be influenced by their GP. In several cases, in the
event of a GP prescribing a medication, the participant then seemed to deem the
particular medication necessary, despite prior reluctance they had about it given their
dislike of medication. For example:
Fred2 (62yrs): well I'm not keen on that either but for no reason you know
because I really don't know a lot about er medicines or even medication you
know, I mean if the doctor gives me antibiotics that's different thing you know,
then I'll take the course I'm gi'en, er but I'm always reluctant even to take them
you know. But it's just something that I went through all my life you know doing
you know er I'd rather- maybe it sounds stupid but I'd rather put up with
headache than take a paracetemol or something you know, I just don't fancy
having these things in my body sort of thing you know and that's all
HE: you said like if the doctor prescribes something, that's slightly different
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Fred2: well yes, I know- because if I go 'o the doctor, you know to find out
what's wrong with me you know maybe a chest infection
HE: yeah
Fred2: well if I go to find out why Eve got it such like, he tells me why Eve got
it but to cure it...he's got to give me these antibiotics then you know I go 'o the
doctor who I trust then Eve gotta take them you know reluctantly but I take them
you know. Um.. .so I know it sounds stupid but that's the way it is you know
Participants who had this attitude often said they would take whatever their doctor
prescribed, often like Fred2 quoted above, mentioning their faith and trust in their GP or
the assumption that the GP must know best, or at least know a great deal more than their
self. One participant emphasised several times during her interview how good her doctor
was:
Susan5 (53yrs): whatever she says, Ell do, you know so I don't really know
anything about aspirin, I just take it, she said "take two a day" and that's
it...()...and she said Eve got to take two, I don't understand that but I just do
what she say because she's good, I trust her...()...Well as I say I trust the doctor,
she's a good doctor, um and she is really concerned about your health, it's not
just a doctor who says "take this, take that" you know without thinking so I do
trust her...()... I know what Em doing as I say I trust the doctor, she's obviously
cleverer than I am and she knows that's what I should take so that's it.
For Susan5, knowing the reasoning for her medication was less important than her trust
in her GP's knowledge and advice. Blaxter and Paterson (1982) found this attitude
common in their older participants who expected their doctor to be simultaneously a
family friend and an unquestioned expert. Isaac3's faith in his GP was so strong that
despite anticipated adverse side effects to aspirin given his past experience, as quoted
earlier, he said he would still be willing to try aspirin if his doctor suggested it:
Isaac3 (58yrs): I just go with what the doctor puts me on really...if he said 'ah I
wanna put you on aspirin', yeah I would probably say, 'we'll try it'...
So, for a fair number of participants, their GP's advice could override their preference
for avoiding medication. Where it was appropriate, I asked participants if they would
consider asking their GP about the idea of starting aspirin as a preventive medication.
One participant (GeofD) had done this upon discovering his low ABPI, rather than
entering the trial (his case will be discussed in the trial participation chapter).
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Geoffi (68yrs): and when I found out you knew I was at risk, but you were
prepared to put me on a dummy pill
HE: uh huh
Geoff3: I said get lost, and rather than on aspirin, they can't tell you what you
were on. So I walked out of the trial at that stage and I went to my own doctor
HE: and did you?
Geoffi: I spoke to him and told him what was happening, and he said, "do you
want to go on aspirin?" and I said "well it sounds like I might have to". Ed
sooner be on it rather nothing, so I have the 75mg aspirin.
Such behaviour was considered wrong or inappropriate by other participants, for
example:
Ted4 (77yrs): Ed be wary of doing that, I feel that'd be a negative reaction, if I
was coming to him for advice and then 1'm more or less telling him what he
should be saying you know...
Ted4 felt such an action would be inappropriate considering the roles embedded in the
relationship he had with his GP; requesting a certain medication or even making
suggestions was not considered within his patient role. Similarly Gordon 1 felt that a
doctor's 'permission' had to be granted before taking any medication, as shown in the
following dialogue between him and his wife
Gordonl (67yrs): well yes I would take it bymyselfbut they say you've gotta get
the doctor to get permission first, cause if I need it, I would need to find out if I
needed it and I would take it then, you cannae take it, it tells you in the paper
years ago, you've gotta go 'o the doctor then find out, then he gives you
permission. But aye I was certainly take it if it helps, if you find out it helps, nae
problem, I think everybody would do that really
Wife: my sister and her man take half an aspirin each
Gordonl: ah but did they ask for permission from the doctor?
Wife: I never asked them
So compared with Geoff3 who seemed to have a more partnership style patient-doctor
relationship, other participants tended to be more passive, whether accepting their GP's
advice without question, or waiting for their GP to make recommendations.
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Self-medicating
A different type of active choice discussed by some participants was self-medicating.
Regarding aspirin, one participant had started self-medicating in a preventive way after
discovering her low ABPI at the screening:
HE: so what did you do after that, did you decide to go on aspirin yourself?
Patricia3 (61yrs): yeah I take my aspirin, I take a soluble aspirin most days
HE: and did you go to the doctor?
Patricia3: no
HE: no, oh right
Patricia3: no I actually- I got them in- I buy them in Superdrug, and I just take
one you know dissolved in water, most days, you know maybe 5 times a week
HE: yeah uh huh, and you haven't told your GP or anything
Patricia3: no I haven't been to see the GP for quite a long time
HE: oh right
Patricia3: so I keep meaning, I keep thinking about it and saying maybe I should
go along and see him cause maybe I should be taking 'coateds if I'm going to
take them as regular as that
HE: what size of aspirin are you taking?
Patricia3: just I think it's 500 mg soluble...so I mean I think probably aspirin
does make a difference
So Patricia3 had not felt the need to consult her GP about her self-medicating until the
interview, when she considered checking with him at some point. She took soluble
aspirin and had considered sugar-coated aspirin too, as she was conscious of the possible
side effects on her stomach; the dosage she was taking however was particularly high.
Craig4 described how a doctor friend self-medicated aspirin in a preventive nature:
Craig4 (54yrs): oddly enough I have a doctor friend who I know takes a quarter
of an aspirin every day, which she's got no cause to believe that there's any
necessity for this but
HE: has she had heart problems?
Craig4: no
HE: oh right
Craig4: well I think she's just scared of having heart problems you know and um
that's her response to that is to
HE: interesting
Criag4: yes uh huh
HE: there seem to be a lot of people who are on aspirin after heart problems,
after a heart attack, but
Craig4: but they don't bother beforehand, yeah...yes but then this is obviously a
highly informed person who's doing this
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Craig4 emphasised this friend's knowledge and experience from being a GP herself,
implying that she must have good reason for taking aspirin preventively despite having
stated no clear necessity for this action. Following a discussion about awareness and use
of aspirin in focus group 2, one participant questioned fellow participants about
preventive self-medicating:
Emma (70yrs): well I suppose we've read a lot about the supposed benefits of
aspirin, but have any of us here actually decided, 'well offmy own back, I'll take
an aspirin'?
Deirdre (68yrs): my friend has
Cath (63yrs): my cousin has
Emma: I mean I've often thought about it, then I thought, 'well I've not been told
to do it, I'm not going to'
Her conclusion related once again to the absence of being directed to take the drug,
presumably by her GP, which had dissuaded her from any further consideration of self-
medicating.
In summary, participants spoke about known others who self medicated with aspirin in a
preventive way and some considered doing this themselves, but with the exception of
one participant, consideration was as far as they had gone. The influence of a GP
prescribing, recommending or approving aspirin as a preventive medication seemed
more influential and seemed to be related to perceived necessity.
Aspirin- a special case?
Participants' views about preventive medication were not only embedded in their beliefs
about medication in general; it became evident that many participants held attitudes
about aspirin specifically which appeared to have a large influence on their views about
using the drug as a preventive drug and/or entering the trial. Of course, the study was
about the trial and aspirin, so attitudes towards these were explicitly explored. This
section examines participants' views about aspirin and its attributes, and argues that as
attitudes towards aspirin often differed from attitudes towards medication in general,
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many participants seem to treat aspirin as a special case. This section highlights
perceived attributes of aspirin that probably contributed to this differential attitude.
Awareness of aspirin: Old wives'tales and current hearsay
Awareness of the benefits of aspirin emerged as not only a recent trend; some
participants spoke of older relatives who had sworn by daily aspirin:
Monica 1 (66yrs): my mother always had an aspirin you know every day
HE: did she?
Monica 1: uh huh, I mean and that was for years and years and years
HE: what made her do that?
Monical: I don't know, it was just something that she seemed to know was good
for her and she used to take it uh huh, yeah, soluble, she used to take, she used to
get a little water
Emma (focus group 2, 70yrs): my husband's parents always took half an aspirin
every night... and his father was 96 when he died and his mother was 89, and
they always took it, it was the first that I'd ever heard anybody taking it, and they
always took it...
Participants who mentioned such "old wives' tales" seemed to feel there was some truth
in them, as they attributed these relatives' long lives to the daily aspirin they took.
Furthermore, they talked about relatives 'knowing' that daily aspirin was good for them
but not knowing why. Some participants who mentioned current recommendations of
taking aspirin for 'general health' seemed similarly unclear, for example:
Bob (focus group la, 70yrs): aspirin's been on the go for many many years, it
was used for most things before all the modern drugs
Julie (56yrs): 'cause in magazines it sometimes tells you over a certain age you
should take an aspirin, not specifically for heart disease but just for general
health
Bob: (in agreement) general health
Awareness of aspirin: cardiovascular related uses
A couple of participants were bemused by the discovery of aspirin's use for heart
disease given its long history as a general household drug; Graham3 described how
aspirin had been used for a multitude of ailments over the years and found its heart
related benefits amusing:
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Graham3 (58yrs):...aspirin, as I say, it's funny how all of a sudden it's became
this great medication for heart problems.... I don't think it's a thing I've ever
taken really in my life
HE: no
Graham3: well not ever having a sore head, I wouldnae need to
HE: uh huh
Graham3: it was always- when I was a youngster there was always a bottle of
aspirin in everybody's sort of house you know? Like what the murdering stuff
now that everybody seems to have you know? Ibuprofen or whatever it is,
paracetemol, that's the one, everybody seems to have them in their house, but in
my day it was aspirin
HE: yeah yeah
Graham3: so if they were taking it for sore heads...they wouldn't be able to die
in a heart attack (laughing).
More often than not, participants' discussion of current recommendations showed some
awareness, albeit vague, of the reasoning behind the advice:
Alison2 (55yrs): no I read t' paper and you know health pages even in books
(magazines), you know and I found it and even in America they've done this
aspirin thing different places as of 'ere and now they're saying that more people
should be taking aspirin aren't they?...()...I did read in the paper that they're
now saying that it could be a factor that more people to take it would prevent er
heart thing like
Such hearsay seemed to originate from the media; participants usually referred to having
read some recommendations but often acknowledged that their understanding was
vague:
HE: where did [your awareness of aspirin's use for heart disease] come from?
Warren2 (71yrs): well I suppose I've read articles in the papers, I'd heard it on
the television, um saying that aspirin- common aspirin, as they talk about it, was
found to be helpful in um treating heart conditions and I think it was to do with
preventing clots and thinning of the blood and something like that
HE: yeah
Warren2: so that's how vague I am about it, but I was aware
Other participants showed greater awareness of the research:
Isaac3 (58yrs): yes I've read in the paper sort of reports and that on it, so I have
read that there was research being done, they were trialing aspirin and they were
getting a fairly good success rate back out of it, the implications were that it was
successful.
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One of the main properties of aspirin which participants talked about was its ability to
thin the blood or to stop the blood clotting as demonstrated by Warren2 above. Ted4
explained his awareness of atherosclerosis and aspirin's blood thinning ability but
struggled to grasp a full understanding:
Ted4 (77yrs): well does the aspirin thin the blood, is that what happens?
HE: er...yeah...
Ted4: well that's my layman's impression of what the aspirin would do,
preventing obviously preventing clotting which you could also get from the
furring up of the arteries as well so that could be smoking. I can't see that the
aspirin is- you know the furring up of the arteries is like, this is in my mind, I
might have heard but I don't think the message has got through about the aspirin
too much no I don't think so
One participant discussed how aspirin's use as a blood-thinner replaced the old wives'
tale ofwhisky (or brandy)'s use for the same purpose:
Gordonl (67yrs): but they did discover what you're saying Helen, the heart,
definitely it thins the blood, but mind we're going back in the olden days again,
all the older ones, they're living longer now, but some of them did live for a long
time, in fact cross there (over the road) they're all in their nineties. But they all
took their tipple, you know
HE: oh yeah?
Wife: oh yeah
Gordonl: whisky, rum and brandy, and that was the secret because it thinned the
blood.
HE: oh right
Gordonl: and they're strong going to this day, now they've discovered aspirin
thins the blood
Wife: but you get maere pleasure out of the whisky!
When describing awareness of aspirin's heart related uses, a commonly discussed issue
which participants themselves had engaged in was the prevention of deep vein
thrombosis (DVT):
Morag3 (64yrs): I sometimes have taken aspirin myself
HE: oh?
Morag3: I take it if I'm going to be flying on a long journey
HE: yeah
Morag3: I would buy junior aspirin or something equivalent to that and take it
for that
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Awareness of aspirin's use for preventing deep vein thrombosis while flying was
probably due to the recent media coverage of the debate; one participant was aware that
this was still an area where further research was required:
Keithl (59yrs): I don't know I mean, we're going on holiday shortly and what
happens is the wife is on- you know you get the deep vein thrombosis, travelling
in planes and that, so she said to the doctor, she was there this morning, saying
"what about taking some aspirin you know before I go?", and he says, "well take
it if you want an' all but the jury's still out on whether it is effective or not
effective
Keithl's comment demonstrates how some people were more sceptical than simply
accepting the latest recommendation publicised through the media, preferring to wait for
further research findings, again seeking advice from their trusted GP.
Another use that had received media coverage several years previously that some
participants spoke about was aspirin's use for a heart attack.
Lucy (focus group 4b, 57yrs):...in fact there was period where I carried an
aspirin in my handbag, there must have been something on the television or
so... (laughter)... and if you know you came upon someone who'd obviously had
a heart attack and you're waiting for the ambulance you were supposed to put an
aspirin under their tongue right? I carried one around until it became all crumbly
and disgusting (laughter). You know perhaps er should I mean is that a thing to
do? I mean do you happen to know that, supposing you come upon somebody
you know the chances are and they're having a heart attack
Lucy pointed out that she had seen this on television and others spoke how they 'had
heard' this advice without being specific as to the source, interestingly another
participant said she had been advised this on a first aid course she had attended.
Participants often talked about people they knew who were on prescribed aspirin for
established heart conditions such as angina or after a heart attack, for example the
following dialogue took place in focus group lb:
HE: so about aspirin generally, were you aware of aspirin's use with heart
disease and things before this?
Nigel (64yrs): I was, my wife's got angina
HE: oh right
Nigel: she takes the aspirin every day, she has to
HE: oh right uh huh
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Nigel: so I knew about aspirin and heart problems, it thins the blood
Wayne (69yrs): I've got a pal had a bypass and he's now on an aspirin every day.
Just keeps the blood thin
HE: how about other people?
Yvonne (72yrs): my husband he had a heart attack...um '94 that's about 8 years
ago, and he takes 2 75mg dispersible aspirin every morning, so I know about
that, cause he kept saying, "well you should take it", but I don't take any- I'm not
taking any aspirin.
Few participants had heard of the idea of using aspirin specifically as a preventive
medicine (other than preventing DVT); only a couple of participants mentioned
preventive use when I asked them if they knew of people who took aspirin, and there
was some awareness through the media:
Molly4 (75yrs): well I just hear of it occasionally, I don't think I know of
anybody personally, but you hear of people mentioning and of course interviews
and so on are on television and radio um that they're doing- that they take half an
aspirin a day just a case it help you know, I think it's a good thing
Most participants, however, did not seem to distinguish between aspirin's use as a
preventive medication, and its use for established heart conditions. A few explicitly
stated their assumption that aspirin's benefits had been proven, and thus questioned the
need for more research:
Beatrice (focus group 2, 75yrs): I thought aspirin had been a proven blood
thinner and so was accepted as such, and most people, once they've had a stroke,
heart attack, anything like that without complications in the digestive system are
given a daily aspirin at this moment
Awareness of positive attributes and adverse side effects came from personal
experience, knowledge of others' experiences and the media. For a couple of
participants, the mixed messages appearing in the media led to feelings of uncertainty
about aspirin:
Miriam3 (73yrs): yes, I mean I've read about it in the press or heard about it on
television, and there are always people who are very much in favour and there
are some who've said they didn't think it made any difference, so there's a big
variation in opinions isn't there?
HE: do you have an opinion on it yourself from all that that you've read and
seen?
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Miriam3: no not particularly, er...I'm not just quite sure what part the aspirin
plays in it
Others spoke about ignoring the media's take on the situation:
Richardl (54yrs):...you know what the papers are like with risk, they'll no-
journalists have no conception of risk
HE: yeah
Richardl: you know any tiny thing that goes wrong with something, journalists
will make a big fuss about it as if the whole planet's gonna die of it tomorrow
you know. Um so it's I'm sure if there'd been any of that kind of risk with
aspirin, it'd long since been all over the newspapers, so there isn't [one].
To summarise, aspirin's place as a longstanding medication and awareness of current
recommendations led to perceptions of its benefits for general health. Commonly
discussed attributes were blood thinning and clot preventing, and there was awareness of
its use as a preventive drug for DVT and as a treatment drug for heart attacks and
angina; its potential use for preventing heart disease was less well known. Aspirin's
longstanding status probably contributed to its widely perceived safety as discussed
earlier. Generally across the sample, trust in aspirin and its benefits was widespread. As
discussed, for many participants, despite knowledge of potential adverse effects, these
were clearly outweighed by very positive views about aspirin. For some, such positive
views seemed to override dislike of medication, which seemed to lead to aspirin being
treated as a special case.
Some participants talked explicitly about their faith and trust in the drug, for example
participants who were on aspirin (and had not entered or were no longer in the trial):
Jack5 (66yrs):...I've spoken to other chaps about my age and there's a few that
are on it and er...I'm quite happy to be on it, I feel very confident about it, I feel
it's a strange thing but I feel it's a real help the aspirin because it's had such good
reports and er
HE: reports, where?
Jack5: well in the newspapers, you're reading the Daily Mail for instance and
certain days they've got health sections and er there's been write-ups about it,
how various tests have been done and it's proved itself over a number of years,
it's not just it's only come lately sort of thing, and so I feel confident about using
the aspirin I feel it's a real help and er there's no side effects of any of the tablets
I take so
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For two participants, their faith in aspirin was so strong that despite having a second
heart attack since being on daily aspirin their faith continued, for example:
Timothy5 (61 yrs): no well ur I take it faithfully every day because I believe it
does good you know, I believe it does me good you know so...it didnae stop me
having another.. .angina pain or anything like that but
Some participants mentioned how they preferred aspirin to other drugs. Regarding
painkillers, it was regarded as more trustworthy for its comparative safety (earlier
Graham3 was quoted as comparing it to ibuprofen which he described as "murdering
stuff') and lack of advertisement (focus group 4b). Regarding cardiovascular treatment,
a couple of participants who were on prescribed warfarin expressed their keenness to
switch to aspirin. Often participants who disliked medication generally had more
acceptance of aspirin, for example Mandy3 who had no clear reason for this preference:
Mandy3 (59yrs): actually of all the things like paracetemols and things like that
in- I've always in the past taken aspirin for pain, recently I'm taking brufen but
aspirin's always the one I would take but I do have problems
HE: do you?
Mandy3: yeah, I only take aspirin very occasionally, but that was always my
preferred um painkiller
HE: why's that?
Mandy3: I never felt right- well it's probably imagination paracetemol and things
I've never I don't know it just didn't seem right, whereas aspirin didn't seem to
affect me in the way, make me feel that you know there's something more right
when I take an aspirin
(italics: my emphasis)
Similarly, Susan5 admitted not taking other items of her prescribed medication but she
faithfully, albeit reluctantly, took her prescribed aspirin:
Susan5 (53yrs): yeah it's gone down uh huh, since I've been on the high blood
pressure tablets and the aspirin it's...one thing though mind you it was up and
she gave me other tablets which I don't take...er water tablet I think they're
water tablets, it wouldn't be any good showing you if you're not a medic, but
anyway I just take the high blood pressure and the aspirin, I know the aspirin- I
think that does do you good
For some participants, dislike of medication in general applied to their views on aspirin
too. However for a large number, certain favourable attributes of aspirin contributed to a
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perception of aspirin as a preferred medication that seemed to be treated as a special
case. This is important when considering the use of aspirin as a preventive medicine, as
it seems that for certain people starting a course of aspirin for a preventive purpose
would be preferable to taking other drugs. However, lack of awareness of aspirin
specifically for preventing heart disease and general reluctance to engage in preventive
medication use may form a huge barrier for the promotion of aspirin in this way. Once
again, this reluctance seems to relate to low perception of cardiovascular risk in
particular regarding the ABPI.
Preventive medication: an alternative strategy?
Given that the preventive method being investigated in the trial was preventive
medication rather than lifestyle behaviour changes such as stopping smoking, an issue of
particular interest was investigating people's opinions on the idea of preventive
medication as an alternative to making changes to their lifestyle. Considering the picture
of aspirin which has emerged and been discussed so far in this chapter as a seemingly
'special case' for many participants, I was interested to explore people's attitudes
towards the idea of taking daily aspirin and their views on an 'unhealthy' lifestyle. I was
particularly interested in whether preventive aspirin might be views as an alternative to
lifestyle change as a strategy for preventing heart disease. In a few interviews, the
participant brought up this idea themselves, for example by discussing people who
engaged in taking aspirin and continuing an unhealthy lifestyle.
Joe2 (56yrs): my wife's mother, she took it- she had heart problems as well... er
and she always took an aspirin and she had great faith in that and it kept her
going for years despite her smoking and everything
Where participants did not raise this issue, I asked their opinion of preventive
medication as an alternative strategy. A few participants could see the potential success
of the strategy, particularly as they felt that promoting lifestyle change was not
successful, for example:
Richardl (54yrs): I mean I think it's perfectly feasible, if something proves- if
you work on the assumption that people are not gonna change their lifestyle and
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people are going to- I think you have to start from that assumption because the
fact of the matter is, they're not having success changing people's lifestyles yet,
well not seriously, so if you say, "well if you do continue to smoke and drink and
do all the things that are bad for you, then at least take this aspirin, it'll help a
bit"
Similarly participants could see how such a strategy would appeal to the general public:
Isobel3 (60yrs): I think it's wonderful because I know that if a lot of people who
will benefit from that, for the simple reason that they can pop an aspirin or pop a
pill...they do that and still continue to have fish and chips and all the food that
they take (). So that type of person, it's wonderful for. I'm quite happy to deny
myself the fish and chips, the meat, um and things, and discipline myself to what
I think is necessary. But years ago that would probably considered a prank! The
majority of people, your 7 out of 10 people are quite happy to go along, take 4 or
5 medicinal things from the doctor, instead of an alternate lifestyle and food.
Isobel3 felt that an aspirin could be 'easy' solution for people who do not want to
change their lifestyle, but regarding her own health, would not have considered it, rather
preferring a holistic approach. Similarly, a couple of participants favoured a holistic
approach to prevention, but suggested that preventive medication could be offered
alongside promotion of lifestyle change, for example:
Owen4 (52yrs): I mean I think at the end of the day if people have any
vulnerability to these things, it's entirely reasonable that we should try and give
them the preventative medicine, particularly if it's going to be a preventative
medicine which doesn't have any dramatic negative side effects. Er and without
sounding like some kind of new age person, I mean that at the same time it's
important to stress the holistic approach to things and that you know- absolutely
fine to use the chemical remedy but you know you try and use the personal
lifestyle approach to things as well, not that I'm trying to be holier than thou
'cause I mean my wife still does not by any means! But I think you try to balance
the two things.
HE: that's one things actually that I was going to come onto...()...what do you
think about aspirin as an alternative to these ways of reducing risk factors
Owen4:1 think things should be as complementary rather than as alternatives
HE: yeah...so would it appeal to people who don't want to give up smoking?
Owen4: well I think that I wouldn't remotely suggest that you don't encourage
folk to take aspirin if they're not prepared to look at their own lifestyle but I
think you could use getting onto the aspirin as a means of trying to persuade
them also to look at their own lifestyle.
Interestingly, one participant revealed how she engaged in this strategy herself:
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HE: because in a way you're kind of doing this approach, "if I stop smoking I'd
reduce my chances of heart problems, but then again I could take this aspirin" so
do you think that it helps?
Patricia3 (61yrs): not really, no I don't really believe that, I think the main thing
is to stop smoking, would be the main thing. I take the aspirin really because I
can't stop smoking, I have tried it and I should try it, I will try again, and I hope
that it'll- I don't take the aspirin so I can go on smoking, I take the aspirin
because I smoke and I hope that it might reduce the chances you know of a heart
attack. But in my own mind I probably realise that smoking does so much
damage it probably won't help, but it's worth a try
However despite doing this herself, rather than regarding it a good strategy, Patricia3 felt
that it was wrong, probably ineffective and that stopping smoking would be preferable.
Interesting to note is the distinction she made between taking aspirin so she could
continue smoking, and taking aspirin because she smoked; she emphasised that she did
the latter as a way of coping with her lack of success at quitting but her ultimate aim was
to quit the smoking.
Richard 1 (quoted above) felt that the medical profession would consider preventive
medication wrong, and that anything that allowed people to continue their unhealthy but
pleasurable behaviours would not be encouraged in British culture:
Richard1:...my impression is that the medical profession do not like to advertise
preventive medicine, on the grounds that if you do so, you might encourage
people to think that you can just keep taking the risks and take the preventive
medicine and that will reduce the risk, 'cause you don't actually see that
happening on any front, they tell you not to do things, you can keep on doing it
and this will help, and I think there's a great um sort of resistance and it must
come from medical profession 'cause I cannae see where else it's coming from,
to that kind of approach. I mean it may be a sort of cultural thing in- in the UK
that the proper thing to do is to cut out doing the things that you find pleasurable,
rather than to start doing something which will ameliorate the effects of doing
something pleasurable. I mean I could see somebody doing a campaign like that
in Italy, where people have got different attitudes. But I can't actually see it in
this country, or in the States for example, 'cause it's this puritan ethic that you
get which says basically, "good things are bad for you, therefore you should cut
the things that you enjoy doing out to improve your health" rather than say,
"keep on doing all the bad things that you do but um-um take this as well".
Several participants questioned the medical effectiveness of such a strategy:
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Peter2 (55yrs): as you say, if it is preventative, yeah I would think it'd be a good
thing you know. If you were eating chips every day, or smoking many cigarettes
a day, yeah I suppose it would
HE: do you think it would?
Peter2: er would an aspirin...counteract all the side effects of all the fat intake
and things like that? If it did help it would be good, it would be great, I mean aye
you could indulge your vices and then take an aspirin and feel better sort o'
thing.
Joe2 also questioned the efficacy, believing that such a preventive strategy for heart
disease could not be so simple (which I was not trying to imply):
Joe2 (56yrs):...- there's no quick fix for anything, it needs to be god forbid, a
lifetime thing of taking whatever but you should certainly have one eye on that if
you like to just prevent things happening to you
Others felt that it would be pointless or a waste of time, and not dealing with the root of
the problem, for example:
Ursula (focus group 2, 61yrs): well it's like fighting one thing against the other,
if you're taking something that's rotten for you and they say, 'well just take an
aspirin anyway", OK it might help but you're really defeating the cause if you're
all still doing the wrong things, but if it helps, well...
Similarly, many participants were adamant that encouraging such a strategy would be
promoting the wrong message and would encourage people to continue and/or engage in
an unhealthy lifestyle:
Mandy3 (59yrs): mm... but that would be the wrong attitude I suppose...but um
a bit daft cause it's no cure and if they still continue to smoke or whatever then
eventually the aspirin I don't think is going to be of any use
Daniel4 (54yrs): someone who's in drinking a lot at night, eating all greasy
foods, stodgy foods, you can't say to him, "don't go and do any exercise, don't
bother changing your diet, just take the aspirin", what good are you gonna do?
No the all three must go along in tandem
Such strong attitudes were expressed by a large number of participants. To them, the
idea of preventive medication as an alternative strategy to lifestyle change was wrong;
rather they advocated changing to a healthier lifestyle and generally felt that the onus
should be on promoting healthier lifestyles once again invoking individual
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responsibility. Some participants found the idea completely ridiculous: the following
quote (from pilot study a) sums up this attitude and adds a particular Scottish context:
Greg: what have a deep fried mars bar and an aspirin?
(Laughter)
Jon: and have twenty fags at the same time
Interestingly, despite the majority of participants advocating lifestyle change rather than
preventive medication to prevent disease, many who voiced this attitude actually
engaged in 'unhealthy' behaviour themselves, for example Joyce4 (a smoker):
Joyce4 (54yrs): I don't know if it would work if you didn't, I think you would
have to change your lifestyle slightly if you were susceptible I would think you'd
have to do the whole thing yeah I don't think taking an aspirin and carrying on
the way
HE: how about with the smoking?
Joyce4: think I could take an aspirin and it would...no I would say no, I think
you'd have to do the whole thing
As discussed in the screening chapter, Joyce4 did not perceive much risk from her
smoking and thus distinguished herself from those who she referred to as susceptible.
Similarly Fergus 1, a smoker and trial participant himself, seemed to attribute blame to
smokers and felt that the trial was to benefit those with healthy lifestyles:
Fergusl (72yrs): well I don't think that's proper is it, I don't think that's right
you know what I mean. Er the aspirin trial I suppose it's to help people that
havenae smoked and still have heart problems you know what I mean, smoking's
just a side issue, I know it doesn't help your heart...but the aspirin trial is I
suppose, for people that don't smoke or drink even you know
It was surprising that so many people felt that such a strategy was wrong, in particular
participants who admitted to engaging in unhealthy behaviours themselves. It was also
interesting to consider the few individuals who did see the benefit of such a strategy;
these tended to be individuals who led particularly healthy lifestyles themselves (such as
one of the initial quotes from Isobel3), but perhaps could recognise the difficulties of
lifestyle change for other people.
To summarise, whilst a few participants could see the benefits of a drug that could be
taken to help prevent cardiovascular disease, thus requiring less emphasis on a healthy
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lifestyle, the majority of participants rejected the idea of promoting preventive
medication without making changes to lifestyle. The majority opinion was that once
diagnosed with a risk, one should change one's whole lifestyle; this often seemed to be
based on disapproval of encouraging unhealthy lifestyle or due to the belief that without
lifestyle change, the drug would have little effect. Generally, a large emphasis on
individual responsibility was again apparent when discussing this issue. This view was
also prevalent amongst those who led unhealthy lifestyles themselves.
Summary and conclusions: Attitudes towards prevention and preventive
medication
It is useful to consider the findings in this chapter and their implications for a prevention
programme (as being trialed) involving aspirin for heart disease. On the surface, a
positive attitude towards prevention was common as illustrated by widespread use of
phrases such as "prevention is better than cure". However, participants' accounts
revealed lifestyles that seemed to contradict this attitude; further analytical exploration
revealed reasons and explanations behind this apparent contradiction including
preference for avoiding medication, and only medicating when 'necessary', usually
meaning once symptomatic or on a doctor's diagnosis and advice.
It is interesting to consider why the phrase "prevention is better than cure" is so
prevalent in participants' accounts, despite not being matched completely by their own
health related lifestyles. Participants may truly believe it as an ideal or they may not,
they may be reciting it like a mantra as an initial response to questions about preventive
health. Such a question is difficult to answer from people's accounts alone but regardless
it is interesting to reflect on use of the phrase; as a well-known and used phrase, it seems
to have become an 'old wives' tale' itself. However, whilst in the past it may be have
been used to refer to lay beliefs about avoidance of illness, for example by wrapping
oneself up in warm clothes in the winter to avoid catching a chill, in current society with
health promotion emphasising preventive health and personal responsibility, together
with the existence and promotion of preventive medication, the phrase has become
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particularly pertinent. While people may ideally believe that prevention is better than
cure, when it comes to behaviours such as taking daily aspirin for the rest of one's life to
prevent heart disease, engaging in this behaviour is not straightforward as there are
many factors (as illustrated in this chapter) which will have an influence on such a
decision, both consciously and unconsciously.
From participants' attitudes towards aspirin, a picture emerged of the drug being
considered a 'special case' due to properties such as its place as a longstanding
medication and awareness of its benefits, which contributed to trust, faith and a low
perceived risk. Thus, promoting aspirin as a preventive medication would probably have
more success than other, less familiar, drugs. However, lack of awareness of its specific
use as a preventive drug for heart disease and a general unwillingness to engage in
preventive medication use when asymptomatic may well be a major barrier. The idea of
preventive medication as an alternative to improving one's lifestyle was regarded as a
useful approach by a few participants who could see the possible appeal to 'other
people'. But the majority, including those with unhealthy lifestyles themselves, felt that
such an approach was wrong and that once diagnosed a person should engage in a more
holistic approach.
Finally, participants' attitudes towards aspirin as preventive medication for heart disease
could be summed up as 'prevention is better than cure, but...' Despite apparent positive
attitudes towards prevention as typified by common use of the phrase 'prevention is
better than cure', invocation of individual responsibility and a favoured opinion of
aspirin, the low perceived risk from atherosclerosis whilst asymptomatic and lack of
perceived risk from the ABPI measure demonstrate the difficulty there may be in
promoting this preventive method.
However, rather than paint a completely negative picture for such a possible prevention
programme, the chapter has revealed areas of interest for those promoting such
programmes. As explained, participants' accounts of prevention and preventive
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medication and explanations behind their views, revealed varying personal and
contextual influences on their views. Certain factors such as the GP's role in
participants' views about the necessity of medication (and in the perceived risk of the
condition), and the favourable view of aspirin help to tailor promotion of prevention
programmes. Nonetheless, the widespread assumption of aspirin's safety should be
considered and patients should be fully informed of the risks alongside the benefits.
Awareness of asymptomatic atherosclerosis and the ABPI measure, whilst difficult, is an
important challenge for public health and health promotion.
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Chapter 6:
Gullible guinea pigs or good gift-givers?:
Attitudes towards participation in the randomised control trial
Introduction
This part of the thesis presents and explores participants' attitudes towards
participating in the AAA research trial. The first section outlines and discusses the
altruistic attitudes and self dominant views which emerged in participants'
discussions about the trial and their decision about participating. The second section
explores participants' views on the potential benefits and risks from participating in
the trial. This includes attitudes towards aspects of the randomised control trial
procedure, in particular the placebo and blinding, reactions to trial experiences such
as side effects, views on the trial tablet, and their beliefs about incentives and
barriers. Finally participants (mis)understandings of the trial are discussed.
Part 1:
For oneself or for others?: Altruism and self benefit
In the first interview carried out in the present research, Michelle5 (ineligible for trial
due to prior heart attacks), spoke about her keenness to participate in research, giving
the example of volunteering for a different trial whilst waiting for a heart operation.
Her reasoning, "well ifI can help them in any way, 'cause I've had a lot ofhelp from
the hospitals", was the first example of altruism that emerged in the research. In
many of the interviews that followed, altruism was expressed in people's accounts of
their decision-making making it a salient issue for analysis. Sometimes it was
presented in terms of reciprocity like Michelle5, but there were various other
explanations all of which will be discussed in the present chapter. Conversely, self-
benefit in individuals' reasoning was equally salient in accounts. However, the
altruism and self dominance which emerged was not a dichotomous categorisation,
rather it appeared that the two fell at ends of a spectrum of varying dimensions.
Furthermore, seemingly opposing dimensions along the spectrum could be salient to
the same individual, sometimes at different points of time due to situational context,
but also within the same decision making process.
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This section will work through different 'dimensions' of the altruism-self benefit
spectrum which were expressed in the accounts. Apparent influences behind these
beliefs will be discussed. Social psychology attempts to explain the pathways and the
motivating factors leading to pro-social behaviour, including altruism. In the present
research it is dangerous to attribute motivations to people's decisions as often this
was not elaborated on in such detail; second it is also possible that situational factors
within the individual interview and focus group environment were influential on how
participants expressed their beliefs; and third, interviews and focus groups produce
accounts of motivations and opinions only, not what actually happens in a
participant's mind. So possible influencing factors will be discussed whilst
acknowledging this.
Altruism
There was evidence of altruism in many participants' accounts, sometimes this was
explicitly discussed and in other cases it was more subtle in their discourse. A few
participants mentioned their altruistic feelings almost immediately in response to the
initial interview question about their thoughts on receiving the first screening
invitation, however with others the altruism emerged later in the interview as they
talked in more depth. Furthermore, the altruism talked about was not uniform across
all individuals, rather the explanations given and context in which it was discussed
could be broken down in the following ways:
Firstly, some participants spoke about 'general' altruistic feelings such as the hope
that their participation would help contribute to research and thus other people in
general, as summed up in the following quote:
Hamishl (70yrs): basically if it was anything that was gonnae help people in
general, you know.. .1 was quite happy to get involved sort of thing
Other participants were slightly more specific about wanting to help 'ill people', and
many spoke about helping people in the future or helping advances in medical
science. A few people mentioned how benefit to the future generations was more
important than to themselves:
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Patricia3 (61yrs): I'm quite happy to take part in any research that will
improve things and maybe help in the future, even if it doesn't help people at
the moment...()...things that you might gain or learn from this group, you
might be able to apply to people in the future, I'm quite happy if that's the
case.
Only one participant explicitly used the term altruism:
Moiral (53yrs): well to be quite honest, altruism, I mean you know,
somebody saying this could be really helpful. I appreciate that members of
my family have died in the past, albeit not at a young age, of heart disease, so
why not? It's not taking up much ofmy time
A second form of altruistic expression that emerged seemed to have more of a moral
tone to it; the most common example of this was describing participating as a "good
thing" to do and "worthwhile":
Craig4 (54yrs): Um and on a wider perspective, yes um I think these things
are for the greater good really, you have to find out what's- what works and
what doesn't work, yeah, yeah.
Miriam3 (73yrs): well I thought someone wanted help looking into er.. .heart
problems and I wasn't particularly tied as far as time and whatnot, so I would
go along and if it was any help, it would be time well spent
Janice (focus group 4a, 70yrs): but as I say my main motivation was to
volunteer and be useful
The term 'good' was used by many participants regarding trial participation. In
addition to doing a 'good' thing, the feeling that one has done good and been a good
person may have other effects such as receiving positive evaluation and/or avoiding
social rejection by oneself and others. Evaluation by oneself could involve the idea
of one's conscience. Conscience was something which Molly4 (75yrs) brought up
when I probed about her mention of altruistic motivation:
HE: I think right at the beginning you mentioned benefits for the wider
society as well
Molly4: mm
HE: do you think that's quite important?
Molly4: oh yes, you couldn't have a conscience and never think that
Batson (1991) used the idea of personal and social evaluation in his proposed
pathways leading to pro-social behaviour - that we experience feelings of self-reward
for our responsible behaviour. It is possible that a participant's emphasis on
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participation being a 'good' thing to do could be altruistic or could signify more self-
dominated motivation. Also the research setting may have influenced the expression
of altruistic attitudes, as it is possible that participants may have wanted such positive
evaluation from myself in the interviewer setting or from other participants in the
focus group setting. However, the expression of self-dominant attitudes was equally
abundant. Regarding one's conscience, a different pathway proposes that pro-social
behaviour can alleviate guilt (Batson, 1991).
Imogenl (61yrs): ...I almost feel as though if I do this, it's helping somebody
somewhere
Another kind of altruism apparent in several accounts was the naming of specific
'others' as the imagined recipients of the benefits from the research; these were
children or more often grandchildren. For example in focus group 4a:
HE: what are the advantages in taking part in such a trial?
Colette (52yrs): It helps further advance medical science, there must be
something
Janice (70yrs): that's what my reasoning behind it, that there is money to do
these things and you've got to have people to take part in them
Wilf (65yrs): well I would say the same reason, I mean after all, ifwe've got
families, it's for everyone's benefit
HE: do you see any benefits for yourself as well?
Janice: I was more thinking of my son, I suppose it could be... but I was
more...
Colette:...no I think when you get to this age, if you're [ill], you're [ill]
anyway
Janice: I was thinking very much of my son, there's more a history on his
father's side as well as my side
Badcock's (1996) kin altruism proposed that if people can identify with the recipient
of their prosocial behaviour, through familiarity or similarity, they are more likely to
act prosocially. Dawkins' (1989) selfish gene theory suggests that it is the survival of
the gene which is most important; similarity with the imagined recipient indicates
that they share similar genes thus improved health in the recipient means survival of
the giver's gene. However, attributing such motivating factors behind people's
altruistic participation according to psychological and sociobiological theory here is
suggestive.
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When participants mentioned their offspring, in addition to wanting to help research
that would lead to advances in medicine from which their offspring could benefit,
they also seemed to imply a notion of responsibility. For example, the following
participant, aware of his family history of heart disease, worried about the impact of
the family history on his children:
Jed (focus group 4b, 57yrs): that's probably true I mean I'm not a very
frequent visitor of the doctor but I think like with my wife having heart
disease in my family, both my parents died () of heart attacks.. .massive heart
attacks, so if you can learn and help in the research about the illness () which
you can pass onto your children
Naming specific others who may benefit keeps the issue personal to the individual;
often people described how heart disease was already a particularly salient issue to
them due to personal experience.
Personal context
The experience of a close 'other' having a heart attack or heart disease tended to
increase the salience of the disease to the individual and was often mentioned as a
reason for participation and/or screening attendance. Such 'others' were usually the
individual's spouse, other family members and sometimes their peers. This salience
initiated action for two predominant reasons: altruism or personal benefit, or a
combination of the two. Regarding altruism, witnessing someone else suffering
sometimes led to wanting to help prevent others enduring a similar suffering. On the
personal side, the experience seemed to motivate behaviour aimed at preventing
suffering in oneself. Joe2 summed this up nicely when asked about his initial
thoughts on the screening invitation:
Joe2 (56yrs): I didn't have a problem with it, my father died of a heart attack
very suddenly and so anything at all that was a) gonna help me and b) could
help somebody else, then I was quite happy to go with that. Er my mother,
she was taking tablets for high blood pressure and I also take tablets for high
blood pressure, so yes heart disease is something you think about.
The following extract from Focus Group 2 shows how personal context of different
types influenced the decisions of this group ofwomen:
HE:...so it's about a year and a half ago since your screenings so I just
wanted you to think back to when you first got that invitation to screening,
and what your initial thoughts were on attending and getting that letter
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Deirdre (68yrs): well my husband died of a stroke, and I thought if it was
going to help anyone else, that's why I attended
Cath (63yrs): and I was just interested in it because um I had high blood
pressure and I thought, it'd be good to get a check out for my health you
know perhaps it's better than perhaps just going the doctor or something so
that's another reason why I thought it was a good thing
Ella (70yrs): my husband had had two bypasses and erm apart from that, I
was quite happy to do anything that might help research as well as perhaps
help myself, but I didn't know whether it would help because I didn't know
what I was taking
Emma (70yrs): well my mother's family all had strokes, so I actually felt it
was good for me, and I'd never been to the doctors for anything like that for
cholesterol or anything so, I was quite happy to
Ursula (61yrs): My husband takes aspirin as well, cause he had angina.. .a lot
better now but he was put on aspirin as well as beta-blockers and other things
you know, so I felt that I wanted to do my bit!
These 5 women all spoke about personal context but this motivated them in slightly
different ways: For three (Deirdre, Ella and Ursula) the personal context was the
experience of their husband: Deirdre spoke of altruistic reasoning; Ella gave both
altruistic and self beneficial reasons and Ursula's reasoning is unclear although
comments later in the discussion imply a fairly altruistic attitude. Where the personal
context was a family history, Emma and Cath (who explained her family history later
in the focus group) spoke of the benefits to themselves. Perhaps there is a greater
underlying perception of personal risk when there is family history of heart disease
rather than witnessing the disease in one's spouse.
A few participants were unfortunate to have witnessed heart problems in both their
biological family and their spouse, for example:
Nancy4 (69yrs): well, my sister, my parents, my husband and everything so
obviously I'm conscious of it my blood pressure
HE: so you've got a history of high blood pressure or heart problems in the
family then?
Nancy4: well my mother had a very bad stroke at the age of 60, survived for
twenty years after that, but had a very bad stroke at 60 and minor strokes after
that. Er my father had a heart attack followed by a stroke, and then followed
by a stroke,.. .well I mean he was, he was into his mid 70s by then I think
HE: did this make you
Nancy4: So I'm conscious of it, there's a hereditary factor somewhere there
yes
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The cumulative experiences had made Nancy4 equally keen to check her own health
and participate for the benefit of others. In focus group 4a Janice (70yrs) had a
similar history, she repeatedly stated how her willingness to help the British Heart
Foundation arose predominantly from her husband's death:
Janice: well I contribute to the British Heart Foundation and I thought "well
what's the point of giving money if they can't get people to take part in the
things", so I decided that I would take part because I've heard they do trials
etc, it's the first time I've been asked to take part in one
HE: is there any reason you contribute to the British Heart Foundation?
Janice: yes, my husband dropped dead
A different family experience concerned participants' siblings; Maureen4's altruistic
feelings arose from the recent death of her sister, when I asked how she saw herself
with regard to heart disease, altruistic feelings emerged:
Maureen4 (53yrs): I think urn...I'm OK you know, I kind of don't think
about it um because I was diagnosed with breast cancer four years ago so
that's kind ofmore relevant than sort of heart disease, but in saying that eight
weeks ago my sister died of a heart attack, she's just- she'd been with me on
the Monday and she was perfectly fit and fine and healthy and on the
Tuesday she was getting ready to go to a keep fit class and collapsed and
died.
HE: gosh
Maureen4: and she had the blood pressure like I did, you know she had kind
of like um high blood pressure but when she was put on medication she was
fine, she'd no symptoms of heart disease whatsoever and yet her post mortem
said she had ischaemic heart disease, so that's kind ofworrying.
HE: so did she think her blood pressure was under control?
Maureen4: uh huh yeah
HE: and how old was she?
Maureen4: 69 but she was a very very fit 69, yeah, and she went to keep fit
and she went to bowling and you know she was really sensible about her diet
HE: that was quite a shock for you then
Maureen4: pretty sad
HE: did that sort of change how you felt about your own health
Maureen4: probably not, I don't really you know give it much thought you
know but I think it made me more aware that well I should come here today
and sort ofhelp in whatever way I can you know
Initially, there appeared to be a pattern whereby family history of heart disease
seemed to lead to interest in the trial for checking one's own health, and heart events
in a spouse seemed to lead to more altruistic motivations, but the picture was not so
straightforward. Altogether it is evident in the accounts of people I interviewed that
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increased salience of heart disease from witnessing it in significant others served as
trigger to participate in the trial, regardless ofwho the imagined beneficiaries were.
As demonstrated in the screening chapter, experiencing heart disease in significant
others led some participants to assess their own risk compared to that 'other', and in
some cases to take action in the form of showing interest in the trial, either for a
personal health check, for helping towards research aimed at preventing the disease
in other people, or both. However personal context also led to no action in a few
cases, as comparative analysis of their own risk with that of family members or peers
could result in distinctions between themselves and others regarding lifestyle,
available medical treatment, genetics and so on. For example, Geoffi (68yrs)
described cardiovascular episodes in his peers but comparative risk perception
increased his optimism.
Reciprocity
One of the most strongly expressed altruism resulting from personal context was in
Imogenl's account; she explicitly described how witnessing much heart disease in
close family members led to her participation:
Imogenl (61yrs): yes I mean well my mother died at 53 with a coronary, and
my brother was 60, my father had about three or four heart attacks, but he
lived till he was 83 so it was a stroke that killed him () and then of course my
husband had major heart surgeries so he had his first heart attack at 46, so
anything that- if it would help- anything that I can give to them, to stop
anybody else-1 mean you think of your grandchildren...
In addition to wanting to help prevent the disease in future generations, she
expressed immense gratitude for the life-saving heart surgery and care her husband
received
Imogenl: he was about 46 when he had his first heart attack, and then he was
50-there again () when he had open heart surgery at the hospital, but at first
they thought he would have to have a heart transplant, cause it was so bad but
they kept him in for about two months to build him up, to prepare him for the
surgery and when they sort of done whatever tests they'd done, () And in an
ideal situation, for him not to have any more medication, but sadly six weeks
later, when he went back for the check ups, they had to take him back in, and
put him back on these drugs. But, it kept him alive
HE: and how is he now?
l:trial participant 2:stopped trial tablet 3:trial decliner 4:healthy ABPI 5:screen non-attendee 182
Imogenl: well he's slowly getting.. .he's not as good as he would like to be. I
mean we're talking 16 years
HE: yeah
Imogenl: I mean that's marvellous, I mean they've kept him alive, they've
given him life for 16 years and that's marvellous. And there's always
something new
Thus her own participation was due to strong reciprocal altruism.
Imogenl:...and to me this is something, you know if you can learn from
other people, it goes back to your grandchildren, it can help them perhaps
HE: so was that your main reason for taking part in the trial for future for
other people?
Imogenl: yes it's for future of other people, and um. ..this might sound silly
but it's a thank you for all that they've done for my family
HE: yeah yeah
Imogenl: you know for my husband. As I say I mean it's because the
research that probably went into that they've done this for my husband which
they probably wouldn't have known about if somebody else not come up
about it. You know if it hadn't these- sort of when people went on to these
trials for these new drugs which he's gone onto. I mean he wouldn't be here
today. I don't think so anyway, if he hadn't have had the surgery"
Later in the interview she talked about the cost involved with heart operations which
reinforced her desire to 'pay back' something to the NHS; her husband's post
operation lifestyle behaviour changes are another way of demonstrating appreciation.
Other participants expressed similar gratitude, however resulting from care received
personally, for example:
HE: do you see any advantages of going into the trial?
Mandy3 (59yrs): er...I can't really except they might pick up something
quicker but I think basically because it came at the time that it did, but also I
was up- you know I have had- been in hospital a few times and I felt well this
is a very small way maybe putting something back into the health service you
know but it's nothing much but I thought "well yeah I could possibly do this"
There may have been some guilt involved with Mandy3, as elsewhere in the
interview she spoke about being a "bad diabetic" in the past and not adhering to her
medication so perhaps she felt guilty for having received treatment that she could
have avoided.
A further reciprocity expressed by some a couple of participants was directed
towards their respective GPs, for example:
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HE:...so I just want to start by thinking about when you first received the
invite to screening, what did you think when you got it?
Maureen4 (53yrs): I was a bit surprised but I thought well, I assumed that it
was my GP that had put my name forward and I thought because he's been so
good to me then I would just come along
The cases above show that where personal context of heart disease has involved a
great deal of medical care and attention, feelings of reciprocity can provoke action in
such as trial participation. Titmuss (1970) found that reciprocity for blood received
personally or by known others was the reason given by approximately a tenth of
donors in his research. In addition to focussing on care already received, this also
incorporated contemplation of future care needed, so the altruism presented earlier in
the chapter such as wanting to help people in the future and one's grandchildren
could also fit under the umbrella of reciprocity.
Mutual benefits
There was evidence of further reciprocal systems; many participants spoke of how
they believed or hoped that their participation would benefit both them self and
others.
Molly4 (75yrs): I was just quite interested to take part in anything that might
help, me and others
Fergus 1 (72yrs): I mean every little helps, () if this aspirin trial comes- throws
up something to help people in the future, myself included, I'm doing well
you know.
Fergusl's idea was that both parties (self and others) would benefit in the same way,
through improvements in cardiovascular medicine. Others distinguished between the
types of benefit to each party: their personal benefits were the screening and health
check up, and other people would benefit from the research results. For example:
Hilary2 (77yrs): well I thought it was a good idea to get everything (laughs)
you know, know what's wrong and what-have-you, if there is anything wrong
HE: and what were your expectations about-what did you think they might
find or not find or-
Hilary2: not really, I just thought I was trying these things just for research
A further way of thinking about benefits to self and others expressed by Monica 1
(66yrs) and Martha2 (65yrs) was the belief that in the worst case scenario at least one
party will benefit:
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HE: how did that make you feel (ABPI result)?
Martha2: different (pressures) uh huh, you've just got to accept it and you
know, and as I thought well I'll go ahead with the trial and if it doesn't help
me, it helps someone in the future
Moiral (53yrs) pointed out that it was unlikely that she would have thought of taking
aspirin herself, so by participating her health would either stay the same as before (if
on placebo) or possibly benefit (if on aspirin)
Moiral:...as far as I'm concerned, I wouldn't be taking an aspirin a day
anyway so what's the harm? If I am taking one, so be it, but if I'm not, it's
not as if I would have anyway.
A different reciprocal system expressed by some was a system of give and take
where action preceded benefit, as opposed to reciprocal action for benefit (care)
already received:
Julie (focus group la, 56yrs): but that's the reason we went on it as well, we
could be on placebo or an aspirin, it was research, we hope that we're being
helped at the same time
Sometimes, underlying this, there seemed to be an attitude that in today's society, no
benefit comes without cost:
Lorraine (52yrs): well it was on the basis that somebody's got to do it you
know?
HE: yeah
Lorraine: and I think I'd be er happy to take advantage of any results or you
know, you've got to give something to get something
HE: uh huh
Lorraine: it doesn't seem like much of a hardship (focus group lb)
Isaac3 similarly described the trial as a "two way thing" and drew an analogy with
trials of new equipment in his workplace:
Isaac3 (58yrs): I've always been keen to help, even in my job, an outside
body and that, if somebody said well we want to trial this particular object in
your place of work () if you don't give people opportunities to research stuff
and that, then you're never gonna advance. () also you're gonna benefit as
well because there's advantages to the company () if it improved your
production methods great. And this, well if it improves your health then great
yeah.
A further reciprocal system that emerged in a few participants' accounts was less
altruistic, but rather a form of loaded reciprocity whereby the pro-social behaviour
was talked in terms of bargaining power to attain a reward of some sort. For
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example, a member of focus group la felt she deserved some reward for her altruistic
behaviour:
Alice (65yrs): I hate to think that I've done all this goody-goody bit.. .stopped
smoking. ..took a year to stop, but I've stopped smoking, and I've changed all
the food ideas to the ways it suggests in the book...and if I'm not on the
aspirin, I'm on the placebo.. .1 would be.. .(acts angry)
Similarly a focus group lb member talked about the reward he wanted for his
participation:
Henry (67yrs):.. .1 think ifwe're good enough to do this for them, they should
make sure that we get feedback
Reciprocity, mutual benefits to self and others, and more 'loaded' reciprocity could
all be regarded as exchange systems. Similarly to Titmuss's (1970) exploration of
altruism applied to blood donation, there was no obligation to participate in the trial,
and voluntariness and altruism seemed to drive the behaviour of some participants
according to their accounts. But, as discussed in this last section, other participants
regarded their participation in reciprocal terms and some had reciprocal expectations,
which echoes Tutton's (2002) findings regarding blood donation for genetic research.
Altogether, this section has demonstrated different types of altruistic attitude that
were expressed by trial participants regarding participating in the AAA trial.
Participants' explanations behind these attitudes ranged from the non-specific to
particular experiences that had provoked such feelings. Social psychology is
interested in exploring the motivations behind apparent altruistic behaviour, and the
behaviour could be examined in terms of an exchange system in social anthropology.
Regardless of their 'true' motivations, participants' accounts and interpretations of
the reasons for their own behaviour are useful and important to listen to and examine.
Many participants displayed more self-dominant attitudes, and the subsequent
section will explore how the benefits and risks to self were dominant aspects for
many when contemplating participation. However, the emergence of altruistic
expressions revealed useful and interesting findings regarding participants'
explanations and reasons for participating, for example the importance of personal
context and/or experience in contributing to their altruistic accounts.
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Part 2:
Personal benefits and potential risks
Whilst the last section has demonstrated how altruism and reciprocal exchange
emerged as particularly salient in many participants discussions of their views about
participating, when contemplating the effects on oneself (both benefits and potential
adverse effects) aspects of the trial procedure were central to these discussions. This




Individuals discussed pros and cons of the trial, which could have been weighed up
against each other, although not necessarily in a conscious manner, in a decision
about participating. Much of the discussion of cons centred on dislike of the RCT
procedure and its requirements. The predominant reason arose from the ubiquitous
assumption of aspirin's efficacy applied to cardiovascular health that ran through
most participants' accounts; many participants thus voiced a clear preference for the
aspirin over the placebo rather than the actual 50% chance in the trial.
Julie (focus group la, 56yrs): if you thought you were on a dummy tablet and
there is a chance that you can avoid a heart attack by taking an aspirin a day,
you would want to go onto an aspirin a day
Some explained further reasoning behind this assumption: Richardl (54yrs),
knowledgeable about conducting RCTs due to his occupation and experience, felt
that the trial would not be being conducted unless there was strong evidence for
aspirin's benefits.
HE: what are your feelings about the fact that you're taking this tablet and
you don't know whether it's aspirin or the placebo?
Richardl: well I suppose I would have liked to have known that it was the
aspirin rather than the placebo because obviously I do know that the reason
they're doing this trial is basically because there are recognised health effects
of taking aspirin, um I know the purpose of this trial is not so much erm to
add further proof to the original sort of evidence () yeah, I think it's partly
that but I think it's also what they're trying to prove in this trial more than
anything else is that the aspirin might help prevent heart disease ever
materialise in the first place
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HE: yeah
Richardl: and I think from what I've read, there's some evidence to suggest
that that in fact is the case and they wouldn't be doing the trial on this scale if
they didn't think that was the case
HE: yeah
Richardl: I mean really the purpose of the trial is to get absolute definite
proof
HE: uh huh yeah
Richardl: that's why you need such a big trial, so from that point of view, it's
obviously nicer to think, "well I'm taking the aspirin", and therefore I'm
actually involved in active prevention
So Richardl's belief emanates from his informed perspective that unless there was
good evidence for aspirin's efficacy in prevention, the trial would not be in process.
Unlike other participants, he also noted the distinction between aspirin's use post
heart condition from its potential preventive use being tested.
As discussed in the prevention chapter there seemed to be great faith in aspirin
amongst some participants; this faith was the explanation given for a few
participants' actual or hypothetical declining:
HE:.. .so what do you think about that at all, about the trial?
Jack5 (66yrs): well I don't know if that would be such a good idea, in a sense
I feel confident about the aspirin and I don't think I'd like the idea of me
personally if I took a dummy pill
HE: yeah?
Jack5: er, I'd feel uneasy about that, that's with me personally, I feel uneasy
about that because er to be quite honest with you I've a great confidence in
the aspirin because it's had such a good write up over a number of years and
it's been proved through tests and various things that I don't think I'd be too
keen on that idea.. .as I say purely because if I ended up with the dummy pill,
I'd just, you know...
HE: you'd?
Jack5: I know it's mind over matter, but the same token I () no I wouldn't be
getting the benefit as I feel confident just now with the aspirin, quite happy
with it you know
Although emphasising his faith in aspirin (he is on GP-prescribed aspirin), Jack5 also
implied that in a trial situation one's mind is more influential than the drug, which
could perhaps make the placebo work, but personally his faith in aspirin would
inhibit him from taking a chance at not being on aspirin. Similarly, many group 4
members (ineligible for the trial) admitted that given the choice to enter the trial, they
would have acted on their preference for actual aspirin and declined to participate:
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Maureen4 (53yrs): Yeah I'm not really- I'm not a great um- I'm not in favour
of placebos, I think if people are going to do a research trial then I know you
have to have half and half, but I think it's unfair and I think it's unfair to the
people who perhaps might benefit from being on the actual drug and yet
they're just taking sugary- you know sugary tablets. So no if I'd.. .if I'd gone
on your trial, ifmy results had been that I'd had to go on your trial I'd have
gone out and bought aspirin and chucked your placebo in the bin (laughter).
You know if you're asking for honesty then that's what I'd have done.
And many of these participants seemed to feel that such a preference would be a
shared view:
Dennis4 (75yrs): I think if they're-1 think there would be quite a lot would be
'cause once they know that they've got er the lower blood pressure in their
legs, they'd be worried about it
Others shared the preference, but said that a preference was the extent of their
feeling:
Owen4 (52yrs): But yes like everybody else, if I was going into the trial, I
would rather be one of the folk who got the real medication rather than
phoney stuff you know, but I still think it's- I would be prepared to take that
risk I think.
Of those who were eligible for the trial, this assumption about and preference for
actual aspirin was acted upon in various ways: Firstly, as mentioned in the
prevention chapter, GeofO declined to participate in the trial and consulted his own
GP for prescribed aspirin. The following quote shows more details of his views after
being invited to participate in the trial:
GeofO (68yrs): I tried to analyse what it was and analyse what you were
offering under the aspirin trial
HE: uh huh
GeofO: and when I found out you knew I was at risk, but you were prepared
to put me on a dummy pill
HE: uh huh
GeofO: I said get lost, and rather than on aspirin, they can't tell you what you
were on. So I walked out of the trial at that stage and I went to my own doctor
HE: and did you-?
GeofO: I spoke to him and told him what was happening, and he said, "do
you want to go on aspirin?" and I said, "well it sounds like I might have to".
I'd sooner be on it rather nothing, so I have the 75mg aspirin
HE: right so you went and got it
GeofO: yeah, I wasn't gonna walk away and do nothing and find out I was
liable for a stroke or er heart attack or something
HE: and the main reason was that this trial- you didn't wanna be on the
dummy pill?
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GeofB: uh huh, that was the only reason, I wasn't gonna take a 50:50 chance
of not being on the aspirin, and find out you know 6 months down or 6 years
down the road I got hit, that's not on ()...er but you know I didn't expect to
be in the trial, I wasn't expecting it...and when they said, "you did" I said,
"no, I'm not gonna be a guinea pig, if I need something, I want it."
Also, as suggested by Maureen4 above, he explained that if he had entered the trial
he would have self-prescribed aspirin instead of taking the trial tablet:
Geoffi: .. .'cause they hit the roofwhen they said come on the trial and I said
"yes but I'll be taking aspirin as well" (laughs). You know I was quite
prepared to get a 300mg aspirin and cut it in four and have a quarter a day.
Also mentioned in the prevention chapter was the case of Patricia3 (61yrs) who, like
GeofB, held a strong preference for aspirin and thus declined the trial, but rather
than consult her GP she self prescribed aspirin:
HE: yeah, yeah, uh huh.. .so when the nurse asked you, your main reason was
because you didn't want to take the placebo
Patricia3: yeah
HE: so what did you do after that, did you decide to go on aspirin yourself?
Patricia3: yeah I take my aspirin, I take a soluble aspirin most days
HE: and did you go to the doctor?
Patricia3: no
HE: no, oh right
Patricia3: no I actually- I got them in- I buy them in Superdrug, and I just
take one you know dissolved in water, most days, you know maybe 5 times a
week
These two participants demonstrated how their strong attitudes and preference for
aspirin had led them to decline the trial in favour of guaranteed aspirin. Although a
minority in the present study, as noted earlier this attitude was shared albeit
hypothetically by some of Group4. However for Geoffi and Patricia3, a further
contributing factor towards their decision was perceived risk from the ABPI result. In
contrast, a couple of individuals who declined to participate, due to apparent dislike
of the chance of receiving the placebo, did not self prescribe or consult their GP for
aspirin but took no action. This seemed to be linked with lower risk perception from
the ABPI:
Morag3 (64yrs): the reason I declined to take part was simply that when I
learned that I might be taking a placebo for five years, I felt that I didn't want
to participate
HE: uh huh, OK...so you really didn't want that, you felt- what were your
sort ofmain reasons for not wanting
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Morag3:1 felt it was a waste of time
HE: yeah
Morag3: it was something that I was going to have to remember to do, and
remember to check up upon and I wouldn't know whether I was taking
aspirin or whether I was taking a placebo and I just decided for that reason
not to go for it
HE: yeah uh huh, so if it had been say you'd definitely have got the aspirin,
would you have
Morag3:1 think I would have tried it yes
Morag3's low risk perception from the ABPI was discussed in the screening chapter;
she also had a strong dislike ofmedication so it is not surprising that she declined. It
is interesting therefore that her reason given for declining was dislike of the chance
of receiving the placebo, and that if guaranteed aspirin she claimed she would have
participated.
Interestingly, such assumptions about aspirin's efficacy and dislike of the possibility
of receiving the placebo were also expressed by many adherent trial participants. For
example, trial participants in focus group la highlighted their perceived unfairness of
the RCT procedure:
Bob (70yrs): going back to the original concept of this trial, I'm using the
word 'trial', you go in and you do the screening and they find that there's
some difference in one leg and they say to you, "would you like to go in this
trial? you'll be given a tablet which you take every day for so many years".
Now they tell you, you don't know whether it's an aspirin tablet or whether
it's a placebo, so for five years, you've got furring up of the arteries and
you're taking a placebo, what other remedies are there to catch you if your
situation deteriorates? It seems a bit strange you see, if you're gonna get the
placebo and I'm gonna get the tablet,
HE: that's one of the reasons for today is to find out what you think about
that
Julie (56yrs): yes that's the one thing that I disagree with, I think if you are
made aware that you are at risk, and you're put on an aspirin or a placebo,
you really want to know what you are on because you would probably want
to go on the aspirin if you thought you were on the placebo
Bob: sorry I think the converse of that is that if you know you're on the
placebo, you won't take your tablets, you know if if s just a wee sugary pill
This raises questions about these participants' reasons for participating, if they
disagreed with the process of the RCT. Perhaps their involvement with this part of
the study was the first time they had voiced their opinions about the trial process, and
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in particular in the focus group situations, the first time they had discussed it with
other participants.
Some participants' preference for aspirin led them to question the need for the trial,
as they assumed aspirin was already 'proven' in its treatment of heart disease. For
example in focus group lb:
Maive (67yrs): what is it they think that aspirin does? Thin the blood?
Lorraine (52yrs): I think that's the only thing that's slightly surprised me
about this trial, was that I thought that was pretty well accepted
Similarly a few participants with this belief thus felt the RCT method was unfair, for
example:
Maureen4 (53yrs):...I also think that you know, if you're gonna do
something, why don't you just do it, you know I mean, we know statistically
what the rate of heart disease is in this country and therefore if you're trying
to reduce it or eliminate it which you never will, but if you're trying to reduce
it then why not give everybody a fighting chance, you know if you really
believe that aspirin works then why not let everybody have it? I mean it's one
of the cheapest drugs on the market isn't it? And if it reduces the cost of
people being in coronary care units, for whatever length of time, you know
then it would sort of like be economically sound in the end, but I don't know.
I mean I know you have to do trials, but I mean aspirin has been going on for
years now hasn't it? It's not a new thing.
Robinson et al. (2003) found that people were reluctant to accept either the idea of
equipoise (the basis for RCTs, that clinicians can be completely unsure which of two
treatments is best), or randomisation for determining treatment choice in trials. In the
present research, participants' own beliefs about the drug in question (their
assumptions about aspirin's efficacy) probably contributed to similar thinking, i.e.
reluctance to accept that equipoise exists regarding aspirin as a preventive medicine
and not acknowledging that this was a different use for aspirin, in turn contributing to
their questioning of the need for the trial.
Blinding
A further aspect of the trial that caused some discontent was the blinding involved.
The AAA trial follows double blind procedure, i.e. neither the participants nor the
research team know any participant's tablet identity. Some participants would have
preferred to know what medication they were taking; one participant described the
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blinding as "scary". Other participants were less bothered but described being
intrigued about their tablet identity, and some took this further by attempting to guess
their medication. Julie (focus group la, 56yrs) misunderstood the double blinding
element, and assumed the research team were aware of the tablet identity so tried to
trick the nurse into revealing the medication identity:
Julie:...and I have also enquired if you go on holiday now you don't know if
you're on aspirin or not, but this DVT, you would want to take an aspirin
before you went, so I asked the nurse, "do you take an aspirin?", () you know
trying to catch her out, am I on it or not?...
Later in the focus group she mentioned other attempts to guess:
Julie: I've even tried chewing it as well and to me it tastes like aspirin
David: you could go and find a friendly scientist and he'll test it for you
Julie: it's just curiosity I think, being curious
However, as Julie's curiosity had not deterred her participation. Other participants,
initially intrigued, seemed to lose interest as trial duration progressed:
Keithl (59yrs): ...first it worried me but I thought, "well am I taking
something that I could be just as well not be taking?" you know? But er I
dunno...if it is aspirin or if it's not aspirin, I couldn't actually tell you. but
like a lot of these things, it all depends how mentally you feel about it.
HE: yeah, how do you feel about taking it now?
Keithl: well at first I wondered about it, if it was or if it wasn't aspirin
HE: yeah
Keithl: and since then, it's just something that you do every day, so you just
end up, it gradually goes into the (habit) with time, you just do it anyway you
know
Several participants, whilst happy with the blinding process, expressed a desire to
know the tablet identity at the end:
Jennifer2 (61yrs): no that didnae bother me that, 'cause it was quite exciting
that in fact, when I'd got to the end I'd've been quite happy 'o (to) know
what I had been on and to see if they had found a difference, I would have
liked to have found out, with somebody who'd the opposite for the two o'
(of) us to see what the ootcome was, if the dummy was all in the mind in
other words.
Other participants wanted their GP to know the identity of their trial medication; in
this extract from focus group lb Henry expressed concern over the quality of care his
GP would be able to provide without knowing the tablet's identity:
Yvonne (72yrs): but I don't think the doctor knows whether you're on the
Maive (67yrs): no
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Lorraine (52yrs): but probably take into account that you may be taking a
dose of aspirin every day as part of this you know, presumed if he was going
to prescribe something else for you
Henry (67yrs): that's a point, if people are on aspirin, and they shouldn't be
for some medical reason, I think the doctor at least should know about it, so if
the doctor doesn't know, I think that's wrong, I didn't appreciate that, I just
assumed that they were told, as I've never seen the doctor
HE: the doctor knows that there's a possibility that you're on the aspirin or
the placebo
Henry: but that could change his attitude to what he's giving me if he knows-
if he's got to guess that you're on aspirin or not, he'll give you a different
medicine for some things. I think the doctors should know.
This demonstrates how some participants seemed to think that the trial situation
altered the standard duty of care in a doctor-patient relationship from a doctor's duty
to provide the best treatment. A participant from focus group la was particularly
articulate in expressing this viewpoint:
David (71yrs): but on the other side of the coin that Bob was talking about, if
the AAA trial people know that I'm at risk, if they're all doctors, are they not
obliged to take some action in order to save my life, to reduce that risk in
which case they should not give me a placebo, they should give me aspirin
Others: (some agreement)
David: are they not obliged to, if I'm a doctor, my job is to say, "right, I have
a duty, I took the Hippocratic oath so you are at risk so have an aspirin"
Later...
David: there was a bit a paper that said, "you may get some benefit out of this
trial or you may not", one of the very first bits of paper we got. In other
words that was their back up, to say that, "we know you're at risk and we're
not giving you an aspirin, we're giving you a placebo"
Bob (70yrs): a get-out clause
David: that's right, from our side, that's catch 22, that they know I'm at risk
but they're giving me a placebo, but they should be in fact treating me
In the above quote, David voiced awareness of a doctor's Hippocratic obligation to
care; this echoes debate in medical journals regarding the distinction between the
doctor-patient relationship in a standard care setting and that in a research setting and
the associated conflict between the duty of therapy and the duty to contribute to
research beneficial to wider society (De Deyn & D'Hooge, 1997; Elander &
Hermeren, 1995; Groudine & Lumb, 1997; Hellman & Hellman, 1991). Whilst being
particularly vocal in expressing this opinion and demonstrating his knowledge, David
was an adherent trial participant, again raising a question of why he chose and
continued to participate. It was my impression that David enjoyed engaging in
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discussions and may have been trying to elicit responses from other participants by
voicing such strong and provocative statements (particularly useful in focus groups
research). Whilst generating a good critical discussion, this did not seem to lead to
any significant discontent with the trial; certainly none of the focus group
participants seemed sufficiently provoked to end their participation. But it
demonstrated that it is not only doctors and researchers who deliberate over how
research trials alter doctor-patient relationships.
It has been demonstrated elsewhere that many trial participants still expect the
standard doctor-patient role to exist, which can lead to confusion over their beliefs
about how their treatment was determined (Featherstone & Donovan, 2002;
Snowdon et al., 1997; Heaven, 2003).
The Trial Procedure
Evidence for some discontent with the trial emerged in focus group lb where the
setting evoked perceptions of inconsistencies in the trial procedure, mainly due to
individuals' misunderstandings or poor recall when comparing the information and
contact that they had received:
Nigel (64yrs): it doesn't seem to be very consistent then does it? Different
results for different people
Yvonne (72yrs): but the last two years the doctor also got the- you know he
got the same letter as I did
Nigel: yeah but Henry's had nothing.. .I'm just into the programme so
Yvonne: but there was nothing this year, but talking about getting feedback,
when I started I don't know about you, I was told that er I probably wouldn't
know what the results was, and it would be after 5 years
Nigel: that's what I was told as well
A few individuals raised questions about the research and procedure, in particular
statistical analysis. In focus group la, David brought up the case of possible
confounding variables
David (71yrs): the case that he (Rod) gave, he didn't give up his drink, he
didn't give up his smoking, he didn't give up the type of food he was eating,
now.. .had he done so.. .how do you know, and if he was taking- he's actually
taking aspirin, how do you know which was the one that saved his life so to
speak, giving it up or the aspirin?
Owen4 wondered how analysis would account for non-adherence:
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Owen4 (52yrs): I think the main difficulty I would have found I suspect is in
the statistical- not your statistical but the statisticians in the actual trial will
have to deal with is you know the proof that people have stopped taking
them. It's just so easy I think when you're doing something regular like that
to forget for a day, to be somewhere out of your normal routine and you don't
have it with you you know that kind of thing, but that's not my problem, it's
my observation
Peter2 was generally suspicious of the way in which trials are analysed:
Peter2 (55yrs): well I think there is a lot of confusion comes out about it, and
from these figures that these people go on, do they interpret them the right
way or are there two or three different ways of interpreting the figures, do
they always get the interpretation right? I mean and I don't know, I'm only
saying, is this the case?
These participants' questioning of the day-to-day running of the trial and its analysis,
had not inhibited any of them from wanting and/or continuing to participate.
As demonstrated above, disagreement with the trial process and of the potential
danger of not receiving the aspirin was expressed in both focus groups comprising
adherent trial participants. When considering possible reasons for participation
despite expressed discontent, it became apparent from examining the discourse used
that whilst participants were aware that there was a 50% chance, some participants
seemed to believe that they were actually receiving the aspirin. In fact some even
referred to the tablet as aspirin, for example this member of focus group lb:
...I certainly don't see any disadvantages because so far I've done nothing,
you know I've been twice and this today and just take an aspirin a day
This was sometimes the case even when the participant had indicated a good
understanding of the RCT process; Gordon 1 discussed his understanding of the trial
and the blinding, however, later in the interview he referred to the tablet as aspirin:
Gordonl (67yrs): So every morning I get up, Helen, I go 'o (to) the shops and
I come back, and I take these pills, and I take that aspirin pill every
morning,...
Gordonl's use of the words "that aspirin pill" could have been a simple way of
describing the trial tablet rather than actually believing it was aspirin because the trial
literature advised participants to treat the tablet as aspirin for example any pain relief
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medication taken should not contain aspirin. Some participants spoke about doing
this:
Imogen 1 (61yrs): I just take it that it is an aspirin, I treat it as an aspirin, and
if I take any other medication I make sure there's no aspirin in it, just to make
sure, but I don't know and I'm quite happy with it
But Gordonl's subsequent sentence implies that despite acknowledging an
understanding of the trial process he appeared to believe not only that he was
receiving aspirin but that he was therefore benefiting:
Gordonl (67yrs):...I think it's- the main thing is it's helping you, this aspirin
tablet you'll see it's keeping the old ticker going and I think that's a- yes aye
I would say that I'm quite happy.
Some participants even admitted that they believed they were receiving aspirin; one
therefore realised he cannot have really thought about it:
HE: how did you feel about the fact that you didn't know whether you were
taking aspirin or the dummy pill?
Warren2 (72yrs): I suppose I just presumed to myself that it would be aspirin,
yeah yeah
HE: cause some people say they don't like the idea of not knowing, and some
people say they wouldn't want to go in because they wanted the aspirin
Warren2: I don't know that I felt that, I just thought, "it probably is
aspirin".. .which suggests I didn't think too hard about it
This finding may be indicating evidence of a kind of optimistic bias; whilst
participants were aware that there is a 50% chance of being on the aspirin, there may
be a tendency to think that they were in the half receiving aspirin. As Richard 1
commented before, he found it preferable to think that he was involved in active
prevention. Whether it is more misconception or optimistic bias, it is an important
issue relating to informed consent (discussed further in the misunderstanding
section).
Contrary to those who voiced discontent with the RCT procedure, many participants
accepted the idea, often due to their awareness of it being the most efficient way of
conducting a trial and subsequently improving medicine.
Owen4 (52yrs): well I mean that's one of these ethical questions that I mean
you will never solve, because it's very difficult to run any kind of medical
trial without having some kind of placebo side to it, er I suppose it's
something that we would wish to try and limit as much as possible but it's
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like many aspects of medical research there are bits of that you might not be
entirely comfortable with in terms of ethics but until there's some better way
of doing it you're stuck with it.
In interviews where people did not express the preference for aspirin over placebo, I
put this perspective to them by saying, "some people have said to me that they
wouldn't want to participate because they wouldn't want to get the placebo, what do
you think?" Some participants could understand this viewpoint but realised the need
for the process:
Janice (focus group 4a, 70yrs): I had a wee passing thought about the people
that were on the placebo might not do as well as the ones on the aspirin.. .but
um I know they've got to do it that way and it's got to be blind but I just
thought I wonder if it might have saved someone's life, just a passing thought
as I say it wouldn't change my taking part in it. But my- if there was someone
out there whose life could have been saved by the aspirin and they weren't
taking that
Others disagreed completely probably due to their willingness to help:
Molly4 (75yrs): oh no, no, that wouldn't cross my mind at all. I'd be happy at
the end to know I'd only had a placebo
A few participants were very critical of those who expressed discontent with the idea
of the placebo, Craig4 (54yrs) described this as "an extremely blinkered point of
view", and Daniel4 (54yrs) implied it was ignorant:
HE: are you happy with the chance of getting the drug and not getting the
drug?
Daniel4: yeah, that's a chance you take
HE: yeah
Daniel4: you know that not everybody in the trial is gonna get the drug, you
know that, if you don't you haven't read a paper or read anything or seen the
television, the news. To think "well I'm in the trial, I'm gonna get this tablet"
you may as well be in cloud cuckoo land. You should know that it's a 50/50
chance of getting the pill or getting the other one.
Moiral commented similarly regarding the blinding aspect:
Moiral (53yrs): well then there's no trial, that's the whole point, you cannot
do a proper trial like that without absolute blind dishing out of samples, I
totally appreciate that. I mean no, no, no, I can understand why they say that
but if you're want things, medical research to advance, as far as I'm
concerned, I wouldn't be taking an aspirin a day anyway so what's the harm?
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Others accepted the process as requirements for successful research, for example
Keith 1 contemplated his reaction to discovering the tablet identity at the end:
Keithl (59yrs): "you mean I've been taking chalk for five years?!"
HE: how do you think you'd feel if you found that out?
Keithl: well somebody's got to take the placebo
A couple of participants specifically stated how they would have been happy to be a
guinea pig, invoking altruism again:
Timothy5 (61yrs): no, I don't think there's any disadvantage...I cannae see
any disadvantage but the simple reason is...you might not know any of the
results or anything like that because somebody else is doing the research-
doing the groundwork and you're just one of the guinea pigs for it. But it
wouldn't make any difference to me, whether I had been taking a placebo or
an aspirin.. .it wouldn't have made much difference to me
Some participants seemed indifferent about the trial tablet. The following extract
from focus group la illustrates contrasting opinions of trial participants:
HE: do you see [the trial tablet] as different or the same?
Alice (65yrs): no it's just another pill to take in the morning
(laughter)
Alice: another one of those white things you swallow them, I just take them
and that's it
HE: how do you feel about taking like that number ofpills?
Alice: it doesn't bother me, there's three- you have to take them two of them
er- I forget what they're for...()...they're only white pills, there's nothing to
stop you- they're small, they're not big pills, so you just have a cup of coffee
and that's it, you'll live for another day
Bob (70yrs): but you must believe that they're gonna do you some good?
Alice: not the aspirin one because I don't think it's aspirin, I honestly do not
think it is, it doesn't taste like it and as far as I'm concerned it's not
Bob: you see I consider that it is an aspirin, I'm hoping it is an aspirin, I have
a positive attitude towards it, if it is an aspirin, then it's gonna do me some
good, otherwise I wouldn't take it, I wouldn't be in the trial
Alice: well it doesn't bother me, it's just another pill
Bob: well I could never, I'm sorry I could never have that attitude that it's
just another pill
Alice: nothing bothers me about my health
Bob: but you must have a reason for taking it, if you've got a headache you
would take a wee paracetomol or something
Alice: but that's a pain and that's different
Bob: something's gonna happen
Alice: yeah pain's different, but I've not got any pain
Bob: but if you've got cholesterol, say you've got high cholesterol
Alice: uh huh
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Bob: and you're taking a tablet, then surely you imagine that that tablet's
gonna be beneficial for you or you wouldn't take it other wise
Alice: I honestly don't think about it
Bob: you don't think about that
Julie (56yrs): I'm the same as you (to Bob), I hope it's doing me good
Aileen: so do I
Bob: I find that pretty strange (to Alice)
Alice: it's just the whole thing is- goes over the top ofmy head, I really don't
think about my health at all, it's only when somebody says, "do something",
that I do it, but quite honestly, I don't think about it at all
Altogether, I have illustrated the varying attitudes participants had regarding the
RCT procedure, in particular regarding the placebo and blinding, and how
participants explained these as important in their decisions regarding participation.
As demonstrated, for some participants discontent with aspects of the trial procedure
overrode their altruistic feelings, but others participated despite expressing similar
disgruntlement. For the majority, assumptions about aspirin's efficacy seemed to
underlay their attitudes.
Adverse trial experiences: side effects and events
I was intrigued to know the feelings of any group2 participants who had stopped trial
medication due to a cardiovascular event; in particular if they had made subsequent
conclusions about their tablet identity and whether this had changed their opinion
about the RCT and its process. For example, if they held assumptions about aspirin's
benefits, their event may have led them to conclude that they had been receiving the
placebo and maybe thus blaming of the trial for not preventing their event. Contrary
to this, I found no blaming of this sort by the participants I interviewed. Harold2,
who experienced a heart attack one year into the trial, spoke of how he accepted the
trial process:
HE: so how did you feel about that, about going into the trial?
Harold2 (63yrs): no I was glad in a sense, I was glad in the sense that they
found something that maybe, you know you don't know if you're taking the
real aspirin or the dummy aspirin, I felt in a sense that it was helping you
know, till I actually took the heart attack you know
HE: 'cause some people say they don't um you know that not knowing
whether they've got the aspirin or the dummy pill
Harold2: uh huh
HE: um some people have said to me, "oh no I wouldn't wanna go in the trial
because of you know I want the aspirin"
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Harold2: it didn't bother me that much, no I didn't bother
HE: did you ever, did you ever wonder which you were on?
Harold2: did I?
HE: did you- did it ever go through your mind trying to work out whether you
were on the aspirin or the dummy pill?
Harold2: no. well sometimes, as I say it didn't bother me so I just took them
and I sometimes I'd say I wonder if this is the dummy I'm taking but it didn't
bother me you know, ()
HE: did it change how you felt about the trial after having the heart attack?
Harold2: in what sense, do you mean whether the trial contributed?
HE: um or that...
Harold2: I thought maybe the trial to me in a way highlighted it, my heart
was bad you know
HE: yeah
Harold2: no I didn't blame anything on the trial, no, I felt that after all if it
was gonna do it, then it was gonna happen you know...
Even when probed, Harold2 refused to attribute blame for his heart attack to the trial,
despite his comment, "I felt in a sense that it was helping you know, till I actually
took the heart attack", instead he indicated a fatalistic view about his event. Harold2
was the only participant in the present study who had experienced a cardiovascular
event and thus stopped the trial tablets due to the medication he required (including
aspirin) post event. A handful of group 2 participants had experienced less severe
changes in their cardiovascular health such as angina or raised blood pressure, which
had led to them requiring prescribed aspirin or warfarin thus stopping the trial tablet.
Like Harold2, these participants expressed no regret regarding participation and
largely spoke altruistically.
As discussed, underlying the majority of participants' discussion about the trial,
particularly the preference for the aspirin over the placebo, was the assumption of
aspirin's efficacy. However alongside this was an additional assumption that aspirin
could only be beneficial, i.e. there was little discussion of the potential risks of being
allocated the aspirin rather than the placebo. I was thus interested to hear reactions of
participants who had experienced side effects since starting the trial tablets.
Side effects experienced included effects typical of aspirin such as bruising and
heartburn, but in addition people reported more peculiar ailments that they attributed
to the tablets, such as tongue tingling, knee swelling and general aches and pains.
With the advice of trial staff and their GP, those experiencing possible side effects
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stopped and restarted the medication to test whether the trial tablet was the cause or
not. Participants in focus group 2 compared their side effects:
Cath (63yrs): I was taking it and I kept saying, "I can't be ill, I don't even
know what it is", I stopped it and started it on two occasions and did find that
I was waking up at night with a slight gnawing feeling in the stomach and
Ursula (61yrs): I was exactly the same
Cath: did you have the same? Well that's good to know yeah
Ursula: yes, yes exactly the same
Cath: cause I think I was surprised because as a child I took aspirin and
through my life and I never had any problems but I did have it there
Later:
Ella (70yrs): I stopped whatever it was because I got this tingling in the front
ofmy tongue, and um when I stopped taking whatever it was, that stopped
HE: interesting side effect
Ella: I mean I don't know what I was on and at one point I said to the doctor,
"was on I aspirin?" and he said, "well I don't know", so er but anyway but
when I stopped whatever it was, this stopped
Regarding effects such as bruising and aches and pains, people tended to tolerate
these and continue on the trial, echoing attitudes as outlined in the prevention chapter
that mild side effects of aspirin were worth tolerating in favour of the potential
benefits:
Julie (focus groupla, 56yrs): I just thought, "well if I am on the aspirin, it's
obviously doing me good" like the side effects, you just put up with them
Discussed earlier was Julie's curiosity regarding the identity of the tablet; her side
effects had led her to further speculation. A fellow focus group participant described
a scenario that had provided evidence for similar speculating:
Alf (74yrs): I'm not sure if I may be on the aspirin, because just over a month
ago I was in for a hernia operation, and before going in we got three sides of
(paper) telling us all about the operation before and after, and one of the
things they said was there might be bruising around- if you are on aspirin, if
you're taking aspirin, there might be bruising around the area the operation
cuts. Well I didn't- they said the bruising wouldn't be painful, I had quite a
bit of bruising, it wasn't painful but it make me wonder if I may be on the
aspirin.
But as a fellow participant jokingly pointed out:
Andrew (59yrs): I think there's better ways (of finding out the identity) than
going for a hernia operation!
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Similarly to group 2 who had experienced a cardiovascular event, I was interested to
hear the views of group 2 who had stopped the trial tablet due to side effects, which
in some cases had involved a great deal ofpain for example Alison2's experience:
Alison2 (55yrs): I really felt I'd got gall bladder trouble again because it was
from here right through into me kidneys and really severe. So I went to my
GP, and she just checked round and said straight away, "don't take anymore,
and ring Aspirin (trial) and tell them" and that was it, she gave me a course of
tablets which- I had to go back, which the pain had eased, it was still there
but nothing like it had been so she said, "give another fortnight and see, and if
everything's OK don't come back". Well it had gone altogether then but she
never actually said what it were causing, she just said she thought it could be
causing some damage to me liver or kidneys, you know, not me stomach, so
that was it, so now I've got one of these things round me neck that says I'm
allergic to aspirin (...)
HE: uh huh...so once you got it sorted out, how did you feel about the trial
then?
Alison2:1 felt like well I've let them down, but at same time your health does
come first and if that tablet aspirin were gonna kill me!
HE: did you feel angry for getting the symptoms that you got?
Alison2: no, no, because you go into it and you do know what you're doing I
mean that were it, it were just one of them things, there's some people as you
know who've started with it and they've still no problem.
Of the participants I spoke to who had stopped the trial medication due to adverse
side effects, not one blamed the trial or regretted participating. Instead, like Alison2,
they tended to speak of their disappointment at letting the trial down, indicating more
altruism. One participant who had experienced moderate side effects was keen to
restart and did so after the interview.
Participants who had not experienced side effects themselves commonly spoke of
reassurance they felt due to the provision of information regarding possible side
effects and the existence of safeguards in place for dealing with adverse events. For
example participants in focus group la showed awareness of side effects to look out
for and action to take if these are experienced:
Aileen (67yrs): if it causes bleeding
Andrew (59yrs): bleeding in the stomach
David (71yrs): but now we're taking it once a day for five years
Julie (56yrs): yeah but it's warning you that if you have any of these
symptoms
Aileen: it's on your sheet
Julie: you stop taking it
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Andrew: and they always ask you when you go back
Aileen: I've got a friend who.. .and she started this tablet the same as me and
she suddenly started to bleed and they took her off it immediately about a
fortnight ago, and they said it could be a side effect, but they did lots of tests,
but immediately they took her off the aspirin
One participant explained how she had specifically enquired what to do in the event
of a side effect. In addition to trial participants monitoring their own health and
symptoms, a couple ofparticipants discussed reassurance from regular monitoring by
the research nurses:
Richardl (54yrs): And I know basically it's just as statistical study, and as
long as you're given the checks so somebody was gonna say.. .well I assume,
maybe I'm being too generous to them but I assume that if they noticed that I
was actually looking seriously, likely to get seriously ill, they would tell me
to go and see a doctor, rather than just keep me on the study and see if I
kicked the bucket! (laughs) erm that might be unfair to them, maybe they're
much more callous than I think, frankly I don't think so, I think that would
have been the case, so provided that they're giving you the checks, it means
that they're...you know they're not gonna be letting you carry on doing
something like that if you're health was in any way deteriorating, at least I
imagine they wouldn't.
These findings indicate that the provision of full information regarding action to take
if experiencing possible side effects or events, in addition to being a requirement for
informed consent in a trial, can also contribute to perceived safety. The issue of
informed consent was brought up by only one participant; Owen4 expressed the
importance of clarity in the screening letter:
Owen4 (52yrs):...I would imagine that what would make a difference would
be that you successfully strike up the balance between making it reasonably
straightforward to follow the letter and the purpose and the research, and at
the same time giving enough information treating people as responsible
adults er 'cause I think people are probably are prepared to participate in
research as long as they are sure what it's about. But at the same time they
don't necessarily want several pages out The Lancet to read before they sign
up for it, and I have to say that's a difficult balance to strike. ()...Um so I
think as well as long as the people.. .somebody in the trial knows that clearly
that they may be taking something which is completely useless er and that
they may be therefore getting the protection that somebody else is getting,
that's their business as long as they are fully informed, it's informed consent
that matters.
Inherent in discussion about safeguards is the trust that participants demonstrated in
the trial; similar trust related to the trial tablet:
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Martha2 (65yrs): to take it, it's not gonna give you- they're not gonna give
you anything that's gonna do you any harm so, just take it
Whilst participants' views about medication and aspirin were discussed in the
prevention chapter, it is interesting to explore their attitudes specifically regarding
the trial tablet. So far in this chapter, it has been demonstrated how for many
participants, their trust in aspirin, and its perceived efficacy and safety, led them to
express discontent with the RCT process due to their preference for aspirin over the
placebo.
This trust in aspirin manifested in an additional few ways: the fact that the tablet
would either be a placebo or aspirin and nothing else seemed to contribute to trust in
the trial, particularly in comparison to the idea of a trial for a 'new' drug, for
example:
Eleanor3 (62yrs): obviously it would depend what it was, but like taking a
pill, obviously as long as I kind of know that it wouldn't be doing me any
harm so, you know so, if it was a trial for something like a new drug that they
were testing, you know I think I would uh huh make it a bit different, but I
mean given that it was either aspirin or a placebo
HE: do you that's something- do you think that the fact that aspirin's been
around for such a long time has an influence?
Eleanor3: well given that it's a tried and tested drug that you would have
been taking, I mean obviously it's a small dose you'd be taking wasn't it? So
really they...certainly wouldn't do you any harm, one way or the other, well
if anything it would possibly do good, given what they'd discovered. So but
as I say if it had been something, if they'd said to have come and it was a
drug they were just testing, that would've been different but given it was
aspirin, I wouldn't have had a problem with it one way other
Also for some participants who expressed a general dislike for medication (due to
reasons discussed in the prevention chapter), their willingness to participate seemed
to be related to their trust in aspirin. For example, the following participant described
how her sister disliked the idea ofmedication and did not want to start on cholesterol
tablets, but she happily participated in the trial:
Elsie (focus group 4b, 60yrs):...I think I would be the same I don't think I
would like to take tablets, I could obviously if I had to, if you've tried
HE: is that...'cause obviously she's still taking the trial taking the trial tablets
so does that not bother her?
Elsie: no, she's happy to take them
HE: why is that different?
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Elsie: well I think again it's because it's aspirin, I think if it was anything else
I think.. .or it's possibly aspirin
For other participants who expressed a dislike of medication in general, there were
other reasons given for their willingness to take the trial tablet. For example Monical
quoted in the prevention chapter as emphasising that she was "not a pill popper", had
a favourable attitude towards the trial tablet
Monical (66yrs):...I don't like to take pills if I can help it you know, even
headache pills, you know. If I got- if I had it all day and I was forced to take,
I'd take a paracetemol, that's the only medication I would ever use,
ordinarily.
HE: how do you see about the trial tablet as compared with that, if you don't
like taking medication, but do you mind taking that?
Monical: I don't mind taking that, because it's supposed to be helpful
hopefully
So despite having avoided medication for most of her life, Monical thought that she
could benefit from the trial tablet, implying that she probably hoped it was aspirin.
For Alison2, who used the same phrase to emphasise her non-"pill popper" status,
altruism overrode her dislike of medication that had arisen from medication she was
required to take for another condition:
Alison2 (55yrs): it's the side effects of both the tablets, the ones for me neck,
that I take, they just knock me out completely, I feel like "phhh I've got to get
up" you know and you're so lethargic and same with the painkillers, you just
feel like you're in a dream walking, you see things going about you but that's
the only way I can describe it now and that's reason why I won't take them
on a regular basis, plus fact that I think is you keep popping 'em, your
immune system breaks down and then you waste of time because you just
don't get any better do you? that's my system of working, probably wrong
way
HE: did you- but you were still quite happy to take the trial medication?
Alison2: yes
HE: did you see that in a different way?
Alison2: I just felt that it could be helping other people
So beliefs about aspirin's safety and efficacy as well as altruism overrode several
participants' avoidance ofmedication and led to willingness to take the trial tablet.
For some participants, dislike of medication led to declining to participate, as
discussed in the prevention chapter, explanations included fear of anticipated side
effects and dislike of chemicals. Isobel3 strongly disliked conventional medicine,
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thus the prospect of five years ofmedication into her body had dissuaded her, despite
her keenness to attend screening and interest in the research:
Isobel3 (60yrs):... so when it was explained to me that it was the research for
5 years and I hadn't even thought about it, and I thought, "no I'll try and take
care ofmyself other ways"
HE: oh right, so you decided not to go into the trial
IsobeB: yeah
HE: how did you decide to take care of yourself as you say?
IsobeB: well I take supplements, um I'm also vegetarian anyway, so I
thought I would increase my fruit and veg... I take oils, I read a lot of health
supplements, I also attend an Ayuverdic doctor. That's a Hindu, herbalism
but it's there since much much longer, so I attend him
Interestingly, she expressed similar distrust as to the placebo as she pointed out that
its ingredients were not clear and was unhappy taking anything without knowing
more about it.
Altogether, participants' reflections regarding their experience of events and side
effects whilst participating in the AAA trial generally indicated positive opinion, for
example, little blame for any adverse experiences. Trust in the trial expressed by
these participants seemed to be often linked to trust in aspirin, which reflects the
findings discussed in the prevention chapter, and whilst for some, general dislike of
medication applied to the trial tablet, for others it was treated differently.
Benefits and incentives of participation
On the whole, when asked about reasons for participating and benefits of the trial,
participants referred to benefits of the screening and focussed on these rather than
benefits of the trial itself, for example:
Amy2 (76yrs): no, as I say I think it's a good thing that people get the
opportunity to go into these things, so there must be a lot of people who are
found out er you know, they could do with their help, no I think it's a good
thing
When asked specifically about advantages of the trial, one participant who had
declined to enter the trial felt that the screening in fact was the only benefit of the
trial.
Morag3 (64yrs): well I wasn't aware that there was anything else other than
perhaps a check up and intermediate interview
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However, several participants saw additional benefits to the initial screening, most
commonly having one's health and reaction to the tablets monitored over the 5 years
duration:
Monica 1 (66yrs): I thought that's good because um I thought to myself
"this'll, it screens my health for the next five years and other aspects of it as
well you know" and I thought "well it's a good thing to do"
For others, this ongoing monitoring was less specific to heart health but simply
someone keeping an eye on their general health:
Harriet (focus group 4b, 61yrs): you'd feel like somebody was watching you
or you know somebody you know...somebody would be checking on you,
whereas you might not have gone for this test, you might not go to the doctor
every few months
An additional benefit mentioned by a handful of participants was their increased
awareness about their cardiovascular health, which served as a warning giving them
the chance to take steps to reduce that risk by making lifestyle changes:
Julie (focus group la, 56yrs): there are people that I know and you're not
talking about a relative you're helping, you're thinking of yourself and I think
you're also given the opportunity in this five year period, that if you are on a
placebo, you've got a chance to do something else, you've got a chance to
improve your diet, get fit, you've still got an option, you can still improve
yourself in five years, even if you're not on the aspirin, you've been given the
opportunity or a warning that you're susceptible
Whilst Julie regarded this as an opportunity to make changes, the tone was slightly
different in the following participant's statement, who emphasised responsibility
which she would have felt to actively reduce her risk had she been at risk:
Lucy (focus group 4b, 57yrs):...I expect that people that take part in the trial,
that would be me...I would also be conscious of the fact that I should be
watching my lifestyle at the same time. I think-I wouldn't know as you say
which 1 was on whether I was on aspirin or not but the fact I was taking part
in a trial like that, I think I would find some- there would be some
responsibility on me to do the best...I could for myself. So in a kind of way
people who are on it are doing themselves a favour I would say
Another participant implied that people who failed to take this opportunity would be
foolish:
Daniel4 (54yrs): if you look after yourself, you know you've got starting- the
arteries are starting to fur up, if you're told they're starting to fur up, "how
can I help? How can I do this? How can I assist in getting rid of it or easing
1 :trial participant 2:stopped trial tablet 3:trial decliner 4:healthy ABPI 5:screen non-attendee 208
it?" you say "well you might be on this tablet...but what else can I do?" and
if you don't do it, then...
Regarding more overt incentives to participate, one participant's non-participation
was due to lack of expenses or financial compensation being offered (Paul3).
Discussion in the literature however has found that financial incentive tends not to
increase uptake (Fouad et al., 2000); certainly Paul3 was one of only two participants
who voiced the opinion that financial incentives were appropriate. The second,
Susan5, could not imagine why people would happily take the chance of receiving
the placebo with no reward as such:
Susan5 (53yrs): I don't like this dummy pill, you either know you're taking
something or you're not
HE: yeah
Susan5: so if someone's gonnae give you something say either it's aspirin or
it's not
HE: people know that they could be on either so it's not like people have
been lied to, but they go in knowing that they.. .but you wouldn't want...
Susan5: no way, nobody's gonnae say to me "it might be this and might be
that" not for me
HE: can you see any advantages at all?
Susan5: a wee bit er...it may be a stupid person thought they were taking
something, no I don't agree.. .it'd just need to be a no for that one
HE: that's fine. There are a lot of people in this trial so a lot of people are
doing that I mean why do you think-
Susan5: are they getting paid?
HE: no
Susan5: (laughs), they're off their head (laughs) sorry
However the majority did not agree; rather some stated how financial incentives
would be wrong and perhaps entice the wrong type of person, for example in focus
group 4a:
Wilf (65yrs): no well I was thinking more of what you said earlier when you
were talking about incentives and I was thinking about a pal of mine who
regularly goes and gets him 50 pound a day at (name) University where they
do er things like research, so obviously it must have been- it must be an
incentive, and at (name of University) they sent it to a lot of people who
would like to go into these studies but to me it would become a wrong reason
HE: yeah does money alter things?
Janice: but then if they were suitable people
Wilf: well this guy's young, I mean he's in his thirties, he said "well I need
some money so I'll just go along here, I'm fit and healthy, the doctor
approves, he goes along to day care and they do studies for this that and the
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other, and he's gets 50 pound a day, he comes out in a couple ofweeks with a
big bundle ofmoney.. .he can't walk but!
(laughter)
Maureen4 (53yrs) talked with regret about participating in trials in the past for
money when she was younger and fitter:
Maureen4: well I've been involved in drug trials before, yeah when I worked
in (hospital), nurses used to volunteer to go in trials, 'cause they used to get
paid for it (laughter), but no not for a long time
HE: how do you think about that- people being paid for it?
Maureen4: I think it's obscene actually, I mean I think we did it as student
nurses because you were broke you know but I think a lot of people took
things that hadn't a bloomin' clue what they were taking, and um a lot of
people were quite ill, but they really didn't care that they were ill as long as
they got the cash you know and I think that's bad. I think it attracts perhaps
people you know that maybe not want to be involved in the trial in the first
place, but money's very attractive isn't it?
HE: yeah. I mean there's no money involved in this trial...
Maureen4: yeah if you'd just sent out a hundred letters saying "if you come
here we'll pay you one hundred pounds" you'd have a queue outside the door
(laughter). But whether or not that's the right kind of thing you want to do, I
don't think it's right you know.
So money had been an attractive incentive to a younger, fitter and less well off
Maureen4 but being 53 now, she regretted it as she realised the risks involved with
these past drug trials and shared the belief that money attracted the wrong type of
person. This is interesting, given she had been attracted by money in the past.
Audrey5 described being offered expenses for a trial in the past and discussed how it
seemed morally wrong to her to even claim expenses emphasising her altruistic
intentions:
Audrey5 (72yrs): well some people do it for medical knowledge and some
people do it for something different, because I discovered- here's another
example, I discovered after I'd finished with Dr C and Mrs C, I didn't realise
at the beginning that Mrs C she asked the consultants we should be getting
paid for it, she said at the end, I said, "oh I don't have any expenses not at all"
and she said, "you must have expenses", "no", I said, "I don't, cause it wasn't
that far and at that time I was quite fit, now I understood afterwards when she
did tell me, I was sent some flowers and some chocolates as a gift, cause of
course some of them were putting in 50, 70 pounds expenses from the
travelling point, they were taking taxis up and taxis back and it's quite
expensive, and they were entitled to their expenses as you know, but I didn't
want expenses, I was helping somebody else, (...) perhaps people would
think, "I'll make something out of this too" you know, I don't know
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Participants who emphasise their altruistic reasoning as distinct from others'
participation for incentives are interesting; these participants could be indeed getting
some reward from presenting themselves as altruistic. This moral discussion about
money inciting the wrong type of person to participate is interesting; the idea that
financial incentives would attract the 'wrong' sort of person echoes Titmuss's (1970)
discussion of paid blood donation attracting unsuitable people, however Titmuss was
referring to blood donation, which is a different situation in that the suitability (and
healthiness) of the blood is crucial, whereas in the current situation, if a trial
participant is eligible and adheres to the trial requirements, their reasons for
participating whether for incentives or for altruism will not affect their contribution
to the trial and their 'suitability'.
A couple of individuals found it hard to imagine people who would want to
participate:
Ted4 (77yrs): well my initial thoughts are if you were in the half where you
were taking the placebo, well you know that would have a negative
impression because if I thought I was doing something which wasn't really
anything, I wouldn't feel very happy about it. And yet I know what you're
talking about, you have to have some way of compar-of getting comparisons,
but if I knew I was on the placebo, then why should I be doing that?
Clinically I can understand why you're doing it, but you wouldn't surely find
that many people would be happy to know that they were taking something
that wasn't doing-
He elaborated to say how he found it hard to imagine people who would be this
altruistic, which is interesting to contrast against the altruism expressed by many
participants as discussed earlier:
Ted4: unless there are a lot ofpublic spirited individuals who would do that, I
still feel it difficult to believe that somebody who was pretty old, would think
along these lines. I'm sure that when they're getting very old, they're
thinking only of things which are going to be improving their condition,
rather than something which improves somebody else's, but er I know you
can't tell lies or anything like that, you can't do that kind of thing, and I'm
glad to hear there are people that take it up
His difficulty of imagining sufficient numbers of altruistic people led him to suggest
lying to increase recruitment!:
Ted4: I think you have to do it, I suppose you have to do it irrespective of the
feelings of the individual because you'd have to do it by stealth you know
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because how are you gonna get the information otherwise? You have to do
make comparisons with one and the other, er I think you would have to be a
wee bit unfair by you know playing down the fact that people might not be
taking anything to get the information you want. That would- which in the
long run would benefit society if you like generally, I think you couldn't be
paying too much attention to the feelings of- you might have to tell lies
(laughs)
HE: you can't do that!
Ted4:1 know you can't but how else are you gonna get it?
Ted4 appeared fairly altruistic himself, he spoke of his interest in social research as
he had conducted research and was keen to participate in this interview study, and
said his initial interest in the trial was due to wanting to help. However he seemed to
have a negative impression of other people's attitudes, and thought that generally
people would not be sufficiently altruistic to participate. Maureen4, after honestly
admitting how she herself would have discarded the trial tablets and bought her own
aspirin, and regretting paid participation in the past, continued by suggesting that
other people's participation was not altruistic but due to either lack of initiative to
make their own decisions or to poor awareness and misunderstanding:
Maureen4 (53yrs): But I think a lot of people that come you know, they won't
have this sort of gall to do that you know they'll just take what they've been
given because well this is what the nurse or the doctor says you're to have,
you know
HE: so do you think they don't really understand it they just do as they're told
Maureen4: I think they're just like you know little sheep, led, but uh huh I
think any trial you know people are very willing to sort of think "well we're
helping" you know but in actual fact they're not really totally aware of the
consequences that from all this, if half of them who are on the trial have got
you know high blood pressure, and they're not being given- they're being
given the placebo, then I think they're probably not fully aware that you
know- you're not doing them one bit of good so why bother coming?
Similarly Timothy5 indicated that participants probably believe they are receiving
the active drug and that emphasising the possibility of the placebo would decrease
participation rates:
HE: and what do you think about the fact that you've got half a chance of
getting an aspirin and half a chance of getting a dummy pill?
Timothy5 (61yrs): as long as you don't know it doesn't make any difference.
HE: uh huh
Timothy5: 'cause nine times out of ten people will believe that they're getting
an aspirin
HE: yeah
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Timothy5: so...if you're happy enough doing that then yeah...but if
somebody hinted for one minute you were just getting a wee sugary
tablet.. ."waste of time this"
Timothy5's insight about people believing they are receiving the aspirin reflects the
finding discussed earlier that some participants do indeed imply this misconception.
The last three quotes have shown perspectives of those who were not trial
participants. Their impressions of trial participants are interesting; altruism was
considered an unlikely reason for participation as opposed to being 'sheep-like' or
having poor awareness. This contrasts with the beneficial reasons given by
participants discussed earlier in the section.
Barriers: commitment and convenience
Costs of the trial that were discussed related to the commitment, 'hassle' or
inconvenience seen by some to result from participating. For example, duration of
the trial process was sometimes regarded as inhibiting:
Miriam3 (73yrs): well she (nurse) explained the business about the tablet and
it would be a whatsit- a pretend one or a real one, and then she said for 5
years, and then I decided I wasn't joining
HE: right yeah
Miriam3: the thought of this going on for 5 years, seemed to me seemed a
long time, I didn't want to commit myself
HE: no, no
Miriam3: live for the present
Ted4 pointed out that duration would be a particular problem if recruiting people at
the older age end of the age spectrum:
Ted4 (77yrs): I think it would also depend how old you were, maybe if you
were 50, you wouldn't, if you were getting on in life and coming up towards
80 I don't think you would talk about some 5 year plan, you might not even
do the five years but no I think you would again it would depend how old you
were. A younger person might be quite happy to do that, someone who was
advance-what's advanced age now? The 93 year old- how do you think she
would respond to that? Because in 5 years she'll not be here- well she might
be...
()... the thing is that it's 5 years, it's such a long time that's the thing, it's not
as if you're saying "do this for the next two to three weeks" but you're asking
someone 5 years
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Conversely Fergus 1 (aged 71 at trial entry) looked on the invitation to participate for
5 years as a positive statement about his health:
Fergus 1: Er I didn't take it on board it was a trial, and I had to think about the
period, so when they said last year this trial would last over 5 years, I said,
"thanks for the vote of confidence you know!"
Five years was thus regarded as too much of a commitment by some; it was
interesting to pinpoint what participants viewed as this commitment involving. At the
younger end of the age spectrum a busy life, thus no time to participate, was regarded
as a valid reason by several participants. For example:
Molly4 (75yrs): Well it wouldn't have been simple 'cause I was still teaching
and I went on till 60 or so, so it wouldn't have been so easy, it would just be a
lack of time, it wouldn't be-1 know you're saying you go on till the evening.
Well I think your lifestyle makes it more difficult at that time to attend
something else...
Another participant described accessing the hospital as too much 'hassle'. Thus the
reasons given reflect the barriers against attending screening as discussed in the
screening chapter. And similar to earlier discussions, other participants regarded 'not
having time' as a lame excuse for non-participation. For example in focus group la,
one participant challenged another on this issue:
Julie (56yrs): or it could be that they have such a busy life that they don't
want to get involved in something, it takes up too much time
Andrew (59yrs): what taking a tablet every morning?
Julie: no but you've got to come to every six months, you've got to go for
your check up and things like that
In actual fact, after screening and baseline visits, all the trial required was annual
clinic visits as Richard 1 was well aware:
Richardl (54yrs):...and it's not all that inconvenient, I mean you get in the
habit of taking the pills every day, and um you know going once a year, to
keep in touch with them isn't exactly a burden you know. So it's just
something you do you know, it's relative and if people want 'o do it, they'll
do it.
A few participants said they had trouble remembering to take the tablet and in a
couple of cases this had led to dropping out of the trial, for example:
Peter2 (55yrs): the only reason I stopped was simply because I kept forgetting
to take the tablets you know and it's just I take brufen now and again for my
ills and that and I even forget to take it in the morning before going 'o work
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sort o' thing you know, so I'm getting to the stage that they're calling myself
A1 for Alzheimer you know cause I'm getting terrible forgetful. And I mean it
would just be a sort o' sham for me to say, "I've been taking it when I
haven't" you know. I think trials are- they are good things you know...
So despite emphasising their positive attitude towards research trials, Peter2 and
Warren2 stopped the trial tablets due to their apparent difficulty remembering.
Warren2 distinguished between this and lack of commitment, perhaps in attempt to
justify his dropping out of the trial:
Warren2 (72yrs): simply because I wasn't good at taking a tablet each day,
you know. I think if it had been medication that I needed to take, I would
have taken it
HE: right
Warren2: and that sounds as though I wasn't committed, but I was when I
started certainly, but you know I'd go to take them and "goodness me, I
haven't taken them this week" it was just something that didn't imprint itself
on me and I mean I take tablets every morning now, um and they're not
medication, they're dietary supplements
Warren2's quote once again implies perceived lack of necessity associated with the
trial tablet and the low ABPI as previously discussed.
To a couple of participants, it appeared that it was the lack of disadvantages or hassle
involved in the trial that persuaded them to participate, i.e. they could not see a
reason not to participate. For example:
Martha2 (65yrs):...when they said they would put me on the trial and you
know I thought, "well fine, It's not gonna affect me- the way I live or what I
do
Marie2 (77yrs):I mean I was perfectly fit myself and I thought, "why
shouldn't I go in?".
So for a few of these participants then, it was not the case that any benefits persuaded
them to participate, rather the lack of strong reason for why not to participate or that
they accepted participating without much thought.
The last two sections have illustrated participants' ideas about the benefits and
barriers of participating in the AAA trial. At one end of the spectrum some
participants felt that the benefits of the trial, both to self and others, prevailed over
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the costs. For example, when asked about disadvantages of participating, Craig4's
attitude was:
Craig4 (54yrs):...of being in a trial? Um these would be grossly outweighed
by the advantages I'd say
Conversely, Geoffi (68yrs) who could only see risk and no benefit from
participating:
GeofB: no, I don't see any advantage to me. Advantage to the researchers,
yes. They can say "oh look that fellow died and he was on the dummy pill,
maybe if he'd been on the right pill he wouldn't have died". So I see the
benefit there, but I'm not prepared to be a blind guinea pig.
These are two extreme viewpoints; the chapter has demonstrated the wide range of
opinions ranging from altruism to self-dominance, and attitudes about the pros and
cons of participating. The Health Belief Model (Rosenstock, 1966; 1974; Becker et
al., 1977) proposes that individuals weigh up barriers and benefits (along with
perceived severity and susceptibility, and health motivation) when making decisions
about carrying out a health related behaviour. Although criticised for assuming that
rational thought processing takes place, and for ignoring the context in which people
form beliefs about their health, it is apparent in the accounts of people in the present
research that specific benefits and barriers are indeed mentioned when discussing
attitudes towards participating in the trial. Referring back to Geoff3 for example, he
explicitly described the cost-benefit analysis he had carried out when deciding to
participate or not. For others there was less evidence for a cost-benefit analysis as
such, rather certain aspects (for example dislike of medication, wanting to help
others) appeared to dominate over others in their personal decision to participate,
whilst still acknowledging and discussing less dominant factors. Also included in the
HBM is the perception of risk and severity; as indicated in the chapter so far,
participants' perceptions (high and low) of cardiovascular risk and risk from aspirin
appeared to underlie many participants' participation decisions. This will be explored
further in the subsequent chapters.
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Part 3:
(Mis)understandings concerning participation
In the chapter so far, many misunderstandings have emerged. This section highlights
those outlined so far, adding further instances not yet discussed.
Selection criteria for the trial
In the screening chapter I outlined the common misunderstandings and/or recall
difficulties that emerged regarding the ABPI measure and its meaning; I
demonstrated how many participants did not consider the ABPI a significant risk,
and the impact that the screening experience, in particular the nurse-participant
dialogue, appeared to have had on this risk perception. As the selection criteria for
the trial was a low ABPI, participants' perceptions and understandings of the ABPI
consequently related to their attitude towards participating in the trial.
It also emerged that many participants misunderstood the selection criteria for the
trial and believed their invitation to, and subsequent eligibility for the trial as due to
different reasons than the ABPI measure. A couple of participants assumed that
family history of heart disease had led to their initial invitation:
Alice (focus group la, 65yrs): I presumed the doctor had put me in for the
screening because of my mother and father, both of them died of heart
attacks, well my Mum had a stroke but you know what I mean, anyway so I
presumed that was why I had been put in for it
Regarding eligibility assessed at the screening, a few participants believed high
cholesterol was the reason for this:
David (focus group la, 71yrs): After the very first screening, the AAA people
sent a report to my doctor...I had occasion to see him about two or three
weeks later on another matter, and I brought this up, he said, "oh yes we've
just got the report, you've got slightly high cholesterol now," he said
something like .5 above, he said, "but they've only just lowered that level
about a year or so ago". So had I been the same level and took that test the
year before, then I would not be sitting here today, 'cause they just recently
lowered it to whatever it is now
Not only did David misunderstand the selection criteria for the trial, but he also
perceived little risk after discussing his cholesterol with his GP. Another common
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mistake was to assume that high blood pressure was the determining factor for
inclusion:
Keithl (59yrs): well it didn't really bother me, I mean they were inquiring
you know if I was- it was my own doctor actually I think who got in touch
with, and I take it their idea being is to try and get people who'd get in touch
with their doctors and people who have raised blood pressure would be the
people they would want to see, you know people who didn't have it, they
wouldn't be bothering. So I take it that was how they got in touch with me.
Interestingly, a few participants felt that the research nurse's opinion of their lifestyle
had swayed their inclusion; Monical felt that her healthy lifestyle had led to her
being included:
Monical (66yrs): I had no problems with that, she said to me I was on the
borderline
HE: right
Monical: right she said "but I think I'll include you, in the trial", I was just-1
forget what figures they used, er and I was just on it
HE: right
Monical: or just about on it, you know I wasn't way off you know, and she
said "I think I'll include you in it", I don't know why she decided that, when
it wasn't over you know. Possibly because of what I was telling maybe
because I tried to help myself, she thought "I'll give her the benefit" or
whatever.
Contrary to Monical's healthy lifestyle, Fred2 felt that his smoking had contributed
to his inclusion:
Fred2 (62yrs): I did, she- I also think I was- I'm positive that both feet
readings were the same, but being at the age I was, and I smoke
HE: oh right
Fred2: er.. .and the lady at the time said, "well you know we'll put you on the
trial" sort of thing, I think the smoking had something to do with it you know
The choice of words used by a few participants when discussing eligibility appeared
to indicate that they regarded their eligibility in a positive light:
Wendyl (55yrs): well I was glad I got accepted 'cause they say maybe you're
not gonna be accepted, and I was glad I got accepted, I was quite happy about
that
David (focus group la, 71yrs): my wife and I both received the invitation at
the same time, we both went down to the western general, and I was selected
and she wasn't
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The following participant expressed similarly positive opinions on being included in
the trial and showed awareness that the trial recruited from a 'healthy' population.
However, she seemed to still consider herself healthy after having a low ABPI and
thus included in the trial, again indicating low risk perception from the ABPI result:
Lorraine (focus group lb, 52yrs): I think I was quite pleased whenever I got
the initial letter out because the sort of person they were looking for was sort
of you know basically quite healthy...
RCT procedure
As outlined earlier it emerged that some participants did not fully comprehend the
RCT procedure. As previously mentioned, a couple of participants misunderstood the
double blinding, believing instead that the research nurse and other health
professionals knew the identity of their medication. Regarding the randomisation
process, a few participants demonstrated awareness, but many despite indicating an
awareness of the randomisation, appeared to believe that they personally were
receiving the aspirin. This echoes previous literature where participants could
seemingly accurately describe how treatments are allocated at random whilst
simultaneously demonstrating inconsistent beliefs regarding their own treatment
allocation for example allocation thought to result from symptoms or other criteria
(Featherstone & Donovan, 1998; 2002; Snowdon et al., 1997).
A common misconception was that the trial followed a crossover RCT procedure, i.e.
that each participant would receive periods of the aspirin and periods of the placebo.
Alison2 seemed to think this, however her involvement in a previous trial, possibly a
crossover design, probably contributed to her belief:
Alison2 (55yrs): no I mean I knew that I were gonna be given a dummy as
well as aspirin
Gordon 1 too seemed to think the design was a crossover, and as discussed earlier
misunderstood the need for the trial due to his assumption of aspirin's proven
efficacy:
Gordonl (67yrs): that's right. So I take that faithfully all the time but as I say
it's some's aspirins and some's blank tablets, I don't know what that's for.
They should just keep you on aspirin and see how your blood pressure
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HE: yeah I was going to say, how do you feel about that? Because obviously
this is a trial and what they're doing is like half the people are on aspirin and
half are on-
Gordonl: that's right, so you don't know what you're on, which
HE: so how do you feel about that?
Gordon 1: well I think it should just be aspirin only, you know so you ken that
you're taking it and then but they must have a reason, but they're half, they
put in half
Harold2's account is interesting as it revealed inconsistencies in his understanding as
he contradicted himself at several points in the interview; it could be the case that he
was attempting to reinterpret his prior thoughts about the trial having had a heart
attack, or it could be that the interview process itself led him think about the trial in
more depth than he had before. At points in the interview he spoke about how he
thought the aspirin might help him, so despite appearing to understand the RCT
process he may have believed that he was on aspirin, as quoted earlier:
Harold2 (63yrs): no I was glad in a sense, I was glad in a sense that they
found something that maybe, you know, you don't know if you're taking the
real aspirin or the dummy aspirin, I felt in a sense that it was helping you
know, till I actually took the heart attack you know
Then maybe trying to justify why he had a heart attack despite being on the 'aspirin',
he talked about aspirin not being able to 'cure' all heart attacks:
Harold2: I thought I was helping, in a sense that the aspirin would have- I
don't know cured you or anything, I don't think they could cure heart attacks,
whether it would have prevented me having a heart attack. But I took it you
know
Later he considered the idea that he may have been on the placebo which could
explain why he still had the heart attack (so making the assumption about aspirin's
efficacy), but he then showed that his understanding of the RCT process was not
entirely accurate after all, similarly to Gordon 1 he seemed to think the trial was a
crossover design.
Harold2: But now Em sorry that I never maybe took an aspirin 'cause it could
have prevented () No I didn't- it didn't bother me taking aspirin but then
again maybe it did bother me 'cause I was taking the dummy and it didn't
help! But you're getting some aspirin some of the time so it must have been
helping me.
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These seemingly contrary quotes in Harold2's account implies that he struggled
trying to grasp the concept of the trial procedure, and demonstrates how the concept
can be difficult to understand for a member of the general public, indeed for anyone
with no knowledge of medical research. There was a wide range of educational level
in the participants in the study, and misunderstandings and/or assumptions were
revealed in some participants even at the upper level.
I discussed the findings ofmisunderstandings with the research nurses. They told me
how at annual clinic visits it was apparent that participants had forgotten aspects of
the trial (such as those misunderstandings covered above); they pointed out that five
years, or even one year, is a long time for people to remember details particularly
medical details which were often novel to them. The nurses explained the ABPI and
details of the trial to participants, and administer participant-friendly information
documents, but questioned how they could guarantee that each individual had
completely understood and would remember.
These misunderstandings are a concern regarding the issue of informed consent, in
particular raise the issue of the difficulty of guaranteeing informed consent from the
initial screening throughout the duration of the trial.
Summary: Attitudes towards participation in the randomised control
trial
The AAA trial provided the opportunity to explore attitudes and experiences of
members of a healthy population alongside an ongoing large RCT for preventive
medicine. The present chapter has outlined and discussed the diversity of
participants' attitudes to general and specific aspects of the research trial. The first
section demonstrated the emergence of altruism in participants' accounts, and
explored the different explanations given for these feelings. The second section
focused on more self-dominant attitudes including the potential personal benefits and
costs regarding aspects of the RCT procedure. Also illustrated were assumptions,
misunderstandings and ideas about risk perception implied in participants' accounts.
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Altogether the chapter has demonstrated the large number of different aspects, issues
and feelings that appeared to influence the decision to participate in the AAA trial.
Furthermore, the quotes used have illustrated how participants can have seemingly
opposing opinions regarding the costs and benefits of the trial, further demonstrating
the complexity of the decision. In some cases, weighing up the multiple pros and
cons, whether consciously or not, became straightforward, for example the case of
Alison2: this participant expressed clear altruistic views about participating and had
participated in previous trials, she disliked medication but was willing to take the
trial tablet for research. However a severe reaction attributed to the trial tablet led to
her having to stop the medication because, "at the end of the day, your health's got
to come first". Similarly other participants explained how their attitudes changed
over time according to different experiences.
For some participants, their attitudes appeared to change and contradict within the
interview leading to further examination of their transcripts. Sometimes this seemed
to reflect misunderstanding for example the case of Harold2, but for others such as
Maureen4 (quoted in many parts of this chapter), it further demonstrated the
multitude of experiences that could contribute to the decisions of some participants.
In addition, the emergence of misunderstandings regarding the trial raised the issue
of the difficulty in guaranteeing informed consent throughout the trial duration,
despite ethically approved participant-friendly documentation and training of
research staff with participant contact. This is a serious issue that should be
considered further by those running research trials and the medical community.
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Chapter 7:
Perception of cardiovascular risk
Introduction
Regarding participants' attitudes towards screening, prevention and AAA trial
participation, a key underlying theme that emerged was participants' perception of
cardiovascular risk. This final data chapter will present further analysis specifically
relating to participants' cardiovascular risk perception.
The data in this chapter emerged in two different ways: first, interview questions
included, "did/do you see yourself as the type of person to have heart disease?"
and/or "who do you see as the type of person to have heart disease?" Thus these
formed direct questions about cardiovascular risk. Second, from participants'
comments and discussion about screening, prevention and participation, their
feelings about cardiovascular risk emerged in a subtler manner.
The chapter is split into sections relating to different risk factors. First, family history
of the disease is discussed, exploring how participants perceived this as affecting
their risk and the comparisons they made between themselves and affected others
including peer comparisons; this was a particularly salient issue. The second group of
risk factors discussed concerns lifestyle, in particular focusing on the risk perceived
by those who continue to engage in 'unhealthy' behaviours. Third, the idea of heart
disease being a particular problem for Scotland is considered. The final section
highlights attitudes towards clinical diagnoses of cardiovascular risk factors.
Family history of cardiovascular disease, and self-others comparisons
Family history of heart disease or heredity was particularly salient in many
participants' accounts; some members implied it was the most important risk factor.
Discussion in focus group 2 returned to this several times. For example, the
following extract was part of a discussion about causes of cardiovascular risk;
participants gave examples where lifestyle and physical build appeared to be
irrelevant, which led them to conclude that genes could overpower other factors:
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Cath (63yrs): there's a lot more to it than just eating and drinking and
lifestyle and whether you're overweight or whether you know, there's a lot to
it you know. 'Cause my mother who was overweight, well she struggled with
her weight most of her life, had no problems with high blood pressure or high
cholesterol, and my father who wasn't overweight, he had all these things you
know
Ursula (61yrs): is it in the genes?
Others: mmm (agreement from other focus group participants)
Emma (70yrs): that's what my doctor said, "you can help everything but not
your genes", what can you do?
Later, participants presented descriptions of relatives, their cardiovascular health and
their lifestyle; participants seemed to use the cases to build a theory of lifestyle being
overridden by heredity. The following extract begins with the last case described:
Emma: my husband takes full cream and everything like that and he gets up
in the morning and goes to bed at night and there's nothing ever wrong with
him, and he's got more energy than I have
Ursula: he's very lucky, very lucky
Emma: he says he comes from good stock! (laughs)
Ursula: he's not far from wrong that's probably right, he comes from good
stock, there is a lot to that.
HE: do you think any of it is luck?
Ursula: it's got a lot to do with your family and as you say if the family has
had certain things you know, erm for my dad it was a heart attack, my mum
was cancer, erm
Ella (70yrs): well my father I said, my husband has had two bypasses, his
mother died of a heart problem, his aunts died of heart problems you know
Emma: yes
Ursula: it's in the family
Cath: I do think that even though you have a tendency to these things, you
can help yourself, you know I would say you can, I do believe that, that you
can take exercise and eat healthily and you can try and relax as often as
possible and I think that does help
The examples participants gave contributed to their conclusion of the dominance of
genes over lifestyle; only one participant in the group (Cath) seemed to think that
lifestyle could intervene, whereas the other participants seemed to equate heredity
with a degree of inevitability. In another focus group (la), where similar conclusions
were being reached, there was also some recognition that heredity was not the only
risk:
David (71yrs): yeah but other people who are not from families with heart
disease, do die of heart disease
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Applying the same belief to her own perceived risk, Morag3 implied that due to no
family history of heart disease, she had no reason to worry about her low ABPI:
Morag3 (64yrs): ...I imagine that people who have a concern about their
health might well want to participate regardless of whether it's aspirin or
placebo. I think people where there's a history in their family of strokes and
high blood pressure, may have more concern than I had.
In contrast to the cases of people with unhealthy lifestyles not being at risk due to
"coming from good stock", Imogen 1 presented cases of those who despite leading
healthy lives were afflicted, which she found unfair:
Imogen 1 (61yrs):...but as I say I never smoked and my mother never
smoked, and you see my brother never smoked, but you see they both had
heart attacks.
HE: yeah
Imogenl: I see people-
HE: how old were they?
Imogenl: my mother was 53 and my brother was 60. I mean I can never
understand when I see people how they abuse their body by- you know you
see them drinking, I'm- fair enough you can have a drink, don't
misunderstand me I don't- people have to live their life, do what they want to,
but when you think how they abuse their bodies you know.
Some participants were concerned due to their own family history of heart disease,
but others regarded such worrying as unnecessary:
HE: how about like, some people talk about family history of heart related
problems, have you got anything in your family?
Martha2 (65yrs): well my brother had a heart attack three years ago, when he
was um 70, er he didn't know he'd had it...()...And my mother died of a
heart attack when she was 77..()...but she'd asthma and bronchitis, lots of
chest complaints
HE: so had that influenced the way you thought about your own risk?
Martha2: no, not really, no, family history, medical history does...it's there
but I don't think it does to dwell on these sort of things, you just you know
everyone's different.
Whilst Martha2 felt that individual differences could counteract heredity, a few
participants went further emphasising particular differences between themselves and
affected family members which they seemed to use to minimise their personal risk
perception. Echoing previous findings (Davison et ah, 1989), distinctions were made
regarding individuals' 'build': for example, in focus group lb, participants were
discussing whether they had a family history of heart disease. Lorraine contemplated
her husband's family history:
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Lorraine (52yrs):...my father-in-law and one brother-in-law, but interestingly
enough, they probably, they're different physical types if you know what I
mean, my husband and his other brother are much more like their mother, so I
don't know whether that has something to do with it
A more common distinction related to lifestyle, in particular participants whose
relatives smoked. For example Keith 1 distinguished himself from his father
regarding two lifestyle risk factors, smoking and stressful work:
Keith 1 (59yrs):...I mean he used to go down and started working in the pub
at nine in the morning, I mean he didn't get back home until about 11, well he
came home during the day, after he'd shut you know when it was- he used to
come home, so it was quite a long period ofwork. He smoked as well which
didn't help, I mean he smoked- I mean people knew smoking was bad for
them thirty, forty years ago but people didn't- weren't informed, told. () So
I've never smoked or- my mother smoked, my sister smoked, my father
smoked, but I never had any desire to smoke, I don't like the smell of it and
various things...().. .But anyway so what happened was he'd sort of had these
problems, and he had three or four strokes or three or four heart attacks, he
died of that eventually. So it was I was at the doctors and I thought, "well, are
these things gonna happen to me?" I mean they're all saying genes are passed
from each other to each other so that was it so he took my blood pressure
Despite the distinction between his own and his father's lifestyle, he reported both
his father's history and events in his peers as influential on his decision to get a
check up. When I asked him which he thought was the most significant, similarly to
the discussions quoted above, he concluded that family history was most dominant:
Keith 1: well I would say the biggest risk factor is the genes
HE: yeah
Keithl: I mean what is hereditary, you can try and, you can't change it, but
you can try and do something about it, but I don't know really if your genes
are built that way, that your family have all heart problems or whatever that
you can do much more about it. You can try and modify your lifestyle and
various other things, but I don't think I suppose what you might do, you
might cull all things but there's no way you can avoid it.
Echoing the findings ofEmslie et al. (2001) there was a tendency not to attribute 'old
age' heart attacks to family history, thereby providing another method of
distinguishing between oneself and affected family members. For example:
Morag3 (64yrs):.. .1 was interested in the study because both my parents died
from strokes
HE: right
Morag3: but then well not my father- I wouldn't have described him as
elderly although he was early seventies, my mother was towards mid eighties,
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and an aunt, dies two years ago from stroke, again she was late eighties so
you can't really comment on that
HE: so you feel it wasn't really family history
Morag3: well they weren't young people to die
A few participants concluded that there was little to worry about regarding family
history despite providing examples of a couple of cases of heart disease and some
strokes. For example:
HE: yeah um.. .you mentioned before that your Dad had a heart attack
Alison2 (55yrs): he died of heart trouble
HE: so have you got any other heart disease in the family?
Alison2: no
HE: how about your grandparents?
Alison2: there was only Grandma (maternal) who had a dickie heart, my
mum did tell me when I went on this, um she had a problem with heart but
nothing drastic, I mean she died of cerebral haemorrhage, as did me other
Grandma and me Grandad (paternal) he didn't die, he just had a stroke didn't
he, it weren't heart with him?
Sister: it were Parkinson's wan't it? what about Grandad (maternal)
Alison2:1 think it were just a stroke weren't it?
Sister: I can't remember now
Alison2: but it definitely wasn't heart, you know I mean even me dad's
brother it were cancer, as is with his sisters weren't it?
Alison2 did not seem to see a connection between heart disease and stroke despite
the shared risk factors. In reflection this could have indeed been due to the terms I
used in questions, and my tendency to use the phrase 'heart problems' to reflect local
vernacular.
Generational comparisons
Participants often distinguished between themselves and other family members by
noting the differences between generations regarding cardiovascular risk factors; in
particular when discussing diet, many participants reflected on the post wartime diet.
Some now blamed this for current cardiovascular risk, for example Dennis4
attributed his wife's premature stroke to a high fat diet during her schooling:
Dennis4 (75yrs): my wife's been on aspirin for years, well it'd be about mid
thirties
HE: oh right
Dennis4: it was the furring up of the arteries.. .and thinking back she had a lot
ofmilk and beef dripping as a child.. .and it could have been something to do
with it
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Later...
Dennis4:1 think in my wife's case, it caught up with her.. .her diet as a school
child. You know quite a lot of milk...as a school-, you know they used to
give you a third of a pint of milk er free with your morning break and they
went on until years after the war, they still...But I mean...we always liked
milk, there were some boys who wouldn't take it so we'd have an extra one
often (laughs)...but I mean...the wartime diet was quite good...quite a lot of
suet puddings to fill you up, dumplings and suet puddings
A couple of participants noted how current dietary advice contradicted many of the
recommendations in the post war diet, for example:
Graham3 (58yrs): I find diet's a bit harm- because here's another thing again
looking back on life, when I was at school we were always taught that the
healthy way- to be healthy was er farm produce...butter, eggs, cheese, milk,
and now these are the things that are, "don't eat these things" you know,
"cholesterol"
However, the majority of participants who discussed the post war diet considered it
healthier than the diet that they attributed to younger generations. For example focus
group lb concluded that rationing was healthy, similarly focus group la:
Jen (65yrs): that's what we were brought up to isn't it? Healthy diet
Julie (56yrs): and I think after the war as well, the diet was healthy because it
was minimum
Aileen (67yrs): yeah the diet's worse now I think
Jen: I mean I still like my mince and potatoes
Julie: and two veg!
Jen: I like anything that's homemade
Julie: but I think the youngsters as well, I mean they're working all day and
they're going home, they're not want to start doing that like we did at home,
when we were children, they've not got time.
Some maintained this viewpoint even after discovering high risk attributed to their
diet. For example Wendyl who had recently changed her diet drastically including
cutting down from two eggs a day to two a week due to discovering high cholesterol:
HE: 'cause some people I've spoken to talked about the post-war diet, and
you know you were encouraged to eat eggs and butter and these things
Wendyl (55yrs): in saying that, we were lean, we were healthy because it
was dieticians that arranged it for the nation and you got your amount for
your week...
Participants often commented on the sedentary lifestyle of younger people today
compared to the very active lives they led when young; often they felt this activity
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had counteracted the high fat diet at the time. Several participants felt that the whole
'way of life' had evolved into an unhealthy one, for example:
Alison2 (55yrs): I think it's worse yeah. I mean we were told dinner time
were 'ere, you sat down, you ate what you had in front o' you. You had
(proper) meals and nowadays everything seems fast food, I mean when
you're shopping, you've only got to look in somebody's trolly, and the
biggest majority of stuff is there square boxes that you just plonk in
microwave...and a lot of young ones don't even know how to put a proper
meal together or even do a stew. So I feel that food wise, a lot of young ones,
they're more at risk aren't they?
Many participants emphasised the benefit of a 'haeme made' (home made) diet, in
particular traditional home made Scottish soups, which they regarded as healthier
than what today's generation cook and eat. Many, like Alison2, felt that today's
generation's inability to make home made food was a particular contributor to the
dietary problems, and thus heart disease. These participants seemed to be associating
healthiness with the morality ofputting all the work in oneself as much as the quality
of the ingredients, echoing Ruston and Clayton (2002) and Blaxter and Paterson
(1982).
On the contrary, other participants felt that younger people today were healthier, for
example Gordon 1 and his wife compared themselves to foreign students they had
hosted and their own children. This was linked to awareness of food and health that
was seen as much more publicised than when participants themselves were younger:
Gordonl (67yrs): so yes, the younguns what we're saying is, the younger
ones are starting to get maere health conscious...()...aye, tell you this Helen,
I'll say about when I was in the- we didnae care about this, aye we know now
but we didn't know at the time, at that stage. Cause we were what you'd say
Wife: ignorant
Gordonl: aye well we had tellies just, but it's a wee bit maere broadcast now
you know, it's on television
Wife: well there's more health on the TV
Peer comparison
Several male participants commonly talked about how hearing about heart attacks in
their peers had provoked sudden assessment of their personal risk. Typically they
referred to friends from their past such as school friends which may have particularly
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personalised the event due to the shared age. This experience had made a few of
these men worry, it made Peter2 re-evaluate his lifestyle:
Peter2 (55yrs): I never really thought, you know it's one of these things, I've
known people that I went to school with that have died early, as a matter of
fact I bumped into a fellow I used to know months ago and he was talking
about these four guys that we used know, you know when we were 18, 19, 20
and that, and they're dead, various things, one was a heart attack, it does, it
comes home to you and you say "well I'm at that age", and you don't know
what's round the corner sort of thing you know
HE: did it make you think about your own health that?
Peter2: er well aye I suppose it did I mean I always was conscious that maybe
you shouldn't eat too many fatty things you know what I mean cause I know
it's not good for you...
However these participants typically distinguished themselves from the affected
peers for example regarding lifestyle, thus reducing their own risk perceived:
Warren2 (72yrs): but not, but not heart attacks. I mean the older you get, the
more people you see that die before you, from heart attacks, um we moved in
here 5 years and there was a young guy, 40, and he helped us with all the
outside decorating and inside decorating when we moved in 5 years ago, and
he took a heart attack at 40 you know and died. So I see heart attacks but
strokes are much more common I think, so
HE: so has that been in your sort of friendship group or in your family or?
Warren2: friendship group, yeah, friendship group and um, but that's only
one, that's only one, but I suppose I tend to think of strokes as being much
more common than heart conditions
HE: when this has happened did this made you um sort of re-evaluate your
own risk of stroke at all?
Warren2: probably and again I suppose I had the feeling that I'm less likely
to suffer from them than a lot ofmy peers um simply because of the fact you
know ofmy past lifestyle
To summarise, comparisons with others were often made when people considered
and discussed cardiovascular risk. Due to the salience of family history in people's
ideas about the aetiology of heart disease, participants often reflected on this and
generally seemed to conclude either that there was or was not family history of risk
in their own family. For those who considered themselves to have a family history,
this was often mentioned as being in their thoughts when contemplating attending
screening. However when applying perceived family history to their own personal
risk, participants often made distinctions between themselves and the affected family
members regarding physical type, lifestyle or differences associated with differing
generations, often minimising their personal risk perception. Similarly while
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cardiovascular events in peers were discussed as provoking analysis of one's own
risk due to the shared age, distinctions which were often made regarding lifestyle
seemed to minimise personal risk perceived.
Lifestyle
Many participants described in detail the healthiness of their current lifestyle. For
many of the women this was associated with being conscious of keeping their weight
under control which had been part of their lifestyle for a number of years. Many
other participants discussed their current healthy lifestyle in comparison to an
unhealthy lifestyle they had led in the past; the change had typically having been
triggered by a cardiovascular event, a diagnosis, or another life change such as
retirement. Whilst these participants' views on cardiovascular risk were interesting
and important, I was particularly interested in hearing from participants who still
engaged in 'unhealthy' behaviours, regarding their attitudes towards the risk arising
from continuing to engage in such lifestyle. A couple of participants pointed out that
'unhealthy' behaviours were enjoyable:
Andrew (focus groupla, 59yrs): ...surprised me that I was so healthy cause I
smoke like a chimney and drink like a fish
(laughter)
Later...
Andrew: I've not gone changing my life, I still smoke, I've not stopped, I still
smoke, I've not stopped drinking, I always eat the same things and I eat
what's nae good for you, cause these health foods and that I don't like 'em.
Putting it quite bluntly, I dinnae eat to look after my heart, I eat what I like
David: he's gonna die happy
(laughter)
In focus group settings, disclosure of unhealthy behaviours was often accompanied
by laughter from fellow participants. There was only one instance where a participant
challenged another on their lifestyle, the rest of the time the setting may have seemed
a comfortable place to admit unhealthy habits.
A few participants weighed up the potential risk from aspects of their lifestyle
against wanting to enjoy life, for example:
Richardl (54yrs): ...I think I'd a fair idea what the risks were already and I
knew I was taking a certain amount of risks, I'd given up smoking a long
time ago
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HE: oh have you?
Richardl: oh yeah I don't smoke, I haven't smoked since I was er in my
thirties and er.. .but that was partly because it was silly, it was costing me a
lot ofmoney, you know.. .but er I don't actually think I'm a terrible excessive
lifestyle so I don't think I've a really high risk, I've probably got more risk
than I need to have, I could keep fit or I could eat better, there's no question
about that, but um actually I've got this strange idea that you might as well
enjoy life while you've got it, and um the idea that you should sort of drag on
living like a monk or a nun thirty or forty years, just so that you can manage
another 10 years when you're 80 strikes me as being a pretty stupid way to
live! (laughs) you know it's I mean different people see things differently but
that tends to be my approach to things you know. If you cannae enjoy it, you
might as well not be there, you know, so. That's maybe not answering your
questions but...
Richardl seemed to see the possible effects of lifestyle as concerning the older end
of the age spectrum rather than affecting health at his age (50s); some fatalism
emerged in his account:
HE: so do you see not yourself as the type of person to get heart disease or?
Richardl: well I wouldn't say that, no, I'm the right age group, and I eat far
too much, I eat all the wrong things so yeah I mean- but I'm not really
bothered with heart disease in that sense, you've got to die of something you
know! (laughs) frankly I think I'd rather die of heart disease than some
lingering cancer, and it strikes me that if you survive long enough you die of
cancer eventually anyway! I mean that's the bottom line you know, you either
die of something else or you die of cancer. But you know you're gonna die of
something some day, I mean even when you live to 101, you eventually kick
the bucket don't you! (laughs)
HE: so do you see heart disease as a kind of favourable, preferable
Richardl: it's relatively preferable way to go, it's quick...in general, I mean
if you get a stroke obviously it's (not) but you know but um you know a
straight forward heart attack, most folk would die of that pretty quickly you
know.
Richardl's view of regarding heart disease as preferable echoes findings of Emslie et
al. (2001), demonstrating the lack of severity associated with heart disease for many,
and illustrating another reason for not wanting to make lifestyle changes. Some
participants who happily admitted engaging in several unhealthy behaviours were
quite critical of people who did lead healthy lifestyles such as vegans and 'health
freaks', for example Alison2 happily admitted unhealthy aspects of her diet.
Comparing herself with her health conscious friend she saw no benefit, only negative
effects from her friend's lifestyle, which she seemed to use to justify her own
lifestyle:
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Alison2 (55yrs): well I eat- my sister thinks I'm a pig! (laughter) no I always
have a cooked meal every day, if not a cooked meal, a salad, er there's fruit, I
eat fruit, er I always have to have a pudding after everything, which is best
part o' meal which can be anything- apple pie, custard, cream
Sister: half a gateau
Alison2: half a gateau! Meringues! And I'm always a nibbler, bars of
chocolate, sweets, and I just drink coffee, very rare do I drink water, unless
I'm taking tablets. As I say I just eat what I want
H and you feel OK about that?
Alison2: yeah, I mean I don't feel ill, but I'm eating more chocolate and
sweet stuff than probably what I should do, but I do get me veg and me fruit
every day
HE: uh huh, how about um do you smoke at all?
Alison2: yeah I do smoke yeah
HE: so with all these things put together I mean did you expect to have some
sort of um risk of heart disease
Alison2: no not really
HE: or where do you see yourself compared to other people?
Alison2: I look sometimes at my friend who I go swimming with, she takes a
lot of these what do you call 'em? From health food shops
Sister: oh heath things, that word, there's a special word she uses
HE: what like vitamins?
Alison2: is it organic? No not organic
HE: what homeopathic things or something?
Alison2: something to do with like natural stuff and what-have-you, and she
always seems to be aching or tired or something, you know vitamin C tablets
and what-have-you, and I don't take any vitamins or anything except just eat
me food, and she watches everything on her diet because of her weight and
also cholesterol. She never eats potatoes, always pastas and stuff like that and
chocolate no sweet stuff, she'll have a yoghurt, but she eats a lot of fruit and
stuff, but during winter time especially she's always really achy and what-
have-you, and I always feel, well why take all that stuff if it's not doing you
any good?
Echoing Davison et al. (1992), some participants drew upon fatalism and lay
awareness of anomalous deaths and survivals to point out fallibility in the direct
lifestyle-heart disease link, proposing that this awareness could be a reason for many
people to continue an unhealthy lifestyle:
Yvonne (focus group 4b, 72yrs): the west of Scotland diet you know, I dare
say, well I think we've got the second highest heart disease rate in Europe or
something like that, so there must be something in it
Lorraine (52yrs): I think as you're saying though, it's not as clear cut as that,
and what's easy is to point the finger at the lifestyle, if it wasn't for the fact
that I'm sure all of you sitting round here can give you examples where
there's they would say this was not the case. So I think people tend to get a
little bit, "oh what the hell"
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(laughter)
Wayne (69yrs): eating healthy foods has a lot to do with it...
Lorraine: but I'm meaning, you know it's not quite as simple as that, the
correlations between the two things
A few participants implied that as their unhealthy lifestyle had not yet had a
(noticeable) effect on their health, they saw no need to change, particularly when
they had 'got away with it' for so long:
Fergusl (72yrs): ...I drink and smoke, and I do all the things that are wrong,
and every time I go for a- my wife- every time I go for a medical, er I come
back from the medical, the doctor, I come back and I tell her, "how d'you get
on?", I might leave the house with house with a wheezy chest and all that and
this, and when I come back, say "my heart's fine, my chest is clear, my blood
pressure's OK" and she's totally amazed, she' totally amazed at the whole
thing. I'm the one that should be ill, you know
HE: so have you ever thought you know you say you do all the wrong things,
have you ever thought therefore that you might be susceptible for heart
disease?
Fergusl: not really no, it's too late to think about that isn't it? Erm no, no.
Och aye, everybody thinks about it you know but, it's not- to be honest with
you, it's not gonna stop me. I tried stopping- we both tried to stop smoking. I
do drink to excess sometimes, you know, er.. .not just late now, you know
There were a handful of participants who shared this attitude of knowing the
potential consequences of their lifestyle but due to no symptoms or clinical diagnosis
of effects on their health, they were unmotivated to change. In some cases, even a
diagnosis of increased risk did not motivate change, for example Alison2's raised
cholesterol result:
HE: so how did you- what did you do to try and lower that- did you go on
medication or anything?
Alison2 (55yrs): no, nothing. She told me- she asked me about my dairy
intake, and er if I have butter on anything, I have lurpak and I have butter on!
So you can see you teeth in it and if I have cheese, I have cheese. And she
suggested I just stop having butter altogether, and I says, "well I can't eat
bread with margarine on" I had enough eating bread dry when I had gall
bladder troubles so- I honestly didn't do anything, I didn't go on to a diet or
anything, I just ate me chocolate as usual! Me cream buns, I kept me butter
on and everything and when I went back, it were bang on- in fact it were
under what it should be, so that were it. naughty girl!
Alison2's view on her lifestyle was backed up by her second cholesterol test result
that was lower despite making no changes to her diet. I asked Fred2 (aged 62) what
would make him quit smoking, it seemed it would require a major event:
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Fred2 (62yrs): I don't know, it's funny that you should say that you know I
keep looking to the future and saying oh you know, "what can happen that
would make me stop?" Apart from maybe taking a heart attack you know,
and then someone saying, "right you know, because it's smoking related,
you've got to stop." But er no, 1 don't know um I keep looking for some
purpose to say, "well that's it, you know I'll stop." So I've not reached that
decision yet.
A few participants justified continuing an unhealthy behaviour as they concluded that
the rest of their lifestyle was healthy so they could 'get away' with one risk factor,
for example:
HE: does it make you think about your risks of heart disease, do you ever
think about that about smoking's effect?
Beatrice (focus group 2, 75yrs): yes! But that's all I do!
(laughter from other participants)
Beatrice: of course you know about it, you read The Lancet, you read articles,
you read, you know their findings and various drugs...
A couple ofparticipants whilst aware of the risks from the lifestyle that they engaged
in, seemed unable to apply this to themselves:
Harold2 (63yrs): well here you know I said this before, I really can't
understand why I took a heart attack, in the sense that I'd always worked, but
then again I look back on my life, I think maybe the smoking and maybe
taking a drink didn't help, you know because I was always active you know
and I worked 7 days a week and you know
HE: what is the sort of person that you see as the type of person that would
have a heart attack different to yourself?
Harold2: well, that's a good question in the sense that er...I would say a
person that doesn't work, and smokes and drinks, and he's not getting any
exercise, as I say I was always active in the sense that I felt when I was
smoking and drinking I was getting it out o' my system
HE: yeah
Harold2: you know you can sweat drink out your system but I don't think you
can sweat smoke. I think that my main concern I think is the smoking
contributes to my heart attack rather than the diet because as I say I was off
the drink for a year, when I took the heart attack you know. I don't think I
live any kind o' life that would contribute to my heart attack in a sense you
know except when I was smoking and drinking, but then again as I say it was
9 year after that I took that, but maybe it was a build up you know, you know
in a sense that it was coming and I didn't know it, no
As illustrated, despite stating the main cardiovascular risk factors as smoking,
drinking and being unemployed, and admitting that these factors applied to himself,
Harold2 still questioned why he had a heart attack.
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Altogether all participants showed an awareness of the risks of engaging in smoking,
drinking, eating unhealthily and not being active. However, those that reportedly
continued to engage in one or several of these behaviours provided justification or
explanation for their behaviour ranging from awareness that certain individuals can
'get away' with such lifestyle without noticeable effect on their health, to admitting
that engaging in such behaviours is enjoyable.
Scottish Identity
Many participants spoke about heart disease being a particular problem for Scotland,
thus the Scottish identity was often regarded as increasing one's risk, or more often
as an explanation of one's risk. Where participants did not raise this issue, I
introduced the issue. In most cases the Scottish lifestyle, in particular diet, was seen
as central to the problem, for example in focus group la:
Aileen (67yrs, DEPCAT 2): but it's such a problem in Scotland isn't it, heart?
(agreement)
HE: do you think that- have you got any reasons for that?
Aileen: diet, diet
David (71yrs, DEPCAT 1): Scotch pies
Aileen: pies
Andrew (59yrs, DEPCAT 5): they say it's diet but we also drink a lot
Aileen: we lived in England for 30 years, and we came back and I was on the
bus going through Glasgow and the thing I noticed more than anything else
was how fat people are, not everybody obviously, but the number of
overweight people that I saw in Glasgow. Not just in Glasgow but I think this
is something in Scotland
Other participants saw the diet as embedded in the culture:
Richardl (54yrs, DEPCAT 5): it's to do with diet, um I would think that's
probably true, you know we don't eat a lot of things that help ameliorate it,
but we do eat a lot of things that exacerbate it, you know I feel that's right
you know. If we eat fish, we fry it in batter, and probably do it in lard or
something like that, you know it's that kind of thing you know, I'm sure
that's right. I wouldn't eat a lot of the sort of things that are probably better
for you. and the lower income, the less likely we are to do it. You know I
think that's probably true in the North of England to a certain extent as well.
Um it's- its just traditional diets.
Similarly other participants felt that diet, and lifestyle, was passed on through
families:
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Miriam3 (73yrs, DEPCAT 1): aye there's hardly a week goes by then they're
on about the bad diet and...
HE: what do you think about that?
Miriam3: I think that they're just bad habits, that they're brought up to have
greasy chips and burgers and it's handed down from father to son, um I dare
say it all started in the days when- there are lots of the foods that we take for
granted now-just weren't available
Later...
Miriam3: I think it's what they've inherited...I think it's what they've
inherited, poverty um lack of experience.. .1 think they smoke more cigarettes
than anybody else
Another participant and her husband reflected on the lifestyle that they had been
brought up on, suggested a further explanation: the industrial history:
Amy2's husband (DEPCAT 3): generally as regards the West of Scotland I
think there was always a bad diet we had in the West of Scotland, we were all
the same, you know eating sliced sausage and bacon and egg and
Amy2: my mother used to say, "oh aye, the fat's good for your tubes!"
(laughs) she didnae tell me it was blocking up my tubes
Husband: and fish and chips and things like that
HE: yeah
Husband: and the lifestyle generally you know
Amy2: go for a drink
Husband: heavy drinking, heavy smoking
Amy2: aye
Husband: and besides that, when it was an industrial area, it had all the
pollution here
HE: yeah
Husband: you know so it's clean now but when we had all the ironworks and
steel works and coal mines and coal fires
Whilst these two saw the environmental effects of the industrial history as important,
another participant suggested the industrial history as affecting the pace of life and
thus lifestyle:
Daniel4 (54yrs, DEPCAT l):...they must do something in the west of
Scotland, because the west of Scotland is bad
HE: yeah?
Daniel4: really, because it's an old industrial idea, they work shift work, eat
at all hours, drink heavily, and that hasn't changed. The west of Scotland- the
difference in between the west of Scotland and the east um, life's a lot slower
on the east, the west of Scotland is what we call a rat race, they're always
rushing about to get here to get this done
A fair number of participants attributed the Scottish diet to the climate; participants
spoke about healthy food (typically salad) not providing sufficient warmth on a cold
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Scottish winter evening, rather large helpings of hot meaty meals or fish suppers
were needed. Similarly drinks of tea were seen as preferable to water. Interestingly a
couple of participants felt that the climate had a more direct influence on physical
health:
HE: you mentioned before, about the Scottish diet and stuff, do you think
that's a particular problem in Scotland?
Monical (66yrs, DEPCAT 4): well I think the weather might have something
to do with it as well, you know all the damp that we get, you know they say
that's not very good for you. That and that's chest and heart I suppose you
know.
Many participants regarded the bad Scottish diet as immersed in the widespread
poverty particularly in Glasgow:
HE: you said about the West of Scotland diet and so do you think that's all
linked in?
Moiral (53yrs, DEPCAT 4): yes I do, I know that you know the deep fried
mars bar joke tends to be overplayed, I also know that even in my lifetime, I
mean when I was a little girl you just didn't see things like courgettes, they
just weren't there. Um so in that sense I think um the lifestyle, the diet, the
heavy smoking, the addiction to sweeties because we also have an appalling
er record for tooth decay, that's really bad. Um there is a lifestyle there and I
do think it's heavily linked with poverty, whatever anyone says, of course it's
linked with poverty, it's linked with a lack of hope about having some kind of
reasonable future in terms of employment and so on and so forth.
HE: 'cause people talk about the Scottish diet, but the West of Scotland...?
Moiral: I think it is possibly particularly the West of Scotland, and I think it's
not everywhere in the West of Scotland, but I think Glasgow's one of these
cities where you can lead a very pleasant middle class life and you don't need
to see the nasty bits, if you see what I mean, you don't have to confront them
and it's therefore perfectly possible to forget about them if you see what I
mean.
A couple of participants went into great depth when discussing the influence of
poverty on the lifestyle in deprived parts of Scotland, for example Owen4:
Owen4 (52yrs, DEPCAT 6 but occupation suggests more advantaged):...And
I think (the trial)'s just useful from the point of view in a further sense of
getting the public to relate to medical research and the importance of it, and
in the context of Scotland with the very sad medical history that we have as a
nation you know I mean so it's even more important.
HE: A few people have mentioned this Scottish thing about health and what-
do you have any sort of opinions about that- why do you think it is?
Owen4: well it's a deep seated cultural pheno- issue but er I mean I don't
think it's gonna change overnight, I just hope that in the context of um what
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has been achieved in other parts of Europe in terms of improving health that
you know that we in Scotland could do the same.
Owen4 continued to go into great detail about the measures that Glasgow city
council were undertaking and his opinion of them, but also mistakes he believed they
had made, such as closure of swimming pools in schools. These extracts illustrate his
points:
Owen4: And I think that it's very easy for people like myself who're sitting
there in their middle class lifestyle with a reasonable income and their kind of
family and personal background, to take a family to places where they can
learn to swim and where they can get exercise and encourage them to do it. I
think it's very easy for folk in that situation to overlook the fact that for many
people in Glasgow, given their personal and financial circumstances and their
family circumstances, that they can't do that, they don't have the background
in doing it, so you have to provide sports facilities and exercise facilities as
conveniently to people as you can.
Later...
Er you know because again it seems to be that these messages have got home
to the more articulate better educated wealthier section of the community
anyway, but they havenae got to the more deprived and disadvantaged section
of the community in the same way and that raises the question that can you
ever really solve all the problems in the health sector in Glasgow and parts of
Scotland without solving the social problems that make people disregard their
health in the first place. I'll shut up there!
Altogether whilst heart disease was seen as a particular problem in Scotland due to
the typical 'unhealthy' lifestyle among other factors, the problem was seen as
complex and embedded within historical, cultural and social issues, particularly
relating to poverty, which were seen as very difficult to change, and an issue for
those at the policy making level. However, several participants may have used the
Scottish identity as an explanation for their own increased risk so as to remove some
personal responsibility.
Clinically diagnosed risk
Several participants implied they would wait for a clinical diagnosis of risk or a
condition considered a risk factor for cardiovascular disease before changing their
behaviour. An example quoted in the screening chapter was Joyce4 who, despite
being a smoker and admitting she could make other improvements to her lifestyle,
considered herself at no risk due to a normal ABPI. For these participants there was
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an implication of having 'got away with' their unhealthy lifestyle as there was no
symptomatic or diagnostic indication that the lifestyle had had a physical effect.
Many participants seemed to treat clinical measures ofblood pressure and cholesterol
as a black and white issue: a cut off point above which was 'risk', and below which
was 'no risk'. Several participants seemed to be particularly focused on the numbers,
for example:
Amy2 (76yrs): and very last thing at night, they said to me my cholesterol
was 7.5,1 think and I thought, "my cholesterol's never been 7.5" but I mean it
had been 6.5, we got it down slightly but I now realise why I'm on it, I mean
Dr C said to me, "well...your cholesterol comes from what you eat, and the
rest of it is what you make in yourself' because when the two of us went onto
a [diet] to- you know this was a while back, about the cholesterol, he
[husband] went down and mine went up (laughs), so I thought, "well now I
can understand why his maybe went down and mine went up because I'm
making it"... so I take a tablet at night, pravastatin.. ..So they give me a blood
test every so often, er can check up whether-1 don't know how they count it
you know, if it's getting to high and so on
HE: and how's that now, has it levelled off?
Amy2: no, it hasn't nearly levelled off they never said it levelled off, but it's
not going up high enough to take me off this stuff. I don't like- well I like
taking the pravastatin because it certainly brings it down, my cholesterol's
now down to 5.5.. .which is acceptable.
Focusing on the numbers of the results may have emanated from participants' GPs'
use of the numbers:
Graham3 (58yrs): I have a lot of time for my doctor I mean he's very
meticulous... if you're one digit out, he will try and get that digit down to
normal. He says "while you're here I'll just check your blood pressure and
that "oh my God" he says, "that's far too high" and took blood sample and
what-have-you, urine sample, made provisions for me to go to the (hospital)
A couple of participants spoke about these measures as being directly related to
behaviour, for example Rebecca3 felt her blood pressure revealed how she had been
behaving:
Rebecca3 (73yrs): ...I go down to the surgery, I think I'm down there next
month, sometime and erm she always takes my blood-, the nurse always takes
my blood pressure, and then she might say- well the last time I was down
there about 3 weeks ago...
HE: uh huh
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Rebecca3: ...and I was just the same as I was the time before, but slightly a
little bit up. Because if it's natural, I've been a good girl, but because it's up a
bit, I haven't been very good! (laughs) this is our little joke you know.
Despite many treating cut-off points as black and white, members of focus group 4b
discussed how there seemed to be inconsistency between the cut off points that
different doctors used for diagnosis:
Lucy (57yrs): so do you not check up every so often?
Harriet (61yrs): I go maybe every 6 months I go...I used not- I never asked
the number, it would just be "oh that's alright" and now it's like "well um
what's the number?" then I realised what the numbers were, because what
one doctor says is not always the same as another, one doctor might think that
140 over whatever 95 is fine whereas another doctor might think "well no it's
not" 'cause they've done that before, one said totally different to another, you
thought you were quite- but I wasn't at all. So I think there is a quite a wide
difference in how doctors see blood pressure, I don't know maybe I was just
confused I don't know about that
Jed (57yrs): I always thought that it was fairly factual, that there was a clear-
cut distinction that whether your blood pressure was low or high
Another participant noted how practice guidelines seemed to change regarding blood
pressure monitoring:
Keith (59yrs):...my wife, she's had to go for an ECG, because the doctor has
changed their ideas about blood pressure at the practice, I mean before I- I
went three or four times over a period of time, and they actually average out
of things are done or not done. But now it seems that they send them off for
an ECG, I think she's had her cholesterol checked, her blood was checked I
think as well. I don't know all what they've done but they've done all that
before. She said to the doctor about it, and he had said "well things have
moved on a bit and we've changed our ideas. Before, if there was something
wrong with you, "here you are, here's a pill" that's it. Now their idea is they
want to check to see if there is something else wrong.
Such observations of perceived inconsistency and change could have reduced faith in
such clinical measures, however the majority of participants who spoke about having
the measures taken seemed to maintain trust in their GP's clinical judgement. Thus
the idea of being diagnosed as having high blood pressure or not, i.e. as a black and
white issue, seemed to prevail, and generally most treated such diagnoses seriously,
considering it a risk and saw the need for prescribed medication.
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ABPI:
In the screening chapter when presenting participants' differing reactions to their
ABPI result, I illustrated how many participants had not treated the measure as a
significant indicator of risk. To reiterate, several participants had misunderstood
and/or did not recall the meaning of the measure, and others had confused the ABPI
with standard blood pressure. Several participants, particularly those who had not
anticipated being at risk, searched for alternative explanations for the result, and
many latched onto phrases used by the research nurse such as "borderline" which
seemed to help them minimise the amount of risk perceived from the ABPI.
Low significance of the ABPI, and thus low perceived risk from a low ABPI, was
probably due to it being a novel measure compared to clinical measures of blood
pressure and cholesterol. There were mixed understandings of what the ABPI
measured and how this related to cardiovascular risk. Several participants struggled
to make sense of the condition of atherosclerosis; Jennifer2 complained that it was
not adequately explained:
Jennifer2 (61yrs): all I'd like to have known was more myself about the
furring of the arteries, because you werenae really told anything when you
went there, they just done it, I heard for myself, she said, "did you hear that,
there was a slow block" you could hear the block and then it was slow, so she
says you're a candidate- but I'd like to have known, has it not got any other
bit that's furring because, does you doctor know you go 'o that?
A few participants reported awareness of having poor circulation for many years and
wondered whether and how this related to their low ABPI:
Keithl (59yrs): I mean since I've been young, my feet have always been cold,
I mean I go cold quite quickly, so I've always had poor circulation in my feet,
so I don't know if that's maybe that could be because my blood pressure is
slightly higher?
Some made a link between the ABPI and their already diagnosed high blood
pressure, for example:
Cath (focus group 2, 63yrs): I was surprised because um I didn't expect to
have any tendency to that because I'd always been quite physical active and
you know and I was just surprised, but then I thought, "well if I've had high
blood pressure for a while that would be the cause of it, the furring of the
arteries
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A few realised the impact of their lifestyle on the condition, for example a couple
talked of the effect of a high fat diet on the arteries and a few participants realised the
impact of their smoking:
Peter2 (55yrs): I can always remember my father saying that "it greases your
tubes", what he didn't know was that it furs up your tubes!
Patricia3 (61yrs): .. .when the girl told me that I did have erm arteriosclerosis
in my foot, um then I was quite happy to take aspirin, but had I gone onto the
trial and been given a placebo then I wouldn't have had that benefit
HE: uh huh, so what um you said you were expecting to get this, why was
that?
Patricia3 well more or less because of the fact that I smoke...age group, and
because of the fact I smoke.
Despite awareness of the condition, some participants expressed little concern:
Peter2 (55yrs): I was hoping I would be alright, I think it was alright other
than er I believe she told me that as I did smoke at one time sort o' thing you
know because of that, I know smoking causes bad circulation
HE: yeah so it was slightly lower?
Peter2: slightly lower, that was she said aye slightly lower in the ankle than it
was elsewhere, er and I certainly have noticed er a few years ago I found my
feet were always warm now they're getting a wee bit colder. I mean they're
no' cold freezing, you know.
HE: how did you feel when she told you that at the time?
Peter2: it didn't really bother me because she say well you're-1 don't think it
was giving her any cause for concern sort o' thing
But later in his interview Peter2 distinguished himself from those whom he
considered prone to furring of the arteries implying lack of true awareness.
Overall there seemed to be much variation in participants' understandings of the
ABPI and atherosclerosis. Some participants showed awareness of the link between
lifestyle and furring of the arteries, and tried to make sense of the link with blood
pressure, whereas many others struggled. In comparison to treating more widely
known measures (blood pressure and cholesterol) as black and white issues with
diagnostic cut off points signifying increased risk, participants seemed to focus more
on the grey area regarding their ABPI diagnosis, for example as mentioned in the
screening chapter, their "borderline status". This may have been related to their
uncertainty regarding its meaning.
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Summary: perception of cardiovascular risk
In this final data chapter I have presented factors that contributed to participants'
ideas about cardiovascular risk, and how they seemed to use these factors to assess
their personal risk. Family history of heart disease emerged as a particularly
dominant risk factor; for many heredity appeared to be equated with inevitability.
However, when applying this to one's own perceived risk, distinctions were often
drawn between oneself and affected family members. Similarly, distinctions were
made when comparing oneself to affected peers, often focusing on lifestyle
differences. Awareness of the behaviours that increase cardiovascular risk was
omnipresent; continuation of such behaviours was explained in terms of enjoyment,
awareness of fallibility in the lifestyle-heart disease link, and lack of personal risk
from lack of noticeable physical effects or significant diagnoses. Lifestyle was seen
by some as embedded in Scottish culture and/or widespread poverty around
Glasgow. The Scottish climate and industrial history were proposed as having both
direct and indirect effects on health. Clinical diagnoses of blood pressure and
cholesterol were generally accepted as markers of cardiovascular risk, indicated by
numerical values. With the ABPI, participants focused on the grey area around a
diagnosis of risk; this could have been related to the novelty of the measure and
uncertainty regarding its meaning and the condition of atherosclerosis.
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Chapter 8: Discussion
Introduction
A central underlying theme in participants' accounts when discussing screening,
prevention, trial participation and cardiovascular health was that of risk; the risk that
participants perceived seemed to be related to their decisions and/or actions, or certainly
in their accounts of these. In this chapter, I will draw together the analyses of risk
perception in the data chapters to highlight its importance in participants' reports of their
behaviour regarding screening, preventing heart disease and participating in the AAA
trial, and relate this to existing relevant literature.
Perceived cardiovascular risk was not the only risk that emerged as important regarding
attitudes towards screening and prevention; perceived risk from medication, in particular
aspirin also emerged as salient. This chapter will first focus on participants' perceptions
of cardiovascular risk and how this related to attitudes towards screening attendance.
Second, I will discuss the relationship between these perceptions of risk and
participants' reactions to the screening experience. Third, I will discuss how
participants' views about preventive medication related to their perceived cardiovascular
risk and perceived risk from medication, in particular aspirin, and the interplay between
these two risks. I will discuss how these two risks and their interrelationship related to
attitudes towards participation in the AAA trial. Finally I will focus more generally on
the notion of risk and its usefulness as a concept in research. To conclude, I will discuss
implications of the findings for screening and prevention programmes and clinical trials,
and for further research in a similar context.
Perceived risk and screening attendance
As demonstrated, 'at risk' results were often unanticipated; various other reasons were
given for screening attendance. Exploring accounts and explanations revealed factors
that seem to contribute to participants' ideas about cardiovascular risk, the type of
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person regarded as susceptible to this risk, and whether they considered themselves at
risk or not.
Davison et al.'s (1991) research into lay beliefs about heart disease identified and
explored the notion of lay epidemiology: a dynamic process through which people
interpret health risks by observing, discussing and noting cases of heart disease in their
social network and as publicised through the media, resulting in an explanatory theory of
the type of person likely to experience heart disease: a 'coronary candidate' (Frankel et
al., 1991). Coronary candidacy comprised physical factors, social, occupational and
environmental factors, and personal factors, but also the importance of family history of
heart disease (Davison et al 1989; Emslie et al., 2000). Incorporated into coronary
candidacy were noted fallibilities including unwarranted survivors, anomalous deaths,
and recognition of the randomness of heart disease. Awareness of these fallibilities
contributed to fatalistic feelings about heart disease (Davison et al., 1991) and
challenged the efforts of health promotion.
As demonstrated in the data chapters, a very similar picture emerged in the present
research in terms of participants' ideas about a typical coronary candidate. There was,
however, a difference between the context of this and previous research: the present
research explored participants' ideas about cardiovascular risk within the context of a
screening programme and a preventive medicine trial, thus both the context, the
population (people invited to screening), and the topics covered in the interviews
(screening, preventive medication and the AAA trial) placed a different angle on the
topic, despite still focussing on heart disease.
Davison et al. (1991) described how the coronary candidacy mechanism operated in four
ways: retrospective explanation of other people's cardiovascular illness or death,
retrospective explanation of one's own cardiovascular illness, prediction of other
people's cardiovascular illness or death, and assessment of one's own risk of
cardiovascular illness or death. The latter is particularly pertinent to the context of the
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present research; the activity of assessing one's own risk of cardiovascular disease
appeared to have been provoked or at least heightened by the invitation to a screening.
From participants' accounts, the main factors that emerged of their ideas about coronary
candidacy will now be discussed and I will consider how these appeared to relate to their
own expectations of risk and screening attendance.
Family history
Family history of heart disease and the influence of genes were discussed by many
participants, many of whom appeared to regard this as the most dominant factor,
generally equating heredity with inevitability. Those who reported having heart disease
"in the family" gave this as a common reason for screening attendance. Some
participants with no perceived personal family history mentioned not needing to be as
concerned about other risk factors (such as the ABPI) as those with. Furthermore
"coming from good stock", i.e. from a family of "long livers", was regarded as an
advantage; participants described such individuals as fortunate due to their apparent
ability to "get away" with unhealthy behaviours. Participants were divided about the
extent to which they believed lifestyle could counteract the power of heredity.
These findings echo those of Emslie et al. (2001) and Davison et al. (1989) who found
heredity spontaneously mentioned by two thirds and a third (respectively) of their
participants as an important determinant of heart disease and health status (respectively).
Davison et al. (1989) divided participants' views of how heredity operated into three
groups of meaning regarding what was inherited: discrete physical attributes, one's
constitution, personality and behaviour. Participants in the present research seemed to
imply similar meanings; genetic dominance was particularly common possibly due to
the increasing amount of media coverage of genetic influence, for example the surge of
media articles surrounding the human genome project. Regarding one's constitution,
length of life was significant for some who reported wondering if "history would repeat
itself'. Inheriting personality was less discussed, but the idea of 'inheriting' behaviour
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featured particularly when discussing the typical Scottish diet, demonstrating a cultural
component to notions of heredity.
In a quantitative study, Hunt et al. (2000) reported that people who perceived themselves
as having a family history of heart disease were more likely to perceive themselves at
risk personally and to see behavioural factors as important in the development of this
disease. However, qualitative research by the same researchers revealed that perceiving
oneself to have a family history did not always lead to perceived personal risk and was
not a straightforward dichotomous construct (Emslie et al., 2001). Factors that
complicated predictive ability included making distinctions between the risk applied to
one's family as a whole and to oneself personally, looking for patterns in the number of
affected relatives, and discounting 'elderly' cardiovascular deaths. Similarly, Davison et
al. (1989) found that participants described two different sides of their family, and
individuals as "taking after" one or the other side. Thus, despite evidence of a family
history of a disease, an individual's personal risk seemed to depend on their perceived
similarity to the affected side. This was further complicated if individuals were regarded
as taking after one side regarding one factor (such as build), but the other side regarding
a different factor (such as temperament) (Davison et al., 1989). As discussed, there was
evidence for most of these ideas in participants in the present research; assessing family
history of a disease and its perceived relevance to each individual appeared to be a
complex process. However, participants usually seemed to have reached a conclusion of
either perceiving having a family history of the disease or not. Furthermore, assessing
one's own family history seemed to be subjective; events and cases seemed to be
interpreted in a way that fits with how a participant wanted to perceive them, thus could
reinforce their low risk perception or their feelings of inevitability. The presence of
family history was thus subject to very different interpretations.
Regarding perceived family history's relation to behaviour, Davison et al (1989)
suggested four possible ways in which those who have assessed their own personal risk
of inherited heart disease could apply their conclusion to decisions about lifestyle. Those
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who perceive an inherited risk could a) decide to engage in a healthy lifestyle to prevent
further increasing their risk, or b) decide that due to their risk there is no point engaging
in a healthy lifestyle. Those who perceive no inherited risk could a) decide to engage in
a healthy lifestyle to maintain low risk, or b) feel that their lack of inherited risk will
allow them to get away with an unhealthy lifestyle. These were not proposed as discrete,
explicit and conscious decision making processes, rather that the logic of these
conclusions is echoed in discussions of their thoughts on family history (Davison et al.,
1989). Similar logic was apparent in accounts of several participants in the present
research.
Fatalism
Fallibilities of the coronary candidacy, outlined by Davison et al. (1991), emerged in
participants' accounts in the present research illustrated by similar examples. The recent
death of a local young footballer served as a particularly salient case that participants
used to demonstrate the randomness of heart disease and an unwarranted death, and
several cases were presented fitting the '90-year-old fat smoker' (unwarranted survivor).
Whilst fatalism was proposed as inhibiting screening attendance in 'others', for
participants who demonstrated fatalism in their own accounts, it had not inhibited
attendance. It did however appear to contribute to ideas about personal susceptibility; for
some, "not knowing what lies round the corner" seemed to justify maintaining unhealthy
behaviours.
More subtle indications of fatalistic beliefs in the form of recognition of influences that
individual effort cannot overcome included luck or chance, genes, the social
environment and the physical environment (Davison et al, 1991). Perceived genetic
dominance has been discussed. Assessment of one's own family history of heart disease
can lead an individual to realistic perceptions of their own risk, but believing that
heredity is an influence insurmountable through individual effort demonstrates fatalism,
and, as mentioned, could inhibit preventive behaviours thus increasing one's risk further.
Also, any cardiovascular events that occur are likely to be attributed to heredity rather
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than personal behaviour. Regarding the social and physical environment, Scottish
identity emerged as a commonly discussed risk factor. Socially, poverty (in particular
around Glasgow) and the constraints upon lifestyle that it brings was brought up;
participants described social disadvantage as extremely difficult for those affected to
escape, without effective policy intervention at the local or national level. Thus, while
not talking fatalistically about their own life, they recognised the potential impact on the
more disadvantaged. Physically, the cold, damp, and dark climate was given as a reason
for the high prevalence of heart disease in Scotland, both as a direct influence on health
(although it was not clear exactly how), but also indirect through a diet higher in fat and
volume to keep one warm. This seemed to be brought up in a fatalistic manner.
Furthermore, the West of Scotland's industrial history was suggested by some as
influencing inhabitants' health both directly and indirectly through lifestyle, with no
clear operational explanation.
Lifestyle
All participants demonstrated awareness of lifestyle behaviours that increased
cardiovascular risk. However, this did not mean that all participants followed this
advice; it is a well documented finding that awareness of the risks from lifestyle is rarely
sufficient in provoking lifestyle change alone (for example Lupton, 1993; Gabe, 1995).
Many participants reported improving their lifestyle since they retired, had reached their
fifties or sixties, or after a cardiovascular related diagnosis or event, and several
admitted they could make further improvements. Others continued to engage in one or
more unhealthy behaviours, explaining this as due to enjoyment and awareness that the
behaviour was not the only risk and would not necessarily lead to a cardiac event. Others
referred to "getting away with" unhealthy behaviours and having "lasted this long"
without noticeable effects on their physical health.
The importance of the social and cultural context of upbringing emerged in generational
comparisons of lifestyles. When reflecting on the post-war diet and rationing, some
participants realised the likelihood that the dairy products in this past diet probably
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contributed to their current high cholesterol and furring of arteries. Others deemed it
healthier than today's generation's typical diet. Further generation differences focused
on the benefits of "haeme (home) made" food compared to today's culture of 'ready
meals'. Echoing Ruston and Clayton (2002), this seemed to be related to ideas about
morality: the act of working hard to produce a homemade meal seemed to be equated
with healthiness.
Age
Despite many participants advocating cardiovascular risk screening at age 50 (or 40),
being fifty plus did not necessarily mean that participants considered themselves a
candidate. Cardiovascular events in the 70s and 80s seemed to be explained due to "old
age" rather than family history or other risk factors, echoing previous work (Rogers et
al., 2000; Emslie et ah, 2001). A few participants explained their own diagnosed
increased cardiovascular risk as due to their increasing age. So it seemed that age was
used more to explain events and diagnoses retrospectively rather than as a risk factor to
consider in ideas of likely candidates.
Despite widespread awareness of cardiovascular risk factors as illustrated, several
participants did not seem to apply this awareness to themselves, thus not considering
themselves at risk. The screening chapter demonstrated several key beliefs that relate to
risk perception that appeared to have influenced screening attendance: fatalism (as
discussed), optimistic bias, denial and perceived lack of necessity.
Optimistic bias and perceived cardiovascular risk
As demonstrated, optimistic bias regarding heart disease was common in participants'
accounts of their own beliefs (usually referring to their past beliefs) or the known or
suspected beliefs of others. Optimistic bias is a difficult barrier for health promotion to
overcome. The asymptomatic nature of the indicators of cardiovascular risk could
contribute to or reinforce this belief, as lack of experience of a particular illness has been
associated with optimistic bias regarding that illness (Weinstein, 1987). Ideas about
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coronary candidacy are likely to reinforce optimistic bias if a typical candidate is
perceived as distinct from how an individual views themselves. Indeed, some
participants described comparing themselves with others, which often seemed to have
led to a belief along the lines of, "it happened to them, but it won't happen to me". Such
self-other comparisons included participants distinguishing themselves from affected
family members by attributing events to other risk factors that they perceived not to
share themselves. Also participants reported cardiovascular events in their peers of the
same age as having triggered personal risk assessment, but they typically perceived
themselves as leading a healthier lifestyle than the affected peers, or attributed events to
non-shared factors such as family history.
Optimistic bias may have led participants to search for factors on which they could
distinguish themselves from affected family members or peers, or conversely such
comparative assessment may have led to optimistic bias. Such optimism, however, may
not have always been unrealistic, participants may have been fairly accurate in their
comparisons. Other participants' personal risk assessment led to high perceived risk.
Applying optimistic bias to screening, it seemed to have inhibited participants from
attending other health checks, and some 'known others' from attending the AAA
screening. It thus remains a barrier for health promotion and screening uptake.
Denial, avoidance and lack ofperceived necessity
Not wanting to know one's cardiovascular risk was suggested by many participants as a
reason for non-attendance at screening, usually when discussing other people, both in
general and specific cases. "Not wanting to know" was suggested as masking suspected
increased risk, thus denial could prevent facing the reality of one's risk. The analysis
also suggested that such avoidance was related to unwillingness to make changes to
one's lifestyle.
Participants described, often with hindsight, how the asymptomatic nature of
undiagnosed cardiovascular risk inhibited screening attendance. Most participants saw
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the benefits of regular 'MOT' style check-ups but consulting a GP to check on one's
health whilst asymptomatic is not a typical consulting style in Britain; rather consulting
requires symptoms. Non-attendees at bowel cancer screening (McCaffery et al., 2001)
reported two consequences of lack of symptoms: perceived lack of necessity of
screening, and avoidance of thinking about the illness thus preventing psychological
harm. So in fitting with other conditions and research, it seems that as long as one feels
healthy, worrying is considered unnecessary and, borrowing another common phrase,
"ignorance is bliss". Furthermore, participants talked negatively and distinguished
themselves from frequent consulters or "hypochondriacs" seemingly to emphasise their
own healthiness, echoing Blaxter and Paterson (1982) and the connection between
health status and moral worth.
To summarise this section, the present research demonstrated evidence of a very similar
coronary candidacy mechanism to that depicted in previous research (Davison et al.,
1989, 1991; Emslie et al., 2000, 2001; Hunt et al., 2000, 2001; Hunt & Emslie, 2001).
Risk factors particularly salient in participants' accounts included personal factors
(especially family history of heart disease and lifestyle), social factors (particularly
Scottish identity) and physical factors, awareness of the randomness of the disease was
also incorporated. Participants drew upon these factors when considering and discussing
their own perceived risk, but there was variety regarding which particular factors
different participants drew upon and in the importance attributed to each factor. Beliefs
which participants reported as inhibiting screening attendance both in themselves (past
or present) and in others included optimistic bias, fatalism, denial, avoidance and lack of
perceived necessity. These beliefs seemed to serve to minimise the level of perceived
risk. Some participants reported engaging in such personal risk assessment as a result of
a trigger such as a cardiovascular event or diagnosis in an acquaintance, relative or
personally. When the experience was that of a known other, participants often compared
themselves with the affected individual regarding risk factors. For others, risk
assessment seemed to have been provoked by being invited and/or attending the
screening; for example a few participants reported not having considered their risk of
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heart disease prior to the screening. This points to the possibility that being invited to
screening, regardless of whether one attends or not, could increase worry and anxiety
from the personal risk assessment the invitation may provoke. Thus, whilst the goal of
screening is to improve physical health, it also has the potential to cause psychological
harm. Shickle and Chadwick (1994) writing on the ethics of screening stated that
screening casts doubt over our 'healthiness' and has the potential to provoke anxiety
until a healthy result is received.
Perceived risk and the screening experience
This section moves on to participants' reactions to and interpretations of the screening
experience and result; these were related to their expectations and perceptions risk
discussed in the first section.
Participants who received a 'healthy' ABPI result were very positive about screening in
general and their AAA trial screening experience possibly met their expectations of their
healthiness. Some of these reported receiving the reassurance that they had sought,
rather than having anticipated any personal risk echoing previous research (Howson,
1998). For a few, a 'certificate of health' effect was apparent, i.e. a healthy result
provided 'false reassurance' and a green light to continue their unhealthy lifestyle
(Tymstra & Bieleman, 1987). Thus, despite awareness of the riskiness of their lifestyle,
the fact ofno noticeable physical effect of their behaviour had led to little perceived risk.
Awareness of unwarranted survivors may have contributed to feelings of personal
invulnerability.
Thus, for some participants, a clinical diagnoses of risk seemed necessary to provoke
personal risk perception and is perceived differently from riskiness of unhealthy
behaviours. This highlights the problem of asymptomatic conditions such as
atherosclerosis: the tendency to wait for a clinical diagnosis before perceiving oneself at
risk, added to the tendency not to consult one's GP for a clinical measure unless
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symptomatic, is dangerous due to the fact that conditions such as atherosclerosis can
progress to a severe level whilst asymptomatic. Furthermore, without symptoms or a
clinical diagnosis, some individuals will see less need to change from an unhealthy
lifestyle, thus their maintenance of smoking and other behaviours that increase
cardiovascular risk, will continue to increase their risk.
The importance of pre-screening beliefs was highlighted. Some participants who had not
anticipated being at risk, in reflection, appeared to re-interpret their pre-screening beliefs
and perceptions about their healthiness and risk to find plausible explanations for their
unexpected result. Some realised the contribution of their lifestyle, past and/or present
thus acknowledging some responsibility. Others drew upon more fatalistic explanations
such as heredity or increasing age, perhaps easier than admitting personal responsibility
and blame. Many participants maintained their pre-screening low perceptions of risk
despite receiving a low ABPI; for example drawing upon alternative (false)
explanations. Lack of significance attributed to the ABPI can be explained in terms of
issues with recall and understanding of the measure or of atherosclerosis, factors about
the screening experience, in particular the nurse-participant dialogue, and perceived
attitudes of a nurse or GP. Aspects of the nurse-participant dialogue that were latched on
to, such as a "borderline" ABPI, indicated that these participants seemed to be using
these particular memories to minimise the risk perceived from their result. This
highlights the issue and difficulty of ensuring that participants are fully informed of their
risk. Regarding communicating screening results to the participant, the middle ground of
ensuring full comprehension of the meaning of the result without causing anxiety seems
to be a difficult task.
Duncan et al. (2001) discussed how women who were diagnosed with Chlamydia
through screening reinterpreted their meanings of the disease to maintain their image
and avoid stigmatisation. Whilst atherosclerosis and cardiovascular risk lack the same
type of stigmatisation as a sexually transmitted disease, there may be some stigma.
Previous research (for example: Blaxter and Paterson, 1982; Cornwell, 1984)
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demonstrated the negative connotations associated with being an ill person and the
moral significance attached to maintaining one's healthy status. Thus, by maintaining an
image as a healthy individual, individuals avoid such negative social evaluation. Being
labelled "hypertensive" has been associated with increased psychological distress (Irvine
et al., 1989), but less adverse effects were reported from labelling with high cholesterol
(Irvine and Logan 1994). The distinction was suggested as relating to differences
between the associated perceived control of each condition, with cholesterol regarded as
more under the individual's control (Irvine and Logan, 1994). In the present research,
there seemed to be mixed views about perceived control over atherosclerosis. Regarding
causality, there was awareness that lifestyle factors under individual control can cause
furring of the arteries, but there was also a high perceived dominance of heredity,
environment and culture, typically seen as beyond the individual's control.
Current screening available includes national cancer screening programmes, and general
health check-ups in the workplace or at 'well man/woman' clinics at surgeries. A couple
of participants divulged having more fear of cancer than of heart disease, echoing
previous research (Emslie et al., 2001; Nic Gabhainn et al., 1999; MacFarlane &
Kelleher, 2002). Despite awareness of the randomness of heart disease, it may still be
regarded as more under individual control than cancer in terms of risk factors, and so
less feared.
Comparisons of perceptions of the ABPI with other clinical measures revealed
interesting meanings and interpretations of the different measures amongst research
participants. Regarding cholesterol and blood pressure, both were generally perceived as
indicating significant risk, participants seemed to treat cut off points as a black and white
issue, despite the continuum along which measures fall. In contrast, for the majority, the
ABPI measure was a novel concept, and there was confusion in people's knowledge of
atherosclerosis, in particular regarding the link between circulation and the heart. Rather
than black and white, there was more emphasis on the grey area around the cut off point.
It is probably the case that acceptance of the ABPI as a marker of cardiovascular risk
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and increased awareness of atherosclerosis will take time to filter into lay knowledge;
use of the measure in general practice would increase awareness, and the present
findings imply that use by a known GP would increase its perceived significance.
Participants knew that this ABPI screening was part of a trial, which may have had
implications regarding their perception of the measure; this awareness and the novelty of
the measure may have led to the perception that the measure was on trial and thus not
considered significant.
This section discussed how pre-screening beliefs were an important factor in
participants' reactions to the screening and their result. When the screening result met
expectations, these beliefs persisted, and false reassurance was found in a minority.
There was a variety of effect on risk perception in those who experienced a mismatch
between their expectations and result: risk perception changed in some, by reinterpreting
their prior beliefs to make sense of their low ABPI. Others maintained their pre-
screening beliefs about their healthiness, drawing upon alternative ('false') explanations
for their result. Aspects of the screening experience such as the nurse-participant
dialogue seemed to minimise their perception of personal cardiovascular risk.
Participants' meanings of the ABPI result can explain why many did not see it as a
significant risk. Risk was often not perceived until diagnosed by a clinical measure. But
whilst measures of blood pressure and cholesterol were accepted as signifying a risk
which required treatment or lifestyle change, the ABPI was less accepted. The novelty of
the ABPI, in particular its lack of use in current primary care, appeared to contribute to
its lack of perceived significance. In addition, atherosclerosis appeared not to be
regarded as overly concerning particular in comparison to diseases such as cancer.
Prevention, preventive medication and perceived risk
The first two sections discussed how participants' attitudes to screening and their
reaction to and interpretation of the screening experience related to and was embedded
within their perceived cardiovascular risk. This section discusses how participants'
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perceived risk appeared to relate to their views about prevention, in particular aspirin as
a preventive medication. Rather than focusing on perceptions of cardiovascular risk
only, perceived risk from medication and the possible conflict between these two areas
ofperceived risk are also considered.
Perceived risk from medication
I demonstrated earlier how despite voicing phrases such as, "prevention is better than
cure" regarding heart disease, many participants' accounts revealed lifestyles that
differed from this, rather indicating a "prevention is better than cure, but" viewpoint.
Central to this there seemed to be a dislike of medication. This related to perceived risks
from medication relating to one's physical health, well being and social appearance.
First, participants discussed potential adverse side effects from medication. While some
participants felt that adverse effects depended on the particular drug, the dose and the
individual's "constitution", others considered all medicines harmful. This echoes
findings from research on patients' meanings of medication, particularly when exploring
adherence and non-adherence to medication, for example negative properties of
medication (Britten, 1994). Second, some expressed fear of the risk of becoming
dependent on medication. Third, for many participants, medication seemed to signify
transformation from a well person to an ill one, which had negative connotations, was
thus a risk to be avoided. Britten (1994) identified fear of shame and labelling as 'ill' as
the negative orientations her participants had towards medication; Blaxter and Paterson
(1982) found that women presented themselves as not giving in to illness, and preferring
to avoid medication in favour of a 'mind over matter' approach to cure. Similarly, many
participants in the current research distinguished themselves from "pill poppers" about
whom they expressed negative attitudes; they seemed keen to be regarded as healthy,
which could be related to positive social and moral evaluation.
Perceived risk from aspirin
Most participants showed awareness of at least one possible risk from aspirin in the form
of specific side effects to aspirin or risks ofmedication in general. For some participants,
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the possibility of side effects (with and without knowledge of personal susceptibility)
was sufficient risk to lead to avoidance of aspirin. Many others appeared to regard
aspirin as a 'special case'; contributors to this included its status as a longstanding and
common drug, old wives' tales and current hearsay about its benefits. Associated with
this apparent special status seemed to be low risk perception. For some, risk was
lessened due to the low dose, soluble or sugar-coated forms of the drug. For others,
optimistic bias seemed to explain their low perceived personal risk as they talked about
side effects happening only to those people who were 'susceptible', and distanced
themselves from this group.
Bissell et al.'s (2001) study of reactions to a scare with a non-prescriptive medication led
the authors to conclude that regarding non-prescriptive medicine, there is more trust, lay
reskilling and reflexivity than risk society theories would suggest, rather than that
specific health scares lead to occasional episodes of such thinking. Aspirin is both a non-
prescriptive and a prescriptive medication; its over-the-counter status seemed to
contribute to its perceived safety by participants. Whilst unlike Bissell et al.'s (2001)
research, interviews were not carried out before and after a real scare so it was
impossible to investigate participants' direct reactions to a scare, however, participants
did mention 'scares' publicised through the media. Some participants emphasised their
continuing faith in the benefits of aspirin whilst indicating awareness of publicised
scares. Similarly Bissell et al. (2001) reported how participants continued to use the
hayfever medication following the scare due to their belief in the therapeutic benefits.
Media coverage of possible risks from aspirin had contributed to increased awareness,
however, such instances did not seem to have led to great concern. Indeed, some
participants were quite critical of the media's take on health risks particularly regarding
mixed messages and reported discounting such information in favour of an "a little of
everything in moderation" approach. Applying lay epidemiology to beliefs about aspirin,
the data demonstrated how input came from participants' own experience and that of
their family or friends, their GP's attitude, and media coverage. Multiple sources of
259
competing information can create difficulties for the layperson in establishing the 'real
facts', particularly when sources are 'expert' (Bissell et al., 2001).
Cardiovascular risk versus risk from aspirin
For some participants, willingness to take aspirin despite dislike ofmedication may have
resulted from weighing up the potential risks and benefits of aspirin against the potential
risks and benefits of not taking aspirin. Such deliberation was explicitly discussed in a
few participants' accounts. The situation of increased cardiovascular risk seemed to
outweigh the potential risks from medication for some participants who normally would
have actively avoided medication. Britten's (1994) participants similarly reported
balancing risks and benefits when making decisions about appropriate use of
medication; she emphasised the importance of situational and contextual influences on
this process.
Perceptions of the necessity of medication emerged as what seemed to be the deciding
factor regarding acceptance of medication. Participants had particular ideas regarding
necessary medication, such as that which kept them alive, whereas medication described
as being taken "for the sake of it" and people associated with this such as
"hypochondriacs", seemed to be frowned upon, including use of over-the-counter
medication such as vitamins and some preventive drugs. Generally, ongoing conditions,
including high blood pressure and high cholesterol, and acute symptomatic episodes
were deemed necessary, but for many atherosclerosis as diagnosed by the ABPI was not.
The idea of preventive medication use as an alternative to making changes to one's
lifestyle was rejected by the majority of participants. Rather, once diagnosed with a risk
it was generally considered that one should change all aspects of one's lifestyle, again
emphasising the necessity of a clinically diagnosed risk to provoke preventive
behaviour, including medication use. Perceptions of necessity seemed to be influenced
by participants' GP, linked to trust and faith, again echoing Britten's (1994) participants,
several of whom reported taking "whatever the doctor prescribed". Other research has
described the increasingly assertive and inquisitive public as less trusting and more
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critical of medicine (Vaughan & Seifart., 1992; Williams et al., 1995); Bissell et al.
(2001) regarded mistrust and awareness of science's limitations as giving rise to lay
reskilling. In the current research some participants displayed mistrust towards
medication, but there was little expression ofmistrust of doctors.
This section has discussed the relationship between participants' perceived risk (both
cardiovascular and from aspirin) and their views about prevention of heart disease,
specifically aspirin as a preventive medication. Seemingly positive views towards
prevention of heart disease were compromised by perceived risks from medication.
Despite these views, willingness to take aspirin revealed the drug's seemingly special
status as safe and trusted, and from weighing up cardiovascular risk against risk from
aspirin, the latter typically was regarded as more controllable in the event of its
occurrence. Risks of aspirin, as publicised through the media, had increased awareness
but had generally not led to great concern. Ideas about necessity, which related to
participants' meanings of the ABPI measure, emerged as a critical factor in the weighing
up process.
Distinctions from previous literature regarding lay attitudes towards medication (such as
Britten, 1994; Bissell et al., 2001; Benson & Britten, 2002) include both the preventive
purpose of the medication and also the trial situation of this current research. Despite
many participants' assumptions, aspirin's efficacy in preventing cardiovascular events in
those with a low ABPI remains unknown until the results of the AAA trial are known.
This presents a different situation in that whilst participants may indeed weigh up their
ideas and perceptions about risks from aspirin against cardiovascular risks without
aspirin, the actual risks are still to be quantified.
Trial participation and risk perception
The previous section discussed participants' attitudes towards taking aspirin as a
preventive medication in terms of how this related to their perceptions of cardiovascular
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risk, perceptions of risk from aspirin and the interplay and weighing up of the two types
of risk perception. Attitudes towards participating in the AAA trial were rooted in the
same beliefs and perceptions of risk, with additional factors such as altruistic feelings
adding to the potential influences on an individual's decision to participate. This section
will discuss how participants' perception of risk, both cardiovascular and from aspirin,
appeared to affect participants' decision regarding participation in the trial, and how the
two perceptions were weighed up against each other and against other factors.
Participation decision and weighing up risks
For many participants, attitudes towards trial participation were embedded in their
perceptions of personal risk. In considering this relationship, it is useful to reflect on the
different decisions participants made and compare and contrast the perceptions between
those who made different decisions. However, in doing so, it is evident that there was no
straightforward pattern between level of perceived cardiovascular risk and decision
made; indeed two participants could perceive very similar personal cardiovascular risk
but make opposing decisions, and two participants who made the same decision could
hold very different perceptions of risk. I will consider participants' attitudes by dividing
them into groups depending on their decision regarding participation and their perceived
risk.
For participants who received a low ABPI but declined to participate, explanations were
varied and revealed differing perceptions of personal risk. For a couple of participants
the discovery of their low ABPI provoked the perception of increased risk for which the
trial situation offered them no solution, so rather than enter the trial they engaged in
alternative solutions. For a few of these, perceived cardiovascular risk was high
compared with potential risk from aspirin, thus they sought aspirin themselves. For
others, heightened perceived cardiovascular risk was equalled by a high perceived risk
from aspirin, so rather than declining to participate for the purpose of guaranteeing
receiving aspirin, they declined, in order to avoid any possibility of receiving aspirin. So,
for these participants, high perceived cardiovascular risk appeared to lead to declining to
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participate in the trial, but choice of subsequent action seemed to be affected by
perceived risk from aspirin. At the other end of the spectrum, participants declined to
participate in the trial, or stopped taking the trial tablets, due to lack of significant risk
perceived from their low ABPI result. Unlike those described above, they neither made
changes to their lifestyle nor sought medication. Their own explanations included being
too late for any action given their age, perceived invulnerability and dislike of
medication.
Moving onto those who chose to participate in the trial, some of these perceived
significant risk from their low ABPI. Contrasting their accounts and views with the
participants described above (for whom perceived risk had led to declining) revealed
apparent differences between the two groups' understandings of the trial procedure.
Those who had declined demonstrated a more accurate comprehension of the RCT
process (including the randomisation of treatment allocation) than some of those who
chose to participate. This implies that some participants who perceived high risk from
their low ABPI may have believed they were benefiting from their participation and that
their risk was being controlled through believing they were receiving the aspirin. Other
trial participants indicated little significant risk perceived from their low ABPI. Rather,
their reasons for participation included altruistic feelings, recognition of need for the
trial, a "why not?" attitude, and the belief that the trial tablet would at best help their
health. The lack of significant perceived risk from the low ABPI raises the possibility
that given a more accurate understanding, these participants may have chosen to decline
to enter. The willingness of this group to take the trial tablet also indicated they felt little
or no perceived risk from aspirin.
Altogether there was no straightforward relationship between perceived risk and
decision to participate. Whilst a participant's decision regarding participation was
related to and explained in terms of level of perceived cardiovascular risk, the
relationship between the two differed from participant to participant. Furthermore, the
decision was also related to perceived risk from aspirin, and other factors including
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understanding of the trial and altruistic feelings. The decision was thus very complex.
The wide range in perceptions of risk from the ABPI within those who were diagnosed
with a low ABPI further emphasises the importance of effectively communicating the
meaning of novel clinical measures such as the ABPI to the layperson.
Preference for aspirin
As described above, some participants disliked the randomisation element to RCTs;
many participants revealed a preference for the aspirin over the placebo. This preference
was acted on by some in a variety of ways, or for others it remained a preference not
acted upon; action appeared to be related to participants' personal perceived risk (both
cardiovascular and from aspirin).
As discussed, the strongest preference for aspirin over the placebo was demonstrated by
a couple of participants who were eligible for the trial but declined to participate, rather
seeking aspirin themselves. Previous literature has found only a small number of
participants to explain their non-participation in trials as due to dislike of the placebo
and trial procedure (Schwarz & Fox, 1995; Mohanna & Tunna, 1999), however another
qualitative study found a strong preference for the experimental treatment expressed by
those actually participating (Snowdon et al., 1997). The preference for aspirin over the
placebo was expressed by and emerged in the accounts of AAA trial participants; these
same individuals reported taking their trial medication and mentioned no intention to
stop, despite this preference. There are several possible explanations for their continued
participation. First, many of these participants seemed to perceive little risk from their
low ABPI result, so the preference for aspirin may have been regarded as requiring
action only in the case of perceived high risk. Second, despite showing apparent
awareness of the 50% chance of receiving aspirin, some participants implied that they
believed that they personally were receiving the aspirin. For some, their suspicion had
been reinforced by the occurrence of minor side effects such as increased bruising.
Similar 'therapeutic misconceptions' have been reported in previous qualitative studies
of trial participation (Appelbaum et al., 1982; Snowdon et al., 1997; Featherstone &
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Donovan, 2002). Participants in a prostate trial demonstrated awareness of the trial
design but struggled to accept and make sense of it (Featherstone & Donovan, 2002).
This was echoed in the accounts of AAA trial participants, some of whom seemed to
demonstrate a good understanding of the RCT design but elsewhere in their account
implied otherwise.
Expressing that one was owed the aspirin due to willingness to participate and one's
"good" nature echoed moral overtones about being owed the experimental treatment
expressed by parents of neonatal babies in a trial (Snowdon et al., 1997). Believing that
one is receiving the aspirin may be a method of making sense of the unfairness
perceived about the RCT procedure.
Assumptions about aspirin
The commonly expressed preference for aspirin revealed the ubiquity of two
assumptions about aspirin: its efficacy regarding cardiovascular health and its safety.
Regarding the former, many participants had not distinguished between aspirin's use for
established heart conditions and that being tested in the trial, i.e. as a preventive
medication in those with early atherosclerosis. This assumption led a couple of
participants to question the need for the trial. However, until the results from the AAA
trial are analysed and reported, the efficacy of aspirin as a preventive medication for
those with atherosclerosis as diagnosed by a low ABPI remains unquantified. So this
assumption made by many participants, albeit common, remains unproven. The ubiquity
of the assumption of efficacy of the experimental treatment relates to misunderstandings
of clinical equipoise (Featherstone & Donovan, 1998; 2002; Robinson et al., 2003).
Even with a full explanation of the state of clinical equipoise, people found the
possibility of clinical uncertainty amongst doctors about the best treatment unacceptable
(Robinson et al., 2003); the assumption that the doctor will always act in the patient's
best interest seems to prevail (Appelbaum et al., 1982; 1986). However, one
participant's comment that unless epidemiologists had a strong suspicion of aspirin's
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efficacy for this particular use, the trial would not be in process, may indeed be well-
founded; does clinical equipoise really exist in this particular situation?
As noted earlier, assumptions of aspirin's perceived safety seemed to have arisen from
views of its longstanding and common status, old wives' tales and current hearsay. Its
longstanding status certainly seemed to have influenced participation in some cases: a
couple of participants commented on how they would have been more wary about
participating in a trial of a new and unknown drug. Snowdon et al. (1997) also found
few concerns about risk of the experimental treatment in the parents' trial, which unlike
aspirin, was a treatment new to the UK; parents did, however, report awareness of the
treatment's use overseas and the trial was a potential life and death situation unlike the
preventive nature of the AAA trial.
As discussed earlier, when explicitly weighing up the risks from aspirin against
cardiovascular risk, several participants stated that the potential risks from the trial tablet
could be dealt with if they occurred. This indicates that in addition to perceived safety
and trust in aspirin, participants' accounts implied trust in the trial itself, including
monitoring and safeguards in place to deal with adverse effects or events. Snowdon et al.
(1997) suggested that the trust in the trial that their participants demonstrated could have
been one way of making sense of the randomisation process which the majority
considered unfair; the same could apply to AAA trial participants. Other perceptions of
trust were directed to one's GP, similarly GP approval has been reported as contributing
to perceived safety of past trials (Fouad et al., 2000; Daugherty et al., 1995). Others
indicated trust in the University as an institution running the trial or the British Heart
Foundation funding the trial, in particular compared to drug companies for whom much
mistrust was expressed.
Adverse effects attributed to the trial tablet or cardiovascular events had apparently not
affected participants' trust in the trial; neither blame on the trial nor a negative attitude
towards aspirin was expressed by any of those affected. Similarly, participants who had
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stopped the trial medication due to changes in their cardiovascular health, expressed no
blame on the trial for not having prevented their event. Thus, it seemed that trust in the
trial was strong and prevailed. Expressions of mistrust in the trial included
dissatisfaction with the blinding element and perceived inconsistencies in the running of
the trial. Similarly to randomisation and equipoise, blinding has previously been
reported as a difficult concept for people to grasp and thus may provoke discontent
(Madsen et al., 2000; Purdy et ah, 2000).
A risk of medication outlined earlier was its association with an ill identity; preference
to maintain one's healthy identity thus preventing negative social evaluation related to
medication avoidance. Despite implying this attitude, several were keen to participate in
the trial and willing to take the trial tablet. It is possible that the trial tablet could be
distinguished from other medication due to its trial tablet status; indeed participating in a
trial may be regarded as increasing positive social evaluation if one emphasises one's
altruism, although social psychologists would argue that the term altruism no longer
applies due to more personally oriented motivation. This demonstrates how apparent
altruism may help a participant cope with an otherwise perceived risk.
Altruism and risk
As demonstrated in the participation chapter, altruistic feelings emerged in participants'
discussions about trial participation. Considering how such feelings related to perceived
risk, some participants seemed happy with the potential risks involved in the trial due to
their willingness to help or recognition of the need for the trial; these participants were
either prepared to take the risk of entering the trial, or did not perceive it as sufficiently
risky to not participate. However, perceived risk might have been a stronger influence
than altruism; altruism seemed to last as long as participants perceived no risk to
themselves, but an event signifying risk resulted in consideration of one's own health
dominating over helping others. Thus, it seemed that whilst altruism can be an important
influence on the decision to participate in a trial, participation should not jeopardise
one's own health.
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This section has discussed how the risk participants perceived, both of heart disease and
from aspirin, and their weighing up of these two risks against each other and against
other factors, related to their attitude towards participating in the trial. As demonstrated,
no straightforward relationship between level of perceived risk and participation
decision was evident, rather the relationship emerged as complex, and differed from
participant to participant. Discontent with the placebo, blinding and widespread
preference for the aspirin revealed pervasive assumptions about aspirin's efficacy and
safety. Evidence of these assumptions in adherent trial participants implied a lack of
acknowledgement of the reality of the RCT procedure, in particular randomisation,
therapeutic misconceptions, and a lack of acceptance of participants' own low ABPI.
Meaning of the ABPI and comprehension of the RCT process were important; there was
a wide range of understanding of both which has implications concerning informed
consent. Altruistic attitudes were reported as influencing participation, however only as
long as personal health was not jeopardised it seemed. When personal risk reached a
significant level, concerns about participants' own health dominated.
Risk
In this final section, I will draw together discussion from the preceding sections to focus
on how the present research and its findings have contributed to knowledge about risk.
Existence of cardiovascular risk
The research has demonstrated that the concept of cardiovascular risk existed and was
salient for the participants in this study; it is clearly a notion about which people have
ideas and opinions. The findings have provided support for previous work on lay beliefs
of heart disease including the notions of lay epidemiology, the 'coronary candidacy' and
awareness of fallibilities of the concept. The data has demonstrated that a multitude of
factors contribute to people's ideas about cardiovascular risk, and that certain factors
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appear to be weighted more than others in terms of their relative importance, but this
differs from individual to individual. Also illustrated were evident differences in how
individuals apply risk factors to themselves when engaging in risk assessment compared
to when assessing cardiovascular risk in others.
Markers of risk
Although a multitude of factors are considered when assessing likely cardiovascular risk
in oneself and others, it seems that a definite marker is required to provide a significant
acknowledgement of personal risk. The most common of these markers is experiencing a
cardiovascular event, such as a heart attack or angina. The second group of markers
involve receiving a diagnosis from a clinical measure. However, at present, whilst
measures of high blood pressure and high cholesterol are largely associated with such
significance, the ABPI measure is more likely to be met with ambivalence and
uncertainty.
Minimising risk perceived
In addition to factors that contribute towards perceptions of cardiovascular risk, other
factors minimise the level of risk perceived and instead contribute to perceptions of
invulnerability. The well-documented phenomenon of optimistic bias, our tendency to
believe that we are less likely to suffer from health problems than our peers, is one of
such factors. Fatalism regarding health problems, supported by awareness of fallibilities
of the coronary candidacy and the randomness of heart disease, is another factor. Denial
and avoidance of contemplating or acknowledging likely cardiovascular risk are further
contributors. The asymptomatic nature of conditions of increased cardiovascular risk,
such as atherosclerosis, can support optimistic bias, denial and avoidance, and enhance
feelings of lack of perceived necessity of testing our perceived risk, for example with a
clinical measure. Beliefs about our healthiness and likely risk can be strong; anything
that maintains and supports our beliefs is likely to be more welcome than something that
threatens this perception, which is more likely to be avoided or rejected.
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The impact of risk perception
The data has demonstrated the importance of risk and its perception in people's attitudes
and decisions about preventive health.
♦ on attitudes towards screening
Regarding screening for cardiovascular risk, the strength of pre-screening perceptions of
risk may mean that diagnoses of an 'at risk' result may not be accepted. Such a
mismatch may lead to a search for alternative explanations for the risk indicated by the
clinical measure as a way of minimising the level of threat perceived. Although voicing
the benefits of such a screening, and willingly attending, people may not consider 'risky'
results significant.
♦ on attitudes towards preventive medication
Again, although voicing positive attitudes towards the identification of cardiovascular
risk and engaging in active prevention of heart disease, unless significant risk is
perceived (through an event or diagnosis), preventive behaviour in the form of
medication taking may not be welcomed. Where a diagnosis of risk is accepted, the level
of risk perceived is likely to be weighed up against the level of risk perceived from
suggested solutions such as medication recommended. Perceived risk from medication
can include risks to one's physical and psychological health and one's social appearance.
In comparison to less well-known drugs, aspirin will be more accepted due to its
perceived safety and efficacy.
♦ on attitudes towards participation in trials
The findings have expanded knowledge regarding beliefs and understandings of
participation in clinical trials; both the trial's preventive nature and use of a well-known
drug in a RCT provided a novel situation for qualitative research. Supporting previous
research into different types of trials, elements of the RCT principles and procedures
such as equipoise, randomisation and blinding are evidently hard for some people to
make sense of and accept. Perceptions of risk seem to dominate decisions regarding
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participation; here both cardiovascular risk and risk from aspirin, were considered and
weighed up against each other, as well as other factors such as altruism acting as an
influence. The relationship between the level of perceived risk and the decision to
participate is complex; similar levels of perceived risk may lead to different decisions,
and other factors including understanding will have an impact. Perceived risk appears to
dominate over other factors; here altruism was an apparent and strong influence, but was
overridden when perceived personal risk was heightened.
The concept of risk has been the subject of an immense amount of research and writing
across many disciplines. Chapter 2 outlined selected literature on risk spanning several
disciplines reflecting the interdisciplinary approach to the present research. The
increasing awareness of risk in modern society (as noted by researchers such as Lupton,
1993, and Gabe, 1995) highlights the need to understand public understandings of risk.
The present research studied lay accounts of risk to explore the associated meanings; it
'borrowed' concepts of risk from both psychology and sociology in trying to understand
these meanings. The data presented in this thesis demonstrated how a risk defined by
epidemiology, and useful for preventive medicine, was received and considered by
members of the public, as they were invited to participate in screening and a trial.
Implications
Implications for preventive health
• The beliefs, perceptions and meanings people hold about personal cardiovascular
risk may be strong and somewhat resistant to challenges. Preventive health
programmes should recognise potential 'barrier beliefs' related to these
perceptions that may exist and may inhibit preventive behaviour (such as
screening attendance) including: optimistic bias, fatalism, avoidance, and lack of
perceived necessity, which are heightened in the case of asymptomatic
conditions. Preventive health initiatives should work with and address these
feelings, both at the stage of inviting people to screening and during the
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screening experience, particularly when explaining the meaning of the screening
result.
• The potential negative effects of screening should be considered. A positive (at
risk) result may induce feelings of labelling and stigma, and may threaten an
individual's identity as a healthy person. A negative (healthy) result may inhibit
change to a healthier lifestyle.
• Use of medication in a preventive manner will be met not only by barriers
relating to perceptions ofpersonal risk, but also barriers relating to perceived risk
from medication. Such beliefs may lead to 'non-adherence' to prescribed
preventive medication. Again, these beliefs should be recognised, and time
dedicated to working with and addressing these within the practitioner-patient
encounter. It may be the case that, for some patients, preventive medication is
not an ideal approach.
Implications for clinical trials
• The findings highlight the importance of ensuring informed consent not only at
the point of ascertaining eligibility and making the decision to participate, but
also throughout the duration of the trial. Informed consent should ensure
understanding of the purpose of the research (including the concept of
equipoise), understanding of the RCT process (including randomisation and
double blinding), and awareness of the potential risks involved and procedures in
place to deal with adverse events.
• The research has revealed many reasons given for participating in the AAA trial.
It would be unethical for those recruiting into trials to use the findings to
manipulate uptake by focusing on these, and thus overshadowing potential risks
involved in the trial. However, the findings could point to certain groups of
people who may be keen to participate, for example those for whom the focus of
the research has a particular personal context.
• More importantly, the findings about attitudes towards particular aspects of the
trial process can inform those running trials of how to develop trials that are
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sensitive to people's expectations and needs, for example the provision of
monitoring and health checks, and to make the informed consent process more
robust and meaningful.
Implications for research
• The present research has demonstrated the benefits of an interdisciplinary
approach to investigating an important public health issue. Furthermore, it has
highlighted how qualitative research can make valid contributions to public
health research alongside randomised control trials.
• Future research in this area would ideally find ways of reaching people who do
not attend screening to which they are invited, within the constraints of current
data protection law.
• A longitudinal study of people's experiences throughout screening and trial
processes would further knowledge of the dynamic nature of risk perception;
such research could explore people's perceptions prior to being invited to
screening, upon receipt of a screening invite, and after a screening result.
Similarly trial participants' beliefs could be explored at several stages throughout
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A1 Details of recruitment process of the 5 groups (presented in the
chronological order in which I recruited the groups):
Group5: People who had not attended the screening.
It was important to start recruitment with this group as soon as possible due to the
ethical constraints limiting my access: Due to the introduction of the Data protection
Act (ref), amongst other considerations, in two of the three health boards I was
prevented from contacting people who had not attended the screening. In one of the
two this was not anticipated as approval had originally been granted; however, later
changes to the running of the trial prevented my access to the data used to access
potential recruits. Although the third health board granted approval of access to this
group of people, this health board covered the area where the trial had began
screening two years previously and screening had finished in this area approximately
ten months prior to the start of my fieldwork. The main difficulty therefore in
attempting to recruit in this area was the length of time which had elapsed since
receiving the invite to the trial: for people who had either refused to attend screening,
not replied to the invite or not attended their appointment, ten months was
presumably a long period of time to remember something which they had been
invited to, but not attended. I posted out 213 invites (the last batch of people invited
to screening in this area). From this I received 9 positive replies who I then
contacted; I arranged interviews with 6 of these respondents and conducted all of
these in participants' own homes. Of the remaining three, two could not be contacted
and one stated preference for a focus group which could not be carried out due to low
response. Of these six participants, not one would have been eligible for the trial
regardless of their ABPI as three had heart conditions and two were on medication
contraindicating to aspirin, and one was on prescribed aspirin. Therefore none of the
participants were people who had simply not wanted to attend the screening.
Recruitment of group 5 was therefore frustrating and disappointing, particularly as I
felt that this group of people could have informed one of the research questions: why
do people not attend screening for heart disease? In my initial naivety when
beginning the research I believed I could access this group of people, but later
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reflection led to the conclusion that people who do not wish to attend screening
and/or participate in a research trial are probably similarly unlikely to wish to be
interviewed on the subject.
Group 4: People who had attended the screening but were not eligible
for the trial (normal ABPI).
The screening appointment process was as follows: From the trial office, invites to
the screening were posted in batches working through different general practices, and
appointments were made upon receipt of the reply slip, therefore those attending
screening appointments within the same week or so tended to be from the same area.
Therefore it was possible, with the help of the trial office staff, to identify from the
screening appointment lists, weeks when attendees were from areas with different
DEPCAT scores. In addition to the trial office staff, the research nurses were the key
gatekeepers in recruiting of this group of participants. Using the DEPCAT
information, when I started recruiting from this group we chose a 3 week period and
during this period at one clinic the research nurses asked every attendee who
received a normal ABPI if they would be interested in participating in my interview
study. Individuals were given information leaflets. If the attendee expressed an
interest, the nurse provided me with the individual's name and phone number. I
subsequently contacted the individual to check their interest, ascertain preference for
interview or focus group and arrange a date, time and place convenient to them. The
research nurses and I continued this process until I arranged ten interviews and two
focus groups. I carried out nine interviews (all but one were carried out at the same
location as the clinic, the remaining one was in the participant's office at their
request). I conducted two focus groups also at the clinic, one comprised of three
participants (there were several non-attendees) and one six participants.
Group 3: People who had attended the screening, were eligible to enter
the trial but had declined to participate.
To recruit this group, with the help of the trial office staff, I used the trial database to
identify attendees who had been eligible for the trial but had declined to participate
(either by informing the research nurse when invited to participate, or by deciding
294
not to participate and cancelling their baseline clinic visit). As this was a relatively
small proportion of attendees, I wrote to all those fulfilling the criteria over a period
of 3 months explaining the purpose of my research in a letter and information sheet
inviting them to participate in my interview study. If interested, they were asked to
send the reply slip to me and upon receipt of the reply I contacted each individual to
arrange an interview. Due to the smaller numbers of people fulfilling this criteria and
interested, and the responders being spread across two cities and a wide range of
areas within the cities, I did not manage to arrange a focus group of participants
within this group, but arranged and conducted eleven individual interviews (six in a
research clinic, one in my office and four in participants' homes).
Group 1: Adherent trial participants.
This was one of the easiest groups to recruit from and the research nurses were again
crucial in recruiting trial participants. During a 3 week period research nurses invited
all participants attending for an annual clinic visit, to participate in my interview
study. Those interested were given an information leaflet and their name and details
were passed onto me, I then contacted them to ensure interest, ascertain choice of
interview type and arrange a date, time and place for their interview or focus group. I
was keen to interview trial participants with a wide range of time in the trial and my
participants ranged from those who had been in the trial three years to three months.
I interviewed nine trial participants (five in their home or workplace, three at my
office and one in the research clinic). I also conducted two focus groups, one in the
research clinic in one health board area, the other in a University location in a
different health board area.
Group 2: Trial participants who had stopped the trial medication but
were still receiving annual follow up by the trial.
The research nurses were once again crucial to recruiting this group. Participants
who are no longer taking the trial tablet receive an annual telephone call from the
research nurse to check any changes in their health and medication; monthly lists of
follow up telephone calls are produced corresponding to the month participants
would have been due for their annual clinic visit. All participants receiving their
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annual follow up telephone call during one month were invited at the end of the call
to participate in my interview study. Names of those interested were passed onto me,
I then contacted them, checked their interest, ascertained their preference for
interview type and arranged a convenient interview. I conducted eleven individual
interviews (ten in participants' homes and one in my office) and one focus group in a
University location.
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A2 Recruitment letters and participant information sheets
A2.1: Letter to Group 5
Dear [participant name]
We recently wrote to you, inviting you to take part in a research trial to combat heart disease
in Scotland. We understand that you did not wish to take part in the study and respect your
decision.
However, I would like to invite you to take part in an interview study which is a separate part
of the Aspirin trial. I am a Ph.D. student based in the Department of Public Health Sciences
of the University of Edinburgh and I am carrying out this research under the supervision of
Professor Fowkes and Dr. Cunningham-Burley. This part of the study aims to understand
people's attitudes towards heart disease, screening and use of aspirin. I am
particularly interested in hearing the opinions of people who did not want to take part
in the trial, as their views about these issues are especially important.
The enclosed leaflet contains further information about this study which is called the Public
Attitudes study. You can take part in either an individual interview or a focus group where 6-
8 people discuss issues together. Interviews will be carried out at a venue convenient to you
or in your own home and will last for approximately one hour. Focus groups will also be
carried out at a venue convenient to you and the other participants and will last for
approximately an hour and a half. If you are interested in taking part please complete the
reply slip below and return it in the reply paid envelope; you will then be allocated to either
an interview or a focus group unless you have stated a particular preference.
I would like to point out that you are under no obligation to take part in this additional
interview. Please complete the attached reply slip and return to me in the enclosed reply-
paid envelope.
If you have any questions or wish to discuss this additional study please do not hesitate to
contact me on 0131 650 3242 and I will be happy to give you more information.





[name & ID no.]
Public Attitudes study
Please tick one box (□):
□ I am interested in taking part in the Public Attitudes study and I can be contacted
on (Tel. No.)
If interested in taking part, please circle one of the following:
interview / focus group / no preference
□ I do not wish to take part in the Public Attitudes study
It would be useful if you could also tell us your reasons for not taking part in the Aspirin
trial:
Please tick one box (□):
1 i My GP has prescribed daily aspirin
I 11 take daily aspirin myself (non GP prescribed)
I I Aspirin would interfere with my other medication/medical conditions
I 11 could not commit to the time involved in the trial
I 11 was not interested in taking part
I | Other reason
(pleasespecify)
Signed Date
Please reply to: Public Attitudes study, AAA Trial, Public Health Sciences, Medical School,
Teviot Place, Edinburgh EH8 9AG
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A2.2 Letter to Group 4
Dear [Participant name]
Thank you for your recent interest in the Aspirin research trial by attending the Kelvin Hall
clinic. After measuring the pressure in your ankle and arm, you were not eligible to take part
in the trial.
However, I would like to invite you to take part in an interview study which is a separate part
of the Aspirin trial. I am a Ph.D. student based in the Department of Public Health Sciences
of the University of Edinburgh and I am carrying out this research under the supervision of
Professor Fowkes and Dr. Cunningham-Burley. This part of the study aims to understand
people's attitudes towards heart disease, screening and use of aspirin. I am
particularly interested in hearing the opinions of people who attended the research
clinic for screening.
The enclosed leaflet contains further information about this study which is called the Public
Attitudes study. You can take part in either an individual interview or a focus group where
6-8 people discuss issues together. Interviews will be carried out at a venue convenient to
you or in your own home and will last for approximately one hour. Focus groups will also
be carried out at a venue convenient to you and the other participants and will last for
approximately an hour and a half. If you are interested in taking part please complete the
reply slip below and return it in the reply paid envelope; you will then be allocated to either
an interview or a focus group unless you have stated a particular preference.
I would like to point out that you are under no obligation to take part in this additional
interview.
If you have any questions or wish to discuss this additional study please do not hesitate to
contact me on 0131 650 3242 and I will be happy to give you more information.




[name & ID no.]
Please tick one box (□):
□ I am interested in taking part and I can be contacted on (Tel. No.)
If interested in taking part, please circle one of the following:
interview / focus group / no preference
□ I do not wish to take part
Signed Date
Please reply to: Public Attitudes study, AAA Trial, Public Health Sciences, Medical School,
Teviot Place, Edinburgh EH8 9AG
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A2.3 Letter to Group 3
Dear [participant name]
Thank you for your recent interest in the Aspirin research trial by attending the Kelvinhall
clinic. You were eligible to take part in the trial, but decided against it for medical or other
reasons and we respect your decision.
However, I would like to invite you to take part in an interview study which is a separate part
of the Aspirin trial. I am a Ph.D. student based in the Department of Public Health Sciences
of the University of Edinburgh and I am carrying out this research under the supervision of
Professor Fowkes and Dr. Cunningham-Burley. This part of the study aims to understand
people's attitudes towards heart disease, screening and use of aspirin. I am
particularly interested in hearing the opinions of people who attended the research
clinic for screening and decided not to take part, as their views about these issues are
especially important.
The enclosed leaflet contains further information about this study which is called the Public
Attitudes study. You can take part in either an individual interview or a focus group where 6-
8 people discuss issues together. Interviews will be carried out at a venue convenient to you
or in your own home and will last for approximately one hour. Focus groups will also be
carried out at a venue convenient to you and the other participants and will last for
approximately an hour and a half. If you are interested in taking part please complete the
reply slip below and return it in the reply paid envelope; you will then be allocated to either
an interview or a focus group unless you have stated a particular preference.
I would like to point out that you are under no obligation to take part in this additional
interview.
If you have any questions or wish to discuss this additional study please do not hesitate to
contact me on 0131 650 3242 and I will be happy to give you more information.




(name & ID no.)
Please tick one box (□):
□ I am interested in taking part and I can be contacted on (Tel. No.)
If interested in taking part, please circle one of the following:
interview / focus group / no preference
□ I do not wish to take part
Signed Date
Please reply to: Public Attitudes study, AAA Trial, Public Health Sciences, Medical School,
Teviot Place, Edinburgh EH8 9AG
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A2.4 Letter to Group 2
Dear
I am writing to invite you to take part in a small interview study which is being carried out
alongside the Aspirin (AAA) trial. I am a Ph.D. student based in the Department of Public
Health Sciences of the University of Edinburgh and I am carrying out this research under the
supervision of Professor Fowkes and Dr. Cunningham-Burley. This part of the study aims
to understand people's attitudes towards heart disease, screening and use of aspirin,
and aims to include people from various stages of the trial. You have restarted your trial
medication after a period without taking it; I am particularly interested in hearing the views
and experiences of people like yourself.
The enclosed leaflet contains further information about this Public Attitudes Study. This
study involves one visit only. You can take part in either an individual interview or a focus
group. Interviews will be carried out in your own home or at a venue convenient to you and
will last for approximately 30-45 minutes. Focus groups will also be carried out at a venue
convenient for those involved and will last for approximately an hour. If you are interested
in taking part please complete the reply slip below and return it in the reply paid envelope,
and I will phone you to arrange a suitable date and time.
I would like to point out that you are under no obligation to take part in this additional
interview.
If you have any questions or wish to discuss this additional study please do not hesitate to
contact me on 0131 650 3242 and I will be happy to give you more information.




(name & ID no.)
Please tick one box (□):
□ I am interested in taking part and I can be contacted on (Tel. No.)
If interested in taking part, please circle one of the following:
interview / focus group / no preference
□ I do not wish to take part
Signed Date
Please reply to: Public Attitudes study, AAA Trial, Public Health Sciences, Medical School,
Teviot Place, Edinburgh EH8 9AG
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A2.6 Participant Information sheet
Tackling Heart Disease in Scotland
The Scottish Aspirin Trial
Information sheet
Public attitudes study
Purpose of the study
The Aspirin Trial is currently testing the effectiveness of aspirin in
preventing future heart problems amongst those identified by measuring
their ankle blood pressure. However, it is also important to know what
people themselves think about heart disease, its prevention, screening
and research in order that their needs can be more effectively met by
the health service. We want to know what you think.
To do this we will be carrying out interviews and focus groups with a wide
range of people.
What will it involve?
You will take part in either an individual interview or a focus group
Individual interview: This will involve just you and the researcher (Helen
Eborall). The interview will be carried out at a venue convenient for you
or in your own home, and will last for approximately one hour. These will
be informal with general questions about your views on heart health and
attitudes towards heart disease, its prevention, and what you think
about the use of aspirin. There are no right or wrong answers and all
opinions are welcome!
Confidentiality is assured. If you have no objections, the interview will
be tape-recorded; only the researcher will have access to the tape and
once she has transcribed the interview she will wipe the tape. The
transcripts of all the participants will be used to produce the study
findings. Names and any other identifying information will be removed
from the transcript so no individual will be identifiable.
You can stop the interview and/or the recording at any point.
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Focus group: This will involve a group discussion between 6-8 people and
the researcher. It will be carried out at a venue convenient for those
involved, and will last for approximately an hour and a half. Similar to the
individual interviews, the focus group will be informal with general
discussion about heart health and people's attitudes towards heart
disease, its prevention and the use of aspirin. Again, there are no right
or wrong answers and all opinions are welcome.
Confidentiality is assured. If participants have no objections, the
discussion will be tape-recorded; only the researcher will have access to
the tape and once she has transcribed the interview she will wipe the
tape. Names and any other identifying information will be removed from
the transcript so single individuals will not be identifiable in research
reports.
Should a participant wish to, he/she can leave the focus group at any
point.
What will happen with the research findings?
The findings from the interviews and focus groups will form the basis of
a Ph.D. (research degree) and will lead to publications in scientific
journals. If you are interested in reading the research findings, you will
be able to contact the researcher.
Further information
If you have any questions or wish to discuss this study, you are welcome
to contact me (Helen Eborall) on 0131 650 3242
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A3.1 Participant consent form: individual interviews
INFORMED CONSENT FOR PARTICIPATION IN AN INTERVIEW ON
SCREENING AND PREVENTION OF HEART DISEASE
This interview is part of the research involved in my Ph.D. The purpose of the
interview is to explore understandings and beliefs about heart disease, its screening
and prevention, and research participation.
I will conduct the interview on [date]. The interview will be recorded with the
participant's permission and the recording will be transcribed and analysed by
myself. Names will be removed and the datawill be made anonymous.
There are no foreseeable risks in this research but should any discomfort arise
regarding material addressed in this interview participants should contact me.
Helen Eborall,
Department of Public Health Sciences, University of Edinburgh, Teviot Place,
Edinburgh, EH8 9AG Telephone: 0131 650 3242 Email: Helen.Eborall@ed.ac.uk
I agree to participate in this research project and I understand that:
• The time required for this interview will be around 30-60 minutes.
• The nature of my participation will be an interview on the topic of "Screening
and prevention of heart disease".
• My participation is entirely voluntary and I may terminate my involvement at any
time.
• At the time of the interview my permission will be sought to record the interview.
• All my data will be kept confidential by the researcher; names and identifying
features will be removed from the resulting transcript.
• Data will be used to form the basis of a Ph.D. (research degree) and will lead to
publications in scientific journals.
• If I have questions or need to talk about matters arising from the interview at any
stage I can contact Helen Eborall at the above address.
DateSigned
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A3.2 Participant consent form: focus groups
INFORMED CONSENT FOR PARTICIPATION IN FOCUS GROUP ON
SCREENING AND PREVENTION OF HEART DISEASE
This focus group is part of the research involved in my Ph.D. The purpose of the
focus group is to explore understandings and beliefs about heart disease, its screening
and prevention, and research participation.
I will conduct the focus group on [date]. The discussion will be recorded with the
participants' permission and the recording will be transcribed and analysed by
myself. Names will be removed and the data will be made anonymous.
There are no foreseeable risks in this research but should any discomfort arise
regarding material addressed in this interview participants should contact me.
Helen Eborall,
Department of Public Health Sciences, University of Edinburgh, Teviot Place,
Edinburgh, EH8 9AG Telephone: 0131 650 3242 Email: Helen.Eborall@ed.ac.uk
I agree to participate in this research project and I understand that:
• The time required for this focus group will be around 1 to 1 lA hours.
• The nature ofmy participation will be a focus group on the topic of "Screening
and prevention of heart disease".
• My participation is entirely voluntary and I may terminate my involvement at any
time.
• At the time of the focus group my permission will be sought to record the
discussion.
• All my data will be kept confidential by the researcher; names and identifying
features will be removed from the resulting transcript.
• Data will be used to form the basis of a Ph.D. (research degree) and will lead to
publications in scientific journals.
• If I have questions or need to talk about matters arising from the interview at any
stage I can contact Helen Eborall at the above address.
Signed Date
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A4: Interview and focus group documents
A4.1.1: Introduction template for focus groups
Welcome and thank you all for taking the time to join this discussion on
'screening and prevention of heart disease'.
Introduce myself
• Me: moderating the discussion
• [assistant moderator] will be assisting me and taking notes
Purpose of research and use of results
• I would like to find out more about people's attitudes towards screening
and prevention of heart disease, and participation in research trials. I am
doing similar focus groups and interviews with participants and non-
participants at all stages of the Aspirin trial in Edinburgh, Glasgow and
Lanarkshire.
Why you were selected
• You were all selected because...[for exam/Die for group 2: you have all
been participants in the Aspirin trial, but are no longer taking the trial
medication for varying reasons]
Importance of all contributions - differing opinions
• There are no right or wrong answers but rather differing points of view.
Please feel free to share your opinions, even if it differs from what others
have said.
Check consent to record
Ground rules
Before we begin I'd like to introduce some ground rules.
The aim is to generate a discussion between you however I would ask that
you please...
• speak up
• only one person should talk at a time.
• I'm recording the session because I don't want to miss any of your
comments.
• Please avoid engaging in side conversations between neighbours.
• I would like everyone to participate without one member dominating.
• As mentioned in the consent form, confidentiality is completely assured.
Names will not be used in the writing up of the research
• I would ask you to respect each other's privacy.
• Would anyone like to add any ground rules?
The session will last for about an hour
To start with could you introduce yourselves to me one by one.
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A4.1.2 Introduction template for individual interviews
Thank you for participating
Introduce me
Purpose of research and use of results
I would like to find out more about people's attitudes towards screening and
prevention of heart disease. I am doing similar interviews and focus groups
with participants and non-participants of the Aspirin trial in Edinburgh,
Glasgow and Lanarkshire.
Why you were selected
[For example for group 3:] I'm particularly interested in people who did not
take part in the trial.
Importance of all opinions
There are no right or wrong answers but rather differing points of view.
Please feel free to share your opinions.
Check consent to record
Timing
The session will last between half an hour and an hour
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A4.2.1 Pilot topic guide
Part 1: Explanation of screening process:
• "healthy" population (50-79)
• ABPI
• Who do see as the type of person likely to be at risk of having heart
problems?
• What do you think about the idea of screening the population?
• Do you think many people would attend the screening appointment if
invited?
• What sort ofpeople do you think would attend/not attend the screening?
• (Why would people want/not want to know their risk level?)
• How did you think people would react when told by the nurse they are in
the 'high-risk' group (or not in the 'high-risk' group?)
Part 2: Explanation of use of low dose aspirin as preventive medication
• Has anyone heard of aspirin being used to treat heart problems? What do
you think about this?
• Has anyone heard of aspirin being used to prevent heart problems?
What do you think about this?
• Do you know of any risks involved with taking aspirin ?
• What do you think about daily aspirin compared with other
recommendations for reducing risk of heart problems, for example
stopping smoking or doing exercise?
• How do you think people would feel? And would it affect other behaviours
eg. diet?
Part 3: Explanation of RCT
• 50% chance aspirin/dummy pill, blinding, randomisation
• Do you think people would participate in the trial? Why?
• People taking part in the trial do not know whether they are taking aspirin
or a dummy pill. What do you think about this?
• What do you think are the advantages and disadvantages of taking part in
this trial?
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A4.2.2 Topic guide for group 5 participants
1: Screening
• What did you think when you received the invite?
• Do you think many people would attend the screening appointment if
invited?
• What sort of people do you think would attend/not attend the screening?
And why?
• What do you think about the idea of screening the population?
• (Why would people want/not want to know their risk level?)
• How did you think you would have felt if you had attended the screening
and the nurse told you that you had early signs of future heart problems?
• Do/did you see yourself as the type ofperson likely to be at risk of having
heart problems?
2: Aspirin as preventive medication
• Have you heard of aspirin being used
you think about this?
• Have you heard of aspirin being used
do you think about this?
• You take/are prescribed aspirin, why is
• You can't take aspirin, how do you feel
• Do you know of any risks involved with
• What do you think about daily
recommendations for reducing risk
stopping smoking or doing exercise?
• How do you think people would feel? And would it affect other behaviours
eg. diet?
3: Research participation
• Would you have been interested in taking part in the trial ifyou could have
done?
• Do you think people would participate in the trial? Why?
• People taking part in the trial do not know whether they are taking aspirin
or a dummy pill. What do you think about this?
• What do you think are the advantages and disadvantages of taking part in
this trial?
to treat heart problems? What do
to prevent heart problems? What
this? How do you feel about this?
about this?
taking aspirin?
aspirin compared with other
of heart problems, for example
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A4.2.3 Topic guide for group 4 participants
1: Screening
• What did you think when you received the invite?
• What were your expectations about when you attended
• What do you think about the idea of screening the healthy
population?
• And about the age range 50-75?
• Do you think many people would attend the screening appointment if
invited?
• What sort of people do you think would attend/not attend the screening?
And why?
• (Why would people want/not want to know their risk level?)
• How did you feel during your screening appointment?
• How did you think you would have felt if the nurse told you that you
had early signs of future heart problems?
• How did you feel when you were told you were not eligible (too
healthy) to go into the trial?
• Do/did you see yourself as the type of person likely to be at risk of
having heart problems?
2: Aspirin as preventive medication
• Have you heard of aspirin being used to treat heart problems? What
do you think about this?
• Have you heard of aspirin being used to prevent heart problems?
What do you think about this?
• Do you know ofpeople who take aspirin?
• Would you take aspirin if you considered yourself at risk of future
heart problems?
• Do you know of any risks involved with taking aspirin?
• Newspaper headlines- articles
• How does aspirin compare to any other medication that you take/or know
of?
• What do you think about daily aspirin compared with other
recommendations for reducing risk of heart problems, for example
stopping smoking or doing exercise?





• If you had been eligible, would you have been interested in taking
part in the trial?
• Do you think people would participate in the trial? Why?
• People taking part in the trial do not know whether they are taking aspirin
or a dummy pill. What do you think about this?
• Have you been involved with a similar trial?
• What do you think are the advantages and disadvantages of taking part in
this trial?
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A4.2.4 Topic guide for group 3 participants
1: Screening
• What did you think when you received the invite?
• What were your reasons for deciding to attend?
• What were your expectations about when you attended?
• What do you think about the idea of screening the healthy
population?
• And about the age range 50-75?
• Do you think many people would attend the screening appointment if
invited?
• What sort of people do you think would attend/not attend the screening?
And why?
• (Why would people want/not want to know their risk level?)
• How did you feel during your screening appointment?
• How did you feel when the nurse told you you were eligible for the
trial/had early signs of future heart problems?
• Do/did you see yourself as the type of person likely to be at risk of
having heart problems?
2: Aspirin as preventive medication
• Have you heard of aspirin being used to treat heart problems? What
do you think about this?
• Have you heard of aspirin being used to prevent heart problems?
What do you think about this?
• Do you know ofpeople who take aspirin?
• Would you take aspirin (now that you have early signs of future
heart problems)?
• Do you know of any risks involved with taking aspirin?
• How does aspirin compare to any other medication that you take/or know
of?
• What do you think about daily aspirin compared with other
recommendations for reducing risk of heart problems, for example
stopping smoking or doing exercise?




• Why did you decide not to take part in the trial?
• Do you think people would participate in the trial? Why?
• People taking part in the trial do not know whether they are taking aspirin
or a dummy pill. What do you think about this?
• Have you been involved with a similar trial?
• What do you think are the advantages and disadvantages of taking part in
this trial?
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A4.2.5 Topic guide for group 1 participants
1: Screening
• What did you think when you received the invite?
• What were your expectations about when you attended?
• What do you think about the idea of screening the healthy
population?
• And about the age range 50-75?
• Do you think many people would attend the screening appointment if
invited?
• What sort of people do you think would attend/not attend the screening?
And why?
• (Why would people want/not want to know their risk level?)
• How did you feel during your screening appointment?
• How did you feel when you were told you were eligible to go into the
trial?
• Do/did you see yourself as the type of person likely to be at risk of
having heart problems? Why?
2: Aspirin as preventive medication
• Had you heard of aspirin being used to treat heart problems? What
do you think about this?
• Had you heard of aspirin being used to prevent heart problems?
What do you think about this?
• Did you know ofpeople who take aspirin?
• Do you know people now who take aspirin?
• Do you know of any risks involved with taking aspirin?
• Newspaper headlines- articles
• How does aspirin compare to any other medication that you take/or know
of?
• What do you think about daily aspirin compared with other
recommendations for reducing risk of heart problems, for example
stopping smoking or doing exercise?
• How do you think people would feel? And would it affect other behaviours
eg. diet?
3: Research participation
• How do you feel about being part of this aspirin trial?
• What were you reasons for participating in the trial?
• How do you feel about taking this tablet for 5 years?
• How do you feel about not knowing whether the tablet is aspirin or a
dummy pill?
• What do you think are the advantages of taking part in this trial?
• What do you think are the disadvantages of taking part in this trial?
• Have you been involved with a similar trial?
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A4.2.6 Topic guide for group 2 participants
1: Screening
• What did you think when you received the invite?
• What were your expectations about when you attended?
• What do you think about the idea of screening the healthy
population?
• And about the age range 50-75?
• Do you think many people would attend the screening appointment if
invited?
• What sort of people do you think would attend/not attend the screening?
And why?
• (Why would people want/not want to know their risk level?)
• How did you feel during your screening appointment?
• How did you feel when you were told you were eligible to go into the
trial?
• Previously did you see yourself as the type of person likely to be at
risk of having heart problems? Why?
• And now, how do you feel about your level of risk of heart
problems?
2: Aspirin as preventive medication
• Had you heard of aspirin being used to treat heart problems? What
do you think about this?
• Had you heard of aspirin being used to prevent heart problems?
What do you think about this?
• Did you know ofpeople who take aspirin?
• Do you know people now who take aspirin?
• Do you know of any risks involved with taking aspirin?
• Newspaper headlines- articles
• Do you take anymedication?
• How does aspirin compare to any other medication that you take/or know
of?
• What do you think about daily aspirin compared with other
recommendations for reducing risk of heart problems, for example
stopping smoking or doing exercise?




• How did you feel about being part of this aspirin trial?
• What were you reasons forparticipating in the trial?
• How did you feel about taking this tablet for 5 years?
• How did you feel about not knowing whether the tablet is aspirin or a
dummy pill?
• What were your reasons for stopping the trial medication? How did you
feel about this? Did it change your opinions about the trial in any way?
• What do you think are the advantages of taking part in this trial?
• What do you think are the disadvantages of taking part in this trial?
• Have you been involved with a similar trial?
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A4.3 Template for ending interviews and focus groups
Ending:
• Summarise main opinions brought up then: Would you say that was a fair
summary?
• The purpose of today's interview/focus group was to help me to identify
the most important issues regarding screening and prevention of heart
disease. Have I missed anything?
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A4.4.3
Wonder drug can still be a killer
• Are they good or bad for you? It depends on which expert you believe l-'i'-P,'-
:>ltvfc»c ,, • .v>j ...Vie, -slK-rinlfslriK-li.^pcr I«m »*v IIiji tliiicul i*-x .f%l »«k "*""«»>*
US!gs mmessemm-mm p~^~srs«:^ss; xzszzr- sass^-rcss" srsasr^a,^. r„...












UUvLCJi -C I 11J uJ si LI.. I--K * l«oLI I I I I LI Li ■. f u i ■ ■ »•
riir.iiiilyavpiijii Wonderdrug : Thousands
l'l tfe.n it TV. i n m cwic. uSrertOT oJ lake a splrin cM y bel levl n g
Hit Medical lUi&fmoli Co T.jii it prevenls liearf disease
11111 m i i^i iv" mill Mrrlli'il rova rinlt
321
A4.4.5
How aspirin trial could offer hope to thousands
ONE of the biggest ever
medical trials is to take
place hi Scotland to find
out if aspirin can cut down
on heart deaths.
Mure than 40,000 people
will be asked to join the
By KAWE SHARP
fared heart attacks or other
coronary problems.
But il is now thought that
prescribing it for patients
considered ut risk could pre¬
does hare an impact on stop¬
ping the disease progressbig
then we could be reducing
the number of victims of
heart aMarks and strokes by
150,000 over five years.
'Aspirin Is s relatively cheap
worst incidence of heart
disease in the country, and
Scotland Is considered one of
the unhealthiejt nations in
Europe.
Researchers will recruit
candidates nvur the noxt few
doses of aspirin and others
dummy pills.
The long-term research
aims to discover whether
aspirin helps. Dr Cud inore
said: 'Aspirin thins Ibe blood






DOCTORS are being urged to think
again be Iore persuading patients
threatened by heart disease to lake a
daily dose of aspirin.
'Mie; idvice comes from rescareljem
who found thai, even at very low
doses, long-term use of lire drug
carried a risk of internal bleeding.
Aspirin is used lo help people













IT'S a busy Mondaymorning when Mum
collapses in agony, pain
searing through her
1, TT j. . . . . ■
Parienls will be divided into two
groups with one being asked to cake a
tow dose aspirin every day and the
others given a placebo. Results will
show which groups suffer fewer hearl
attacks and strokes. The results should
be known around 200t>.
Aspirin may also be particularIv






£lm trial for 3000 in sickest parts ofScotland
RAYMOND DUNCAN II is estimated that the Scottish
trial could reduce the number of
RESEARCH in Scotland to test new coses ofcardiovascularheart
the effect ofaspirin on people at disease in those who are ewer the







ALAN MacDEItMiO ;nv published inday in rlie Ihitisfi
Meriical Correspondent Medical hwniiil.I Fiey found lhai giislrinnksrnuil
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method of helping previa.1 heart patients Inking doses wen below








IE fleets of the humble aspirin on heart
lease and strokes arc Id be studied during a
de-scttfc trial to l^anarkshlre, the heurt
iense ca pilal ur Scolfa nd.
Sumc 20.000 middle-aged men and women
Hamihon, Moihtrwell and the MonkJands
ra are lo be screened during the trial, the first
its kind in ftrilain.
By Wendy Fenemore
'
The £1 million project i.s being lunded by ihc
British Heart Foundation and" die Scottish
Office. with support from Lanarkshire Health
Bonid.
It wrll be co-ordinnicd by the University of
Edinburgh's Department of l^ubtic Health Sci¬
ences.
Lanarkshire lias an unenviable record of
coronary bean disease, with almost 20 per cent,
more cases than Che Scottish average.
In 1096. the year of the most recent figures,
coronary lienri disease claimed ihc lives or no
fewer ttari 1655 txnok in Lanarkshire*.
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Appendix 5: Coding framework
Screening
Good opportunity
Screening described as good opportunity or similar
'MOT'/health check
"MOT" analogy, general health checks, workplace check-ups
Prevention is better than cure
Use ofphrase "prevention is better than cure " or similar meaning
Benefits
Other benefits including non-specific
Individual responsibility versus individual rights
Talk ofone's duty to attend screening, or conversely the right to not attend
Age
Screening associated with being a certain age
Denial and fear versus keen to know
Mention ofphrases such as, "it won't happen to me " and "don 't want to know ", or
conversely expressing interest in finding out one's risk
Asymptomatic/"not broken, won't fix"
Use ofphrases such as "not broken, so don'tfix it" and mention ofthe
asymptomatic nature ofconditions such as atherosclerosis
Inevitability/fatalism
Use ofphrases such as, "what's going to happen, will happen " and "you've got to die of
something"
Barriers
Mention offactors that inhibit screening attendance
Other screenings





Talk ofdependence on medication or issues about control
'Alien'
Medication described as an alien substance in body, unnatural, or creating
imbalances
Trust/mistrust
Mention of trust and mistrust ofmedication
Habit
Medication-taking described as becoming a habit
Like/dislike
Expressions of like or dislike ofmedication
Side effects
Discussion ofside effects ofmedication
GP influence
Talk ofthe impact ofone's GP on one's medication-taking
Preventive
"Prevention is better than cure"
Use of this phrase or similar, and linked accounts ofbehaviour that supports or
contradicts this attitude
Preventive medicine as alternative
Comments about the idea ofpreventive medication as an alternative
strategy to behavioural change such as stopping smoking
Aspirin
Discussion about aspirin specifically
Side effects
Discussion ofside effects ofaspirin
Trial tablet comparison
Comparison of the trial tablet with other medication
Contradiction
Trial tablet accepted despite general dislike ofmedication
Necessity
Comments regarding thepoint at which medication becomes a necessity
Current medication




Overt mention ofaltruism by selfor others, or altruistic implied through
discourse
Duty/goodness
Talk ofduty, implications ofmorality, or descriptions ofaction being a
"good" thing to do
Recognition of need for research
Demonstration ofawareness ofneedfor research, trial and RCTprocess
Acceptance




Talk ofappreciation for care received
'Loaded' reciprocity
Implications ofanticipating care needed or some reward in return
forparticipation
Mutual benefits
Mention ofthe benefits to both selfand othersfrom participating
Personal benefit
Talk ofthe benefits to oneselffrom participating
Self dominant




Altruism given as a reason forparticipation
Personal context
Mention ofexperience ofheart disease in one's family, spouse orpeers as
provokingparticipation
Prior trial experience
Discussion ofparticipating in previous trials
Trust
GP
Talk of trust in one's GPprovokingparticipation
Trial
Expressions of trust in the trial
Positive trial attributes
Health check
Health checks received in the trial described as beneficial
Monitoring
Feeling ofone's health being monitored throughout trial
Informed consent
Opinions on the issue of informed consent
Safeguards
Talk ofthe safeguards in place to catch events and side effects
RCTOK
Positive opinions expressed about RCTprocess
Awareness
Trial described as having improved awareness ofone's own health
Barriers to trial participation
Age
Attitude that one is too old to participate
Duration





Concerns expressed about side effects ofaspirin
Side effects of trial tablet
Description ofside effects experiencedfrom trial tablet
Continued over
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Barriers to trial participation (continued)
Dislike RCT process
Discontent with randomisation, blinding andplacebo
Question research
Questioning of the needfor the research, reliability of the process
and analysis
Financial incentives
Lack offinancial compensation forparticipating
Commitment
Dislike at the idea ofthe commitment involved in the trial
Convenience
Talk ofthe convenience/hassle or conversely the inconvenience





Talk of intrigue and guessing ofthe trial tablet's identity
Understandings
Discussion and implications ofunderstandings and misunderstandings of
the trial and RCTprocess
AAA trial experience
Descriptions ofexperiences in the trial including side effects and events
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Risk perception
Perceived risk and participation decisions
No risk perceived, participate




Discussion ofriskperceivedfrom the screening experience, including the
nurse-participant dialogue and terms such as "borderline" and "marginal"
Reaction to screening result
Description ofone's reaction to one's screening result
Risk perception from clinical measures
Discussion and implications ofriskperceivedfrom measure including blood
pressure, cholesterol, and the ABPI
Reaction to discovery of other risk
Description ofone's reaction to discovery ofhigh cholesterol or bloodpressure and similar
Family history
Mention offamily history ofdisease in relation to perceivedpersonal risk
Lifestyle
Discussion ofone's lifestyle, and the relation oflifestyle to cardiovascular
risk
Scottish identity
Mention of 'being Scottish' and its relation to cardiovascular risk, including
Scottish culture, and the impact ofpoverty
Age
Mention ofthe relation ofage to cardiovascular risk
Psychosocial











Discussion offatalism regarding disease, or implications offatalistic
attitude
Lay epidemiology
Discussion echoing this concept
Randomness
Mention ofthe randomness ofheart disease
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